Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors

ABSTRACT

The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.

REFERENCE TO SEQUENCE LISTING

This application includes a Sequence Listing submitted electronically as a text file named 18923805701SEQ, created on Dec. 11, 2021, with a size of 28 kilobytes. The Sequence Listing is incorporated herein by reference.

FIELD

The present disclosure relates generally to the treatment of subjects having metabolic disorders and/or cardiovascular disease with Inhibin Subunit Beta E inhibitors, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or cardiovascular disease, and methods of detecting INHBE variant nucleic acid molecules and variant polypeptides.

BACKGKROUND

Body fat distribution is an important risk factor for cardiovascular and metabolic disease independent of overall adiposity. A body fat distribution characterized by higher accumulation of fat around the waist (such as greater abdominal fat or larger waist circumference) and/or lower accumulation of fat around the hips (such as lower gluteofemoral fat or smaller hip circumference), resulting in a greater waist-to-hip ratio (WHR), is associated with higher cardio-metabolic risk independent of body mass index (BMI). Metabolic conditions associated with body fat distribution include, but are not limited to: type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B or other lipid fractions), obesity (particularly abdominal obesity), lipodystrophy (such as an inability to deposit fat in adipose depots regionally (partial lipodystrophy) or in the whole body (lipoatrophy)), insulin resistance or higher or altered insulin levels at fasting or during a metabolic challenge, liver fat deposition or fatty liver disease and their complications (such as, for example, cirrhosis, fibrosis, or inflammation of the liver), nonalcoholic steatohepatitis, other types of liver inflammation, higher or elevated or altered liver enzyme levels or other markers of liver damage, inflammation or fat deposition in the liver, higher blood pressure and/or hypertension, higher blood sugar or glucose or hyperglycemia, metabolic syndrome, coronary artery disease, and other atherosclerotic conditions, and the complications of each of the aforementioned conditions. Identifying genetic variants associated with a more favorable fat distribution (such as a lower WHR, particularly when adjusted for BMI) can be a pathway to identify mechanisms that can be exploited therapeutically for benefit in these cardio-metabolic diseases.

Inhibin Subunit Beta E (INHBE) is a member of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Inhibins have been implicated in regulating numerous cellular processes including cell proliferation, apoptosis, immune response and hormone secretion. Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins. In addition, INHBE may be upregulated under conditions of endoplasmic reticulum stress, and this protein may inhibit cellular proliferation and growth in pancreas and liver.

SUMMARY

The present disclosure provides methods of treating a subject having a metabolic disorder or at risk of developing a metabolic disorder, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having type 2 diabetes or at risk of developing type 2 diabetes, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having obesity or at risk of developing obesity, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having elevated triglyceride level (hypertriglyceridemia) or at risk of developing elevated triglyceride level (hypertriglyceridemia), the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having lipodystrophy or at risk of developing lipodystrophy, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having liver inflammation or at risk of developing liver inflammation, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having fatty liver disease or at risk of developing fatty liver disease, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having hypercholesterolemia or at risk of developing hypercholesterolemia, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having elevated liver enzymes (such as, for example, alanine transaminase (ALT) and/or aspartate transaminase (AST)) or at risk of developing elevated liver enzymes (such as, for example, ALT and/or AST), the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having nonalcoholic steatohepatitis (NASH) or at risk of developing NASH, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having a cardiovascular disease or at risk of developing a cardiovascular disease, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having cardiomyopathy or at risk of developing cardiomyopathy, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having heart failure or at risk of developing heart failure, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having high blood pressure or at risk of developing high blood pressure, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a metabolic disorder, wherein the subject is suffering from a metabolic disorder, the methods comprise the steps of: determining whether the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in a standard dosage amount, and administering to the subject an INHBE inhibitor; and when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in an amount that is the same as or lower than a standard dosage amount, and administering to the subject an INHBE inhibitor; when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in an amount that is the same as or lower than a standard dosage amount; wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding the INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing the metabolic disorder.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a cardiovascular disease, wherein the subject is suffering from a cardiovascular disease, the methods comprise the steps of: determining whether the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in a standard dosage amount, and administering to the subject an INHBE inhibitor; and when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in an amount that is the same as or lower than a standard dosage amount, and administering to the subject an INHBE inhibitor; when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in an amount that is the same as or lower than a standard dosage amount; wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding the INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing the cardiovascular disease.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a metabolic disorder, wherein the methods comprise: determining or having determined the presence or absence of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide in a biological sample obtained from the subject; wherein: when the subject is INHBE reference, then the subject has an increased risk for developing the metabolic disorder; and when the subject is heterozygous for an INHBE variant nucleic acid molecule or homozygous for an INHBE variant nucleic acid molecule, then the subject has a decreased risk for developing the metabolic disorder.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a cardiovascular disease, wherein the methods comprise: determining or having determined the presence or absence of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide in a biological sample obtained from the subject; wherein: when the subject is INHBE reference, then the subject has an increased risk for developing the cardiovascular disease; and when the subject is heterozygous for an INHBE variant nucleic acid molecule or homozygous for an INHBE variant nucleic acid molecule, then the subject has a decreased risk for developing the cardiovascular disease.

The present disclosure also provides therapeutic agents that treat or inhibit a metabolic disorder for use in the treatment of the metabolic disorder in a subject having: an INHBE variant genomic nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide; an INHBE variant mRNA molecule encoding an INHBE predicted loss-of-function polypeptide; or an INHBE variant cDNA molecule encoding an INHBE predicted loss-of-function polypeptide.

The present disclosure also provides therapeutic agents that treat or inhibit a cardiovascular disease for use in the treatment of the cardiovascular disease in a subject having: an INHBE variant genomic nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide; an INHBE variant mRNA molecule encoding an INHBE predicted loss-of-function polypeptide; or an INHBE variant cDNA molecule encoding an INHBE predicted loss-of-function polypeptide.

The present disclosure also provides INHBE inhibitors that treat or inhibit a metabolic disorder for use in the treatment of the metabolic disorder in a subject having: an INHBE variant genomic nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide; an INHBE variant mRNA molecule encoding an INHBE predicted loss-of-function polypeptide; or an INHBE variant cDNA molecule encoding an INHBE predicted loss-of-function polypeptide.

The present disclosure also provides INHBE inhibitors that treat or inhibit a cardiovascular disease for use in the treatment of the cardiovascular disease in a subject having: an INHBE variant genomic nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide; an INHBE variant mRNA molecule encoding an INHBE predicted loss-of-function polypeptide; or an INHBE variant cDNA molecule encoding an INHBE predicted loss-of-function polypeptide.

BRIEF DESCRIPTION OF THE FIGURES

The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the present disclosure.

FIG. 1 shows association of INHBE predicted loss-of-function (pLOF) variants with a favorable fat distribution (i.e., lower BMI adjusted WHR) in an exome sequencing analysis of over 525,000 people from multiple studies; association analyses were estimated by fitting mixed-effects linear regression models accounting for relatedness and population stratification using the REGENIE software; abbreviations: confidence interval, CI; standard deviation, SD; body mass index, BMI; waist-hip ratio adjusted for BMI, WHRadjBMI; reference-reference allele, RR; reference-alternative allele, RA; alternative-alternative allele, AA; UK Biobank cohort, UKB; European ancestry, EUR; Mexico city prospective study cohort, MCPS; predicted loss-of-function, pLOF.

FIG. 2 depicts a gene model for INHBE showing the location of pLOF variants (top panel) and the phenotypic distribution of BMI-adjusted WHR in carriers of each variant; the blue bar shows the median BMI-adjusted WHR in non-carriers, while the red bar shows the median BMI-adjusted WHR in carriers; two variants highlighted in dark red were individually associated with lower BMI-adjusted WHR; data are from the UK Biobank (UKB) and Mexico City Prospective Study (MCPS) cohorts; abbreviations: body mass index, BMI; waist-hip ratio, WHR.

FIG. 3 shows the in silico predicted functional consequences of the INHBE c.299-1G:C (12:57456093:G:C) splice variant; top sequence =original exon 2 (SEQ ID NO:28); bottom sequence =predicted exon 2 (SEQ ID NO:29).

FIG. 4 shows the wild type INHBE protein sequence (top; SEQ ID NO:8) and the in silico predicted protein sequence for the c.299-1G:C acceptor splice variant (bottom; SEQ ID NO:8 showing change in non-highlighted region).

FIG. 5 shows Chinese hamster ovary (CHO) cells experiments for the c.b 2.99-1G>C variant. The variant occurs in the splice acceptor site for the first and only splice junction in the INHBE gene (Panel A). In CHO cells, the c.299-1.G>C variant results in the expression of a lower molecular weight variant which is present in cell lysates hut not in the media, consistent with a loss-of-function (Panel B).

FIG. 6 shows associations of INHBE pLOF variants with body fat and lean mass, percentage and body-surface adjusted indices as measured by electrical bioimpedance in 423,418 participants from the UKB study.

FIG. 7 shows INHBE expression patterns across tissues (left) and liver cell-types (right). The first panel shows, per tissue, the normalized mRNA expression values for INHBE in counts per million (CPM) using data from genotype tissue expression (GTEx) consortium (GTEx Portal 2021. Accessed 2021, Jun. 1^(st) via world wide web at “gtexportal.org/”). The second panel shows normalized cell-type specific expression levels within liver, in transcripts per million protein coding genes (pTPM), obtained from the human protein atlas (HPA) (Uhlen et al., Nat. Biotechnol. 2010, 28, 1248-50). Box plots depict the median (thick black vertical bar), the interquartile range, and minimum and maximum CPM values across individuals per tissue.

FIG. 8 shows liver mRNA expression of INHBE is upregulated in patients with steatosis and nonalcoholic steatohepatitis (NASH) compared to individuals with normal liver in bariatric surgery patients from GHS. In the top panel, the Figure shows liver mRNA expression levels of INHBE in transcripts per million (TPM; a normalization of RNA molecules for every 1 million molecules detected in a certain experiment) in patients with normal liver (control), steatosis of the liver (simple steatosis) and nonalcoholic steatohepatitis (NASH). In the bottom panel are statistics for comparisons between groups. The simple steatosis group showed higher expression of INHBE in the liver than the control group. The NASH group showed higher expression both when compared to the control and when compared to the simple steatosis groups. All differences in expression between groups were statistically significant.

DESCRIPTION

Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definitions provided herein.

Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-expressed basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.

As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

As used herein, the term “about” means that the recited numerical value is approximate and small variations would not significantly affect the practice of the disclosed embodiments. Where a numerical value is used, unless indicated otherwise by the context, the term “about” means the numerical value can vary by ±10% and remain within the scope of the disclosed embodiments.

As used herein, the term “comprising” may be replaced with “consisting” or “consisting essentially of” in particular embodiments as desired.

As used herein, the term “isolated”, in regard to a nucleic acid molecule or a polypeptide, means that the nucleic acid molecule or polypeptide is in a condition other than its native environment, such as apart from blood and/or animal tissue. In some embodiments, an isolated nucleic acid molecule or polypeptide is substantially free of other nucleic acid molecules or other polypeptides, particularly other nucleic acid molecules or polypeptides of animal origin. In some embodiments, the nucleic acid molecule or polypeptide can be in a highly purified form, i.e., greater than 95% pure or greater than 99% pure. When used in this context, the term “isolated” does not exclude the presence of the same nucleic acid molecule or polypeptide in alternative physical forms, such as dimers or Alternately phosphorylated or derivatized forms.

As used herein, the terms “nucleic acid”, “nucleic acid molecule”, “nucleic acid sequence”, “polynucleotide”, or “oligonucleotide” can comprise a polymeric form of nucleotides of any length, can comprise DNA and/or RNA, and can be single-stranded, double-stranded, or multiple stranded. One strand of a nucleic acid also refers to its complement.

As used herein, the term “subject” includes any animal, including mammals. Mammals include, but are not limited to, farm animals (such as, for example, horse, cow, pig), companion animals (such as, for example, dog, cat), laboratory animals (such as, for example, mouse, rat, rabbits), and non-human primates. In some embodiments, the subject is a human. In some embodiments, the human is a patient under the care of a physician.

It has been observed in accordance with the present disclosure that loss-of-function variants in INHBE (whether these variations are homozygous or heterozygous in a particular subject) associate with a decreased risk of developing a metabolic disorder, such as type 2 diabetes, obesity, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, elevated liver enzymes (such as, for example, ALT and/or AST), NASH, and/or elevated triglyceride level, and/or a cardiovascular disease, such as cardiomyopathy, heart failure, and high blood pressure. It is believed that loss-of-function variants in the INHBE gene or protein have not been associated with metabolic disorders and/or cardiovascular disease in genome-wide or exome-wide association studies. Therefore, subjects that are homozygous or heterozygous for reference INHBE variant nucleic acid molecules may be treated with an INHBE inhibitor such that a metabolic disorder and/or cardiovascular disease is inhibited, the symptoms thereof are reduced, and/or development of symptoms is repressed. It is also believed that such subjects having metabolic disorders and/or cardiovascular disease may further be treated with therapeutic agents that treat or inhibit a metabolic disorder, such as type 2 diabetes, obesity, high blood pressure, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, elevated liver enzymes (such as, for example, ALT and/or AST), NASH, and/or elevated triglyceride level, and/or cardiovascular disease such as cardiomyopathy, heart failure, and high blood pressure.

For purposes of the present disclosure, any particular subject, such as a human, can be categorized as having one of three INHBE genotypes: i) INHBE reference; ii) heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide; or iii) homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. A subject is INHBE reference when the subject does not have a copy of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. A subject is heterozygous for an INHBE variant nucleic acid molecule when the subject has a single copy of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. An INHBE variant nucleic acid molecule is any nucleic acid molecule (such as, a genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule) encoding an INHBE polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function. A subject who has an INHBE polypeptide having a partial loss-of-function (or predicted partial loss-of-function) is hypomorphic for INHBE. A subject is homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide when the subject has two copies (same or different) of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

For subjects that are genotyped or determined to be INHBE reference, such subjects have an increased risk of developing a metabolic disorder, such as type 2 diabetes, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, elevated liver enzymes (such as, for example, ALT and/or AST), obesity, high blood pressure, and/or elevated triglyceride level (hypertriglyceridemia), and/or a cardiovascular disease, such as cardiomyopathy, heart failure, and high blood pressure. For subjects that are genotyped or determined to be either INHBE reference or heterozygous for an INHBE variant nucleic acid molecule, such subjects or subjects can be treated with an INHBE inhibitor.

In any of the embodiments described herein, the INHBE variant nucleic acid molecule can be any nucleic acid molecule (such as, for example, genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding an INHBE polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function. In some embodiments, the INHBE variant nucleic acid molecule is associated with a reduced in vitro response to INHBE ligands compared with reference INHBE. In some embodiments, the INHBE variant nucleic acid molecule is an INHBE variant that results or is predicted to result in a premature truncation of an INHBE polypeptide compared to the human reference genome sequence. In some embodiments, the INHBE variant nucleic acid molecule is a variant that is predicted to be damaging by in vitro prediction algorithms such as Polyphen, SIFT, or similar algorithms. In some embodiments, the INHBE variant nucleic acid molecule is a variant that causes or is predicted to cause a nonsynonymous amino-acid substitution in INHBE and whose allele frequency is less than 1/100 alleles in the population from which the subject is selected. In some embodiments, the INHBE variant nucleic acid molecule is any rare missense variant (allele frequency <0.1%; or 1 in 1,000 alleles), or any splice-site, stop-gain, start-loss, stop-loss, frameshift, or in-frame indel, or other frameshift INHBE variant.

In any of the embodiments described herein, the INHBE predicted loss-of-function polypeptide can be any INHBE polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function.

In any of the embodiments described herein, the INHBE variant nucleic acid molecules encoding variations in the protein sequence can include variations at positions of chromosome 12 using the nucleotide sequence of the INHBE reference genomic nucleic acid molecule (SEQ ID NO:1; ENST00000266646.3 chr12:57455307-57458025 in the GRCh38/hg38 human genome assembly) as a reference sequence.

Numerous genetic variants in INHBE exist which cause subsequent changes in the INHBE polypeptide sequence including, but not limited to: Gln7fs, Arg18STOP, GIn37STOP, Arg40STOP, Leu55fs, Cys139fs, Arg144STOP, Cys192fs, Arg224fs, Arg224STOP, Arg233fs, Arg250STOP, Asp251fs, Tyr253STOP, Tyr275STOP, Ser293fs, Trp308fs, Pro309fs, Arg320STOP, Leu323fs, and Ter351Tyrext*?. Additional variant genomic nucleic acid molecules of INHBE exist, including, but not limited to (using the human genome reference build GRch38): C298+1G:T (12:57455835:G:T), c.299-2A:G, c.299-1G:C (12:57456093:G:C), and 12:57259799:A:C. Additional variant INHBE polypeptides exist, including, but not limited to INHBE polypeptide having the methionine at position 1 removed.

Any one or more (i.e., any combination) of the INHBE pLOF variants can be used within any of the methods described herein to determine whether a subject has an increased risk for developing a metabolic disorder and/or a cardiovascular disease. The combinations of particular variants can form a mask used for statistical analysis of the particular correlation of INHBE and increased type 2 diabetes/BMI risk and/or a cardiovascular disease.

In any of the embodiments described herein, the metabolic disorder is type 2 diabetes, obesity, NASH, and/or elevated triglyceride level. In any of the embodiments described herein, the metabolic disorder is type 2 diabetes. In any of the embodiments described herein, the metabolic disorder is obesity. In any of the embodiments described herein, the metabolic disorder is NASH. In any of the embodiments described herein, the metabolic disorder is elevated triglyceride level. In any of the embodiments described herein, the metabolic disorder is lipodystrophy. In any of the embodiments described herein, the metabolic disorder is liver inflammation. In any of the embodiments described herein, the metabolic disorder is fatty liver disease. In any of the embodiments described herein, the metabolic disorder is hypercholesterolemia. In any of the embodiments described herein, the metabolic disorder is elevated liver enzymes (such as, for example, ALT and/or AST).

Metabolic disorders/conditions associated with body fat distribution also include, but are not limited to: type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B or other lipid fractions), obesity (particularly abdominal obesity), lipodystrophy (such as an inability to deposit fat in adipose depots regionally (partial lipodystrophy) or in the whole body (lipoatrophy)), insulin resistance or higher or altered insulin levels at fasting or during a glucose or insulin challenge, liver fat deposition or fatty liver disease and their complications (such as, for example, cirrhosis, fibrosis, or inflammation of the liver), higher or elevated or altered liver enzyme levels or other markers of liver damage, inflammation or fat deposition, higher blood pressure and/or hypertension, higher blood sugar or glucose or hyperglycemia, metabolic syndrome, coronary artery disease, and other atherosclerotic conditions, and the complications of each of the aforementioned conditions.

In any of the embodiments described herein, the cardiovascular disease is cardiomyopathy, heart failure, or high blood pressure. In any of the embodiments described herein, the cardiovascular disease is cardiomyopathy. In any of the embodiments described herein, the cardiovascular disease is heart failure. In any of the embodiments described herein, the cardiovascular disease is high blood pressure.

The present disclosure provides methods of treating a subject having or at risk of developing a metabolic disorder, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing type 2 diabetes, the methods comprising administering an INHBE inhibitor to the subject. The present disclosure also provides methods of treating a subject having or at risk of developing obesity, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing elevated triglyceride level, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing NASH, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing lipodystrophy, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing liver inflammation, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing fatty liver disease, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing hypercholesterolemia, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing elevated liver enzymes (such as, for example, ALT and/or AST), the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing a cardiovascular disease, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing cardiomyopathy, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing heart failure, the methods comprising administering an INHBE inhibitor to the subject.

The present disclosure also provides methods of treating a subject having or at risk of developing high blood pressure, the methods comprising administering an INHBE inhibitor to the subject.

In some embodiments, the INHBE inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs). Such inhibitory nucleic acid molecules can be designed to target any region of an INHBE mRNA. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes to a sequence within an INHBE genomic nucleic acid molecule or mRNA molecule and decreases expression of the INHBE polypeptide in a cell in the subject. In some embodiments, the INHBE inhibitor comprises an antisense RNA that hybridizes to an INHBE genomic nucleic acid molecule or mRNA molecule and decreases expression of the INHBE polypeptide in a cell in the subject. In some embodiments, the INHBE inhibitor comprises an siRNA that hybridizes to an INHBE genomic nucleic acid molecule or mRNA molecule and decreases expression of the INHBE polypeptide in a cell in the subject. In some embodiments, the INHBE inhibitor comprises an shRNA that hybridizes to an INHBE genomic nucleic acid molecule or mRNA molecule and decreases expression of the INHBE polypeptide in a cell in the subject.

In some embodiments, the antisense nucleic acid molecules comprise or consist of the nucleotide sequences shown in Table 1.

TABLE 1 SEQ ID Sequence NO: ACAGCUCAUGUCUGGCUACU 30 UGACCCUCACAGCUCAUGUC 31 UUGACCCUCACAGCUCAUGU 32 UGCUUGACCCUCACAGCUCA 33 GUGCUUGACCCUCACAGCUC 34 UAGCUGUGCUUGACCCUCAC 35 AUAGCUGUGCUUGACCCUCA 36 GAUAGCUGUGCUUGACCCUC 37 GGAUAGCUGUGCUUGACCCU 38 UGGAUAGCUGUGCUUGACCC 39 AUGGAUAGCUGUGCUUGACC 40 GAUGGAUAGCUGUGCUUGAC 41 UGAUGGAUAGCUGUGCUUGA 42 AUCUGAUGGAUAGCUGUGCU 43 CAUCUGAUGGAUAGCUGUGC 44 AUCAUCUGAUGGAUAGCUGU 45 GAUCAUCUGAUGGAUAGCUG 46 AGAUCAUCUGAUGGAUAGCU 47 UAGAUCAUCUGAUGGAUAGC 48 GUAGAUCAUCUGAUGGAUAG 49 GAAAGUAGAUCAUCUGAUGG 50 GCUGAAAGUAGAUCAUCUGA 51 AGGCUGAAAGUAGAUCAUCU 52 AAGGCUGAAAGUAGAUCAUC 53 GAAGGCUGAAAGUAGAUCAU 54 GGAAGGCUGAAAGUAGAUCA 55 AGGAAGGCUGAAAGUAGAUC 56 GUCUGGGACUCAGGAAGGCU 57 UAUUGUCUGGGACUCAGGAA 58 CUAUUGUCUGGGACUCAGGA 59 UCUAUUGUCUGGGACUCAGG 60 CUUCUAUUGUCUGGGACUCA 61 UCUUCUAUUGUCUGGGACUC 62 CACCUGUCUUCUAUUGUCUG 63 CCACCUGUCUUCUAUUGUCU 64 GCCACCUGUCUUCUAUUGUC 65 AGCCACCUGUCUUCUAUUGU 66 AUGAGGGCACAGUGACAGCA 67 CAAUGAGGGCACAGUGACAG 68 CCAAUGAGGGCACAGUGACA 69 CGUCUGUUGAGUCUGAUUGC 70 CCGUCUGUUGAGUCUGAUUG 71 UCCGUCUGUUGAGUCUGAUU 72 CUCCGUCUGUUGAGUCUGAU 73 GCUCCGUCUGUUGAGUCUGA 74 UGCUCCGUCUGUUGAGUCUG 75 UUGCUCCGUCUGUUGAGUCU 76 AGUUGCUCCGUCUGUUGAGU 77 GCAGUUGCUCCGUCUGUUGA 78 GGCAGUUGCUCCGUCUGUUG 79 GAUGGCAGUUGCUCCGUCUG 80 GGAUGGCAGUUGCUCCGUCU 81 AGCCUCGGAUGGCAGUUGCU 82 AGGAGCCUCGGAUGGCAGUU 83 UUCAGGAGCCUCGGAUGGCA 84 UGGUUCAGGAGCCUCGGAUG 85 CUGGUUCAGGAGCCUCGGAU 86 CUGGUGAAUGGCCCUGGUUC 87 CCUGGUGAAUGGCCCUGGUU 88 UCCUGGUGAAUGGCCCUGGU 89 UGGACAUCAGGGAGCCGCAU 90 AGGAUUUGCUGCUUGGCUAG 91 CAGGAUUUGCUGCUUGGCUA 92 UCCAGGAUUUGCUGCUUGGC 93 ACCCAUCCAGGAUUUGCUGC 94 AACCCAUCCAGGAUUUGCUG 95 CAACCCAUCCAGGAUUUGCU 96 UGCAACCCAUCCAGGAUUUG 97 GUGCAACCCAUCCAGGAUUU 98 GGUGCAACCCAUCCAGGAUU 99 AGGUGCAACCCAUCCAGGAU 100 CAGGUGCAACCCAUCCAGGA 101 UCAGGUGCAACCCAUCCAGG 102 GUCAGGUGCAACCCAUCCAG 103 GGUCAGGUGCAACCCAUCCA 104 UGGUCAGGUGCAACCCAUCC 105 CUGGUCAGGUGCAACCCAUC 106 ACUGGUCAGGUGCAACCCAU 107 GACUGGUCAGGUGCAACCCA 108 ACGACUGGUCAGGUGCAACC 109 GACGACUGGUCAGGUGCAAC 110 GGACGACUGGUCAGGUGCAA 111 UCUGGGACGACUGGUCAGGU 112 UUCUGGGACGACUGGUCAGG 113 AUUCUGGGACGACUGGUCAG 114 UAUUCUGGGACGACUGGUCA 115 UUAUUCUGGGACGACUGGUC 116 GUUAUUCUGGGACGACUGGU 117 AGUUAUUCUGGGACGACUGG 118 GAGUUAUUCUGGGACGACUG 119 UGAGUUAUUCUGGGACGACU 120 AUGAGUUAUUCUGGGACGAC 121 GAUGAGUUAUUCUGGGACGA 122 GGAUGAGUUAUUCUGGGACG 123 UGGAGGAUGAGUUAUUCUGG 124 GUGGAGGAUGAGUUAUUCUG 125 GGUGGAGGAUGAGUUAUUCU 126 GGGUGGAGGAUGAGUUAUUC 127 AAAGCUGAUGACCUCCUCCC 128 CAAAGCUGAUGACCUCCUCC 129 AGCAAAGCUGAUGACCUCCU 130 UAGCAAAGCUGAUGACCUCC 131 GUAGCAAAGCUGAUGACCUC 132 AGUAGCAAAGCUGAUGACCU 133 ACAGUAGCAAAGCUGAUGAC 134 UGACAGUAGCAAAGCUGAUG 135 GUGACAGUAGCAAAGCUGAU 136 GUCUGUGACAGUAGCAAAGC 137 AGUCUGUGACAGUAGCAAAG 138 GAGUCUGUGACAGUAGCAAA 139 UGGAGUCUGUGACAGUAGCA 140 GUGGAGUCUGUGACAGUAGC 141 AGUGGAGUCUGUGACAGUAG 142 AAGUGGAGUCUGUGACAGUA 143 UGAAGUGGAGUCUGUGACAG 144 CUGAAGUGGAGUCUGUGACA 145 GCUGAAGUGGAGUCUGUGAC 146 GGCUGAAGUGGAGUCUGUGA 147 AGGCUGAAGUGGAGUCUGUG 148 UAGGCUGAAGUGGAGUCUGU 149 GUAGGCUGAAGUGGAGUCUG 150 GCUGUAGGCUGAAGUGGAGU 151 AGCUGUAGGCUGAAGUGGAG 152 GAGCUGUAGGCUGAAGUGGA 153 GGGAGCUGUAGGCUGAAGUG 154 AGGGAGCUGUAGGCUGAAGU 155 AAGUGAGCAGGGAGCUGUAG 156 UGGACAGGUGAAAAGUGAGC 157 GUGGACAGGUGAAAAGUGAG 158 AGUGGACAGGUGAAAAGUGA 159 GAGUGGACAGGUGAAAAGUG 160 GGAGUGGACAGGUGAAAAGU 161 AGGAGUGGACAGGUGAAAAG 162 GAGGAGUGGACAGGUGAAAA 163 CGAGGAGUGGACAGGUGAAA 164 CCGAGGAGUGGACAGGUGAA 165 ACCGAGGAGUGGACAGGUGA 166 CAUGGUACAGGUGGUGGGAC 167 GCAUGGUACAGGUGGUGGGA 168 CAAAGAGUGCCAGGAAGGGU 169 GCAAAGAGUGCCAGGAAGGG 170 AAGCAAAGAGUGCCAGGAAG 171 UCAAGCAAAGAGUGCCAGGA 172 CUCAAGCAAAGAGUGCCAGG 173 CCUCAAGCAAAGAGUGCCAG 174 AUCCUCAAGCAAAGAGUGCC 175 GAUCCUCAAGCAAAGAGUGC 176 GAAGAUCCUCAAGCAAAGAG 177 GGAAGAUCCUCAAGCAAAGA 178 CGGAAGAUCCUCAAGCAAAG 179 AUCGGAAGAUCCUCAAGCAA 180 CAUCGGAAGAUCCUCAAGCA 181 CCAUCGGAAGAUCCUCAAGC 182 CCCAUCGGAAGAUCCUCAAG 183 AUGUGGUGCUCAGCCAGGAG 184 UUGGUGAUGUGGUGCUCAGC 185 GGUUGGUGAUGUGGUGCUCA 186 AGGUUGGUGAUGUGGUGCUC 187 CAGGUUGGUGAUGUGGUGCU 188 AGCCCAGGUUGGUGAUGUGG 189 CAGCCCAGGUUGGUGAUGUG 190 UGCCAGCCCAGGUUGGUGAU 191 AUGCCAGCCCAGGUUGGUGA 192 GUAUGCCAGCCCAGGUUGGU 193 AGGUAUGCCAGCCCAGGUUG 194 AAGGUAUGCCAGCCCAGGUU 195 UAAGGUAUGCCAGCCCAGGU 196 UUAAGGUAUGCCAGCCCAGG 197 GUUAAGGUAUGCCAGCCCAG 198 AGUUAAGGUAUGCCAGCCCA 199 GAGUUAAGGUAUGCCAGCCC 200 AGAGUUAAGGUAUGCCAGCC 201 CAGAGUUAAGGUAUGCCAGC 202 GCAGAGUUAAGGUAUGCCAG 203 AGGGCAGAGUUAAGGUAUGC 204 AGAGGGCAGAGUUAAGGUAU 205 UAGAGGGCAGAGUUAAGGUA 206 CUAGAGGGCAGAGUUAAGGU 207 CACUAGAGGGCAGAGUUAAG 208 GCCACUAGAGGGCAGAGUUA 209 GGACACCAGACUUCUCACCC 210 AGGACACCAGACUUCUCACC 211 CAGGACACCAGACUUCUCAC 212 UUUCAGGACACCAGACUUCU 213 GUUUCAGGACACCAGACUUC 214 UAGUUGCAGUUUCAGGACAC 215 CUAGUUGCAGUUUCAGGACA 216 UCUAGUUGCAGUUUCAGGAC 217 GUCUAGUUGCAGUUUCAGGA 218 AGUCUAGUUGCAGUUUCAGG 219 CAGUCUAGUUGCAGUUUCAG 220 AACUGUGCUGUUGCCUUCUA 221 UAACUGUGCUGUUGCCUUCU 222 GUAACUGUGCUGUUGCCUUC 223 CCAGUAACUGUGCUGUUGCC 224 GUCCAGUAACUGUGCUGUUG 225 UGUCCAGUAACUGUGCUGUU 226 UUGUCCAGUAACUGUGCUGU 227 GGUUGUCCAGUAACUGUGCU 228 CGGUUGUCCAGUAACUGUGC 229 UCGGUUGUCCAGUAACUGUG 230 CUCGGUUGUCCAGUAACUGU 231 CCUCGGUUGUCCAGUAACUG 232 GCCUCGGUUGUCCAGUAACU 233 CGCCUCGGUUGUCCAGUAAC 234 CCGCCUCGGUUGUCCAGUAA 235 UGCUGGUGUCCUGCUGUGUC 236 CUGCUGGUGUCCUGCUGUGU 237 UCUAGGAAGGGCUGCUGGUG 238 UUAAGCUCUAGGAAGGGCUG 239 CUCAUUGGCUCGGAUCUUAA 240 GCUCAUUGGCUCGGAUCUUA 241 GGCUCAUUGGCUCGGAUCUU 242 AGGCUCAUUGGCUCGGAUCU 243 CAGGCUCAUUGGCUCGGAUC 244 UCCAGGCUCAUUGGCUCGGA 245 UCUCGCCUGCAACAUAAGGG 246 CAGAAUGGAAAGAGGCAGCA 247 GCAGAAUGGAAAGAGGCAGC 248 AAGACGGCAGAAUGGAAAGA 249 GAAGACGGCAGAAUGGAAAG 250 UGAAGACGGCAGAAUGGAAA 251 CUGAAGACGGCAGAAUGGAA 252 GCUGAAGACGGCAGAAUGGA 253 GGCUGAAGACGGCAGAAUGG 254 AGGCUGAAGACGGCAGAAUG 255 GGAGGCUGAAGACGGCAGAA 256 AGGAGGCUGAAGACGGCAGA 257 UGUUGGCUUUGAGGAGGCUG 258 CAAGGAUUGUUGGCUUUGAG 259 UGGCAGGCCAAGGAUUGUUG 260 CUGGCAGGCCAAGGAUUGUU 261 ACUGGCAGGCCAAGGAUUGU 262 AGGAGGUACUGGCAGGCCAA 263 AACAGGAGGUACUGGCAGGC 264 CAACAGGAGGUACUGGCAGG 265 ACACAACAGGAGGUACUGGC 266 AGGGACACAACAGGAGGUAC 267 UCGGGCAGUAGGGACACAAC 268 UUCGGGCAGUAGGGACACAA 269 CUUCGGGCAGUAGGGACACA 270 AUGAUCCAGGUAGAGGAGAG 271 UAUGAUCCAGGUAGAGGAGA 272 UUAUGAUCCAGGUAGAGGAG 273 AUUAUGAUCCAGGUAGAGGA 274 CAUUAUGAUCCAGGUAGAGG 275 CCAUUAUGAUCCAGGUAGAG 276 UGCCAUUAUGAUCCAGGUAG 277 UUGCCAUUAUGAUCCAGGUA 278 AUUGCCAUUAUGAUCCAGGU 279 CAUUGCCAUUAUGAUCCAGG 280 ACAUUGCCAUUAUGAUCCAG 281 CCACAUUGCCAUUAUGAUCC 282 GACCACAUUGCCAUUAUGAU 283 UGACCACAUUGCCAUUAUGA 284 UUGACCACAUUGCCAUUAUG 285 UCUUGACCACAUUGCCAUUA 286 GUCUUGACCACAUUGCCAUU 287 CGUCUUGACCACAUUGCCAU 288 CCGUCUUGACCACAUUGCCA 289 UCCGUCUUGACCACAUUGCC 290 AUCCGUCUUGACCACAUUGC 291 CAUCCGUCUUGACCACAUUG 292 ACAUCCGUCUUGACCACAUU 293 CACAUCCGUCUUGACCACAU 294 GCACAUCCGUCUUGACCACA 295 GGCACAUCCGUCUUGACCAC 296 UGGCACAUCCGUCUUGACCA 297 CUGGCACAUCCGUCUUGACC 298 UCUGGCACAUCCGUCUUGAC 299 AUCUGGCACAUCCGUCUUGA 300 UAUCUGGCACAUCCGUCUUG 301 AUAUCUGGCACAUCCGUCUU 302 CAUAUCUGGCACAUCCGUCU 303 CCAUAUCUGGCACAUCCGUC 304 CACCAUAUCUGGCACAUCCG 305 CUCCACCACCAUAUCUGGCA 306 UGGUCUCUUCACUCCAAAGC 307 CUUCAUCUUGGUCUCUUCAC 308 ACUUCAUCUUGGUCUCUUCA 309 AACUUCAUCUUGGUCUCUUC 310 GGAAACUUCAUCUUGGUCUC 311 CCUCCAGUCACAGAUGCCCU 312 GAUGCCUCCAGUCACAGAUG 313 UGAUGCCUCCAGUCACAGAU 314 CAGGUGGUUGUUGGGUUGGG 315 CCAGGUGGUUGUUGGGUUGG 316 GCCAGGUGGUUGUUGGGUUG 317 UGCCAGGUGGUUGUUGGGUU 318 CAUAUUGCCAGGUGGUUGUU 319 UCAUAUUGCCAGGUGGUUGU 320 GUCAUAUUGCCAGGUGGUUG 321 AGUCAUAUUGCCAGGUGGUU 322 GAGUCAUAUUGCCAGGUGGU 323 AGUGAGUCAUAUUGCCAGGU 324 AAGUGAGUCAUAUUGCCAGG 325 CAAGUGAGUCAUAUUGCCAG 326 GUCAAGUGAGUCAUAUUGCC 327 GGUCAAGUGAGUCAUAUUGC 328 GGGUCAAGUGAGUCAUAUUG 329 CCCAUUUGGGUCCCAUAGGG 330 GCCCAUUUGGGUCCCAUAGG 331 UGCCCAUUUGGGUCCCAUAG 332 GUGCCCAUUUGGGUCCCAUA 333 AGUGCCCAUUUGGGUCCCAU 334 AAGUGCCCAUUUGGGUCCCA 335 AAAGUGCCCAUUUGGGUCCC 336 GAAAGUGCCCAUUUGGGUCC 337 AGAAAGUGCCCAUUUGGGUC 338 CAAGAAAGUGCCCAUUUGGG 339 ACAAGAAAGUGCCCAUUUGG 340 GACAAGAAAGUGCCCAUUUG 341 GAGUCUCAGACAAGAAAGUG 342 CCAGAGUCUCAGACAAGAAA 343 GCCAGAGUCUCAGACAAGAA 344 AGCCAGAGUCUCAGACAAGA 345 UAAGCCAGAGUCUCAGACAA 346 AUAAGCCAGAGUCUCAGACA 347 AGCCAACCUGGAAUAAGCCA 348 UCAGCCAACCUGGAAUAAGC 349 CAUCAGCCAACCUGGAAUAA 350 CACAUCAGCCAACCUGGAAU 351 ACACAUCAGCCAACCUGGAA 352 AACACAUCAGCCAACCUGGA 353 CAACACAUCAGCCAACCUGG 354 CUCCCAACACAUCAGCCAAC 355 CGCUUUACCCAUCUCCCAAC 356 AACGCUUUACCCAUCUCCCA 357 AAACGCUUUACCCAUCUCCC 358 AGAAACGCUUUACCCAUCUC 359 AAGAAACGCUUUACCCAUCU 360 GAAGAAACGCUUUACCCAUC 361 AGAAGAAACGCUUUACCCAU 362 UAGAAGAAACGCUUUACCCA 363 UUAGAAGAAACGCUUUACCC 364 AAUCAUGCUUUCUGGGUAGA 365 CUUAGGGCAGGAAAUCAUGC 366 ACUUAGGGCAGGAAAUCAUG 367 GACUUAGGGCAGGAAAUCAU 368 AGGACUUAGGGCAGGAAAUC 369 CAGGACUUAGGGCAGGAAAU 370 ACAGGACUUAGGGCAGGAAA 371 UCUCACAGGACUUAGGGCAG 372 UUCUCACAGGACUUAGGGCA 373 AUCUUCUCACAGGACUUAGG 374 CAUCUUCUCACAGGACUUAG 375 UAGUCCCUGACAUCUUCUCA 376 CUAGUCCCUGACAUCUUCUC 377 CCUAGUCCCUGACAUCUUCU 378 CCCUAGUCCCUGACAUCUUC 379 UCCCUAGUCCCUGACAUCUU 380 CUCCCUAGUCCCUGACAUCU 381 AUCUAUCUGCUUCCUCCUCC 382 CCAUCUAUCUGCUUCCUCCU 383 ACCAUCUAUCUGCUUCCUCC 384 GACCAUCUAUCUGCUUCCUC 385 GGACCAUCUAUCUGCUUCCU 386 UGGACCAUCUAUCUGCUUCC 387 CUGGACCAUCUAUCUGCUUC 388 CUGCUGGACCAUCUAUCUGC 389 GCCUGCUGGACCAUCUAUCU 390 UUCAAGCCUGCUGGACCAUC 391 UGCUUCAAGCCUGCUGGACC 392 CCUCAACAGCCCUUACCCUG 393 UCCCUCUUGACCUUCCCUUA 394 CUCCCUCUUGACCUUCCCUU 395 UCUCCCUCUUGACCUUCCCU 396 CAUCUCCCUCUUGACCUUCC 397 CCAUCUCCCUCUUGACCUUC 398 CCCAUCUCCCUCUUGACCUU 399 GCCCAUCUCCCUCUUGACCU 400 UUGCCCAUCUCCCUCUUGAC 401 CUUGCCCAUCUCCCUCUUGA 402 CCCUAAGCAUCCUCCCUCAG 403 AACUUCUUAGGCUUAGUGCC 404 GGAACUUCUUAGGCUUAGUG 405 GGGAACUUCUUAGGCUUAGU 406 AGGGAACUUCUUAGGCUUAG 407 UGUCUCCCAGUGGGUCCUGU 408 AGUAUAAAUGCUUGUCUCCC 409 GACAGAGCGAGACUCGAUCU 410 UGACAGAGCGAGACUCGAUC 411 GUGACAGAGCGAGACUCGAU 412 GGUGACAGAGCGAGACUCGA 413 UGGUGACAGAGCGAGACUCG 414 CUGGUGACAGAGCGAGACUC 415 CCUGGUGACAGAGCGAGACU 416 AGCCUGGUGACAGAGCGAGA 417 UGCACUCCAGCCUGGUGACA 418 ACUGCACUCCAGCCUGGUGA 419 UCACUGCACUCCAGCCUGGU 420 UGUCACUGCACUCCAGCCUG 421 GUGUCACUGCACUCCAGCCU 422 AGACGGAGGUUGCAGUGAGC 423 GAGACGGAGGUUGCAGUGAG 424 GGAGACGGAGGUUGCAGUGA 425 ACUUGAACCCAGGAGACGGA 426 CACUUGAACCCAGGAGACGG 427 UCACUUGAACCCAGGAGACG 428 AUCACUUGAACCCAGGAGAC 429 AAUCACUUGAACCCAGGAGA 430 GAAUCACUUGAACCCAGGAG 431 AGAAUCACUUGAACCCAGGA 432 AAGAAUCACUUGAACCCAGG 433 GAAGAAUCACUUGAACCCAG 434 AGAAGAAUCACUUGAACCCA 435 CAGAAGAAUCACUUGAACCC 436 GCAGAAGAAUCACUUGAACC 437 GGCAGAAGAAUCACUUGAAC 438 AGGCAGAAGAAUCACUUGAA 439 GAGGCAGAAGAAUCACUUGA 440 UGAGGCAGAAGAAUCACUUG 441 CUGAGGCAGAAGAAUCACUU 442 GCUGAGGCAGAAGAAUCACU 443 GGCUGAGGCAGAAGAAUCAC 444 AGGCUGAGGCAGAAGAAUCA 445 GAGGCUGAGGCAGAAGAAUC 446 GGAGGCUGAGGCAGAAGAAU 447 GGGAGGCUGAGGCAGAAGAA 448 AGAUUGAGACCAUCCUGGCC 449 GAGAUUGAGACCAUCCUGGC 450 AGAGAUUGAGACCAUCCUGG 451 AAGAGAUUGAGACCAUCCUG 452 CAAGAGAUUGAGACCAUCCU 453 GGUGGCUCACGCCUAUAAUC 454 CGGUGGCUCACGCCUAUAAU 455 GCGGUGGCUCACGCCUAUAA 456 CCCUAACCCUUCUUUAUGAC 457 CACCCUAACCCUUCUUUAUG 458 AUCACCCUAACCCUUCUUUA 459 CAUCACCCUAACCCUUCUUU 460 CCAUCACCCUAACCCUUCUU 461 GACCAUCACCCUAACCCUUC 462 GGACCAUCACCCUAACCCUU 463 UGGACCAUCACCCUAACCCU 464 CUGGACCAUCACCCUAACCC 465 UCUGGACCAUCACCCUAACC 466 CUCUGGACCAUCACCCUAAC 467 GCUCUGGACCAUCACCCUAA 468 UGCUCUGGACCAUCACCCUA 469 GUUGCUCUGGACCAUCACCC 470 UGUUGCUCUGGACCAUCACC 471 ACUGUUGCUCUGGACCAUCA 472 AACUGUUGCUCUGGACCAUC 473 GAACUGUUGCUCUGGACCAU 474 GAAGAACUGUUGCUCUGGAC 475 UUGAAGAACUGUUGCUCUGG 476 ACUUGAAGAACUGUUGCUCU 477 CACUUGAAGAACUGUUGCUC 478 UACACUUGAAGAACUGUUGC 479 GAGUACACUUGAAGAACUGU 480 AGAGUACACUUGAAGAACUG 481 CAGAGUACACUUGAAGAACU 482 ACAGAGUACACUUGAAGAAC 483 CUACAGAGUACACUUGAAGA 484 CCUACAGAGUACACUUGAAG 485 GCCUACAGAGUACACUUGAA 486 AGCCUACAGAGUACACUUGA 487 AAGCCUACAGAGUACACUUG 488 CAGAAGCCUACAGAGUACAC 489 CCAGAAGCCUACAGAGUACA 490 AAAAGGGACCUCCCAGAAGC 491 GAAAAGGGACCUCCCAGAAG 492 UGAAAAGGGACCUCCCAGAA 493 CUUUGACUUUGUGGACACCC 494 GCUUUGACUUUGUGGACACC 495 UAGCUUUGACUUUGUGGACA 496 AUAGCUUUGACUUUGUGGAC 497 GUCACACGGCCUCUGGAAAA 498 UGUCACACGGCCUCUGGAAA 499 AUGUCACACGGCCUCUGGAA 500

In some embodiments, the antisense nucleic acid molecules comprise or consist of the nucleotide sequences shown in Table 2.

TABLE 2 SEQ ID Sequence NO: CUUAGUCACUUUUCCCAAGA 501 UCUUAGUCACUUUUCCCAAG 502 CUCUUAGCAUCUUAGUCACU 503 GCUCUUAGCAUCUUAGUCAC 504 UACGCUCUUAGCAUCUUAGU 505 AUACGCUCUUAGCAUCUUAG 506 CUCAGCUAUAAAUACGCUCU 507 GCUCAGCUAUAAAUACGCUC 508 AGCUCAGCUAUAAAUACGCU 509 ACCCUCACUGUCAGAUGCCC 510 CACCCUCACUGUCAGAUGCC 511 CCCACCCUCACUGUCAGAUG 512 GGGAAGUGACAAGAAGUGGC 513 GUAUCAGUAGGCAGUCAGGG 514 GGUAUCAGUAGGCAGUCAGG 515 GUUGGUAUCAGUAGGCAGUC 516 UGUUGGUAUCAGUAGGCAGU 517 CCUGUUGGUAUCAGUAGGCA 518 ACCUGUUGGUAUCAGUAGGC 519 CAGACGGCUUACCUGUUGGU 520 UCAGACGGCUUACCUGUUGG 521 CUCAGACGGCUUACCUGUUG 522 CCUCAGACGGCUUACCUGUU 523 GCCUCAGACGGCUUACCUGU 524 UGCCUCAGACGGCUUACCUG 525 GUGCCUCAGACGGCUUACCU 526 UGGUGCCUCAGACGGCUUAC 527 GUGGUGCCUCAGACGGCUUA 528 AGCAAAGUGGAGGUAUCUAU 529 GUCAGCAAAGUGGAGGUAUC 530 GGUCAGCAAAGUGGAGGUAU 531 UUGGUCAGCAAAGUGGAGGU 532 AUUGGUCAGCAAAGUGGAGG 533 CAUUGGUCAGCAAAGUGGAG 534 ACAUUGGUCAGCAAAGUGGA 535 AACAUUGGUCAGCAAAGUGG 536 UGGAACAUUGGUCAGCAAAG 537 UCUGGAACAUUGGUCAGCAA 538 GGUCUGGAACAUUGGUCAGC 539 GGGUCUGGAACAUUGGUCAG 540 CGGGUCUGGAACAUUGGUCA 541 UCGGGUCUGGAACAUUGGUC 542 CUCGGGUCUGGAACAUUGGU 543 GGAAAUGACAGCCCUCUACC 544 GGGAAAUGACAGCCCUCUAC 545 UGGGAAAUGACAGCCCUCUA 546 GGUUGGGCUGGGAAAUGACA 547 UUGGUUGGGCUGGGAAAUGA 548 UGUUGGUUGGGCUGGGAAAU 549 UCUGUUGGUUGGGCUGGGAA 550 AUUCUGUUGGUUGGGCUGGG 551 CUCCCAGCAACCAUUCUGUU 552 GCUCCCAGCAACCAUUCUGU 553 AGCUCCCAGCAACCAUUCUG 554 AGCUCUGUCCAGUGUUCUCC 555 CUGUCCACCCUGCAUUUCUC 556 AUUAGACCCUCCUGUCCACC 557 GAUUAGACCCUCCUGUCCAC 558 CGAUUAGACCCUCCUGUCCA 559 ACGAUUAGACCCUCCUGUCC 560 GACGAUUAGACCCUCCUGUC 561 AGACGAUUAGACCCUCCUGU 562 GAGACGAUUAGACCCUCCUG 563 UGAGACGAUUAGACCCUCCU 564 CUGAGACGAUUAGACCCUCC 565 ACUGAGACGAUUAGACCCUC 566 CACUGAGACGAUUAGACCCU 567 GCACUGAGACGAUUAGACCC 568 CGCACUGAGACGAUUAGACC 569 GCGCACUGAGACGAUUAGAC 570 GGCGCACUGAGACGAUUAGA 571 ACCUCAGGGCACUCUUUGGU 572 AACCUCAGGGCACUCUUUGG 573 GAACCUCAGGGCACUCUUUG 574 AGAACCUCAGGGCACUCUUU 575 UAGAACCUCAGGGCACUCUU 576 CUAGAACCUCAGGGCACUCU 577 CCUAGAACCUCAGGGCACUC 578 UCCUAGAACCUCAGGGCACU 579 GCUCUUCCUAGAACCUCAGG 580 CCAGGCUCUUCCUAGAACCU 581 ACCAGGCUCUUCCUAGAACC 582 UACCAGGCUCUUCCUAGAAC 583 GUACCAGGCUCUUCCUAGAA 584 UGUACCAGGCUCUUCCUAGA 585 AUGUACCAGGCUCUUCCUAG 586 UGAUGUACCAGGCUCUUCCU 587 GGUGAUGUACCAGGCUCUUC 588 AUGGAGCUUGGUGAUGUACC 589 UGGCAAUGGAGCUUGGUGAU 590 GUGGCAAUGGAGCUUGGUGA 591 CGUGGCAAUGGAGCUUGGUG 592 ACGUGGCAAUGGAGCUUGGU 593 ACCUUUGGUUUUGGACCUCA 594 UACCUUUGGUUUUGGACCUC 595 CUACCUUUGGUUUUGGACCU 596 GCUACCUUUGGUUUUGGACC 597 ACUGCUACCUUUGGUUUUGG 598 CACUGCUACCUUUGGUUUUG 599 UCACUGCUACCUUUGGUUUU 600 AUCACUGCUACCUUUGGUUU 601 GAGAGACUGUCUUCAGGAUC 602 ACACUGCCAGAGAAGAGAGA 603 CACACUGCCAGAGAAGAGAG 604 AGCUGGUUCCUUUGUUCUUU 605 GGGACAAGCUGGUUCCUUUG 606 AGGGACAAGCUGGUUCCUUU 607 CAGGGACAAGCUGGUUCCUU 608 GACAGGGACAAGCUGGUUCC 609 AGACAGGGACAAGCUGGUUC 610 AAGAGACAGGGACAAGCUGG 611 CAAGAGACAGGGACAAGCUG 612 ACAAGAGACAGGGACAAGCU 613 AUGGAGUGAUGAGGAGUGCC 614 CUGGCUUGUAGCUGGCUGGA 615 CCACCAGUGUCCACCAUGUG 616 AGUACCACCAGUGUCCACCA 617 CAGUACCACCAGUGUCCACC 618 CCUCAGUACCACCAGUGUCC 619 GACCUCAGUACCACCAGUGU 620 UGGACCUCAGUACCACCAGU 621 GCUGGACCUCAGUACCACCA 622 AAGGCUGGACCUCAGUACCA 623 GAAGGCUGGACCUCAGUACC 624 GGAAGGCUGGACCUCAGUAC 625 UUGGAAGGCUGGACCUCAGU 626 AUUGGAAGGCUGGACCUCAG 627 AAUUGGAAGGCUGGACCUCA 628 CUAAUUGGAAGGCUGGACCU 629 CCUAAUUGGAAGGCUGGACC 630 UCCUAAUUGGAAGGCUGGAC 631 CUGUCAAGAGAGACUAUUAG 632 GCUGUCAAGAGAGACUAUUA 633 GGCUGUCAAGAGAGACUAUU 634 GGGCUGUCAAGAGAGACUAU 635 CCCUCUGUUUAGAUGAUGGG 636 CUCCACUUUGCUCAUCUCCC 637 UACUCCACUUUGCUCAUCUC 638 UUACUCCACUUUGCUCAUCU 639 UUUACUCCACUUUGCUCAUC 640 CUUUACUCCACUUUGCUCAU 641 UCUUUACUCCACUUUGCUCA 642 GUCUUUACUCCACUUUGCUC 643 GAAAUGUGUCUUUACUCCAC 644 GUGUGAUUUGGAAAUGUGUC 645 GUGGGUGUGAUUUGGAAAUG 646 AGUGGGUGUGAUUUGGAAAU 647 GAAGGUGGGCCUCAUGCUAG 648 CACCACACCCAGUCCUCACU 649 AUGAGCCACCACACCCAGUC 650 CAUGAGCCACCACACCCAGU 651 ACAUGAGCCACCACACCCAG 652 GACAUGAGCCACCACACCCA 653 AGACAUGAGCCACCACACCC 654 UAGACAUGAGCCACCACACC 655 AUAGACAUGAGCCACCACAC 656 GCUCAAGCGAUCCUCUCACC 657 GGCUCAAGCGAUCCUCUCAC 658 GGGCUCAAGCGAUCCUCUCA 659 UGGGCUCAAGCGAUCCUCUC 660 CUGGGCUCAAGCGAUCCUCU 661 UCUUUUGUAGAGACAGGGUC 662 UUCUUUUGUAGAGACAGGGU 663 AUUCUUUUGUAGAGACAGGG 664 ACACCACACAGGCUAAUUUA 665 UGCCACCACACCAACCACAC 666 GUGCCACCACACCAACCACA 667 GCUAAGUCUACAGGUGCGUG 668 UUGACCUCCUGGGUUAAGUG 669 CUUGACCUCCUGGGUUAAGU 670 GCCUUGACCUCCUGGGUUAA 671 UACAGGCAUGAGCCACCGCA 672 UUACAGGCAUGAGCCACCGC 673 AUUACAGGCAUGAGCCACCG 674 GAUUACAGGCAUGAGCCACC 675 GGAUUACAGGCAUGAGCCAC 676 GGGAUUACAGGCAUGAGCCA 677 UGGGAUUACAGGCAUGAGCC 678 CUGGGAUUACAGGCAUGAGC 679 GCUGGGAUUACAGGCAUGAG 680 UGCUGGGAUUACAGGCAUGA 681 GUGCUGGGAUUACAGGCAUG 682 AGUGCUGGGAUUACAGGCAU 683 AAGUGCUGGGAUUACAGGCA 684 AAAGUGCUGGGAUUACAGGC 685 CAAAGUGCUGGGAUUACAGG 686 CCAAAGUGCUGGGAUUACAG 687 GUUAGCCAGGAUGGUCUCCA 688 UGUUAGCCAGGAUGGUCUCC 689 GUGUUAGCCAGGAUGGUCUC 690 UGUGUUAGCCAGGAUGGUCU 691 CUGUGUUAGCCAGGAUGGUC 692 ACUGUGUUAGCCAGGAUGGU 693 CACUGUGUUAGCCAGGAUGG 694 UCACUGUGUUAGCCAGGAUG 695 UUCACUGUGUUAGCCAGGAU 696 UUUCACUGUGUUAGCCAGGA 697 GUUUCACUGUGUUAGCCAGG 698 GGUUUCACUGUGUUAGCCAG 699 GGGUUUCACUGUGUUAGCCA 700 UUCUUCUGCCUCAGCCUCCC 701 AUUCUUCUGCCUCAGCCUCC 702 CAUUCUUCUGCCUCAGCCUC 703 CCAUUCUUCUGCCUCAGCCU 704 ACCAUUCUUCUGCCUCAGCC 705 CACCAUUCUUCUGCCUCAGC 706 ACACCAUUCUUCUGCCUCAG 707 CUCACUGCAAGCUCCACCUC 708 GCUCACUGCAAGCUCCACCU 709 UCGGCUCACUGCAAGCUCCA 710 UCUCGGCUCACUGCAAGCUC 711 AUCUCGGCUCACUGCAAGCU 712 AAUCUCGGCUCACUGCAAGC 713 CAAUCUCGGCUCACUGCAAG 714 ACAAUCUCGGCUCACUGCAA 715 CACAAUCUCGGCUCACUGCA 716 GCACAAUCUCGGCUCACUGC 717 GGCACAAUCUCGGCUCACUG 718 UGGCACAAUCUCGGCUCACU 719 GUGGCACAAUCUCGGCUCAC 720 AGUGGCACAAUCUCGGCUCA 721 CAGUGGCACAAUCUCGGCUC 722 GCAGUGGCACAAUCUCGGCU 723 UGCAGUGGCACAAUCUCGGC 724 AGGCUGAGUCUCGCUCUGUC 725 CCACAUUUUCUCACUGUCUU 726 CUCCUGACCACAUUUUCUCA 727 CCUCCUGACCACAUUUUCUC 728 CCCUCCUGACCACAUUUUCU 729 GCCCUCCUGACCACAUUUUC 730 UCUUGGUUCCCAGUCUCAGC 731 GCAGUCUUGGUUCCCAGUCU 732 CAGCAGUCUUGGUUCCCAGU 733 UACAGCAGUCUUGGUUCCCA 734 AUACAGCAGUCUUGGUUCCC 735 CAAAUACAGCAGUCUUGGUU 736 GCAAAUACAGCAGUCUUGGU 737 GGCAAAUACAGCAGUCUUGG 738 AAGGCAAAUACAGCAGUCUU 739 CAAGGCAAAUACAGCAGUCU 740 GCAAGGCAAAUACAGCAGUC 741 AGCAAGGCAAAUACAGCAGU 742 AAAGCAAGGCAAAUACAGCA 743 CAAAGCAAGGCAAAUACAGC 744 UUGACAACAAAGCAAGGCAA 745 CUCUAAGAGCUUUUGACAAC 746 UUGCCUCAGCCUCCUAAAGU 747 CUUGCCUCAGCCUCCUAAAG 748 ACUUGCCUCAGCCUCCUAAA 749 CACUUGCCUCAGCCUCCUAA 750 CCACUUGCCUCAGCCUCCUA 751 UCCACUUGCCUCAGCCUCCU 752 AUCCACUUGCCUCAGCCUCC 753 UGGGCUCAAGCAAUCCACUU 754 CUGGGCUCAAGCAAUCCACU 755 CCUGGGCUCAAGCAAUCCAC 756 UCCUGGGCUCAAGCAAUCCA 757 CUCCUGGGCUCAAGCAAUCC 758 ACUCCUGGGCUCAAGCAAUC 759 AACUCCUGGGCUCAAGCAAU 760 GAACUCCUGGGCUCAAGCAA 761 UGAACUCCUGGGCUCAAGCA 762 GUCUUGAACUCCUGGGCUCA 763 GGUCUUGAACUCCUGGGCUC 764 UGGUCUUGAACUCCUGGGCU 765 CUGGUCUUGAACUCCUGGGC 766 GCUGGUCUUGAACUCCUGGG 767 GGCUGGUCUUGAACUCCUGG 768 AGGCUGGUCUUGAACUCCUG 769 CAGGCUGGUCUUGAACUCCU 770 CCAGGCUGGUCUUGAACUCC 771 AUUUCCCACAGAGACAGGGU 772 CACCACACCUGGCUAAUUUU 773 CCACCACACCUGGCUAAUUU 774 ACCACCACACCUGGCUAAUU 775 CACCACCACACCUGGCUAAU 776 GCACCACCACACCUGGCUAA 777 AGUUGGGACUACAGGUGCGC 778 CUGCCUCAGCCUCCUUAGUA 779 UCUGCCUCAGCCUCCUUAGU 780 UUCUGCCUCAGCCUCCUUAG 781 CUUCUGCCUCAGCCUCCUUA 782 CCUUCUGCCUCAGCCUCCUU 783 UCCUUCUGCCUCAGCCUCCU 784 AUCCUUCUGCCUCAGCCUCC 785 AAUCCUUCUGCCUCAGCCUC 786 CAAUCCUUCUGCCUCAGCCU 787 CACAAUCAUAGCUCACUGCA 788 GCACAAUCAUAGCUCACUGC 789 CUCAAUCUGUUGUUCAGGCU 790 UCUCAAUCUGUUGUUCAGGC 791 GUCUCAAUCUGUUGUUCAGG 792 GGUCUCAAUCUGUUGUUCAG 793 CCUAGAAGUAGUGCCAGGCC 794 UCCUAGAAGUAGUGCCAGGC 795 AUCCUAGAAGUAGUGCCAGG 796 GCAUCCUAGAAGUAGUGCCA 797 GACUGUGAGAGUUGCCUAAA 798 GGGACUGUGAGAGUUGCCUA 799 AGGGACUGUGAGAGUUGCCU 800 AAGGGACUGUGAGAGUUGCC 801 CAAGGGACUGUGAGAGUUGC 802 UCAAGGGACUGUGAGAGUUG 803 UUCAAGGGACUGUGAGAGUU 804 CUUUCAAGGGACUGUGAGAG 805 UCUUUCAAGGGACUGUGAGA 806 CUCUUUCAAGGGACUGUGAG 807 UCUCUUUCAAGGGACUGUGA 808 CUUCUCUUUCAAGGGACUGU 809 ACUUCUCUUUCAAGGGACUG 810 CACUUCUCUUUCAAGGGACU 811 UGCCACUUCUCUUUCAAGGG 812 ACUUGGGAGGGCCUAUACCC 813 CACUUGGGAGGGCCUAUACC 814 ACACUUGGGAGGGCCUAUAC 815 CAUGACACUUGGGAGGGCCU 816 UCUUACACAGGGCAGAGUCC 817 AUCUUACACAGGGCAGAGUC 818 AAUCUUACACAGGGCAGAGU 819 AUGCAAUCUUACACAGGGCA 820 GUGAUGCAAUCUUACACAGG 821 GGUGAUGCAAUCUUACACAG 822 UGGUGAUGCAAUCUUACACA 823 GUGGUGAUGCAAUCUUACAC 824 GGUGGUGAUGCAAUCUUACA 825 UGGUGGUGAUGCAAUCUUAC 826 UGGUGGUGGUGAUGCAAUCU 827 GUGGUGGUGGUGAUGCAAUC 828 GUGGUGGUGGUGGUGAUGCA 829 AGGUGGUGGUGGUGGUGAUG 830 GAGGUGGUGGUGGUGGUGAU 831 AGAGGUGGUGGUGGUGGUGA 832 AGAGAGGUGGUGGUGGUGGU 833 ACGUGUUCCUGUGAUGUCUG 834 AACGUGUUCCUGUGAUGUCU 835 GAACGUGUUCCUGUGAUGUC 836 UGAUGUGGAGGAGGGCCAGA 837 AUGAUGUGGAGGAGGGCCAG 838 CAUGAUGUGGAGGAGGGCCA 839 GGAGCAUGAUGUGGAGGAGG 840 UGGAGCAUGAUGUGGAGGAG 841 GUGGAGCAUGAUGUGGAGGA 842 UGUGGAGCAUGAUGUGGAGG 843 AUGUGGAGCAUGAUGUGGAG 844 GAUGUGGAGCAUGAUGUGGA 845 UGAUGUGGAGCAUGAUGUGG 846 AUGAUGUGGAGCAUGAUGUG 847 UGGAGCAUGAUGUGGAGCAU 848 GCCUGGAGCAUGAUGUGGAG 849 GGCCUGGAGCAUGAUGUGGA 850 UGGCCUGGAGCAUGAUGUGG 851 UUGGCCUGGAGCAUGAUGUG 852 GUUGGCCUGGAGCAUGAUGU 853 AGUUGGCCUGGAGCAUGAUG 854 CAGUUGGCCUGGAGCAUGAU 855 GCCACGAGGCACAGAAGUCA 856 GAGAAUGGAGCCCUCUUGCU 857 GGUAGGAGAAUGGAGCCCUC 858 GGGUAGGAGAAUGGAGCCCU 859 ACAGGGAUGAGGGUUUGGGC 860 UAGGACAGGGAUGAGGGUUU 861 CUAGGACAGGGAUGAGGGUU 862 UUCCAGUGGGUAUUCCUCUG 863 GUUCCAGUGGGUAUUCCUCU 864 AGUUCCAGUGGGUAUUCCUC 865 GCAGUUUCCAUGAGGCAGCU 866 UGCAGCAGUUUCCAUGAGGC 867 CUAGCUUCACCACUGCUGCA 868 CUUUCUAGCUUCACCACUGC 869 UAGUCUUUCUAGCUUCACCA 870 CUCAUACCUCUAGUCUUUCU 871 CCUCAUACCUCUAGUCUUUC 872 CCCUCAUACCUCUAGUCUUU 873 UCCCUCAUACCUCUAGUCUU 874 UUCCCUCAUACCUCUAGUCU 875 UUUCCCUCAUACCUCUAGUC 876 UUUUCCCUCAUACCUCUAGU 877 AUUUUCCCUCAUACCUCUAG 878 GCAAUUUUCCCUCAUACCUC 879 ACGCCUUAUGAGCCAGGUGG 880 AACGCCUUAUGAGCCAGGUG 881 GAACGCCUUAUGAGCCAGGU 882 GGGAACGCCUUAUGAGCCAG 883 AGGGAACGCCUUAUGAGCCA 884 GAGGGAACGCCUUAUGAGCC 885 GGAGGGAACGCCUUAUGAGC 886 GGGAGGGAACGCCUUAUGAG 887 GAUGAUUUCACAUGCUCAGU 888 AGGAUGAUUUCACAUGCUCA 889 GAGGAUGAUUUCACAUGCUC 890 AGAGGAUGAUUUCACAUGCU 891 CAUGAUGCAAGAAAGAGGAU 892 GCAUGAUGCAAGAAAGAGGA 893 CACGCAUGAUGCAAGAAAGA 894 ACACGCAUGAUGCAAGAAAG 895 GACACGCAUGAUGCAAGAAA 896 GGACACGCAUGAUGCAAGAA 897 UGGACACGCAUGAUGCAAGA 898 GUGGACACGCAUGAUGCAAG 899 UGUGGACACGCAUGAUGCAA 900 AUGUGGACACGCAUGAUGCA 901 CAAUGUGGACACGCAUGAUG 902 GCAAUGUGGACACGCAUGAU 903 GUGCAAUGUGGACACGCAUG 904 GGUGCAAUGUGGACACGCAU 905 GGGUGCAAUGUGGACACGCA 906 UGACUGGGCCUGAAGUAGGG 907 CAUGGUGACUGGGCCUGAAG 908 CUCAGGUUUCACCAUCUGGC 909 CAGCUCAGGUUUCACCAUCU 910 UCAGCUCAGGUUUCACCAUC 911 AUCAGCUCAGGUUUCACCAU 912 CAUCAGCUCAGGUUUCACCA 913 UCUGAGUCCCAGGAUUGGCC 914 CCUCUGAGUCCCAGGAUUGG 915 CCCUCUGAGUCCCAGGAUUG 916 ACCCUCUGAGUCCCAGGAUU 917 UACCCUCUGAGUCCCAGGAU 918 CUACCCUCUGAGUCCCAGGA 919 AGCCGACCUACCCUCUGAGU 920 AACCUAGUGGUCAGCCAGCC 921 AAACCUAGUGGUCAGCCAGC 922 CCAAACCUAGUGGUCAGCCA 923 UCCAAACCUAGUGGUCAGCC 924 UUCCAAACCUAGUGGUCAGC 925 UCUUCCAAACCUAGUGGUCA 926 GUCUUCCAAACCUAGUGGUC 927 GGUCUUCCAAACCUAGUGGU 928 GGGUCUUCCAAACCUAGUGG 929 UGGGUCUUCCAAACCUAGUG 930 CUGGGUCUUCCAAACCUAGU 931 CCUGGGUCUUCCAAACCUAG 932 GCUGCCUGGGUCUUCCAAAC 933 GGGCCUCUUUAGAGCCAGCU 934 AUGUCUGGCUACUGACCUGG 935 UCAUGUCUGGCUACUGACCU 936 CUCAUGUCUGGCUACUGACC 937 GCUCAUGUCUGGCUACUGAC 938 AGCUCAUGUCUGGCUACUGA 939 CAGCUCAUGUCUGGCUACUG 940 ACAGCUCAUGUCUGGCUACU 941 UGACCCUCACAGCUCAUGUC 942 UUGACCCUCACAGCUCAUGU 943 UGCUUGACCCUCACAGCUCA 944 GUGCUUGACCCUCACAGCUC 945 UAGCUGUGCUUGACCCUCAC 946 AUAGCUGUGCUUGACCCUCA 947 GAUAGCUGUGCUUGACCCUC 948 GGAUAGCUGUGCUUGACCCU 949 UGGAUAGCUGUGCUUGACCC 950 AUGGAUAGCUGUGCUUGACC 951 GAUGGAUAGCUGUGCUUGAC 952 UGAUGGAUAGCUGUGCUUGA 953 AUCUGAUGGAUAGCUGUGCU 954 CAUCUGAUGGAUAGCUGUGC 955 AUCAUCUGAUGGAUAGCUGU 956 GAUCAUCUGAUGGAUAGCUG 957 AGAUCAUCUGAUGGAUAGCU 958 UAGAUCAUCUGAUGGAUAGC 959 GUAGAUCAUCUGAUGGAUAG 960 GAAAGUAGAUCAUCUGAUGG 961 GCUGAAAGUAGAUCAUCUGA 962 AGGCUGAAAGUAGAUCAUCU 963 AAGGCUGAAAGUAGAUCAUC 964 GAAGGCUGAAAGUAGAUCAU 965 GGAAGGCUGAAAGUAGAUCA 966 AGGAAGGCUGAAAGUAGAUC 967 GUCUGGGACUCAGGAAGGCU 968 UAUUGUCUGGGACUCAGGAA 969 CUAUUGUCUGGGACUCAGGA 970 UCUAUUGUCUGGGACUCAGG 971 CUUCUAUUGUCUGGGACUCA 972 UCUUCUAUUGUCUGGGACUC 973 CACCUGUCUUCUAUUGUCUG 974 CCACCUGUCUUCUAUUGUCU 975 GCCACCUGUCUUCUAUUGUC 976 AGCCACCUGUCUUCUAUUGU 977 AUGAGGGCACAGUGACAGCA 978 CAAUGAGGGCACAGUGACAG 979 CCAAUGAGGGCACAGUGACA 980 CGUCUGUUGAGUCUGAUUGC 981 CCGUCUGUUGAGUCUGAUUG 982 UCCGUCUGUUGAGUCUGAUU 983 CUCCGUCUGUUGAGUCUGAU 984 GCUCCGUCUGUUGAGUCUGA 985 UGCUCCGUCUGUUGAGUCUG 986 UUGCUCCGUCUGUUGAGUCU 987 AGUUGCUCCGUCUGUUGAGU 988 GCAGUUGCUCCGUCUGUUGA 989 GGCAGUUGCUCCGUCUGUUG 990 GAUGGCAGUUGCUCCGUCUG 991 GGAUGGCAGUUGCUCCGUCU 992 AGCCUCGGAUGGCAGUUGCU 993 AGGAGCCUCGGAUGGCAGUU 994 UUCAGGAGCCUCGGAUGGCA 995 UGGUUCAGGAGCCUCGGAUG 996 CUGGUUCAGGAGCCUCGGAU 997 CUGGUGAAUGGCCCUGGUUC 998 CCUGGUGAAUGGCCCUGGUU 999 UCCUGGUGAAUGGCCCUGGU 1000 UGGACAUCAGGGAGCCGCAU 1001 AGGAUUUGCUGCUUGGCUAG 1002 CAGGAUUUGCUGCUUGGCUA 1003 UCCAGGAUUUGCUGCUUGGC 1004 ACCCAUCCAGGAUUUGCUGC 1005 AACCCAUCCAGGAUUUGCUG 1006 CAACCCAUCCAGGAUUUGCU 1007 UGCAACCCAUCCAGGAUUUG 1008 GUGCAACCCAUCCAGGAUUU 1009 GGUGCAACCCAUCCAGGAUU 1010 AGGUGCAACCCAUCCAGGAU 1011 CAGGUGCAACCCAUCCAGGA 1012 UCAGGUGCAACCCAUCCAGG 1013 GUCAGGUGCAACCCAUCCAG 1014 GGUCAGGUGCAACCCAUCCA 1015 UGGUCAGGUGCAACCCAUCC 1016 CUGGUCAGGUGCAACCCAUC 1017 ACUGGUCAGGUGCAACCCAU 1018 GACUGGUCAGGUGCAACCCA 1019 ACGACUGGUCAGGUGCAACC 1020 GACGACUGGUCAGGUGCAAC 1021 GGACGACUGGUCAGGUGCAA 1022 UCUGGGACGACUGGUCAGGU 1023 UUCUGGGACGACUGGUCAGG 1024 AUUCUGGGACGACUGGUCAG 1025 UAUUCUGGGACGACUGGUCA 1026 UUAUUCUGGGACGACUGGUC 1027 GUUAUUCUGGGACGACUGGU 1028 AGUUAUUCUGGGACGACUGG 1029 GAGUUAUUCUGGGACGACUG 1030 UGAGUUAUUCUGGGACGACU 1031 AUGAGUUAUUCUGGGACGAC 1032 GAUGAGUUAUUCUGGGACGA 1033 GGAUGAGUUAUUCUGGGACG 1034 UGGAGGAUGAGUUAUUCUGG 1035 GUGGAGGAUGAGUUAUUCUG 1036 GGUGGAGGAUGAGUUAUUCU 1037 GGGUGGAGGAUGAGUUAUUC 1038 AAAGCUGAUGACCUCCUCCC 1039 CAAAGCUGAUGACCUCCUCC 1040 AGCAAAGCUGAUGACCUCCU 1041 UAGCAAAGCUGAUGACCUCC 1042 GUAGCAAAGCUGAUGACCUC 1043 AGUAGCAAAGCUGAUGACCU 1044 ACAGUAGCAAAGCUGAUGAC 1045 UGACAGUAGCAAAGCUGAUG 1046 GUGACAGUAGCAAAGCUGAU 1047 ACCUGUGACAGUAGCAAAGC 1048 CACCUGUGACAGUAGCAAAG 1049 CCACCUGUGACAGUAGCAAA 1050 CCCACCUGUGACAGUAGCAA 1051 ACCCACCUGUGACAGUAGCA 1052 CACCCACCUGUGACAGUAGC 1053 GUUGCUCUCUCCCUCACCCA 1054 CCUGUUGCUCUCUCCCUCAC 1055 GCCUGUUGCUCUCUCCCUCA 1056 UGCCUGUUGCUCUCUCCCUC 1057 CCCUGUCUGCUCUUUGCCUG 1058 UUUCCCUGUCUGCUCUUUGC 1059 UCCUCUGCAACCAGUCCCUG 1060 GUCCUCUGCAACCAGUCCCU 1061 GUGUCCUCUGCAACCAGUCC 1062 UGUGUCCUCUGCAACCAGUC 1063 UUGUGUCCUCUGCAACCAGU 1064 ACUGCUUUGUGUCCUCUGCA 1065 GACUGCUUUGUGUCCUCUGC 1066 GAGACUGCUUUGUGUCCUCU 1067 AGAGACUGCUUUGUGUCCUC 1068 UAGAGACUGCUUUGUGUCCU 1069 UCCCUCGAACCUACCUCUAG 1070 CUCCCUCGAACCUACCUCUA 1071 UCUCCCUCGAACCUACCUCU 1072 CUCUCCCUCGAACCUACCUC 1073 ACUGCUCUCCCUCGAACCUA 1074 AGAUGAAGCUCUCCUCUGAG 1075 AUGUGAGUAGAGAUGAAGCU 1076 UGCCCGAAAGACAGAAAAGG 1077 CUGCCCGAAAGACAGAAAAG 1078 AGUGGAGUCUGCCCGAAAGA 1079 AAGUGGAGUCUGCCCGAAAG 1080 GAAGUGGAGUCUGCCCGAAA 1081 AGGCUGAAGUGGAGUCUGCC 1082 UAGGCUGAAGUGGAGUCUGC 1083 GUAGGCUGAAGUGGAGUCUG 1084 GCUGUAGGCUGAAGUGGAGU 1085 AGCUGUAGGCUGAAGUGGAG 1086 GAGCUGUAGGCUGAAGUGGA 1087 GGGAGCUGUAGGCUGAAGUG 1088 AGGGAGCUGUAGGCUGAAGU 1089 AAGUGAGCAGGGAGCUGUAG 1090 UGGACAGGUGAAAAGUGAGC 1091 GUGGACAGGUGAAAAGUGAG 1092 AGUGGACAGGUGAAAAGUGA 1093 GAGUGGACAGGUGAAAAGUG 1094 GGAGUGGACAGGUGAAAAGU 1095 AGGAGUGGACAGGUGAAAAG 1096 GAGGAGUGGACAGGUGAAAA 1097 CGAGGAGUGGACAGGUGAAA 1098 CCGAGGAGUGGACAGGUGAA 1099 ACCGAGGAGUGGACAGGUGA 1100 CAUGGUACAGGUGGUGGGAC 1101 GCAUGGUACAGGUGGUGGGA 1102 CAAAGAGUGCCAGGAAGGGU 1103 GCAAAGAGUGCCAGGAAGGG 1104 AAGCAAAGAGUGCCAGGAAG 1105 UCAAGCAAAGAGUGCCAGGA 1106 CUCAAGCAAAGAGUGCCAGG 1107 CCUCAAGCAAAGAGUGCCAG 1108 AUCCUCAAGCAAAGAGUGCC 1109 GAUCCUCAAGCAAAGAGUGC 1110 GAAGAUCCUCAAGCAAAGAG 1111 GGAAGAUCCUCAAGCAAAGA 1112 CGGAAGAUCCUCAAGCAAAG 1113 AUCGGAAGAUCCUCAAGCAA 1114 CAUCGGAAGAUCCUCAAGCA 1115 CCAUCGGAAGAUCCUCAAGC 1116 CCCAUCGGAAGAUCCUCAAG 1117 AUGUGGUGCUCAGCCAGGAG 1118 UUGGUGAUGUGGUGCUCAGC 1119 GGUUGGUGAUGUGGUGCUCA 1120 AGGUUGGUGAUGUGGUGCUC 1121 CAGGUUGGUGAUGUGGUGCU 1122 AGCCCAGGUUGGUGAUGUGG 1123 CAGCCCAGGUUGGUGAUGUG 1124 UGCCAGCCCAGGUUGGUGAU 1125 AUGCCAGCCCAGGUUGGUGA 1126 GUAUGCCAGCCCAGGUUGGU 1127 AGGUAUGCCAGCCCAGGUUG 1128 AAGGUAUGCCAGCCCAGGUU 1129 UAAGGUAUGCCAGCCCAGGU 1130 UUAAGGUAUGCCAGCCCAGG 1131 GUUAAGGUAUGCCAGCCCAG 1132 AGUUAAGGUAUGCCAGCCCA 1133 GAGUUAAGGUAUGCCAGCCC 1134 AGAGUUAAGGUAUGCCAGCC 1135 CAGAGUUAAGGUAUGCCAGC 1136 GCAGAGUUAAGGUAUGCCAG 1137 AGGGCAGAGUUAAGGUAUGC 1138 AGAGGGCAGAGUUAAGGUAU 1139 UAGAGGGCAGAGUUAAGGUA 1140 CUAGAGGGCAGAGUUAAGGU 1141 CACUAGAGGGCAGAGUUAAG 1142 GCCACUAGAGGGCAGAGUUA 1143 GGACACCAGACUUCUCACCC 1144 AGGACACCAGACUUCUCACC 1145 CAGGACACCAGACUUCUCAC 1146 UUUCAGGACACCAGACUUCU 1147 GUUUCAGGACACCAGACUUC 1148 UAGUUGCAGUUUCAGGACAC 1149 CUAGUUGCAGUUUCAGGACA 1150 UCUAGUUGCAGUUUCAGGAC 1151 GUCUAGUUGCAGUUUCAGGA 1152 AGUCUAGUUGCAGUUUCAGG 1153 CAGUCUAGUUGCAGUUUCAG 1154 AACUGUGCUGUUGCCUUCUA 1155 UAACUGUGCUGUUGCCUUCU 1156 GUAACUGUGCUGUUGCCUUC 1157 CCAGUAACUGUGCUGUUGCC 1158 GUCCAGUAACUGUGCUGUUG 1159 UGUCCAGUAACUGUGCUGUU 1160 UUGUCCAGUAACUGUGCUGU 1161 GGUUGUCCAGUAACUGUGCU 1162 CGGUUGUCCAGUAACUGUGC 1163 UCGGUUGUCCAGUAACUGUG 1164 CUCGGUUGUCCAGUAACUGU 1165 CCUCGGUUGUCCAGUAACUG 1166 GCCUCGGUUGUCCAGUAACU 1167 CGCCUCGGUUGUCCAGUAAC 1168 CCGCCUCGGUUGUCCAGUAA 1169 UGCUGGUGUCCUGCUGUGUC 1170 CUGCUGGUGUCCUGCUGUGU 1171 UCUAGGAAGGGCUGCUGGUG 1172 UUAAGCUCUAGGAAGGGCUG 1173 CUCAUUGGCUCGGAUCUUAA 1174 GCUCAUUGGCUCGGAUCUUA 1175 GGCUCAUUGGCUCGGAUCUU 1176 AGGCUCAUUGGCUCGGAUCU 1177 CAGGCUCAUUGGCUCGGAUC 1178 UCCAGGCUCAUUGGCUCGGA 1179 UCUCGCCUGCAACAUAAGGG 1180 CAGAAUGGAAAGAGGCAGCA 1181 GCAGAAUGGAAAGAGGCAGC 1182 AAGACGGCAGAAUGGAAAGA 1183 GAAGACGGCAGAAUGGAAAG 1184 UGAAGACGGCAGAAUGGAAA 1185 CUGAAGACGGCAGAAUGGAA 1186 GCUGAAGACGGCAGAAUGGA 1187 GGCUGAAGACGGCAGAAUGG 1188 AGGCUGAAGACGGCAGAAUG 1189 GGAGGCUGAAGACGGCAGAA 1190 AGGAGGCUGAAGACGGCAGA 1191 UGUUGGCUUUGAGGAGGCUG 1192 CAAGGAUUGUUGGCUUUGAG 1193 UGGCAGGCCAAGGAUUGUUG 1194 CUGGCAGGCCAAGGAUUGUU 1195 ACUGGCAGGCCAAGGAUUGU 1196 AGGAGGUACUGGCAGGCCAA 1197 AACAGGAGGUACUGGCAGGC 1198 CAACAGGAGGUACUGGCAGG 1199 ACACAACAGGAGGUACUGGC 1200 AGGGACACAACAGGAGGUAC 1201 UCGGGCAGUAGGGACACAAC 1202 UUCGGGCAGUAGGGACACAA 1203 CUUCGGGCAGUAGGGACACA 1204 AUGAUCCAGGUAGAGGAGAG 1205 UAUGAUCCAGGUAGAGGAGA 1206 UUAUGAUCCAGGUAGAGGAG 1207 AUUAUGAUCCAGGUAGAGGA 1208 CAUUAUGAUCCAGGUAGAGG 1209 CCAUUAUGAUCCAGGUAGAG 1210 UGCCAUUAUGAUCCAGGUAG 1211 UUGCCAUUAUGAUCCAGGUA 1212 AUUGCCAUUAUGAUCCAGGU 1213 CAUUGCCAUUAUGAUCCAGG 1214 ACAUUGCCAUUAUGAUCCAG 1215 CCACAUUGCCAUUAUGAUCC 1216 GACCACAUUGCCAUUAUGAU 1217 UGACCACAUUGCCAUUAUGA 1218 UUGACCACAUUGCCAUUAUG 1219 UCUUGACCACAUUGCCAUUA 1220 GUCUUGACCACAUUGCCAUU 1221 CGUCUUGACCACAUUGCCAU 1222 CCGUCUUGACCACAUUGCCA 1223 UCCGUCUUGACCACAUUGCC 1224 AUCCGUCUUGACCACAUUGC 1225 CAUCCGUCUUGACCACAUUG 1226 ACAUCCGUCUUGACCACAUU 1227 CACAUCCGUCUUGACCACAU 1228 GCACAUCCGUCUUGACCACA 1229 GGCACAUCCGUCUUGACCAC 1230 UGGCACAUCCGUCUUGACCA 1231 CUGGCACAUCCGUCUUGACC 1232 UCUGGCACAUCCGUCUUGAC 1233 AUCUGGCACAUCCGUCUUGA 1234 UAUCUGGCACAUCCGUCUUG 1235 AUAUCUGGCACAUCCGUCUU 1236 CAUAUCUGGCACAUCCGUCU 1237 CCAUAUCUGGCACAUCCGUC 1238 CACCAUAUCUGGCACAUCCG 1239 CUCCACCACCAUAUCUGGCA 1240 UGGUCUCUUCACUCCAAAGC 1241 CUUCAUCUUGGUCUCUUCAC 1242 ACUUCAUCUUGGUCUCUUCA 1243 AACUUCAUCUUGGUCUCUUC 1244 GGAAACUUCAUCUUGGUCUC 1245 CCUCCAGUCACAGAUGCCCU 1246 GAUGCCUCCAGUCACAGAUG 1247 UGAUGCCUCCAGUCACAGAU 1248 CAGGUGGUUGUUGGGUUGGG 1249 CCAGGUGGUUGUUGGGUUGG 1250 GCCAGGUGGUUGUUGGGUUG 1251 UGCCAGGUGGUUGUUGGGUU 1252 CAUAUUGCCAGGUGGUUGUU 1253 UCAUAUUGCCAGGUGGUUGU 1254 GUCAUAUUGCCAGGUGGUUG 1255 AGUCAUAUUGCCAGGUGGUU 1256 GAGUCAUAUUGCCAGGUGGU 1257 AGUGAGUCAUAUUGCCAGGU 1258 AAGUGAGUCAUAUUGCCAGG 1259 CAAGUGAGUCAUAUUGCCAG 1260 GUCAAGUGAGUCAUAUUGCC 1261 GGUCAAGUGAGUCAUAUUGC 1262 GGGUCAAGUGAGUCAUAUUG 1263 CCCAUUUGGGUCCCAUAGGG 1264 GCCCAUUUGGGUCCCAUAGG 1265 UGCCCAUUUGGGUCCCAUAG 1266 GUGCCCAUUUGGGUCCCAUA 1267 AGUGCCCAUUUGGGUCCCAU 1268 AAGUGCCCAUUUGGGUCCCA 1269 AAAGUGCCCAUUUGGGUCCC 1270 GAAAGUGCCCAUUUGGGUCC 1271 AGAAAGUGCCCAUUUGGGUC 1272 CAAGAAAGUGCCCAUUUGGG 1273 ACAAGAAAGUGCCCAUUUGG 1274 GACAAGAAAGUGCCCAUUUG 1275 GAGUCUCAGACAAGAAAGUG 1276 CCAGAGUCUCAGACAAGAAA 1277 GCCAGAGUCUCAGACAAGAA 1278 AGCCAGAGUCUCAGACAAGA 1279 UAAGCCAGAGUCUCAGACAA 1280 AUAAGCCAGAGUCUCAGACA 1281 AGCCAACCUGGAAUAAGCCA 1282 UCAGCCAACCUGGAAUAAGC 1283 CAUCAGCCAACCUGGAAUAA 1284 CACAUCAGCCAACCUGGAAU 1285 ACACAUCAGCCAACCUGGAA 1286 AACACAUCAGCCAACCUGGA 1287 CAACACAUCAGCCAACCUGG 1288 CUCCCAACACAUCAGCCAAC 1289 CGCUUUACCCAUCUCCCAAC 1290 AACGCUUUACCCAUCUCCCA 1291 AAACGCUUUACCCAUCUCCC 1292 AGAAACGCUUUACCCAUCUC 1293 AAGAAACGCUUUACCCAUCU 1294 GAAGAAACGCUUUACCCAUC 1295 AGAAGAAACGCUUUACCCAU 1296 UAGAAGAAACGCUUUACCCA 1297 UUAGAAGAAACGCUUUACCC 1298 AAUCAUGCUUUCUGGGUAGA 1299 CUUAGGGCAGGAAAUCAUGC 1300 ACUUAGGGCAGGAAAUCAUG 1301 GACUUAGGGCAGGAAAUCAU 1302 AGGACUUAGGGCAGGAAAUC 1303 CAGGACUUAGGGCAGGAAAU 1304 ACAGGACUUAGGGCAGGAAA 1305 UCUCACAGGACUUAGGGCAG 1306 UUCUCACAGGACUUAGGGCA 1307 AUCUUCUCACAGGACUUAGG 1308 CAUCUUCUCACAGGACUUAG 1309 UAGUCCCUGACAUCUUCUCA 1310 CUAGUCCCUGACAUCUUCUC 1311 CCUAGUCCCUGACAUCUUCU 1312 CCCUAGUCCCUGACAUCUUC 1313 UCCCUAGUCCCUGACAUCUU 1314 CUCCCUAGUCCCUGACAUCU 1315 AUCUAUCUGCUUCCUCCUCC 1316 CCAUCUAUCUGCUUCCUCCU 1317 ACCAUCUAUCUGCUUCCUCC 1318 GACCAUCUAUCUGCUUCCUC 1319 GGACCAUCUAUCUGCUUCCU 1320 UGGACCAUCUAUCUGCUUCC 1321 CUGGACCAUCUAUCUGCUUC 1322 CUGCUGGACCAUCUAUCUGC 1323 GCCUGCUGGACCAUCUAUCU 1324 UUCAAGCCUGCUGGACCAUC 1325 UGCUUCAAGCCUGCUGGACC 1326 CCUCAACAGCCCUUACCCUG 1327 UCCCUCUUGACCUUCCCUUA 1328 CUCCCUCUUGACCUUCCCUU 1329 UCUCCCUCUUGACCUUCCCU 1330 CAUCUCCCUCUUGACCUUCC 1331 CCAUCUCCCUCUUGACCUUC 1332 CCCAUCUCCCUCUUGACCUU 1333 GCCCAUCUCCCUCUUGACCU 1334 UUGCCCAUCUCCCUCUUGAC 1335 CUUGCCCAUCUCCCUCUUGA 1336 CCCUAAGCAUCCUCCCUCAG 1337 AACUUCUUAGGCUUAGUGCC 1338 GGAACUUCUUAGGCUUAGUG 1339 GGGAACUUCUUAGGCUUAGU 1340 AGGGAACUUCUUAGGCUUAG 1341 UGUCUCCCAGUGGGUCCUGU 1342 AGUAUAAAUGCUUGUCUCCC 1343 GACAGAGCGAGACUCGAUCU 1344 UGACAGAGCGAGACUCGAUC 1345 GUGACAGAGCGAGACUCGAU 1346 GGUGACAGAGCGAGACUCGA 1347 UGGUGACAGAGCGAGACUCG 1348 CUGGUGACAGAGCGAGACUC 1349 CCUGGUGACAGAGCGAGACU 1350 AGCCUGGUGACAGAGCGAGA 1351 UGCACUCCAGCCUGGUGACA 1352 ACUGCACUCCAGCCUGGUGA 1353 UCACUGCACUCCAGCCUGGU 1354 UGUCACUGCACUCCAGCCUG 1355 GUGUCACUGCACUCCAGCCU 1356 AGACGGAGGUUGCAGUGAGC 1357 GAGACGGAGGUUGCAGUGAG 1358 GGAGACGGAGGUUGCAGUGA 1359 ACUUGAACCCAGGAGACGGA 1360 CACUUGAACCCAGGAGACGG 1361 UCACUUGAACCCAGGAGACG 1362 AUCACUUGAACCCAGGAGAC 1363 AAUCACUUGAACCCAGGAGA 1364 GAAUCACUUGAACCCAGGAG 1365 AGAAUCACUUGAACCCAGGA 1366 AAGAAUCACUUGAACCCAGG 1367 GAAGAAUCACUUGAACCCAG 1368 AGAAGAAUCACUUGAACCCA 1369 CAGAAGAAUCACUUGAACCC 1370 GCAGAAGAAUCACUUGAACC 1371 GGCAGAAGAAUCACUUGAAC 1372 AGGCAGAAGAAUCACUUGAA 1373 GAGGCAGAAGAAUCACUUGA 1374 UGAGGCAGAAGAAUCACUUG 1375 CUGAGGCAGAAGAAUCACUU 1376 GCUGAGGCAGAAGAAUCACU 1377 GGCUGAGGCAGAAGAAUCAC 1378 AGGCUGAGGCAGAAGAAUCA 1379 GAGGCUGAGGCAGAAGAAUC 1380 GGAGGCUGAGGCAGAAGAAU 1381 GGGAGGCUGAGGCAGAAGAA 1382 AGAUUGAGACCAUCCUGGCC 1383 GAGAUUGAGACCAUCCUGGC 1384 AGAGAUUGAGACCAUCCUGG 1385 AAGAGAUUGAGACCAUCCUG 1386 CAAGAGAUUGAGACCAUCCU 1387 GGUGGCUCACGCCUAUAAUC 1388 CGGUGGCUCACGCCUAUAAU 1389 GCGGUGGCUCACGCCUAUAA 1390 CCCUAACCCUUCUUUAUGAC 1391 CACCCUAACCCUUCUUUAUG 1392 AUCACCCUAACCCUUCUUUA 1393 CAUCACCCUAACCCUUCUUU 1394 CCAUCACCCUAACCCUUCUU 1395 GACCAUCACCCUAACCCUUC 1396 GGACCAUCACCCUAACCCUU 1397 UGGACCAUCACCCUAACCCU 1398 CUGGACCAUCACCCUAACCC 1399 UCUGGACCAUCACCCUAACC 1400 CUCUGGACCAUCACCCUAAC 1401 GCUCUGGACCAUCACCCUAA 1402 UGCUCUGGACCAUCACCCUA 1403 GUUGCUCUGGACCAUCACCC 1404 UGUUGCUCUGGACCAUCACC 1405 ACUGUUGCUCUGGACCAUCA 1406 AACUGUUGCUCUGGACCAUC 1407 GAACUGUUGCUCUGGACCAU 1408 GAAGAACUGUUGCUCUGGAC 1409 UUGAAGAACUGUUGCUCUGG 1410 ACUUGAAGAACUGUUGCUCU 1411 CACUUGAAGAACUGUUGCUC 1412 UACACUUGAAGAACUGUUGC 1413 GAGUACACUUGAAGAACUGU 1414 AGAGUACACUUGAAGAACUG 1415 CAGAGUACACUUGAAGAACU 1416 ACAGAGUACACUUGAAGAAC 1417 CUACAGAGUACACUUGAAGA 1418 CCUACAGAGUACACUUGAAG 1419 GCCUACAGAGUACACUUGAA 1420 AGCCUACAGAGUACACUUGA 1421 AAGCCUACAGAGUACACUUG 1422 CAGAAGCCUACAGAGUACAC 1423 CCAGAAGCCUACAGAGUACA 1424 AAAAGGGACCUCCCAGAAGC 1425 GAAAAGGGACCUCCCAGAAG 1426 UGAAAAGGGACCUCCCAGAA 1427 CUUUGACUUUGUGGACACCC 1428 GCUUUGACUUUGUGGACACC 1429 UAGCUUUGACUUUGUGGACA 1430 AUAGCUUUGACUUUGUGGAC 1431 GUCACACGGCCUCUGGAAAA 1432 UGUCACACGGCCUCUGGAAA 1433 AUGUCACACGGCCUCUGGAA 1434 AAGACCAUACAAGCACACAU 1435 ACAAGACCAUACAAGCACAC 1436 CACAAGACCAUACAAGCACA 1437 AACACAAGACCAUACAAGCA 1438 UAACACAAGACCAUACAAGC 1439 ACUGUAACACAAGACCAUAC 1440 AGACUGUAACACAAGACCAU 1441 AAGACUGUAACACAAGACCA 1442 GCCGAGAUUGUGCCACUGCA 1443 AGCCGAGAUUGUGCCACUGC 1444 GAGCCGAGAUUGUGCCACUG 1445 UGAGCCGAGAUUGUGCCACU 1446 GUGAGCCGAGAUUGUGCCAC 1447 AGUGAGCCGAGAUUGUGCCA 1448 CAGUGAGCCGAGAUUGUGCC 1449 GCAGUGAGCCGAGAUUGUGC 1450 UGCAGUGAGCCGAGAUUGUG 1451 UUGCAGUGAGCCGAGAUUGU 1452 GUUGCAGUGAGCCGAGAUUG 1453 GGUUGCAGUGAGCCGAGAUU 1454 AGGUUGCAGUGAGCCGAGAU 1455 GAGGUUGCAGUGAGCCGAGA 1456 UGGAGGUUGCAGUGAGCCGA 1457 AGGUGGAGGUUGCAGUGAGC 1458 GAGGUGGAGGUUGCAGUGAG 1459 GGAGGUGGAGGUUGCAGUGA 1460 UGGGAGGUGGAGGUUGCAGU 1461 UCCCAGCUACUCAGGAGGCU 1462 AGUCCCAGCUACUCAGGAGG 1463 UAGUCCCAGCUACUCAGGAG 1464 AAAUAGCUGGGCAUGGUGGC 1465 AAAAUAGCUGGGCAUGGUGG 1466 GCAGGCGGAUCACCUCAAGU 1467 AGGCAGGCGGAUCACCUCAA 1468 AAGGCAGGCGGAUCACCUCA 1469 CUGUAAUCCCAGCACUUUGG 1470 CCUGUAAUCCCAGCACUUUG 1471 ACCUGUAAUCCCAGCACUUU 1472 GACCUGUAAUCCCAGCACUU 1473 AGACCUGUAAUCCCAGCACU 1474 CAGACCUGUAAUCCCAGCAC 1475 UCAGACCUGUAAUCCCAGCA 1476 CUCAGACCUGUAAUCCCAGC 1477 AGGCACAGUGGCUCAGACCU 1478 UAGGCACAGUGGCUCAGACC 1479 UUAGGCACAGUGGCUCAGAC 1480 GUUAGGCACAGUGGCUCAGA 1481 GGUUAGGCACAGUGGCUCAG 1482 AGGUUAGGCACAGUGGCUCA 1483 AUUAGGUUAGGCACAGUGGC 1484 GUCAUUAGGUUAGGCACAGU 1485 AGUCAUUAGGUUAGGCACAG 1486 AAGUCAUUAGGUUAGGCACA 1487 AAAGUCAUUAGGUUAGGCAC 1488 GAACACCUUACUUUCUUCUC 1489 AGCUCUCUUAGAACACCUUA 1490 GGUGCCCAGCAAGAAGAGCU 1491 GGUUUAAGCGGUCUUCCGGC 1492 GGGUUUAAGCGGUCUUCCGG 1493 UGGGUUUAAGCGGUCUUCCG 1494 CUGGGUUUAAGCGGUCUUCC 1495 CAUAGCCUCGAACUCCUGGG 1496 UCAUAGCCUCGAACUCCUGG 1497 AUCAUAGCCUCGAACUCCUG 1498 GAUCAUAGCCUCGAACUCCU 1499 GCAGAGGCUAUUCACAAGUG 1500 UGCAGAGGCUAUUCACAAGU 1501 GUGCAGAGGCUAUUCACAAG 1502 AGUGCAGAGGCUAUUCACAA 1503 AGGCUGGAGUGCAGAGGCUA 1504 UUUGCCCAGGCUGGAGUGCA 1505 AUUUGCCCAGGCUGGAGUGC 1506 UAUUUGCCCAGGCUGGAGUG 1507 CUAUUUGCCCAGGCUGGAGU 1508 ACUAUUUGCCCAGGCUGGAG 1509 CCAGAGGAGCUAUUUAUGUA 1510 AGACUAAUGGGCACUGAAAA 1511 GACCAGACUAAUGGGCACUG 1512 CAGACCAGACUAAUGGGCAC 1513 GUCAGACCAGACUAAUGGGC 1514 CCAGCUCAGUCAGACCAGAC 1515 CCCAGCUCAGUCAGACCAGA 1516 GACCCAGCUCAGUCAGACCA 1517 AGACCCAGCUCAGUCAGACC 1518 AGAGACCCAGCUCAGUCAGA 1519 UCAGAGACCCAGCUCAGUCA 1520 UGACCCAGGCUAGUUAUCCC 1521 UUGACCCAGGCUAGUUAUCC 1522 UUUGACCCAGGCUAGUUAUC 1523 CUUUGACCCAGGCUAGUUAU 1524 ACUUUGACCCAGGCUAGUUA 1525 GACUUUGACCCAGGCUAGUU 1526 GGACUUUGACCCAGGCUAGU 1527 UUCAGUCUGAGGGUCAAGGG 1528 GUUCAGUCUGAGGGUCAAGG 1529 UGUUCAGUCUGAGGGUCAAG 1530 CUGUUCAGUCUGAGGGUCAA 1531 ACUGUUCAGUCUGAGGGUCA 1532 AACUGUUCAGUCUGAGGGUC 1533 UAACUGUUCAGUCUGAGGGU 1534 UUAACUGUUCAGUCUGAGGG 1535 GUGGAAGGUCAGUGGGUUAA 1536 GUGUGGAAGGUCAGUGGGUU 1537 GGUGUGGAAGGUCAGUGGGU 1538 UGGGUGUGGAAGGUCAGUGG 1539 UUGGGUGUGGAAGGUCAGUG 1540 UCUGCUUCCAAGAACCACCC 1541 GCUCUGCUUCCAAGAACCAC 1542 AGCUCUGCUUCCAAGAACCA 1543 UAGCUCUGCUUCCAAGAACC 1544 CCUAGCUCUGCUUCCAAGAA 1545 ACAUCCUAGCUCUGCUUCCA 1546 ACCUCCCACAUCCUAGCUCU 1547 GACCUCCCACAUCCUAGCUC 1548 AGACCUCCCACAUCCUAGCU 1549 CAGACCUCCCACAUCCUAGC 1550 GCAGACCUCCCACAUCCUAG 1551 GGCAGACCUCCCACAUCCUA 1552 AGGCAGACCUCCCACAUCCU 1553 ACAGGCAGACCUCCCACAUC 1554 CACAGGCAGACCUCCCACAU 1555 GGAGGAAGCAUGACAAGGAA 1556 AAGAGGAGGAAGCAUGACAA 1557 GGGCAGCAUUUCAGUCUCUG 1558 GAUUUGCAUUGCCAUCGUGA 1559 AGAUUUGCAUUGCCAUCGUG 1560 CUCUUUAGAUUUGCAUUGCC 1561 CCUCUUUAGAUUUGCAUUGC 1562 GCCUCUUUAGAUUUGCAUUG 1563 AAGUGCCCUGCCUCUUUAGA 1564 GAAGUGCCCUGCCUCUUUAG 1565 GGGAAGUGCCCUGCCUCUUU 1566 ACUGCCUGACAGGGAAGUGC 1567 GUACUGCCUGACAGGGAAGU 1568 GGUACUGCCUGACAGGGAAG 1569 CGGUACUGCCUGACAGGGAA 1570 UAUGCCCAGCGGUACUGCCU 1571 UGCUAUGCCCAGCGGUACUG 1572 UUGCUAUGCCCAGCGGUACU 1573 GUUGCUAUGCCCAGCGGUAC 1574 GGUUGCUAUGCCCAGCGGUA 1575 AGGUUGCUAUGCCCAGCGGU 1576 AGAGGUUGCUAUGCCCAGCG 1577 AGAGGCAGAGGUUGCUAUGC 1578 GAGAGGCAGAGGUUGCUAUG 1579 GGAGAGGCAGAGGUUGCUAU 1580 CGGAGAGGCAGAGGUUGCUA 1581 AACGGAGAGGCAGAGGUUGC 1582 GAGAAACGGAGAGGCAGAGG 1583 UGAGAAACGGAGAGGCAGAG 1584 UCUGAGAAACGGAGAGGCAG 1585 AGGAGGUGGAUAUGUGAGCU 1586 CCCAGGAGGUGGAUAUGUGA 1587 AGCCCAGGAGGUGGAUAUGU 1588 AAGCCCAGGAGGUGGAUAUG 1589 AAAGCCCAGGAGGUGGAUAU 1590 AAAAGCCCAGGAGGUGGAUA 1591 UAAAAGCCCAGGAGGUGGAU 1592 UUAAAAGCCCAGGAGGUGGA 1593 GCCCACUUAAAAGCCCAGGA 1594 AGCCCACUUAAAAGCCCAGG 1595 AAGCCCACUUAAAAGCCCAG 1596 AAAGCCCACUUAAAAGCCCA 1597 UAAAGCCCACUUAAAAGCCC 1598 CUAAAGCCCACUUAAAAGCC 1599 CACUAAAGCCCACUUAAAAG 1600 CCUCACUAAAGCCCACUUAA 1601 CCCUCACUAAAGCCCACUUA 1602 GGAGCCCAGUUGAAGGAGGA 1603 AGGAGCCCAGUUGAAGGAGG 1604 GGAGGAGCCCAGUUGAAGGA 1605 AGGAGGAGCCCAGUUGAAGG 1606 AGUCGAAGCAGAAGAGCUGG 1607 GAGUCGAAGCAGAAGAGCUG 1608 GGAGUCGAAGCAGAAGAGCU 1609 CGGAGUCGAAGCAGAAGAGC 1610 UCGGAGUCGAAGCAGAAGAG 1611 CUCGGAGUCGAAGCAGAAGA 1612 GCUCGGAGUCGAAGCAGAAG 1613 CGCUCGGAGCGAAGCAGAA 1614 ACAUGACACCCGCUCGGAGU 1615 ACACAUGACACCCGCUCGGA 1616 UCACACAUGACACCCGCUCG 1617 CUCACACAUGACACCCGCUC 1618 UCUCACACAUGACACCCGCU 1619 UUCUCACACAUGACACCCGC 1620 GUUCUCACACAUGACACCCG 1621 CGUUCUCACACAUGACACCC 1622 UGGCCGUUCUCACACAUGAC 1623 CUGGCCGUUCUCACACAUGA 1624 GCUGGCCGUUCUCACACAUG 1625 UGCUGGCCGUUCUCACACAU 1626 CUGCUGGCCGUUCUCACACA 1627 UCUGCUGGCCGUUCUCACAC 1628 CUCUGCUGGCCGUUCUCACA 1629

In some embodiments, the siRNA molecules comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 3.

TABLE 3 SEQ SEQ ID ID Sense Sequence NO: Antisense Sequence NO: GUAGCCAGACAUGAGCUGU 1630 ACAGCUCAUGUCUGGCUAC 1631 AGACAUGAGCUGUGAGGGU 1632 ACCCUCACAGCUCAUGUCU 1633 AUGAGCUGUGAGGGUCAAG 1634 CUUGACCCUCACAGCUCAU 1635 UGAGCUGUGAGGGUCAAGC 1636 GCUUGACCCUCACAGCUCA 1637 GAGCUGUGAGGGUCAAGCA 1638 UGCUUGACCCUCACAGCUC 1639 AGCUGUGAGGGUCAAGCAC 1640 GUGCUUGACCCUCACAGCU 1641 GUGAGGGUCAAGCACAGCU 1642 AGCUGUGCUUGACCCUCAC 1643 UGAGGGUCAAGCACAGCUA 1644 UAGCUGUGCUUGACCCUCA 1645 GAGGGUCAAGCACAGCUAU 1646 AUAGCUGUGCUUGACCCUC 1647 AGGGUCAAGCACAGCUAUC 1648 GAUAGCUGUGCUUGACCCU 1649 GGGUCAAGCACAGCUAUCC 1650 GGAUAGCUGUGCUUGACCC 1651 CAAGCACAGCUAUCCAUCA 1652 UGAUGGAUAGCUGUGCUUG 1653 CACAGCUAUCCAUCAGAUG 1654 CAUCUGAUGGAUAGCUGUG 1655 ACAGCUAUCCAUCAGAUGA 1656 UCAUCUGAUGGAUAGCUGU 1657 CAGCUAUCCAUCAGAUGAU 1658 AUCAUCUGAUGGAUAGCUG 1659 AGCUAUCCAUCAGAUGAUC 1660 GAUCAUCUGAUGGAUAGCU 1661 GCUAUCCAUCAGAUGAUCU 1662 AGAUCAUCUGAUGGAUAGC 1663 CUAUCCAUCAGAUGAUCUA 1664 UAGAUCAUCUGAUGGAUAG 1665 CAUCAGAUGAUCUACUUUC 1666 GAAAGUAGAUCAUCUGAUG 1667 AGAUGAUCUACUUUCAGCC 1668 GGCUGAAAGUAGAUCAUCU 1669 GAUCUACUUUCAGCCUUCC 1670 GGAAGGCUGAAAGUAGAUC 1671 AUCUACUUUCAGCCUUCCU 1672 AGGAAGGCUGAAAGUAGAU 1673 CAAUAGAAGACAGGUGGCU 1674 AGCCACCUGUCUUCUAUUG 1675 AAUAGAAGACAGGUGGCUG 1676 CAGCCACCUGUCUUCUAUU 1677 CAGGUGGCUGUACCCUUGG 1678 CCAAGGGUACAGCCACCUG 1679 AGGUGGCUGUACCCUUGGC 1680 GCCAAGGGUACAGCCACCU 1681 GGCUGUACCCUUGGCCAAG 1682 CUUGGCCAAGGGUACAGCC 1683 UGGUGUCUGCUGUCACUGU 1684 ACAGUGACAGCAGACACCA 1685 GUCUGCUGUCACUGUGCCC 1686 GGGCACAGUGACAGCAGAC 1687 CUGCUGUCACUGUGCCCUC 1688 GAGGGCACAGUGACAGCAG 1689 UGCUGUCACUGUGCCCUCA 1690 UGAGGGCACAGUGACAGCA 1691 GCUGUCACUGUGCCCUCAU 1692 AUGAGGGCACAGUGACAGC 1693 CUGUCACUGUGCCCUCAUU 1694 AAUGAGGGCACAGUGACAG 1695 UGUCACUGUGCCCUCAUUG 1696 CAAUGAGGGCACAGUGACA 1697 GUCACUGUGCCCUCAUUGG 1698 CCAAUGAGGGCACAGUGAC 1699 ACUGUGCCCUCAUUGGCCC 1700 GGGCCAAUGAGGGCACAGU 1701 CCCAGCAAUCAGACUCAAC 1702 GUUGAGUCUGAUUGCUGGG 1703 GGAGCAACUGCCAUCCGAG 1704 CUCGGAUGGCAGUUGCUCC 1705 GAGCAACUGCCAUCCGAGG 1706 CCUCGGAUGGCAGUUGCUC 1707 AGCAACUGCCAUCCGAGGC 1708 GCCUCGGAUGGCAGUUGCU 1709 GCAACUGCCAUCCGAGGCU 1710 AGCCUCGGAUGGCAGUUGC 1711 CAACUGCCAUCCGAGGCUC 1712 GAGCCUCGGAUGGCAGUUG 1713 GCCAUCCGAGGCUCCUGAA 1714 UUCAGGAGCCUCGGAUGGC 1715 AACCAGGGCCAUUCACCAG 1716 CUGGUGAAUGGCCCUGGUU 1717 ACCAGGGCCAUUCACCAGG 1718 CCUGGUGAAUGGCCCUGGU 1719 CCAGGGCCAUUCACCAGGA 1720 UCCUGGUGAAUGGCCCUGG 1721 CAGGGCCAUUCACCAGGAG 1722 CUCCUGGUGAAUGGCCCUG 1723 GGCCAUUCACCAGGAGCAU 1724 AUGCUCCUGGUGAAUGGCC 1725 GCCAUUCACCAGGAGCAUG 1726 CAUGCUCCUGGUGAAUGGC 1727 CCAUUCACCAGGAGCAUGC 1728 GCAUGCUCCUGGUGAAUGG 1729 CAUUCACCAGGAGCAUGCG 1730 CGCAUGCUCCUGGUGAAUG 1731 AUUCACCAGGAGCAUGCGG 1732 CCGCAUGCUCCUGGUGAAU 1733 UUCACCAGGAGCAUGCGGC 1734 GCCGCAUGCUCCUGGUGAA 1735 UCACCAGGAGCAUGCGGCU 1736 AGCCGCAUGCUCCUGGUGA 1737 AGCAUGCGGCUCCCUGAUG 1738 CAUCAGGGAGCCGCAUGCU 1739 GCAUGCGGCUCCCUGAUGU 1740 ACAUCAGGGAGCCGCAUGC 1741 CAUGCGGCUCCCUGAUGUC 1742 GACAUCAGGGAGCCGCAUG 1743 AUGCGGCUCCCUGAUGUCC 1744 GGACAUCAGGGAGCCGCAU 1745 UGCGGCUCCCUGAUGUCCA 1746 UGGACAUCAGGGAGCCGCA 1747 GCUCCCUGAUGUCCAGCUC 1748 GAGCUGGACAUCAGGGAGC 1749 CUCCCUGAUGUCCAGCUCU 1750 AGAGCUGGACAUCAGGGAG 1751 UCCCUGAUGUCCAGCUCUG 1752 CAGAGCUGGACAUCAGGGA 1753 CCCUGAUGUCCAGCUCUGG 1754 CCAGAGCUGGACAUCAGGG 1755 CCUGAUGUCCAGCUCUGGC 1756 GCCAGAGCUGGACAUCAGG 1757 CUGAUGUCCAGCUCUGGCU 1758 AGCCAGAGCUGGACAUCAG 1759 UCUGGUGCUGGAGCUAGCC 1760 GGCUAGCUCCAGCACCAGA 1761 UGGUGCUGGAGCUAGCCAA 1762 UUGGCUAGCUCCAGCACCA 1763 GGUGCUGGAGCUAGCCAAG 1764 CUUGGCUAGCUCCAGCACC 1765 GUGCUGGAGCUAGCCAAGC 1766 GCUUGGCUAGCUCCAGCAC 1767 GCUGGAGCUAGCCAAGCAG 1768 CUGCUUGGCUAGCUCCAGC 1769 CUGGAGCUAGCCAAGCAGC 1770 GCUGCUUGGCUAGCUCCAG 1771 UGGAGCUAGCCAAGCAGCA 1772 UGCUGCUUGGCUAGCUCCA 1773 GGAGCUAGCCAAGCAGCAA 1774 UUGCUGCUUGGCUAGCUCC 1775 GAGCUAGCCAAGCAGCAAA 1776 UUUGCUGCUUGGCUAGCUC 1777 AGCUAGCCAAGCAGCAAAU 1778 AUUUGCUGCUUGGCUAGCU 1779 GCUAGCCAAGCAGCAAAUC 1780 GAUUUGCUGCUUGGCUAGC 1781 CAGCAAAUCCUGGAUGGGU 1782 ACCCAUCCAGGAUUUGCUG 1783 AGCAAAUCCUGGAUGGGUU 1784 AACCCAUCCAGGAUUUGCU 1785 GCAAAUCCUGGAUGGGUUG 1786 CAACCCAUCCAGGAUUUGC 1787 CAAAUCCUGGAUGGGUUGC 1788 GCAACCCAUCCAGGAUUUG 1789 AAAUCCUGGAUGGGUUGCA 1790 UGCAACCCAUCCAGGAUUU 1791 GGUUGCACCUGACCAGUCG 1792 CGACUGGUCAGGUGCAACC 1793 GUUGCACCUGACCAGUCGU 1794 ACGACUGGUCAGGUGCAAC 1795 UUGCACCUGACCAGUCGUC 1796 GACGACUGGUCAGGUGCAA 1797 UGCACCUGACCAGUCGUCC 1798 GGACGACUGGUCAGGUGCA 1799 UGACCAGUCGUCCCAGAAU 1800 AUUCUGGGACGACUGGUCA 1801 GACCAGUCGUCCCAGAAUA 1802 UAUUCUGGGACGACUGGUC 1803 ACCAGUCGUCCCAGAAUAA 1804 UUAUUCUGGGACGACUGGU 1805 CCAGUCGUCCCAGAAUAAC 1806 GUUAUUCUGGGACGACUGG 1807 CAGUCGUCCCAGAAUAACU 1808 AGUUAUUCUGGGACGACUG 1809 AGUCGUCCCAGAAUAACUC 1810 GAGUUAUUCUGGGACGACU 1811 GUCGUCCCAGAAUAACUCA 1812 UGAGUUAUUCUGGGACGAC 1813 UCGUCCCAGAAUAACUCAU 1814 AUGAGUUAUUCUGGGACGA 1815 CGUCCCAGAAUAACUCAUC 1816 GAUGAGUUAUUCUGGGACG 1817 GUCCCAGAAUAACUCAUCC 1818 GGAUGAGUUAUUCUGGGAC 1819 UCCCAGAAUAACUCAUCCU 1820 AGGAUGAGUUAUUCUGGGA 1821 CCCAGAAUAACUCAUCCUC 1822 GAGGAUGAGUUAUUCUGGG 1823 GACUACAGCCAGGGAGUGU 1824 ACACUCCCUGGCUGUAGUC 1825 ACUACAGCCAGGGAGUGUG 1826 CACACUCCCUGGCUGUAGU 1827 CUACAGCCAGGGAGUGUGG 1828 CCACACUCCCUGGCUGUAG 1829 GAGUGUGGCUCCAGGGAAU 1830 AUUCCCUGGAGCCACACUC 1831 GGGAGGAGGUCAUCAGCUU 1832 AAGCUGAUGACCUCCUCCC 1833 GAGGUCAUCAGCUUUGCUA 1834 UAGCAAAGCUGAUGACCUC 1835 AGGUCAUCAGCUUUGCUAC 1836 GUAGCAAAGCUGAUGACCU 1837 GGUCAUCAGCUUUGCUACU 1838 AGUAGCAAAGCUGAUGACC 1839 GCUUUGCUACUGUCACAGA 1840 UCUGUGACAGUAGCAAAGC 1841 CUUUGCUACUGUCACAGAC 1842 GUCUGUGACAGUAGCAAAG 1843 UUUGCUACUGUCACAGACU 1844 AGUCUGUGACAGUAGCAAA 1845 UUGCUACUGUCACAGACUC 1846 GAGUCUGUGACAGUAGCAA 1847 UGCUACUGUCACAGACUCC 1848 GGAGUCUGUGACAGUAGCA 1849 ACUGUCACAGACUCCACUU 1850 AAGUGGAGUCUGUGACAGU 1851 CUGUCACAGACUCCACUUC 1852 GAAGUGGAGUCUGUGACAG 1853 UGUCACAGACUCCACUUCA 1854 UGAAGUGGAGUCUGUGACA 1855 GUCACAGACUCCACUUCAG 1856 CUGAAGUGGAGUCUGUGAC 1857 UCACAGACUCCACUUCAGC 1858 GCUGAAGUGGAGUCUGUGA 1859 CACAGACUCCACUUCAGCC 1860 GGCUGAAGUGGAGUCUGUG 1861 UCCACUUCAGCCUACAGCU 1862 AGCUGUAGGCUGAAGUGGA 1863 CCACUUCAGCCUACAGCUC 1864 GAGCUGUAGGCUGAAGUGG 1865 CACUUCAGCCUACAGCUCC 1866 GGAGCUGUAGGCUGAAGUG 1867 ACUUCAGCCUACAGCUCCC 1868 GGGAGCUGUAGGCUGAAGU 1869 CCUACAGCUCCCUGCUCAC 1870 GUGAGCAGGGAGCUGUAGG 1871 CUACAGCUCCCUGCUCACU 1872 AGUGAGCAGGGAGCUGUAG 1873 UACAGCUCCCUGCUCACUU 1874 AAGUGAGCAGGGAGCUGUA 1875 GCUCCCUGCUCACUUUUCA 1876 UGAAAAGUGAGCAGGGAGC 1877 CUCCCUGCUCACUUUUCAC 1878 GUGAAAAGUGAGCAGGGAG 1879 GCUCACUUUUCACCUGUCC 1880 GGACAGGUGAAAAGUGAGC 1881 CUCACUUUUCACCUGUCCA 1882 UGGACAGGUGAAAAGUGAG 1883 UGUCCACUCCUCGGUCCCA 1884 UGGGACCGAGGAGUGGACA 1885 UCGGUCCCACCACCUGUAC 1886 GUACAGGUGGUGGGACCGA 1887 CCACCACCUGUACCAUGCC 1888 GGCAUGGUACAGGUGGUGG 1889 CACCACCUGUACCAUGCCC 1890 GGGCAUGGUACAGGUGGUG 1891 ACCACCUGUACCAUGCCCG 1892 CGGGCAUGGUACAGGUGGU 1893 CACCCUUCCUGGCACUCUU 1894 AAGAGUGCCAGGAAGGGUG 1895 ACCCUUCCUGGCACUCUUU 1896 AAAGAGUGCCAGGAAGGGU 1897 CCCUUCCUGGCACUCUUUG 1898 CAAAGAGUGCCAGGAAGGG 1899 CCUUCCUGGCACUCUUUGC 1900 GCAAAGAGUGCCAGGAAGG 1901 UUCCUGGCACUCUUUGCUU 1902 AAGCAAAGAGUGCCAGGAA 1903 UCCUGGCACUCUUUGCUUG 1904 CAAGCAAAGAGUGCCAGGA 1905 CCUGGCACUCUUUGCUUGA 1906 UCAAGCAAAGAGUGCCAGG 1907 CUGGCACUCUUUGCUUGAG 1908 CUCAAGCAAAGAGUGCCAG 1909 UGGCACUCUUUGCUUGAGG 1910 CCUCAAGCAAAGAGUGCCA 1911 GGCACUCUUUGCUUGAGGA 1912 UCCUCAAGCAAAGAGUGCC 1913 GCACUCUUUGCUUGAGGAU 1914 AUCCUCAAGCAAAGAGUGC 1915 CACUCUUUGCUUGAGGAUC 1916 GAUCCUCAAGCAAAGAGUG 1917 ACUCUUUGCUUGAGGAUCU 1918 AGAUCCUCAAGCAAAGAGU 1919 CUCUUUGCUUGAGGAUCUU 1920 AAGAUCCUCAAGCAAAGAG 1921 UCUUUGCUUGAGGAUCUUC 1922 GAAGAUCCUCAAGCAAAGA 1923 UGCUUGAGGAUCUUCCGAU 1924 AUCGGAAGAUCCUCAAGCA 1925 GCUUGAGGAUCUUCCGAUG 1926 CAUCGGAAGAUCCUCAAGC 1927 GCACUCUCCUGGCUGAGCA 1928 UGCUCAGCCAGGAGAGUGC 1929 CUCCUGGCUGAGCACCACA 1930 UGUGGUGCUCAGCCAGGAG 1931 UGGCUGAGCACCACAUCAC 1932 GUGAUGUGGUGCUCAGCCA 1933 GGCUGAGCACCACAUCACC 1934 GGUGAUGUGGUGCUCAGCC 1935 GCUGAGCACCACAUCACCA 1936 UGGUGAUGUGGUGCUCAGC 1937 CUGAGCACCACAUCACCAA 1938 UUGGUGAUGUGGUGCUCAG 1939 CCAACCUGGGCUGGCAUAC 1940 GUAUGCCAGCCCAGGUUGG 1941 CAACCUGGGCUGGCAUACC 1942 GGUAUGCCAGCCCAGGUUG 1943 AACCUGGGCUGGCAUACCU 1944 AGGUAUGCCAGCCCAGGUU 1945 ACCUGGGCUGGCAUACCUU 1946 AAGGUAUGCCAGCCCAGGU 1947 CCUGGGCUGGCAUACCUUA 1948 UAAGGUAUGCCAGCCCAGG 1949 CUGGGCUGGCAUACCUUAA 1950 UUAAGGUAUGCCAGCCCAG 1951 UGGGCUGGCAUACCUUAAC 1952 GUUAAGGUAUGCCAGCCCA 1953 GGGCUGGCAUACCUUAACU 1954 AGUUAAGGUAUGCCAGCCC 1955 GGCUGGCAUACCUUAACUC 1956 GAGUUAAGGUAUGCCAGCC 1957 GCUGGCAUACCUUAACUCU 1958 AGAGUUAAGGUAUGCCAGC 1959 CAUACCUUAACUCUGCCCU 1960 AGGGCAGAGUUAAGGUAUG 1961 AUACCUUAACUCUGCCCUC 1962 GAGGGCAGAGUUAAGGUAU 1963 UACCUUAACUCUGCCCUCU 1964 AGAGGGCAGAGUUAAGGUA 1965 UCUGCCCUCUAGUGGCUUG 1966 CAAGCCACUAGAGGGCAGA 1967 CUGCCCUCUAGUGGCUUGA 1968 UCAAGCCACUAGAGGGCAG 1969 UGCCCUCUAGUGGCUUGAG 1970 CUCAAGCCACUAGAGGGCA 1971 AGAAGUCUGGUGUCCUGAA 1972 UUCAGGACACCAGACUUCU 1973 CAGGACACCAGCAGCCCUU 1974 AAGGGCUGCUGGUGUCCUG 1975 AGGACACCAGCAGCCCUUC 1976 GAAGGGCUGCUGGUGUCCU 1977 ACACCAGCAGCCCUUCCUA 1978 UAGGAAGGGCUGCUGGUGU 1979 CACCAGCAGCCCUUCCUAG 1980 CUAGGAAGGGCUGCUGGUG 1981 ACCAGCAGCCCUUCCUAGA 1982 UCUAGGAAGGGCUGCUGGU 1983 CCAGCAGCCCUUCCUAGAG 1984 CUCUAGGAAGGGCUGCUGG 1985 CAGCAGCCCUUCCUAGAGC 1986 GCUCUAGGAAGGGCUGCUG 1987 AGCAGCCCUUCCUAGAGCU 1988 AGCUCUAGGAAGGGCUGCU 1989 GCCCUUCCUAGAGCUUAAG 1990 CUUAAGCUCUAGGAAGGGC 1991 CCCUUCCUAGAGCUUAAGA 1992 UCUUAAGCUCUAGGAAGGG 1993 AGCUUAAGAUCCGAGCCAA 1994 UUGGCUCGGAUCUUAAGCU 1995 GCUUAAGAUCCGAGCCAAU 1996 AUUGGCUCGGAUCUUAAGC 1997 CUUAAGAUCCGAGCCAAUG 1998 CAUUGGCUCGGAUCUUAAG 1999 UUAAGAUCCGAGCCAAUGA 2000 UCAUUGGCUCGGAUCUUAA 2001 UAAGAUCCGAGCCAAUGAG 2002 CUCAUUGGCUCGGAUCUUA 2003 CGAGCCAAUGAGCCUGGAG 2004 CUCCAGGCUCAUUGGCUCG 2005 CCCUUAUGUUGCAGGCGAG 2006 CUCGCCUGCAACAUAAGGG 2007 CAUUACGUAGACUUCCAGG 2008 CCUGGAAGUCUACGUAAUG 2009 AUUACGUAGACUUCCAGGA 2010 UCCUGGAAGUCUACGUAAU 2011 UUACGUAGACUUCCAGGAA 2012 UUCCUGGAAGUCUACGUAA 2013 ACUGGAUACUGCAGCCCGA 2014 UCGGGCUGCAGUAUCCAGU 2015 CUGGAUACUGCAGCCCGAG 2016 CUCGGGCUGCAGUAUCCAG 2017 UGGAUACUGCAGCCCGAGG 2018 CCUCGGGCUGCAGUAUCCA 2019 GGGUACCAGCUGAAUUACU 2020 AGUAAUUCAGCUGGUACCC 2021 CUGAAUUACUGCAGUGGGC 2022 GCCCACUGCAGUAAUUCAG 2023 UGAAUUACUGCAGUGGGCA 2024 UGCCCACUGCAGUAAUUCA 2025 UGGCAGCCCAGGCAUUGCU 2026 AGCAAUGCCUGGGCUGCCA 2027 GCAUUGCUGCCUCUUUCCA 2028 UGGAAAGAGGCAGCAAUGC 2029 CAUUGCUGCCUCUUUCCAU 2030 AUGGAAAGAGGCAGCAAUG 2031 AUUGCUGCCUCUUUCCAUU 2032 AAUGGAAAGAGGCAGCAAU 2033 UGCUGCCUCUUUCCAUUCU 2034 AGAAUGGAAAGAGGCAGCA 2035 GCUGCCUCUUUCCAUUCUG 2036 CAGAAUGGAAAGAGGCAGC 2037 CUGCCUCUUUCCAUUCUGC 2038 GCAGAAUGGAAAGAGGCAG 2039 UGCCUCUUUCCAUUCUGCC 2040 GGCAGAAUGGAAAGAGGCA 2041 GCCUCUUUCCAUUCUGCCG 2042 CGGCAGAAUGGAAAGAGGC 2043 CCUCUUUCCAUUCUGCCGU 2044 ACGGCAGAAUGGAAAGAGG 2045 CUCUUUCCAUUCUGCCGUC 2046 GACGGCAGAAUGGAAAGAG 2047 CAUUCUGCCGUCUUCAGCC 2048 GGCUGAAGACGGCAGAAUG 2049 CUUCAGCCUCCUCAAAGCC 2050 GGCUUUGAGGAGGCUGAAG 2051 UUCAGCCUCCUCAAAGCCA 2052 UGGCUUUGAGGAGGCUGAA 2053 UCAGCCUCCUCAAAGCCAA 2054 UUGGCUUUGAGGAGGCUGA 2055 CAGCCUCCUCAAAGCCAAC 2056 GUUGGCUUUGAGGAGGCUG 2057 UCCUUGGCCUGCCAGUACC 2058 GGUACUGGCAGGCCAAGGA 2059 CCUGCCAGUACCUCCUGUU 2060 AACAGGAGGUACUGGCAGG 2061 CUGCCAGUACCUCCUGUUG 2062 CAACAGGAGGUACUGGCAG 2063 UGCCAGUACCUCCUGUUGU 2064 ACAACAGGAGGUACUGGCA 2065 GCCAGUACCUCCUGUUGUG 2066 CACAACAGGAGGUACUGGC 2067 CCAGUACCUCCUGUUGUGU 2068 ACACAACAGGAGGUACUGG 2069 CAGUACCUCCUGUUGUGUC 2070 GACACAACAGGAGGUACUG 2071 GUACCUCCUGUUGUGUCCC 2072 GGGACACAACAGGAGGUAC 2073 UACCUCCUGUUGUGUCCCU 2074 AGGGACACAACAGGAGGUA 2075 ACCUCCUGUUGUGUCCCUA 2076 UAGGGACACAACAGGAGGU 2077 CCUCCUGUUGUGUCCCUAC 2078 GUAGGGACACAACAGGAGG 2079 CUCCUGUUGUGUCCCUACU 2080 AGUAGGGACACAACAGGAG 2081 UUGUGUCCCUACUGCCCGA 2082 UCGGGCAGUAGGGACACAA 2083 UGUGUCCCUACUGCCCGAA 2084 UUCGGGCAGUAGGGACACA 2085 GUGUCCCUACUGCCCGAAG 2086 CUUCGGGCAGUAGGGACAC 2087 UGUCCCUACUGCCCGAAGG 2088 CCUUCGGGCAGUAGGGACA 2089 UCUCUCUCCUCUACCUGGA 2090 UCCAGGUAGAGGAGAGAGA 2091 UCUCCUCUACCUGGAUCAU 2092 AUGAUCCAGGUAGAGGAGA 2093 CUCCUCUACCUGGAUCAUA 2094 UAUGAUCCAGGUAGAGGAG 2095 UCCUCUACCUGGAUCAUAA 2096 UUAUGAUCCAGGUAGAGGA 2097 CCUCUACCUGGAUCAUAAU 2098 AUUAUGAUCCAGGUAGAGG 2099 CUCUACCUGGAUCAUAAUG 2100 CAUUAUGAUCCAGGUAGAG 2101 UCUACCUGGAUCAUAAUGG 2102 CCAUUAUGAUCCAGGUAGA 2103 CUACCUGGAUCAUAAUGGC 2104 GCCAUUAUGAUCCAGGUAG 2105 UACCUGGAUCAUAAUGGCA 2106 UGCCAUUAUGAUCCAGGUA 2107 ACCUGGAUCAUAAUGGCAA 2108 UUGCCAUUAUGAUCCAGGU 2109 CCUGGAUCAUAAUGGCAAU 2110 AUUGCCAUUAUGAUCCAGG 2111 CUGGAUCAUAAUGGCAAUG 2112 CAUUGCCAUUAUGAUCCAG 2113 UGGAUCAUAAUGGCAAUGU 2114 ACAUUGCCAUUAUGAUCCA 2115 GGAUCAUAAUGGCAAUGUG 2116 CACAUUGCCAUUAUGAUCC 2117 GAUCAUAAUGGCAAUGUGG 2118 CCACAUUGCCAUUAUGAUC 2119 AUAAUGGCAAUGUGGUCAA 2120 UUGACCACAUUGCCAUUAU 2121 UAAUGGCAAUGUGGUCAAG 2122 CUUGACCACAUUGCCAUUA 2123 AAUGGCAAUGUGGUCAAGA 2124 UCUUGACCACAUUGCCAUU 2125 AAUGUGGUCAAGACGGAUG 2126 CAUCCGUCUUGACCACAUU 2127 AUGUGGUCAAGACGGAUGU 2128 ACAUCCGUCUUGACCACAU 2129 UGUGGUCAAGACGGAUGUG 2130 CACAUCCGUCUUGACCACA 2131 GUGGUCAAGACGGAUGUGC 2132 GCACAUCCGUCUUGACCAC 2133 UGGUCAAGACGGAUGUGCC 2134 GGCACAUCCGUCUUGACCA 2135 GGUCAAGACGGAUGUGCCA 2136 UGGCACAUCCGUCUUGACC 2137 GUCAAGACGGAUGUGCCAG 2138 CUGGCACAUCCGUCUUGAC 2139 UCAAGACGGAUGUGCCAGA 2140 UCUGGCACAUCCGUCUUGA 2141 CAAGACGGAUGUGCCAGAU 2142 AUCUGGCACAUCCGUCUUG 2143 AAGACGGAUGUGCCAGAUA 2144 UAUCUGGCACAUCCGUCUU 2145 AGACGGAUGUGCCAGAUAU 2146 AUAUCUGGCACAUCCGUCU 2147 GACGGAUGUGCCAGAUAUG 2148 CAUAUCUGGCACAUCCGUC 2149 ACGGAUGUGCCAGAUAUGG 2150 CCAUAUCUGGCACAUCCGU 2151 CGGAUGUGCCAGAUAUGGU 2152 ACCAUAUCUGGCACAUCCG 2153 GGAUGUGCCAGAUAUGGUG 2154 CACCAUAUCUGGCACAUCC 2155 GAUGUGCCAGAUAUGGUGG 2156 CCACCAUAUCUGGCACAUC 2157 GCCAGAUAUGGUGGUGGAG 2158 CUCCACCACCAUAUCUGGC 2159 CCAGAUAUGGUGGUGGAGG 2160 CCUCCACCACCAUAUCUGG 2161 CAGAUAUGGUGGUGGAGGC 2162 GCCUCCACCACCAUAUCUG 2163 AGAUAUGGUGGUGGAGGCC 2164 GGCCUCCACCACCAUAUCU 2165 GAUAUGGUGGUGGAGGCCU 2166 AGGCCUCCACCACCAUAUC 2167 AUAUGGUGGUGGAGGCCUG 2168 CAGGCCUCCACCACCAUAU 2169 CCUGUGGCUGCAGCUAGCA 2170 UGCUAGCUGCAGCCACAGG 2171 UGUGGCUGCAGCUAGCAAG 2172 CUUGCUAGCUGCAGCCACA 2173 GUGGCUGCAGCUAGCAAGA 2174 UCUUGCUAGCUGCAGCCAC 2175 UGGCUGCAGCUAGCAAGAG 2176 CUCUUGCUAGCUGCAGCCA 2177 GGCUGCAGCUAGCAAGAGG 2178 CCUCUUGCUAGCUGCAGCC 2179 CUGCAGCUAGCAAGAGGAC 2180 GUCCUCUUGCUAGCUGCAG 2181 CAGCUAGCAAGAGGACCUG 2182 CAGGUCCUCUUGCUAGCUG 2183 GCUAGCAAGAGGACCUGGG 2184 CCCAGGUCCUCUUGCUAGC 2185 AGACCAAGAUGAAGUUUCC 2186 GGAAACUUCAUCUUGGUCU 2187 UGAAGUUUCCCAGGCACAG 2188 CUGUGCCUGGGAAACUUCA 2189 GAAGUUUCCCAGGCACAGG 2190 CCUGUGCCUGGGAAACUUC 2191 UCCCAGGCACAGGGCAUCU 2192 AGAUGCCCUGUGCCUGGGA 2193 GGCAUCUGUGACUGGAGGC 2194 GCCUCCAGUCACAGAUGCC 2195 GCAUCUGUGACUGGAGGCA 2196 UGCCUCCAGUCACAGAUGC 2197 CAACCACCUGGCAAUAUGA 2198 UCAUAUUGCCAGGUGGUUG 2199 AACCACCUGGCAAUAUGAC 2200 GUCAUAUUGCCAGGUGGUU 2201 ACCACCUGGCAAUAUGACU 2202 AGUCAUAUUGCCAGGUGGU 2203 CCACCUGGCAAUAUGACUC 2204 GAGUCAUAUUGCCAGGUGG 2205 CACCUGGCAAUAUGACUCA 2206 UGAGUCAUAUUGCCAGGUG 2207 ACCUGGCAAUAUGACUCAC 2208 GUGAGUCAUAUUGCCAGGU 2209 CCUGGCAAUAUGACUCACU 2210 AGUGAGUCAUAUUGCCAGG 2211 CUGGCAAUAUGACUCACUU 2212 AAGUGAGUCAUAUUGCCAG 2213 UGGCAAUAUGACUCACUUG 2214 CAAGUGAGUCAUAUUGCCA 2215 AAUAUGACUCACUUGACCC 2216 GGGUCAAGUGAGUCAUAUU 2217 CCCUAUGGGACCCAAAUGG 2218 CCAUUUGGGUCCCAUAGGG 2219 CCUAUGGGACCCAAAUGGG 2220 CCCAUUUGGGUCCCAUAGG 2221 CUAUGGGACCCAAAUGGGC 2222 GCCCAUUUGGGUCCCAUAG 2223 UAUGGGACCCAAAUGGGCA 2224 UGCCCAUUUGGGUCCCAUA 2225 AUGGGACCCAAAUGGGCAC 2226 GUGCCCAUUUGGGUCCCAU 2227 CCCAAAUGGGCACUUUCUU 2228 AAGAAAGUGCCCAUUUGGG 2229 CCAAAUGGGCACUUUCUUG 2230 CAAGAAAGUGCCCAUUUGG 2231 CAAAUGGGCACUUUCUUGU 2232 ACAAGAAAGUGCCCAUUUG 2233 AAAUGGGCACUUUCUUGUC 2234 GACAAGAAAGUGCCCAUUU 2235 AAUGGGCACUUUCUUGUCU 2236 AGACAAGAAAGUGCCCAUU 2237 UGGGCACUUUCUUGUCUGA 2238 UCAGACAAGAAAGUGCCCA 2239 GGGCACUUUCUUGUCUGAG 2240 CUCAGACAAGAAAGUGCCC 2241 UGGCUUAUUCCAGGUUGGC 2242 GCCAACCUGGAAUAAGCCA 2243 GGCUUAUUCCAGGUUGGCU 2244 AGCCAACCUGGAAUAAGCC 2245 GCUUAUUCCAGGUUGGCUG 2246 CAGCCAACCUGGAAUAAGC 2247 CUUAUUCCAGGUUGGCUGA 2248 UCAGCCAACCUGGAAUAAG 2249 UUCCAGGUUGGCUGAUGUG 2250 CACAUCAGCCAACCUGGAA 2251 UCCAGGUUGGCUGAUGUGU 2252 ACACAUCAGCCAACCUGGA 2253 CCAGGUUGGCUGAUGUGUU 2254 AACACAUCAGCCAACCUGG 2255 CAGGUUGGCUGAUGUGUUG 2256 CAACACAUCAGCCAACCUG 2257 AGGUUGGCUGAUGUGUUGG 2258 CCAACACAUCAGCCAACCU 2259 GGUUGGCUGAUGUGUUGGG 2260 CCCAACACAUCAGCCAACC 2261 AGAUGGGUAAAGCGUUUCU 2262 AGAAACGCUUUACCCAUCU 2263 GAUGGGUAAAGCGUUUCUU 2264 AAGAAACGCUUUACCCAUC 2265 AUGGGUAAAGCGUUUCUUC 2266 GAAGAAACGCUUUACCCAU 2267 UGGGUAAAGCGUUUCUUCU 2268 AGAAGAAACGCUUUACCCA 2269 GGGUAAAGCGUUUCUUCUA 2270 UAGAAGAAACGCUUUACCC 2271 GGUAAAGCGUUUCUUCUAA 2272 UUAGAAGAAACGCUUUACC 2273 GUAAAGCGUUUCUUCUAAA 2274 UUUAGAAGAAACGCUUUAC 2275 UAAAGCGUUUCUUCUAAAG 2276 CUUUAGAAGAAACGCUUUA 2277 AAAGCGUUUCUUCUAAAGG 2278 CCUUUAGAAGAAACGCUUU 2279 AAGCGUUUCUUCUAAAGGG 2280 CCCUUUAGAAGAAACGCUU 2281 AAAGCAUGAUUUCCUGCCC 2282 GGGCAGGAAAUCAUGCUUU 2283 AAGCAUGAUUUCCUGCCCU 2284 AGGGCAGGAAAUCAUGCUU 2285 AGCAUGAUUUCCUGCCCUA 2286 UAGGGCAGGAAAUCAUGCU 2287 GCAUGAUUUCCUGCCCUAA 2288 UUAGGGCAGGAAAUCAUGC 2289 CAUGAUUUCCUGCCCUAAG 2290 CUUAGGGCAGGAAAUCAUG 2291 AUGAUUUCCUGCCCUAAGU 2292 ACUUAGGGCAGGAAAUCAU 2293 UGAUUUCCUGCCCUAAGUC 2294 GACUUAGGGCAGGAAAUCA 2295 GAUUUCCUGCCCUAAGUCC 2296 GGACUUAGGGCAGGAAAUC 2297 AUUUCCUGCCCUAAGUCCU 2298 AGGACUUAGGGCAGGAAAU 2299 UUUCCUGCCCUAAGUCCUG 2300 CAGGACUUAGGGCAGGAAA 2301 UUCCUGCCCUAAGUCCUGU 2302 ACAGGACUUAGGGCAGGAA 2303 UCCUGCCCUAAGUCCUGUG 2304 CACAGGACUUAGGGCAGGA 2305 AGAAGAUGUCAGGGACUAG 2306 CUAGUCCCUGACAUCUUCU 2307 GAAGAUGUCAGGGACUAGG 2308 CCUAGUCCCUGACAUCUUC 2309 AAGAUGUCAGGGACUAGGG 2310 CCCUAGUCCCUGACAUCUU 2311 AGAUGUCAGGGACUAGGGA 2312 UCCCUAGUCCCUGACAUCU 2313 GUCAGGGACUAGGGAGGGA 2314 UCCCUCCCUAGUCCCUGAC 2315 UACUUAGCCUCUCCCAAGA 2316 UCUUGGGAGAGGCUAAGUA 2317 AGGAGGAAGCAGAUAGAUG 2318 CAUCUAUCUGCUUCCUCCU 2319 GGAGGAAGCAGAUAGAUGG 2320 CCAUCUAUCUGCUUCCUCC 2321 GAGGAAGCAGAUAGAUGGU 2322 ACCAUCUAUCUGCUUCCUC 2323 AGGAAGCAGAUAGAUGGUC 2324 GACCAUCUAUCUGCUUCCU 2325 GGAAGCAGAUAGAUGGUCC 2326 GGACCAUCUAUCUGCUUCC 2327 GAAGCAGAUAGAUGGUCCA 2328 UGGACCAUCUAUCUGCUUC 2329 UAGAUGGUCCAGCAGGCUU 2330 AAGCCUGCUGGACCAUCUA 2331 AGAUGGUCCAGCAGGCUUG 2332 CAAGCCUGCUGGACCAUCU 2333 GAUGGUCCAGCAGGCUUGA 2334 UCAAGCCUGCUGGACCAUC 2335 AUGGUCCAGCAGGCUUGAA 2336 UUCAAGCCUGCUGGACCAU 2337 UGGUCCAGCAGGCUUGAAG 2338 CUUCAAGCCUGCUGGACCA 2339 GGUCCAGCAGGCUUGAAGC 2340 GCUUCAAGCCUGCUGGACC 2341 GUCCAGCAGGCUUGAAGCA 2342 UGCUUCAAGCCUGCUGGAC 2343 UCCAGCAGGCUUGAAGCAG 2344 CUGCUUCAAGCCUGCUGGA 2345 CCCAGGGUAAGGGCUGUUG 2346 CAACAGCCCUUACCCUGGG 2347 GGGUAAGGGCUGUUGAGGU 2348 ACCUCAACAGCCCUUACCC 2349 GGUAAGGGCUGUUGAGGUA 2350 UACCUCAACAGCCCUUACC 2351 GUAAGGGCUGUUGAGGUAC 2352 GUACCUCAACAGCCCUUAC 2353 UAAGGGCUGUUGAGGUACC 2354 GGUACCUCAACAGCCCUUA 2355 AAGGGCUGUUGAGGUACCU 2356 AGGUACCUCAACAGCCCUU 2357 AGGGCUGUUGAGGUACCUU 2358 AAGGUACCUCAACAGCCCU 2359 GGGCUGUUGAGGUACCUUA 2360 UAAGGUACCUCAACAGCCC 2361 GGCUGUUGAGGUACCUUAA 2362 UUAAGGUACCUCAACAGCC 2363 GCUGUUGAGGUACCUUAAG 2364 CUUAAGGUACCUCAACAGC 2365 CUGUUGAGGUACCUUAAGG 2366 CCUUAAGGUACCUCAACAG 2367 UGUUGAGGUACCUUAAGGG 2368 CCCUUAAGGUACCUCAACA 2369 UAAGGGAAGGUCAAGAGGG 2370 CCCUCUUGACCUUCCCUUA 2371 AAGGGAAGGUCAAGAGGGA 2372 UCCCUCUUGACCUUCCCUU 2373 CGCUGAGGGAGGAUGCUUA 2374 UAAGCAUCCUCCCUCAGCG 2375 UGAGGGAGGAUGCUUAGGG 2376 CCCUAAGCAUCCUCCCUCA 2377 GGCACUAAGCCUAAGAAGU 2378 ACUUCUUAGGCUUAGUGCC 2379 GCACUAAGCCUAAGAAGUU 2380 AACUUCUUAGGCUUAGUGC 2381 CACUAAGCCUAAGAAGUUC 2382 GAACUUCUUAGGCUUAGUG 2383 ACUAAGCCUAAGAAGUUCC 2384 GGAACUUCUUAGGCUUAGU 2385 AGAUCGAGUCUCGCUCUGU 2386 ACAGAGCGAGACUCGAUCU 2387 GAUCGAGUCUCGCUCUGUC 2388 GACAGAGCGAGACUCGAUC 2389 AUCGAGUCUCGCUCUGUCA 2390 UGACAGAGCGAGACUCGAU 2391 AGUCUCGCUCUGUCACCAG 2392 CUGGUGACAGAGCGAGACU 2393 GUCUCGCUCUGUCACCAGG 2394 CCUGGUGACAGAGCGAGAC 2395 UCUCGCUCUGUCACCAGGC 2396 GCCUGGUGACAGAGCGAGA 2397 CUCGCUCUGUCACCAGGCU 2398 AGCCUGGUGACAGAGCGAG 2399 GUCACCAGGCUGGAGUGCA 2400 UGCACUCCAGCCUGGUGAC 2401 GGCUCACUGCAACCUCCGU 2402 ACGGAGGUUGCAGUGAGCC 2403 GCUCACUGCAACCUCCGUC 2404 GACGGAGGUUGCAGUGAGC 2405 UCCGUCUCCUGGGUUCAAG 2406 CUUGAACCCAGGAGACGGA 2407 CCGUCUCCUGGGUUCAAGU 2408 ACUUGAACCCAGGAGACGG 2409 CGUCUCCUGGGUUCAAGUG 2410 CACUUGAACCCAGGAGACG 2411 GUCUCCUGGGUUCAAGUGA 2412 UCACUUGAACCCAGGAGAC 2413 UGGGUUCAAGUGAUUCUUC 2414 GAAGAAUCACUUGAACCCA 2415 GGGUUCAAGUGAUUCUUCU 2416 AGAAGAAUCACUUGAACCC 2417 GGUUCAAGUGAUUCUUCUG 2418 CAGAAGAAUCACUUGAACC 2419 GUUCAAGUGAUUCUUCUGC 2420 GCAGAAGAAUCACUUGAAC 2421 UUCAAGUGAUUCUUCUGCC 2422 GGCAGAAGAAUCACUUGAA 2423 UCAAGUGAUUCUUCUGCCU 2424 AGGCAGAAGAAUCACUUGA 2425 CGAGCAGCUGGGAUUACAG 2426 CUGUAAUCCCAGCUGCUCG 2427 CAGCUGGGAUUACAGGCGC 2428 GCGCCUGUAAUCCCAGCUG 2429 ACAUGUUGGCCAGGAUGGU 2430 ACCAUCCUGGCCAACAUGU 2431 CAUGUUGGCCAGGAUGGUC 2432 GACCAUCCUGGCCAACAUG 2433 AUGUUGGCCAGGAUGGUCU 2434 AGACCAUCCUGGCCAACAU 2435 UGUUGGCCAGGAUGGUCUC 2436 GAGACCAUCCUGGCCAACA 2437 GUUGGCCAGGAUGGUCUCA 2438 UGAGACCAUCCUGGCCAAC 2439 UUGGCCAGGAUGGUCUCAA 2440 UUGAGACCAUCCUGGCCAA 2441 UGGCCAGGAUGGUCUCAAU 2442 AUUGAGACCAUCCUGGCCA 2443 GGCCAGGAUGGUCUCAAUC 2444 GAUUGAGACCAUCCUGGCC 2445 GCCAGGAUGGUCUCAAUCU 2446 AGAUUGAGACCAUCCUGGC 2447 CCAGGAUGGUCUCAAUCUC 2448 GAGAUUGAGACCAUCCUGG 2449 CAGGAUGGUCUCAAUCUCU 2450 AGAGAUUGAGACCAUCCUG 2451 AGGAUGGUCUCAAUCUCUU 2452 AAGAGAUUGAGACCAUCCU 2453 AUUAUAGGCGUGAGCCACC 2454 GGUGGCUCACGCCUAUAAU 2455 UUAUAGGCGUGAGCCACCG 2456 CGGUGGCUCACGCCUAUAA 2457 UAUAGGCGUGAGCCACCGC 2458 GCGGUGGCUCACGCCUAUA 2459 GCGCCUGGCUUAUACUUUC 2460 GAAAGUAUAAGCCAGGCGC 2461 CGCCUGGCUUAUACUUUCU 2462 AGAAAGUAUAAGCCAGGCG 2463 CCUGGCUUAUACUUUCUUA 2464 UAAGAAAGUAUAAGCCAGG 2465 CUGGCUUAUACUUUCUUAA 2466 UUAAGAAAGUAUAAGCCAG 2467 CAAAUGUGAGUCAUAAAGA 2468 UCUUUAUGACUCACAUUUG 2469 AAUGUGAGUCAUAAAGAAG 2470 CUUCUUUAUGACUCACAUU 2471 UGAGUCAUAAAGAAGGGUU 2472 AACCCUUCUUUAUGACUCA 2473 AGUCAUAAAGAAGGGUUAG 2474 CUAACCCUUCUUUAUGACU 2475 GUCAUAAAGAAGGGUUAGG 2476 CCUAACCCUUCUUUAUGAC 2477 UCAUAAAGAAGGGUUAGGG 2478 CCCUAACCCUUCUUUAUGA 2479 CAUAAAGAAGGGUUAGGGU 2480 ACCCUAACCCUUCUUUAUG 2481 AAGAAGGGUUAGGGUGAUG 2482 CAUCACCCUAACCCUUCUU 2483 AGAAGGGUUAGGGUGAUGG 2484 CCAUCACCCUAACCCUUCU 2485 GAAGGGUUAGGGUGAUGGU 2486 ACCAUCACCCUAACCCUUC 2487 AAGGGUUAGGGUGAUGGUC 2488 GACCAUCACCCUAACCCUU 2489 AGGGUUAGGGUGAUGGUCC 2490 GGACCAUCACCCUAACCCU 2491 GGGUUAGGGUGAUGGUCCA 2492 UGGACCAUCACCCUAACCC 2493 GGGUGAUGGUCCAGAGCAA 2494 UUGCUCUGGACCAUCACCC 2495 GGUGAUGGUCCAGAGCAAC 2496 GUUGCUCUGGACCAUCACC 2497 ACAGUUCUUCAAGUGUACU 2498 AGUACACUUGAAGAACUGU 2499 CAGUUCUUCAAGUGUACUC 2500 GAGUACACUUGAAGAACUG 2501 AGUUCUUCAAGUGUACUCU 2502 AGAGUACACUUGAAGAACU 2503 CAAGUGUACUCUGUAGGCU 2504 AGCCUACAGAGUACACUUG 2505 AAGUGUACUCUGUAGGCUU 2506 AAGCCUACAGAGUACACUU 2507 GUGUACUCUGUAGGCUUCU 2508 AGAAGCCUACAGAGUACAC 2509 UGUACUCUGUAGGCUUCUG 2510 CAGAAGCCUACAGAGUACA 2511 GUACUCUGUAGGCUUCUGG 2512 CCAGAAGCCUACAGAGUAC 2513 UACUCUGUAGGCUUCUGGG 2514 CCCAGAAGCCUACAGAGUA 2515 GUAGGCUUCUGGGAGGUCC 2516 GGACCUCCCAGAAGCCUAC 2517 UAGGCUUCUGGGAGGUCCC 2518 GGGACCUCCCAGAAGCCUA 2519 AGGCUUCUGGGAGGUCCCU 2520 AGGGACCUCCCAGAAGCCU 2521 GGCUUCUGGGAGGUCCCUU 2522 AAGGGACCUCCCAGAAGCC 2523 GCUUCUGGGAGGUCCCUUU 2524 AAAGGGACCUCCCAGAAGC 2525 CUUCUGGGAGGUCCCUUUU 2526 AAAAGGGACCUCCCAGAAG 2527 UUCUGGGAGGUCCCUUUUC 2528 GAAAAGGGACCUCCCAGAA 2529 UCUGGGAGGUCCCUUUUCA 2530 UGAAAAGGGACCUCCCAGA 2531 CAUGUUAUUUGCCUUUUGA 2532 UCAAAAGGCAAAUAACAUG 2533 AUUUGCCUUUUGAAUUCUC 2534 GAGAAUUCAAAAGGCAAAU 2535 UUUGCCUUUUGAAUUCUCA 2536 UGAGAAUUCAAAAGGCAAA 2537 UUGCCUUUUGAAUUCUCAU 2538 AUGAGAAUUCAAAAGGCAA 2539 UGCCUUUUGAAUUCUCAUU 2540 AAUGAGAAUUCAAAAGGCA 2541 GCCUUUUGAAUUCUCAUUA 2542 UAAUGAGAAUUCAAAAGGC 2543 AUUGUAUUGUGGAGUUUUC 2544 GAAAACUCCACAAUACAAU 2545 UUGUAUUGUGGAGUUUUCC 2546 GGAAAACUCCACAAUACAA 2547 AGUUUUCCAGAGGCCGUGU 2548 ACACGGCCUCUGGAAAACU 2549 GUUUUCCAGAGGCCGUGUG 2550 CACACGGCCUCUGGAAAAC 2551 UUUUCCAGAGGCCGUGUGA 2552 UCACACGGCCUCUGGAAAA 2553 UUUCCAGAGGCCGUGUGAC 2554 GUCACACGGCCUCUGGAAA 2555 UUCCAGAGGCCGUGUGACA 2556 UGUCACACGGCCUCUGGAA 2557 UCCAGAGGCCGUGUGACAU 2558 AUGUCACACGGCCUCUGGA 2559 CCAGAGGCCGUGUGACAUG 2560 CAUGUCACACGGCCUCUGG 2561 CAGAGGCCGUGUGACAUGU 2562 ACAUGUCACACGGCCUCUG 2563 AGAGGCCGUGUGACAUGUG 2564 CACAUGUCACACGGCCUCU 2565 GCCGUGUGACAUGUGAUUA 2566 UAAUCACAUGUCACACGGC 2567 CCGUGUGACAUGUGAUUAC 2568 GUAAUCACAUGUCACACGG 2569 CGUGUGACAUGUGAUUACA 2570 UGUAAUCACAUGUCACACG 2571 GAUUACAUCAUCUUUCUGA 2572 UCAGAAAGAUGAUGUAAUC 2573 AUUACAUCAUCUUUCUGAC 2574 GUCAGAAAGAUGAUGUAAU 2575 UUACAUCAUCUUUCUGACA 2576 UGUCAGAAAGAUGAUGUAA 2577 UACAUCAUCUUUCUGACAU 2578 AUGUCAGAAAGAUGAUGUA 2579 AUCUUUCUGACAUCAUUGU 2580 ACAAUGAUGUCAGAAAGAU 2581 AUUGUUAAUGGAAUGUGUG 2582 CACACAUUCCAUUAACAAU 2583

In some embodiments, the siRNA molecules comprise or consist of the nucleotide sequences (sense and antisense strands) shown in Table 4.

TABLE 4 SEQ SEQ ID ID Sense Sequence NO: Antisense Sequence NO: AAAGUGACUAAGAUGCUAA 2584 UUAGCAUCUUAGUCACUUU 2585 AAGUGACUAAGAUGCUAAG 2586 CUUAGCAUCUUAGUCACUU 2587 AGUGACUAAGAUGCUAAGA 2588 UCUUAGCAUCUUAGUCACU 2589 GUGACUAAGAUGCUAAGAG 2590 CUCUUAGCAUCUUAGUCAC 2591 UGACUAAGAUGCUAAGAGC 2592 GCUCUUAGCAUCUUAGUCA 2593 GACUAAGAUGCUAAGAGCG 2594 CGCUCUUAGCAUCUUAGUC 2595 ACUAAGAUGCUAAGAGCGU 2596 ACGCUCUUAGCAUCUUAGU 2597 CUAAGAUGCUAAGAGCGUA 2598 UACGCUCUUAGCAUCUUAG 2599 UAAGAUGCUAAGAGCGUAU 2600 AUACGCUCUUAGCAUCUUA 2601 AAGAUGCUAAGAGCGUAUU 2602 AAUACGCUCUUAGCAUCUU 2603 AGAUGCUAAGAGCGUAUUU 2604 AAAUACGCUCUUAGCAUCU 2605 GAUGCUAAGAGCGUAUUUA 2606 UAAAUACGCUCUUAGCAUC 2607 AUGCUAAGAGCGUAUUUAU 2608 AUAAAUACGCUCUUAGCAU 2609 UAAGAGCGUAUUUAUAGCU 2610 AGCUAUAAAUACGCUCUUA 2611 AGAGCGUAUUUAUAGCUGA 2612 UCAGCUAUAAAUACGCUCU 2613 GAGCGUAUUUAUAGCUGAG 2614 CUCAGCUAUAAAUACGCUC 2615 AGCGUAUUUAUAGCUGAGC 2616 GCUCAGCUAUAAAUACGCU 2617 GCGUAUUUAUAGCUGAGCU 2618 AGCUCAGCUAUAAAUACGC 2619 CGUAUUUAUAGCUGAGCUC 2620 GAGCUCAGCUAUAAAUACG 2621 GUAUUUAUAGCUGAGCUCU 2622 AGAGCUCAGCUAUAAAUAC 2623 UAUUUAUAGCUGAGCUCUG 2624 CAGAGCUCAGCUAUAAAUA 2625 AUUUAUAGCUGAGCUCUGA 2626 UCAGAGCUCAGCUAUAAAU 2627 UUUAUAGCUGAGCUCUGAC 2628 GUCAGAGCUCAGCUAUAAA 2629 UUAUAGCUGAGCUCUGACG 2630 CGUCAGAGCUCAGCUAUAA 2631 AGCUGAGCUCUGACGUAAG 2632 CUUACGUCAGAGCUCAGCU 2633 GCUGAGCUCUGACGUAAGU 2634 ACUUACGUCAGAGCUCAGC 2635 CUGAGCUCUGACGUAAGUG 2636 CACUUACGUCAGAGCUCAG 2637 UGAGCUCUGACGUAAGUGU 2638 ACACUUACGUCAGAGCUCA 2639 GAGCUCUGACGUAAGUGUC 2640 GACACUUACGUCAGAGCUC 2641 AGGCCAGGCACAGCAGCAA 2642 UUGCUGCUGUGCCUGGCCU 2643 CAGCAAGCGGGUGGGAAGA 2644 UCUUCCCACCCGCUUGCUG 2645 AGCAAGCGGGUGGGAAGAG 2646 CUCUUCCCACCCGCUUGCU 2647 CAAGCGGGUGGGAAGAGCU 2648 AGCUCUUCCCACCCGCUUG 2649 GGGCAUCUGACAGUGAGGG 2650 CCCUCACUGUCAGAUGCCC 2651 GGCAUCUGACAGUGAGGGU 2652 ACCCUCACUGUCAGAUGCC 2653 GUGACUCCUGCAGCCACUU 2654 AAGUGGCUGCAGGAGUCAC 2655 UGACUCCUGCAGCCACUUC 2656 GAAGUGGCUGCAGGAGUCA 2657 ACUCCUGCAGCCACUUCUU 2658 AAGAAGUGGCUGCAGGAGU 2659 CUCCUGCAGCCACUUCUUG 2660 CAAGAAGUGGCUGCAGGAG 2661 UCCUGCAGCCACUUCUUGU 2662 ACAAGAAGUGGCUGCAGGA 2663 CCUGCAGCCACUUCUUGUC 2664 GACAAGAAGUGGCUGCAGG 2665 CUGCAGCCACUUCUUGUCA 2666 UGACAAGAAGUGGCUGCAG 2667 UGACUGCCUACUGAUACCA 2668 UGGUAUCAGUAGGCAGUCA 2669 GACUGCCUACUGAUACCAA 2670 UUGGUAUCAGUAGGCAGUC 2671 ACAGGUAAGCCGUCUGAGG 2672 CCUCAGACGGCUUACCUGU 2673 CAGGUAAGCCGUCUGAGGC 2674 GCCUCAGACGGCUUACCUG 2675 AGGUAAGCCGUCUGAGGCA 2676 UGCCUCAGACGGCUUACCU 2677 GGUAAGCCGUCUGAGGCAC 2678 GUGCCUCAGACGGCUUACC 2679 GUAAGCCGUCUGAGGCACC 2680 GGUGCCUCAGACGGCUUAC 2681 UAAGCCGUCUGAGGCACCA 2682 UGGUGCCUCAGACGGCUUA 2683 AAGCCGUCUGAGGCACCAC 2684 GUGGUGCCUCAGACGGCUU 2685 UAGAUACCUCCACUUUGCU 2686 AGCAAAGUGGAGGUAUCUA 2687 GAUACCUCCACUUUGCUGA 2688 UCAGCAAAGUGGAGGUAUC 2689 AUACCUCCACUUUGCUGAC 2690 GUCAGCAAAGUGGAGGUAU 2691 CCACUUUGCUGACCAAUGU 2692 ACAUUGGUCAGCAAAGUGG 2693 UUUGCUGACCAAUGUUCCA 2694 UGGAACAUUGGUCAGCAAA 2695 UUGCUGACCAAUGUUCCAG 2696 CUGGAACAUUGGUCAGCAA 2697 UGCUGACCAAUGUUCCAGA 2698 UCUGGAACAUUGGUCAGCA 2699 GCUGACCAAUGUUCCAGAC 2700 GUCUGGAACAUUGGUCAGC 2701 CUGACCAAUGUUCCAGACC 2702 GGUCUGGAACAUUGGUCAG 2703 CCAAUGUUCCAGACCCGAG 2704 CUCGGGUCUGGAACAUUGG 2705 GGUAGAGGGCUGUCAUUUC 2706 GAAAUGACAGCCCUCUACC 2707 GUAGAGGGCUGUCAUUUCC 2708 GGAAAUGACAGCCCUCUAC 2709 UGUCAUUUCCCAGCCCAAC 2710 GUUGGGCUGGGAAAUGACA 2711 GAAUGGUUGCUGGGAGCUG 2712 CAGCUCCCAGCAACCAUUC 2713 CUGGACAGAGCUCUUGAAU 2714 AUUCAAGAGCUCUGUCCAG 2715 UGGACAGAGCUCUUGAAUG 2716 CAUUCAAGAGCUCUGUCCA 2717 CAGAGCUCUUGAAUGUGUU 2718 AACACAUUCAAGAGCUCUG 2719 AGAGCUCUUGAAUGUGUUU 2720 AAACACAUUCAAGAGCUCU 2721 AUGUGUUUCAGAGCUUGGG 2722 CCCAAGCUCUGAAACACAU 2723 AAAUGCAGGGUGGACAGGA 2724 UCCUGUCCACCCUGCAUUU 2725 AAUGCAGGGUGGACAGGAG 2726 CUCCUGUCCACCCUGCAUU 2727 AUGCAGGGUGGACAGGAGG 2728 CCUCCUGUCCACCCUGCAU 2729 GGUGGACAGGAGGGUCUAA 2730 UUAGACCCUCCUGUCCACC 2731 GUGGACAGGAGGGUCUAAU 2732 AUUAGACCCUCCUGUCCAC 2733 UGGACAGGAGGGUCUAAUC 2734 GAUUAGACCCUCCUGUCCA 2735 GGACAGGAGGGUCUAAUCG 2736 CGAUUAGACCCUCCUGUCC 2737 GACAGGAGGGUCUAAUCGU 2738 ACGAUUAGACCCUCCUGUC 2739 ACAGGAGGGUCUAAUCGUC 2740 GACGAUUAGACCCUCCUGU 2741 CAGGAGGGUCUAAUCGUCU 2742 AGACGAUUAGACCCUCCUG 2743 AGGAGGGUCUAAUCGUCUC 2744 GAGACGAUUAGACCCUCCU 2745 GGAGGGUCUAAUCGUCUCA 2746 UGAGACGAUUAGACCCUCC 2747 GAGGGUCUAAUCGUCUCAG 2748 CUGAGACGAUUAGACCCUC 2749 AGGGUCUAAUCGUCUCAGU 2750 ACUGAGACGAUUAGACCCU 2751 GGGUCUAAUCGUCUCAGUG 2752 CACUGAGACGAUUAGACCC 2743 GGUCUAAUCGUCUCAGUGC 2754 GCACUGAGACGAUUAGACC 2755 CCCACCAAAGAGUGCCCUG 2756 CAGGGCACUCUUUGGUGGG 2757 CCACCAAAGAGUGCCCUGA 2758 UCAGGGCACUCUUUGGUGG 2759 CCAAAGAGUGCCCUGAGGU 2760 ACCUCAGGGCACUCUUUGG 2761 CAAAGAGUGCCCUGAGGUU 2762 AACCUCAGGGCACUCUUUG 2763 AAAGAGUGCCCUGAGGUUC 2764 GAACCUCAGGGCACUCUUU 2765 AAGAGUGCCCUGAGGUUCU 2766 AGAACCUCAGGGCACUCUU 2767 AGAGUGCCCUGAGGUUCUA 2768 UAGAACCUCAGGGCACUCU 2769 GAGUGCCCUGAGGUUCUAG 2770 CUAGAACCUCAGGGCACUC 2771 AGUGCCCUGAGGUUCUAGG 2772 CCUAGAACCUCAGGGCACU 2773 GUGCCCUGAGGUUCUAGGA 2774 UCCUAGAACCUCAGGGCAC 2775 CCUGAGGUUCUAGGAAGAG 2776 CUCUUCCUAGAACCUCAGG 2777 CUGAGGUUCUAGGAAGAGC 2778 GCUCUUCCUAGAACCUCAG 2779 UUCUAGGAAGAGCCUGGUA 2780 UACCAGGCUCUUCCUAGAA 2781 UCUAGGAAGAGCCUGGUAC 2782 GUACCAGGCUCUUCCUAGA 2783 CUAGGAAGAGCCUGGUACA 2784 UGUACCAGGCUCUUCCUAG 2785 UAGGAAGAGCCUGGUACAU 2786 AUGUACCAGGCUCUUCCUA 2787 AGGAAGAGCCUGGUACAUC 2788 GAUGUACCAGGCUCUUCCU 2789 GGAAGAGCCUGGUACAUCA 2790 UGAUGUACCAGGCUCUUCC 2791 GAAGAGCCUGGUACAUCAC 2792 GUGAUGUACCAGGCUCUUC 2793 AAGAGCCUGGUACAUCACC 2794 GGUGAUGUACCAGGCUCUU 2795 UCACCAAGCUCCAUUGCCA 2796 UGGCAAUGGAGCUUGGUGA 2797 CACCAAGCUCCAUUGCCAC 2798 GUGGCAAUGGAGCUUGGUG 2799 ACCAAGCUCCAUUGCCACG 2800 CGUGGCAAUGGAGCUUGGU 2801 CCAAGCUCCAUUGCCACGU 2802 ACGUGGCAAUGGAGCUUGG 2803 CAAGCUCCAUUGCCACGUG 2804 CACGUGGCAAUGGAGCUUG 2805 AAGCUCCAUUGCCACGUGU 2806 ACACGUGGCAAUGGAGCUU 2807 AGCUCCAUUGCCACGUGUU 2808 AACACGUGGCAAUGGAGCU 2809 CUCCAUUGCCACGUGUUUG 2810 CAAACACGUGGCAAUGGAG 2811 UCCAUUGCCACGUGUUUGU 2812 ACAAACACGUGGCAAUGGA 2813 CCAUUGCCACGUGUUUGUG 2814 CACAAACACGUGGCAAUGG 2815 CAUUGCCACGUGUUUGUGU 2816 ACACAAACACGUGGCAAUG 2817 AAAGGUAGCAGUGAUGUGG 2818 CCACAUCACUGCUACCUUU 2819 AAGGUAGCAGUGAUGUGGA 2820 UCCACAUCACUGCUACCUU 2821 AGGUAGCAGUGAUGUGGAU 2822 AUCCACAUCACUGCUACCU 2823 GGUAGCAGUGAUGUGGAUC 2824 GAUCCACAUCACUGCUACC 2825 GUAGCAGUGAUGUGGAUCC 2826 GGAUCCACAUCACUGCUAC 2827 UAGCAGUGAUGUGGAUCCU 2828 AGGAUCCACAUCACUGCUA 2829 AGCAGUGAUGUGGAUCCUG 2830 CAGGAUCCACAUCACUGCU 2831 GCAGUGAUGUGGAUCCUGA 2832 UCAGGAUCCACAUCACUGC 2833 CAGUGAUGUGGAUCCUGAA 2834 UUCAGGAUCCACAUCACUG 2835 AGUGAUGUGGAUCCUGAAG 2836 CUUCAGGAUCCACAUCACU 2837 GUGAUGUGGAUCCUGAAGA 2838 UCUUCAGGAUCCACAUCAC 2839 GAUGUGGAUCCUGAAGACA 2840 UGUCUUCAGGAUCCACAUC 2841 AUGUGGAUCCUGAAGACAG 2842 CUGUCUUCAGGAUCCACAU 2843 UGUGGAUCCUGAAGACAGU 2844 ACUGUCUUCAGGAUCCACA 2845 GUGGAUCCUGAAGACAGUC 2846 GACUGUCUUCAGGAUCCAC 2847 AUCCUGAAGACAGUCUCUC 2848 GAGAGACUGUCUUCAGGAU 2849 UCCUGAAGACAGUCUCUCU 2850 AGAGAGACUGUCUUCAGGA 2851 AGACAGUCUCUCUUCUCUG 2852 CAGAGAAGAGAGACUGUCU 2853 AGUCUCUCUUCUCUGGCAG 2854 CUGCCAGAGAAGAGAGACU 2855 CUCUUCUCUGGCAGUGUGA 2856 UCACACUGCCAGAGAAGAG 2857 AACCAGCUUGUCCCUGUCU 2858 AGACAGGGACAAGCUGGUU 2859 CAGCUUGUCCCUGUCUCUU 2860 AAGAGACAGGGACAAGCUG 2861 CAGCUGCUGUCCAGAGGCA 2862 UGCCUCUGGACAGCAGCUG 2863 CACGGCACUGCCACAUGGU 2864 ACCAUGUGGCAGUGCCGUG 2865 ACGGCACUGCCACAUGGUG 2866 CACCAUGUGGCAGUGCCGU 2867 AUGGUGGACACUGGUGGUA 2868 UACCACCAGUGUCCACCAU 2869 UGGUGGACACUGGUGGUAC 2870 GUACCACCAGUGUCCACCA 2871 GGUGGACACUGGUGGUACU 2872 AGUACCACCAGUGUCCACC 2873 GUGGACACUGGUGGUACUG 2874 CAGUACCACCAGUGUCCAC 2875 UGGACACUGGUGGUACUGA 2876 UCAGUACCACCAGUGUCCA 2877 GGACACUGGUGGUACUGAG 2878 CUCAGUACCACCAGUGUCC 2879 GACACUGGUGGUACUGAGG 2880 CCUCAGUACCACCAGUGUC 2881 ACACUGGUGGUACUGAGGU 2882 ACCUCAGUACCACCAGUGU 2883 CACUGGUGGUACUGAGGUC 2884 GACCUCAGUACCACCAGUG 2885 ACUGGUGGUACUGAGGUCC 2886 GGACCUCAGUACCACCAGU 2887 CUGGUGGUACUGAGGUCCA 2888 UGGACCUCAGUACCACCAG 2889 UACUGAGGUCCAGCCUUCC 2890 GGAAGGCUGGACCUCAGUA 2891 CUGAGGUCCAGCCUUCCAA 2892 UUGGAAGGCUGGACCUCAG 2893 UGAGGUCCAGCCUUCCAAU 2894 AUUGGAAGGCUGGACCUCA 2895 GAGGUCCAGCCUUCCAAUU 2896 AAUUGGAAGGCUGGACCUC 2897 AGGUCCAGCCUUCCAAUUA 2898 UAAUUGGAAGGCUGGACCU 2899 GGUCCAGCCUUCCAAUUAG 2900 CUAAUUGGAAGGCUGGACC 2901 GUCCAGCCUUCCAAUUAGG 2902 CCUAAUUGGAAGGCUGGAC 2903 UCCAGCCUUCCAAUUAGGA 2904 UCCUAAUUGGAAGGCUGGA 2905 GCCUAGAUCUAAUAGUCUC 2906 GAGACUAUUAGAUCUAGGC 2907 CCUAGAUCUAAUAGUCUCU 2908 AGAGACUAUUAGAUCUAGG 2909 CUAGAUCUAAUAGUCUCUC 2910 GAGAGACUAUUAGAUCUAG 2911 UAGAUCUAAUAGUCUCUCU 2912 AGAGAGACUAUUAGAUCUA 2913 CUAAUAGUCUCUCUUGACA 2914 UGUCAAGAGAGACUAUUAG 2915 UAAUAGUCUCUCUUGACAG 2916 CUGUCAAGAGAGACUAUUA 2917 AAUAGUCUCUCUUGACAGC 2918 GCUGUCAAGAGAGACUAUU 2919 AUGAGCAAAGUGGAGUAAA 2920 UUUACUCCACUUUGCUCAU 2921 UGAGCAAAGUGGAGUAAAG 2922 CUUUACUCCACUUUGCUCA 2923 GAGCAAAGUGGAGUAAAGA 2924 UCUUUACUCCACUUUGCUC 2925 GCAAAGUGGAGUAAAGACA 2926 UGUCUUUACUCCACUUUGC 2927 CAAAGUGGAGUAAAGACAC 2928 GUGUCUUUACUCCACUUUG 2929 AUUUCCAAAUCACACCCAC 2930 GUGGGUGUGAUUUGGAAAU 2931 UCCAAAUCACACCCACUUC 2932 GAAGUGGGUGUGAUUUGGA 2933 CCAAAUCACACCCACUUCC 2934 GGAAGUGGGUGUGAUUUGG 2935 AAAAGCUAGCAUGAGGCCC 2936 GGGCCUCAUGCUAGCUUUU 2937 AAAGCUAGCAUGAGGCCCA 2938 UGGGCCUCAUGCUAGCUUU 2939 AAGCUAGCAUGAGGCCCAC 2940 GUGGGCCUCAUGCUAGCUU 2941 CCCACCUUCAUGAAUUCAA 2942 UUGAAUUCAUGAAGGUGGG 2943 ACCUUCAUGAAUUCAAUGU 2944 ACAUUGAAUUCAUGAAGGU 2945 CCUUCAUGAAUUCAAUGUG 2946 CACAUUGAAUUCAUGAAGG 2947 CUUCAUGAAUUCAAUGUGG 2948 CCACAUUGAAUUCAUGAAG 2949 UCAUGAAUUCAAUGUGGAG 2950 CUCCACAUUGAAUUCAUGA 2951 CAUGAAUUCAAUGUGGAGG 2952 CCUCCACAUUGAAUUCAUG 2953 CAUUUAAAGCCAGUGAGGA 2954 UCCUCACUGGCUUUAAAUG 2955 UUUAAAGCCAGUGAGGACU 2956 AGUCCUCACUGGCUUUAAA 2957 AGGACUGGGUGUGGUGGCU 2958 AGCCACCACACCCAGUCCU 2959 GACUGGGUGUGGUGGCUCA 2960 UGAGCCACCACACCCAGUC 2961 ACUGGGUGUGGUGGCUCAU 2962 AUGAGCCACCACACCCAGU 2963 CUGGGUGUGGUGGCUCAUG 2964 CAUGAGCCACCACACCCAG 2965 UGGGUGUGGUGGCUCAUGU 2966 ACAUGAGCCACCACACCCA 2967 GGGUGUGGUGGCUCAUGUC 2968 GACAUGAGCCACCACACCC 2969 GGUGUGGUGGCUCAUGUCU 2970 AGACAUGAGCCACCACACC 2971 GUGUGGUGGCUCAUGUCUA 2972 UAGACAUGAGCCACCACAC 2973 UGUGGUGGCUCAUGUCUAU 2974 AUAGACAUGAGCCACCACA 2975 GAGGAUCGCUUGAGCCCAG 2976 CUGGGCUCAAGCGAUCCUC 2977 AAAUAAAUUAGCCUGUGUG 2978 CACACAGGCUAAUUUAUUU 2979 AAUUAGCCUGUGUGGUGUG 2980 CACACCACACAGGCUAAUU 2981 AUUAGCCUGUGUGGUGUGG 2982 CCACACCACACAGGCUAAU 2983 GCCUGUGUGGUGUGGUGUG 2984 CACACCACACCACACAGGC 2985 UGUGGUGUGGUGUGGUUGG 2986 CCAACCACACCACACCACA 2987 GGUGUGGUGUGGUUGGUGU 2988 ACACCAACCACACCACACC 2989 UGUGGUUGGUGUGGUGGCA 2990 UGCCACCACACCAACCACA 2991 GUGGUUGGUGUGGUGGCAC 2992 GUGCCACCACACCAACCAC 2993 UGGUUGGUGUGGUGGCACG 2994 CGUGCCACCACACCAACCA 2995 CACGCACCUGUAGACUUAG 2996 CUAAGUCUACAGGUGCGUG 2997 ACGCACCUGUAGACUUAGC 2998 GCUAAGUCUACAGGUGCGU 2999 AGACUUAGCUACUCUGGAA 3000 UUCCAGAGUAGCUAAGUCU 3001 GACUUAGCUACUCUGGAAG 3002 CUUCCAGAGUAGCUAAGUC 3003 ACUUAGCUACUCUGGAAGC 3004 GCUUCCAGAGUAGCUAAGU 3005 GGAAGAAUCACUUAACCCA 3006 UGGGUUAAGUGAUUCUUCC 3007 UCACUUAACCCAGGAGGUC 3008 GACCUCCUGGGUUAAGUGA 3009 UUAACCCAGGAGGUCAAGG 3010 CCUUGACCUCCUGGGUUAA 3011 UAACCCAGGAGGUCAAGGC 3012 GCCUUGACCUCCUGGGUUA 3013 GUCAAGGCUGCAGUGAGCU 3014 AGCUCACUGCAGCCUUGAC 3015 UCAAGGCUGCAGUGAGCUG 3016 CAGCUCACUGCAGCCUUGA 3017 CAAGGCUGCAGUGAGCUGU 3018 ACAGCUCACUGCAGCCUUG 3019 AAGGCUGCAGUGAGCUGUG 3020 CACAGCUCACUGCAGCCUU 3021 CUGCAGUGAGCUGUGAUCA 3022 UGAUCACAGCUCACUGCAG 3023 GUCAGGUGCGGUGGCUCAU 3024 AUGAGCCACCGCACCUGAC 3025 UCAGGUGCGGUGGCUCAUG 3026 CAUGAGCCACCGCACCUGA 3027 UGCGGUGGCUCAUGCCUGU 3028 ACAGGCAUGAGCCACCGCA 3029 GCGGUGGCUCAUGCCUGUA 3030 UACAGGCAUGAGCCACCGC 3031 CGGUGGCUCAUGCCUGUAA 3032 UUACAGGCAUGAGCCACCG 3033 GGUGGCUCAUGCCUGUAAU 3034 AUUACAGGCAUGAGCCACC 3035 GUGGCUCAUGCCUGUAAUC 3036 GAUUACAGGCAUGAGCCAC 3037 UGGCUCAUGCCUGUAAUCC 3038 GGAUUACAGGCAUGAGCCA 3039 GGCUCAUGCCUGUAAUCCC 3040 GGGAUUACAGGCAUGAGCC 3041 AUGCCUGUAAUCCCAGCAC 3042 GUGCUGGGAUUACAGGCAU 3043 CAGCACUUUGGGAGGCCGA 3044 UCGGCCUCCCAAAGUGCUG 3045 AGCACUUUGGGAGGCCGAG 3046 CUCGGCCUCCCAAAGUGCU 3047 GCACCUGUAGUCCCAGCGA 3048 UCGCUGGGACUACAGGUGC 3049 CACCUGUAGUCCCAGCGAC 3050 GUCGCUGGGACUACAGGUG 3051 GGAGGCUGAGGCAGAAGAA 3052 UUCUUCUGCCUCAGCCUCC 3053 GAGGCUGAGGCAGAAGAAU 3054 AUUCUUCUGCCUCAGCCUC 3055 AGGCUGAGGCAGAAGAAUG 3056 CAUUCUUCUGCCUCAGCCU 3057 GGCUGAGGCAGAAGAAUGG 3058 CCAUUCUUCUGCCUCAGCC 3059 GCUGAGGCAGAAGAAUGGU 3060 ACCAUUCUUCUGCCUCAGC 3061 CUGAGGCAGAAGAAUGGUG 3062 CACCAUUCUUCUGCCUCAG 3063 UGAGGCAGAAGAAUGGUGU 3064 ACACCAUUCUUCUGCCUCA 3065 GAGCUUGCAGUGAGCCGAG 3066 CUCGGCUCACUGCAAGCUC 3067 AAAAUGUGGUCAGGAGGGC 3068 GCCCUCCUGACCACAUUUU 3069 AACCAAGACUGCUGUAUUU 3070 AAAUACAGCAGUCUUGGUU 3071 ACCAAGACUGCUGUAUUUG 3072 CAAAUACAGCAGUCUUGGU 3073 CCAAGACUGCUGUAUUUGC 3074 GCAAAUACAGCAGUCUUGG 3075 CAAGACUGCUGUAUUUGCC 3076 GGCAAAUACAGCAGUCUUG 3077 AAGACUGCUGUAUUUGCCU 3078 AGGCAAAUACAGCAGUCUU 3079 GCUGUAUUUGCCUUGCUUU 3080 AAAGCAAGGCAAAUACAGC 3081 UUGCCUUGCUUUGUUGUCA 3082 UGACAACAAAGCAAGGCAA 3083 UGCCUUGCUUUGUUGUCAA 3084 UUGACAACAAAGCAAGGCA 3085 UUGUUGUCAAAAGCUCUUA 3086 UAAGAGCUUUUGACAACAA 3087 UGUUGUCAAAAGCUCUUAG 3088 CUAAGAGCUUUUGACAACA 3089 GUUGUCAAAAGCUCUUAGA 3090 UCUAAGAGCUUUUGACAAC 3091 UUGUCAAAAGCUCUUAGAG 3092 CUCUAAGAGCUUUUGACAA 3093 UCUUAGAGCUCCCAUUUUC 3094 GAAAAUGGGAGCUCUAAGA 3095 ACUUUAGGAGGCUGAGGCA 3096 UGCCUCAGCCUCCUAAAGU 3097 CUUUAGGAGGCUGAGGCAA 3098 UUGCCUCAGCCUCCUAAAG 3099 UUUAGGAGGCUGAGGCAAG 3100 CUUGCCUCAGCCUCCUAAA 3101 UUAGGAGGCUGAGGCAAGU 3102 ACUUGCCUCAGCCUCCUAA 3103 UAGGAGGCUGAGGCAAGUG 3104 CACUUGCCUCAGCCUCCUA 3105 AGGAGGCUGAGGCAAGUGG 3106 CCACUUGCCUCAGCCUCCU 3107 GGAGGCUGAGGCAAGUGGA 3108 UCCACUUGCCUCAGCCUCC 3109 GAGGCUGAGGCAAGUGGAU 3110 AUCCACUUGCCUCAGCCUC 3111 GUGGAUUGCUUGAGCCCAG 3112 CUGGGCUCAAGCAAUCCAC 3113 UGGAUUGCUUGAGCCCAGG 3114 CCUGGGCUCAAGCAAUCCA 3115 GGAUUGCUUGAGCCCAGGA 3116 UCCUGGGCUCAAGCAAUCC 3117 GAUUGCUUGAGCCCAGGAG 3118 CUCCUGGGCUCAAGCAAUC 3119 AUUGCUUGAGCCCAGGAGU 3120 ACUCCUGGGCUCAAGCAAU 3121 UUGCUUGAGCCCAGGAGUU 3122 AACUCCUGGGCUCAAGCAA 3123 UGCUUGAGCCCAGGAGUUC 3124 GAACUCCUGGGCUCAAGCA 3125 UGAGCCCAGGAGUUCAAGA 3126 UCUUGAACUCCUGGGCUCA 3127 AUUAGCCAGGUGUGGUGGU 3128 ACCACCACACCUGGCUAAU 3129 UUAGCCAGGUGUGGUGGUG 3130 CACCACCACACCUGGCUAA 3131 GUGCGCACCUGUAGUCCCA 3132 UGGGACUACAGGUGCGCAC 3133 UGCGCACCUGUAGUCCCAA 3134 UUGGGACUACAGGUGCGCA 3135 GCGCACCUGUAGUCCCAAC 3136 GUUGGGACUACAGGUGCGC 3137 CGCACCUGUAGUCCCAACU 3138 AGUUGGGACUACAGGUGCG 3139 UACUAAGGAGGCUGAGGCA 3140 UGCCUCAGCCUCCUUAGUA 3141 ACUAAGGAGGCUGAGGCAG 3142 CUGCCUCAGCCUCCUUAGU 3143 UUCAAGGCUGCAGUGAGCU 3144 AGCUCACUGCAGCCUUGAA 3145 UCAAGGCUGCAGUGAGCUA 3146 UAGCUCACUGCAGCCUUGA 3147 CAAGGCUGCAGUGAGCUAU 3148 AUAGCUCACUGCAGCCUUG 3149 AAGGCUGCAGUGAGCUAUG 3150 CAUAGCUCACUGCAGCCUU 3151 UGCAGUGAGCUAUGAUUGU 3152 ACAAUCAUAGCUCACUGCA 3153 GCAGUGAGCUAUGAUUGUG 3154 CACAAUCAUAGCUCACUGC 3155 CAGUGAGCUAUGAUUGUGC 3156 GCACAAUCAUAGCUCACUG 3157 GGAGGCCUGGCACUACUUC 3158 GAAGUAGUGCCAGGCCUCC 3159 GAGGCCUGGCACUACUUCU 3160 AGAAGUAGUGCCAGGCCUC 3161 AGGCCUGGCACUACUUCUA 3162 UAGAAGUAGUGCCAGGCCU 3163 GGCCUGGCACUACUUCUAG 3164 CUAGAAGUAGUGCCAGGCC 3165 GCCUGGCACUACUUCUAGG 3166 CCUAGAAGUAGUGCCAGGC 3167 CCUGGCACUACUUCUAGGA 3168 UCCUAGAAGUAGUGCCAGG 3169 CUGGCACUACUUCUAGGAU 3170 AUCCUAGAAGUAGUGCCAG 3171 UGGCACUACUUCUAGGAUG 3172 CAUCCUAGAAGUAGUGCCA 3173 AAUUUAGGCAACUCUCACA 3174 UGUGAGAGUUGCCUAAAUU 3175 AUUUAGGCAACUCUCACAG 3176 CUGUGAGAGUUGCCUAAAU 3177 UUUAGGCAACUCUCACAGU 3178 ACUGUGAGAGUUGCCUAAA 3179 UUAGGCAACUCUCACAGUC 3180 GACUGUGAGAGUUGCCUAA 3181 UAGGCAACUCUCACAGUCC 3182 GGACUGUGAGAGUUGCCUA 3183 AGGCAACUCUCACAGUCCC 3184 GGGACUGUGAGAGUUGCCU 3185 GGCAACUCUCACAGUCCCU 3186 AGGGACUGUGAGAGUUGCC 3187 GCAACUCUCACAGUCCCUU 3188 AAGGGACUGUGAGAGUUGC 3189 CAACUCUCACAGUCCCUUG 3190 CAAGGGACUGUGAGAGUUG 3191 AACUCUCACAGUCCCUUGA 3192 UCAAGGGACUGUGAGAGUU 3193 ACUCUCACAGUCCCUUGAA 3194 UUCAAGGGACUGUGAGAGU 3195 AGAAGUGGCAGCUGGGUAU 3196 AUACCCAGCUGCCACUUCU 3197 GAAGUGGCAGCUGGGUAUA 3198 UAUACCCAGCUGCCACUUC 3199 AAGUGGCAGCUGGGUAUAG 3200 CUAUACCCAGCUGCCACUU 3201 AGUGGCAGCUGGGUAUAGG 3202 CCUAUACCCAGCUGCCACU 3203 GUGGCAGCUGGGUAUAGGC 3204 GCCUAUACCCAGCUGCCAC 3205 UGGCAGCUGGGUAUAGGCC 3206 GGCCUAUACCCAGCUGCCA 3207 GCAGCUGGGUAUAGGCCCU 3208 AGGGCCUAUACCCAGCUGC 3209 CAGCUGGGUAUAGGCCCUC 3210 GAGGGCCUAUACCCAGCUG 3211 AGCUGGGUAUAGGCCCUCC 3212 GGAGGGCCUAUACCCAGCU 3213 GGUAUAGGCCCUCCCAAGU 3214 ACUUGGGAGGGCCUAUACC 3215 GUAUAGGCCCUCCCAAGUG 3216 CACUUGGGAGGGCCUAUAC 3217 UAUAGGCCCUCCCAAGUGU 3218 ACACUUGGGAGGGCCUAUA 3219 AUAGGCCCUCCCAAGUGUC 3220 GACACUUGGGAGGGCCUAU 3221 UAGGCCCUCCCAAGUGUCA 3222 UGACACUUGGGAGGGCCUA 3223 CCCUCCCAAGUGUCAUGCC 3224 GGCAUGACACUUGGGAGGG 3225 CCUCCCAAGUGUCAUGCCC 3226 GGGCAUGACACUUGGGAGG 3227 CCCUGACAGUCCUGAUGGA 3228 UCCAUCAGGACUGUCAGGG 3229 CUGAUGGACUCUGCCCUGU 3230 ACAGGGCAGAGUCCAUCAG 3231 UGAUGGACUCUGCCCUGUG 3232 CACAGGGCAGAGUCCAUCA 3233 UGGACUCUGCCCUGUGUAA 3234 UUACACAGGGCAGAGUCCA 3235 GGACUCUGCCCUGUGUAAG 3236 CUUACACAGGGCAGAGUCC 3237 GACUCUGCCCUGUGUAAGA 3238 UCUUACACAGGGCAGAGUC 3239 CUGCCCUGUGUAAGAUUGC 3240 GCAAUCUUACACAGGGCAG 3241 UGCCCUGUGUAAGAUUGCA 3242 UGCAAUCUUACACAGGGCA 3243 GCCCUGUGUAAGAUUGCAU 3244 AUGCAAUCUUACACAGGGC 3245 CCCUGUGUAAGAUUGCAUC 3246 GAUGCAAUCUUACACAGGG 3247 CUGUGUAAGAUUGCAUCAC 3248 GUGAUGCAAUCUUACACAG 3249 UGUGUAAGAUUGCAUCACC 3250 GGUGAUGCAAUCUUACACA 3251 GUGUAAGAUUGCAUCACCA 3252 UGGUGAUGCAAUCUUACAC 3253 UGUAAGAUUGCAUCACCAC 3254 GUGGUGAUGCAAUCUUACA 3255 CACCACCACCACCACCUCU 3256 AGAGGUGGUGGUGGUGGUG 3257 ACCACCACCACCACCUCUC 3258 GAGAGGUGGUGGUGGUGGU 3259 CCACCACCACCACCUCUCU 3260 AGAGAGGUGGUGGUGGUGG 3261 CACCACCACCACCUCUCUG 3262 CAGAGAGGUGGUGGUGGUG 3263 ACCACCACCACCUCUCUGG 3264 CCAGAGAGGUGGUGGUGGU 3265 UGGCCCUCCUCCACAUCAU 3266 AUGAUGUGGAGGAGGGCCA 3267 GGCCCUCCUCCACAUCAUG 3268 CAUGAUGUGGAGGAGGGCC 3269 GCCCUCCUCCACAUCAUGC 3270 GCAUGAUGUGGAGGAGGGC 3271 CCCUCCUCCACAUCAUGCU 3272 AGCAUGAUGUGGAGGAGGG 3273 CCUCCUCCACAUCAUGCUC 3274 GAGCAUGAUGUGGAGGAGG 3275 CUCCUCCACAUCAUGCUCC 3276 GGAGCAUGAUGUGGAGGAG 3277 UCCUCCACAUCAUGCUCCA 3278 UGGAGCAUGAUGUGGAGGA 3279 CCUCCACAUCAUGCUCCAC 3280 GUGGAGCAUGAUGUGGAGG 3281 CUCCACAUCAUGCUCCACA 3282 UGUGGAGCAUGAUGUGGAG 3283 ACAUCAUGCUCCACAUCAU 3284 AUGAUGUGGAGCAUGAUGU 3285 AUGCUCCACAUCAUGCUCC 3286 GGAGCAUGAUGUGGAGCAU 3287 GCUCCACAUCAUGCUCCAG 3288 CUGGAGCAUGAUGUGGAGC 3289 CUCCACAUCAUGCUCCAGG 3290 CCUGGAGCAUGAUGUGGAG 3291 UCCACAUCAUGCUCCAGGC 3292 GCCUGGAGCAUGAUGUGGA 3293 CCACAUCAUGCUCCAGGCC 3294 GGCCUGGAGCAUGAUGUGG 3295 CACAUCAUGCUCCAGGCCA 3296 UGGCCUGGAGCAUGAUGUG 3297 ACAUCAUGCUCCAGGCCAA 3298 UUGGCCUGGAGCAUGAUGU 3299 CAUCAUGCUCCAGGCCAAC 3300 GUUGGCCUGGAGCAUGAUG 3301 AUCAUGCUCCAGGCCAACU 3302 AGUUGGCCUGGAGCAUGAU 3303 UCAUGCUCCAGGCCAACUG 3304 CAGUUGGCCUGGAGCAUGA 3305 GUGACUUCUGUGCCUCGUG 3306 CACGAGGCACAGAAGUCAC 3307 UGACUUCUGUGCCUCGUGG 3308 CCACGAGGCACAGAAGUCA 3309 GACUUCUGUGCCUCGUGGC 3310 GCCACGAGGCACAGAAGUC 3311 CACCUGGGCCUGAGCAAGA 3312 UCUUGCUCAGGCCCAGGUG 3313 ACCUGGGCCUGAGCAAGAG 3314 CUCUUGCUCAGGCCCAGGU 3315 AGCAAGAGGGCUCCAUUCU 3316 AGAAUGGAGCCCUCUUGCU 3317 GCAAGAGGGCUCCAUUCUC 3318 GAGAAUGGAGCCCUCUUGC 3319 CAAGAGGGCUCCAUUCUCC 3320 GGAGAAUGGAGCCCUCUUG 3321 AGAGGGCUCCAUUCUCCUA 3322 UAGGAGAAUGGAGCCCUCU 3323 GAGGGCUCCAUUCUCCUAC 3324 GUAGGAGAAUGGAGCCCUC 3325 AGGGCUCCAUUCUCCUACC 3326 GGUAGGAGAAUGGAGCCCU 3327 GGGCUCCAUUCUCCUACCC 3328 GGGUAGGAGAAUGGAGCCC 3329 AACCCUCAUCCCUGUCCUA 3330 UAGGACAGGGAUGAGGGUU 3331 ACCCUCAUCCCUGUCCUAG 3332 CUAGGACAGGGAUGAGGGU 3333 CCCUCAUCCCUGUCCUAGC 3334 GCUAGGACAGGGAUGAGGG 3335 CCUCAUCCCUGUCCUAGCC 3336 GGCUAGGACAGGGAUGAGG 3337 GAAUUUUCCUUCUGGCCUA 3338 UAGGCCAGAAGGAAAAUUC 3339 AAUUUUCCUUCUGGCCUAA 3340 UUAGGCCAGAAGGAAAAUU 3341 UGCUGCAGCAGUGGUGAAG 3342 CUUCACCACUGCUGCAGCA 3343 GCUGCAGCAGUGGUGAAGC 3344 GCUUCACCACUGCUGCAGC 3345 CUGCAGCAGUGGUGAAGCU 3346 AGCUUCACCACUGCUGCAG 3347 UGCAGCAGUGGUGAAGCUA 3348 UAGCUUCACCACUGCUGCA 3349 AAAGACUAGAGGUAUGAGG 3350 CCUCAUACCUCUAGUCUUU 3351 AAGACUAGAGGUAUGAGGG 3352 CCCUCAUACCUCUAGUCUU 3353 AGACUAGAGGUAUGAGGGA 3354 UCCCUCAUACCUCUAGUCU 3355 GACUAGAGGUAUGAGGGAA 3356 UUCCCUCAUACCUCUAGUC 3357 CCCACCUGGCUCAUAAGGC 3358 GCCUUAUGAGCCAGGUGGG 3359 CCACCUGGCUCAUAAGGCG 3360 CGCCUUAUGAGCCAGGUGG 3361 CACCUGGCUCAUAAGGCGU 3362 ACGCCUUAUGAGCCAGGUG 3363 ACCUGGCUCAUAAGGCGUU 3364 AACGCCUUAUGAGCCAGGU 3365 CUGGCUCAUAAGGCGUUCC 3366 GGAACGCCUUAUGAGCCAG 3367 CUCAUAAGGCGUUCCCUCC 3368 GGAGGGAACGCCUUAUGAG 3369 UCAUAAGGCGUUCCCUCCC 3370 GGGAGGGAACGCCUUAUGA 3371 AAAUCAUCCUCUUUCUUGC 3372 GCAAGAAAGAGGAUGAUUU 3373 AAUCAUCCUCUUUCUUGCA 3374 UGCAAGAAAGAGGAUGAUU 3375 UCAUCCUCUUUCUUGCAUC 3376 GAUGCAAGAAAGAGGAUGA 3377 CAUCCUCUUUCUUGCAUCA 3378 UGAUGCAAGAAAGAGGAUG 3379 AUCCUCUUUCUUGCAUCAU 3380 AUGAUGCAAGAAAGAGGAU 3381 UCCUCUUUCUUGCAUCAUG 3382 CAUGAUGCAAGAAAGAGGA 3383 CUCUUUCUUGCAUCAUGCG 3384 CGCAUGAUGCAAGAAAGAG 3385 UCUUUCUUGCAUCAUGCGU 3386 ACGCAUGAUGCAAGAAAGA 3387 CUUUCUUGCAUCAUGCGUG 3388 CACGCAUGAUGCAAGAAAG 3389 UUUCUUGCAUCAUGCGUGU 3390 ACACGCAUGAUGCAAGAAA 3391 UUCUUGCAUCAUGCGUGUC 3392 GACACGCAUGAUGCAAGAA 3393 UCUUGCAUCAUGCGUGUCC 3394 GGACACGCAUGAUGCAAGA 3395 CUUGCAUCAUGCGUGUCCA 3396 UGGACACGCAUGAUGCAAG 3397 UCAUGCGUGUCCACAUUGC 3398 GCAAUGUGGACACGCAUGA 3399 CAUGCGUGUCCACAUUGCA 3400 UGCAAUGUGGACACGCAUG 3401 CCCUACUUCAGGCCCAGUC 3402 GACUGGGCCUGAAGUAGGG 3403 CCUACUUCAGGCCCAGUCA 3404 UGACUGGGCCUGAAGUAGG 3405 UUCAGGCCCAGUCACCAUG 3406 CAUGGUGACUGGGCCUGAA 3407 UCAGGCCCAGUCACCAUGG 3408 CCAUGGUGACUGGGCCUGA 3409 CCAGUCACCAUGGCCAGAU 3410 AUCUGGCCAUGGUGACUGG 3411 CAGUCACCAUGGCCAGAUG 3412 CAUCUGGCCAUGGUGACUG 3413 AGCACAGCUGGCCAAUCCU 3414 AGGAUUGGCCAGCUGUGCU 3415 GCACAGCUGGCCAAUCCUG 3416 CAGGAUUGGCCAGCUGUGC 3417 AGCUGGCCAAUCCUGGGAC 3418 GUCCCAGGAUUGGCCAGCU 3419 GCUGGCCAAUCCUGGGACU 3420 AGUCCCAGGAUUGGCCAGC 3421 CUGGCCAAUCCUGGGACUC 3422 GAGUCCCAGGAUUGGCCAG 3423 UGGCCAAUCCUGGGACUCA 3424 UGAGUCCCAGGAUUGGCCA 3425 AUCCUGGGACUCAGAGGGU 3426 ACCCUCUGAGUCCCAGGAU 3427 UCCUGGGACUCAGAGGGUA 3428 UACCCUCUGAGUCCCAGGA 3429 CCUGGGACUCAGAGGGUAG 3430 CUACCCUCUGAGUCCCAGG 3431 CUGGGACUCAGAGGGUAGG 3432 CCUACCCUCUGAGUCCCAG 3433 GGACUCAGAGGGUAGGUCG 3434 CGACCUACCCUCUGAGUCC 3435 GACUCAGAGGGUAGGUCGG 3436 CCGACCUACCCUCUGAGUC 3437 ACUCAGAGGGUAGGUCGGC 3438 GCCGACCUACCCUCUGAGU 3439 CUCAGAGGGUAGGUCGGCU 3440 AGCCGACCUACCCUCUGAG 3441 UCAGAGGGUAGGUCGGCUG 3442 CAGCCGACCUACCCUCUGA 3443 GGCUGGCUGACCACUAGGU 3444 ACCUAGUGGUCAGCCAGCC 3445 GCUGGCUGACCACUAGGUU 3446 AACCUAGUGGUCAGCCAGC 3447 CUGGCUGACCACUAGGUUU 3448 AAACCUAGUGGUCAGCCAG 3449 CUGACCACUAGGUUUGGAA 3450 UUCCAAACCUAGUGGUCAG 3451 UGACCACUAGGUUUGGAAG 3452 CUUCCAAACCUAGUGGUCA 3453 GACCACUAGGUUUGGAAGA 3454 UCUUCCAAACCUAGUGGUC 3455 ACCACUAGGUUUGGAAGAC 3456 GUCUUCCAAACCUAGUGGU 3457 CCACUAGGUUUGGAAGACC 3458 GGUCUUCCAAACCUAGUGG 3459 UAGGUUUGGAAGACCCAGG 3460 CCUGGGUCUUCCAAACCUA 3461 AGGUUUGGAAGACCCAGGC 3462 GCCUGGGUCUUCCAAACCU 3463 CAGGCAGCUGGCUCUAAAG 3464 CUUUAGAGCCAGCUGCCUG 3465 AGGCAGCUGGCUCUAAAGA 3466 UCUUUAGAGCCAGCUGCCU 3467 AGCUGGCUCUAAAGAGGCC 3468 GGCCUCUUUAGAGCCAGCU 3469 GCUGGCUCUAAAGAGGCCC 3470 GGGCCUCUUUAGAGCCAGC 3471 CCAGGUCAGUAGCCAGACA 3472 UGUCUGGCUACUGACCUGG 3473 GUCAGUAGCCAGACAUGAG 3474 CUCAUGUCUGGCUACUGAC 3475 GUAGCCAGACAUGAGCUGU 3476 ACAGCUCAUGUCUGGCUAC 3477 AGACAUGAGCUGUGAGGGU 3478 ACCCUCACAGCUCAUGUCU 3479 AUGAGCUGUGAGGGUCAAG 3480 CUUGACCCUCACAGCUCAU 3481 UGAGCUGUGAGGGUCAAGC 3482 GCUUGACCCUCACAGCUCA 3483 GAGCUGUGAGGGUCAAGCA 3484 UGCUUGACCCUCACAGCUC 3485 AGCUGUGAGGGUCAAGCAC 3486 GUGCUUGACCCUCACAGCU 3487 GUGAGGGUCAAGCACAGCU 3488 AGCUGUGCUUGACCCUCAC 3489 UGAGGGUCAAGCACAGCUA 3490 UAGCUGUGCUUGACCCUCA 3491 GAGGGUCAAGCACAGCUAU 3492 AUAGCUGUGCUUGACCCUC 3493 AGGGUCAAGCACAGCUAUC 3494 GAUAGCUGUGCUUGACCCU 3495 GGGUCAAGCACAGCUAUCC 3496 GGAUAGCUGUGCUUGACCC 3497 CAAGCACAGCUAUCCAUCA 3498 UGAUGGAUAGCUGUGCUUG 3499 CACAGCUAUCCAUCAGAUG 3500 CAUCUGAUGGAUAGCUGUG 3501 ACAGCUAUCCAUCAGAUGA 3502 UCAUCUGAUGGAUAGCUGU 3503 CAGCUAUCCAUCAGAUGAU 3504 AUCAUCUGAUGGAUAGCUG 3505 AGCUAUCCAUCAGAUGAUC 3506 GAUCAUCUGAUGGAUAGCU 3507 GCUAUCCAUCAGAUGAUCU 3508 AGAUCAUCUGAUGGAUAGC 3509 CUAUCCAUCAGAUGAUCUA 3510 UAGAUCAUCUGAUGGAUAG 3511 CAUCAGAUGAUCUACUUUC 3512 GAAAGUAGAUCAUCUGAUG 3513 AGAUGAUCUACUUUCAGCC 3514 GGCUGAAAGUAGAUCAUCU 3515 GAUCUACUUUCAGCCUUCC 3516 GGAAGGCUGAAAGUAGAUC 3517 AUCUACUUUCAGCCUUCCU 3518 AGGAAGGCUGAAAGUAGAU 3519 CAAUAGAAGACAGGUGGCU 3520 AGCCACCUGUCUUCUAUUG 3521 AAUAGAAGACAGGUGGCUG 3522 CAGCCACCUGUCUUCUAUU 3523 CAGGUGGCUGUACCCUUGG 3524 CCAAGGGUACAGCCACCUG 3525 AGGUGGCUGUACCCUUGGC 3526 GCCAAGGGUACAGCCACCU 3527 GGCUGUACCCUUGGCCAAG 3528 CUUGGCCAAGGGUACAGCC 3529 UGGUGUCUGCUGUCACUGU 3530 ACAGUGACAGCAGACACCA 3531 GUCUGCUGUCACUGUGCCC 3532 GGGCACAGUGACAGCAGAC 3533 CUGCUGUCACUGUGCCCUC 3534 GAGGGCACAGUGACAGCAG 3535 UGCUGUCACUGUGCCCUCA 3536 UGAGGGCACAGUGACAGCA 3537 GCUGUCACUGUGCCCUCAU 3538 AUGAGGGCACAGUGACAGC 3539 CUGUCACUGUGCCCUCAUU 3540 AAUGAGGGCACAGUGACAG 3541 UGUCACUGUGCCCUCAUUG 3542 CAAUGAGGGCACAGUGACA 3543 GUCACUGUGCCCUCAUUGG 3544 CCAAUGAGGGCACAGUGAC 3545 ACUGUGCCCUCAUUGGCCC 3546 GGGCCAAUGAGGGCACAGU 3547 CCCAGCAAUCAGACUCAAC 3548 GUUGAGUCUGAUUGCUGGG 3549 GGAGCAACUGCCAUCCGAG 3550 CUCGGAUGGCAGUUGCUCC 3551 GAGCAACUGCCAUCCGAGG 3552 CCUCGGAUGGCAGUUGCUC 3553 AGCAACUGCCAUCCGAGGC 3554 GCCUCGGAUGGCAGUUGCU 3555 GCAACUGCCAUCCGAGGCU 3556 AGCCUCGGAUGGCAGUUGC 3557 CAACUGCCAUCCGAGGCUC 3558 GAGCCUCGGAUGGCAGUUG 3559 GCCAUCCGAGGCUCCUGAA 3560 UUCAGGAGCCUCGGAUGGC 3561 AACCAGGGCCAUUCACCAG 3562 CUGGUGAAUGGCCCUGGUU 3563 ACCAGGGCCAUUCACCAGG 3564 CCUGGUGAAUGGCCCUGGU 3565 CCAGGGCCAUUCACCAGGA 3566 UCCUGGUGAAUGGCCCUGG 3567 CAGGGCCAUUCACCAGGAG 3568 CUCCUGGUGAAUGGCCCUG 3569 GGCCAUUCACCAGGAGCAU 3570 AUGCUCCUGGUGAAUGGCC 3571 GCCAUUCACCAGGAGCAUG 3572 CAUGCUCCUGGUGAAUGGC 3573 CCAUUCACCAGGAGCAUGC 3574 GCAUGCUCCUGGUGAAUGG 3575 CAUUCACCAGGAGCAUGCG 3576 CGCAUGCUCCUGGUGAAUG 3577 AUUCACCAGGAGCAUGCGG 3578 CCGCAUGCUCCUGGUGAAU 3579 UUCACCAGGAGCAUGCGGC 3580 GCCGCAUGCUCCUGGUGAA 3581 UCACCAGGAGCAUGCGGCU 3582 AGCCGCAUGCUCCUGGUGA 3583 AGCAUGCGGCUCCCUGAUG 3584 CAUCAGGGAGCCGCAUGCU 3585 GCAUGCGGCUCCCUGAUGU 3586 ACAUCAGGGAGCCGCAUGC 3587 CAUGCGGCUCCCUGAUGUC 3588 GACAUCAGGGAGCCGCAUG 3589 AUGCGGCUCCCUGAUGUCC 3590 GGACAUCAGGGAGCCGCAU 3591 UGCGGCUCCCUGAUGUCCA 3592 UGGACAUCAGGGAGCCGCA 3593 GCUCCCUGAUGUCCAGCUC 3594 GAGCUGGACAUCAGGGAGC 3595 CUCCCUGAUGUCCAGCUCU 3596 AGAGCUGGACAUCAGGGAG 3597 UCCCUGAUGUCCAGCUCUG 3598 CAGAGCUGGACAUCAGGGA 3599 CCCUGAUGUCCAGCUCUGG 3600 CCAGAGCUGGACAUCAGGG 3601 CCUGAUGUCCAGCUCUGGC 3602 GCCAGAGCUGGACAUCAGG 3603 CUGAUGUCCAGCUCUGGCU 3604 AGCCAGAGCUGGACAUCAG 3605 UCUGGUGCUGGAGCUAGCC 3606 GGCUAGCUCCAGCACCAGA 3607 UGGUGCUGGAGCUAGCCAA 3608 UUGGCUAGCUCCAGCACCA 3609 GGUGCUGGAGCUAGCCAAG 3610 CUUGGCUAGCUCCAGCACC 3611 GUGCUGGAGCUAGCCAAGC 3612 GCUUGGCUAGCUCCAGCAC 3613 GCUGGAGCUAGCCAAGCAG 3614 CUGCUUGGCUAGCUCCAGC 3615 CUGGAGCUAGCCAAGCAGC 3616 GCUGCUUGGCUAGCUCCAG 3617 UGGAGCUAGCCAAGCAGCA 3618 UGCUGCUUGGCUAGCUCCA 3619 GGAGCUAGCCAAGCAGCAA 3620 UUGCUGCUUGGCUAGCUCC 3621 GAGCUAGCCAAGCAGCAAA 3622 UUUGCUGCUUGGCUAGCUC 3623 AGCUAGCCAAGCAGCAAAU 3624 AUUUGCUGCUUGGCUAGCU 3625 GCUAGCCAAGCAGCAAAUC 3626 GAUUUGCUGCUUGGCUAGC 3627 CAGCAAAUCCUGGAUGGGU 3628 ACCCAUCCAGGAUUUGCUG 3629 AGCAAAUCCUGGAUGGGUU 3630 AACCCAUCCAGGAUUUGCU 3631 GCAAAUCCUGGAUGGGUUG 3632 CAACCCAUCCAGGAUUUGC 3633 CAAAUCCUGGAUGGGUUGC 3634 GCAACCCAUCCAGGAUUUG 3635 AAAUCCUGGAUGGGUUGCA 3636 UGCAACCCAUCCAGGAUUU 3637 GGUUGCACCUGACCAGUCG 3638 CGACUGGUCAGGUGCAACC 3639 GUUGCACCUGACCAGUCGU 3640 ACGACUGGUCAGGUGCAAC 3641 UUGCACCUGACCAGUCGUC 3642 GACGACUGGUCAGGUGCAA 3643 UGCACCUGACCAGUCGUCC 3644 GGACGACUGGUCAGGUGCA 3645 UGACCAGUCGUCCCAGAAU 3646 AUUCUGGGACGACUGGUCA 3647 GACCAGUCGUCCCAGAAUA 3648 UAUUCUGGGACGACUGGUC 3649 ACCAGUCGUCCCAGAAUAA 3650 UUAUUCUGGGACGACUGGU 3651 CCAGUCGUCCCAGAAUAAC 3652 GUUAUUCUGGGACGACUGG 3653 CAGUCGUCCCAGAAUAACU 3654 AGUUAUUCUGGGACGACUG 3655 AGUCGUCCCAGAAUAACUC 3656 GAGUUAUUCUGGGACGACU 3657 GUCGUCCCAGAAUAACUCA 3658 UGAGUUAUUCUGGGACGAC 3659 UCGUCCCAGAAUAACUCAU 3660 AUGAGUUAUUCUGGGACGA 3661 CGUCCCAGAAUAACUCAUC 3662 GAUGAGUUAUUCUGGGACG 3663 GUCCCAGAAUAACUCAUCC 3664 GGAUGAGUUAUUCUGGGAC 3665 UCCCAGAAUAACUCAUCCU 3666 AGGAUGAGUUAUUCUGGGA 3667 CCCAGAAUAACUCAUCCUC 3668 GAGGAUGAGUUAUUCUGGG 3669 GACUACAGCCAGGGAGUGU 3670 ACACUCCCUGGCUGUAGUC 3671 ACUACAGCCAGGGAGUGUG 3672 CACACUCCCUGGCUGUAGU 3673 CUACAGCCAGGGAGUGUGG 3674 CCACACUCCCUGGCUGUAG 3675 GAGUGUGGCUCCAGGGAAU 3676 AUUCCCUGGAGCCACACUC 3677 GGGAGGAGGUCAUCAGCUU 3678 AAGCUGAUGACCUCCUCCC 3679 GAGGUCAUCAGCUUUGCUA 3680 UAGCAAAGCUGAUGACCUC 3681 AGGUCAUCAGCUUUGCUAC 3682 GUAGCAAAGCUGAUGACCU 3683 GGUCAUCAGCUUUGCUACU 3684 AGUAGCAAAGCUGAUGACC 3685 GCUUUGCUACUGUCACAGG 3686 CCUGUGACAGUAGCAAAGC 3687 CUUUGCUACUGUCACAGGU 3688 ACCUGUGACAGUAGCAAAG 3689 UUUGCUACUGUCACAGGUG 3690 CACCUGUGACAGUAGCAAA 3691 UUGCUACUGUCACAGGUGG 3692 CCACCUGUGACAGUAGCAA 3693 UGCUACUGUCACAGGUGGG 3694 CCCACCUGUGACAGUAGCA 3695 GCUACUGUCACAGGUGGGU 3696 ACCCACCUGUGACAGUAGC 3697 CUACUGUCACAGGUGGGUG 3698 CACCCACCUGUGACAGUAG 3699 CAGGCAAAGAGCAGACAGG 3700 CCUGUCUGCUCUUUGCCUG 3701 GGCAGGGACUGGUUGCAGA 3702 UCUGCAACCAGUCCCUGCC 3703 GCAGGGACUGGUUGCAGAG 3704 CUCUGCAACCAGUCCCUGC 3705 AGGGACUGGUUGCAGAGGA 3706 UCCUCUGCAACCAGUCCCU 3707 GGGACUGGUUGCAGAGGAC 3708 GUCCUCUGCAACCAGUCCC 3709 GGACUGGUUGCAGAGGACA 3710 UGUCCUCUGCAACCAGUCC 3711 GACUGGUUGCAGAGGACAC 3712 GUGUCCUCUGCAACCAGUC 3713 UUUUCUAGAGGUAGGUUCG 3714 CGAACCUACCUCUAGAAAA 3715 UUUCUAGAGGUAGGUUCGA 3716 UCGAACCUACCUCUAGAAA 3717 UUCUAGAGGUAGGUUCGAG 3718 CUCGAACCUACCUCUAGAA 3719 UCUAGAGGUAGGUUCGAGG 3720 CCUCGAACCUACCUCUAGA 3721 CUAGAGGUAGGUUCGAGGG 3722 CCCUCGAACCUACCUCUAG 3723 UAGAGGUAGGUUCGAGGGA 3724 UCCCUCGAACCUACCUCUA 3725 GAGCUUCAUCUCUACUCAC 3726 GUGAGUAGAGAUGAAGCUC 3727 AGCUUCAUCUCUACUCACA 3728 UGUGAGUAGAGAUGAAGCU 3729 GCUUCAUCUCUACUCACAU 3730 AUGUGAGUAGAGAUGAAGC 3731 CUUCAUCUCUACUCACAUU 3732 AAUGUGAGUAGAGAUGAAG 3733 AUCUCUACUCACAUUUUCU 3734 AGAAAAUGUGAGUAGAGAU 3735 UCUCUACUCACAUUUUCUU 3736 AAGAAAAUGUGAGUAGAGA 3737 UCACAUUUUCUUUCCCUUU 3738 AAAGGGAAAGAAAAUGUGA 3739 CCCUUUUCUGUCUUUCGGG 3740 CCCGAAAGACAGAAAAGGG 3741 CCUUUUCUGUCUUUCGGGC 3742 GCCCGAAAGACAGAAAAGG 3743 CUUUUCUGUCUUUCGGGCA 3744 UGCCCGAAAGACAGAAAAG 3745 UUUCGGGCAGACUCCACUU 3746 AAGUGGAGUCUGCCCGAAA 3747 UUCGGGCAGACUCCACUUC 3748 GAAGUGGAGUCUGCCCGAA 3749 UCGGGCAGACUCCACUUCA 3750 UGAAGUGGAGUCUGCCCGA 3751 CGGGCAGACUCCACUUCAG 3752 CUGAAGUGGAGUCUGCCCG 3753 GGGCAGACUCCACUUCAGC 3754 GCUGAAGUGGAGUCUGCCC 3755 GGCAGACUCCACUUCAGCC 3756 GGCUGAAGUGGAGUCUGCC 3757 UCCACUUCAGCCUACAGCU 3758 AGCUGUAGGCUGAAGUGGA 3759 CCACUUCAGCCUACAGCUC 3760 GAGCUGUAGGCUGAAGUGG 3761 CACUUCAGCCUACAGCUCC 3762 GGAGCUGUAGGCUGAAGUG 3763 ACUUCAGCCUACAGCUCCC 3764 GGGAGCUGUAGGCUGAAGU 3765 CCUACAGCUCCCUGCUCAC 3766 GUGAGCAGGGAGCUGUAGG 3767 CUACAGCUCCCUGCUCACU 3768 AGUGAGCAGGGAGCUGUAG 3769 UACAGCUCCCUGCUCACUU 3770 AAGUGAGCAGGGAGCUGUA 3771 GCUCCCUGCUCACUUUUCA 3772 UGAAAAGUGAGCAGGGAGC 3773 CUCCCUGCUCACUUUUCAC 3774 GUGAAAAGUGAGCAGGGAG 3775 GCUCACUUUUCACCUGUCC 3776 GGACAGGUGAAAAGUGAGC 3777 CUCACUUUUCACCUGUCCA 3778 UGGACAGGUGAAAAGUGAG 3779 UGUCCACUCCUCGGUCCCA 3780 UGGGACCGAGGAGUGGACA 3781 UCGGUCCCACCACCUGUAC 3782 GUACAGGUGGUGGGACCGA 3783 CCACCACCUGUACCAUGCC 3784 GGCAUGGUACAGGUGGUGG 3785 CACCACCUGUACCAUGCCC 3786 GGGCAUGGUACAGGUGGUG 3787 ACCACCUGUACCAUGCCCG 3788 CGGGCAUGGUACAGGUGGU 3789 CACCCUUCCUGGCACUCUU 3790 AAGAGUGCCAGGAAGGGUG 3791 ACCCUUCCUGGCACUCUUU 3792 AAAGAGUGCCAGGAAGGGU 3793 CCCUUCCUGGCACUCUUUG 3794 CAAAGAGUGCCAGGAAGGG 3795 CCUUCCUGGCACUCUUUGC 3796 GCAAAGAGUGCCAGGAAGG 3797 UUCCUGGCACUCUUUGCUU 3798 AAGCAAAGAGUGCCAGGAA 3799 UCCUGGCACUCUUUGCUUG 3800 CAAGCAAAGAGUGCCAGGA 3801 CCUGGCACUCUUUGCUUGA 3802 UCAAGCAAAGAGUGCCAGG 3803 CUGGCACUCUUUGCUUGAG 3804 CUCAAGCAAAGAGUGCCAG 3805 UGGCACUCUUUGCUUGAGG 3806 CCUCAAGCAAAGAGUGCCA 3807 GGCACUCUUUGCUUGAGGA 3808 UCCUCAAGCAAAGAGUGCC 3809 GCACUCUUUGCUUGAGGAU 3810 AUCCUCAAGCAAAGAGUGC 3811 CACUCUUUGCUUGAGGAUC 3812 GAUCCUCAAGCAAAGAGUG 3813 ACUCUUUGCUUGAGGAUCU 3814 AGAUCCUCAAGCAAAGAGU 3815 CUCUUUGCUUGAGGAUCUU 3816 AAGAUCCUCAAGCAAAGAG 3817 UCUUUGCUUGAGGAUCUUC 3818 GAAGAUCCUCAAGCAAAGA 3819 UGCUUGAGGAUCUUCCGAU 3820 AUCGGAAGAUCCUCAAGCA 3821 GCUUGAGGAUCUUCCGAUG 3822 CAUCGGAAGAUCCUCAAGC 3823 GCACUCUCCUGGCUGAGCA 3824 UGCUCAGCCAGGAGAGUGC 3825 CUCCUGGCUGAGCACCACA 3826 UGUGGUGCUCAGCCAGGAG 3827 UGGCUGAGCACCACAUCAC 3828 GUGAUGUGGUGCUCAGCCA 3829 GGCUGAGCACCACAUCACC 3830 GGUGAUGUGGUGCUCAGCC 3831 GCUGAGCACCACAUCACCA 3832 UGGUGAUGUGGUGCUCAGC 3833 CUGAGCACCACAUCACCAA 3834 UUGGUGAUGUGGUGCUCAG 3835 CCAACCUGGGCUGGCAUAC 3836 GUAUGCCAGCCCAGGUUGG 3837 CAACCUGGGCUGGCAUACC 3838 GGUAUGCCAGCCCAGGUUG 3839 AACCUGGGCUGGCAUACCU 3840 AGGUAUGCCAGCCCAGGUU 3841 ACCUGGGCUGGCAUACCUU 3842 AAGGUAUGCCAGCCCAGGU 3843 CCUGGGCUGGCAUACCUUA 3844 UAAGGUAUGCCAGCCCAGG 3845 CUGGGCUGGCAUACCUUAA 3846 UUAAGGUAUGCCAGCCCAG 3847 UGGGCUGGCAUACCUUAAC 3848 GUUAAGGUAUGCCAGCCCA 3849 GGGCUGGCAUACCUUAACU 3850 AGUUAAGGUAUGCCAGCCC 3851 GGCUGGCAUACCUUAACUC 3852 GAGUUAAGGUAUGCCAGCC 3853 GCUGGCAUACCUUAACUCU 3854 AGAGUUAAGGUAUGCCAGC 3855 CAUACCUUAACUCUGCCCU 3856 AGGGCAGAGUUAAGGUAUG 3857 AUACCUUAACUCUGCCCUC 3858 GAGGGCAGAGUUAAGGUAU 3859 UACCUUAACUCUGCCCUCU 3860 AGAGGGCAGAGUUAAGGUA 3861 UCUGCCCUCUAGUGGCUUG 3862 CAAGCCACUAGAGGGCAGA 3863 CUGCCCUCUAGUGGCUUGA 3864 UCAAGCCACUAGAGGGCAG 3865 UGCCCUCUAGUGGCUUGAG 3866 CUCAAGCCACUAGAGGGCA 3867 AGAAGUCUGGUGUCCUGAA 3868 UUCAGGACACCAGACUUCU 3869 CAGGACACCAGCAGCCCUU 3870 AAGGGCUGCUGGUGUCCUG 3871 AGGACACCAGCAGCCCUUC 3872 GAAGGGCUGCUGGUGUCCU 3873 ACACCAGCAGCCCUUCCUA 3874 UAGGAAGGGCUGCUGGUGU 3875 CACCAGCAGCCCUUCCUAG 3876 CUAGGAAGGGCUGCUGGUG 3877 ACCAGCAGCCCUUCCUAGA 3878 UCUAGGAAGGGCUGCUGGU 3879 CCAGCAGCCCUUCCUAGAG 3880 CUCUAGGAAGGGCUGCUGG 3881 CAGCAGCCCUUCCUAGAGC 3882 GCUCUAGGAAGGGCUGCUG 3883 AGCAGCCCUUCCUAGAGCU 3884 AGCUCUAGGAAGGGCUGCU 3885 GCCCUUCCUAGAGCUUAAG 3886 CUUAAGCUCUAGGAAGGGC 3887 CCCUUCCUAGAGCUUAAGA 3888 UCUUAAGCUCUAGGAAGGG 3889 AGCUUAAGAUCCGAGCCAA 3890 UUGGCUCGGAUCUUAAGCU 3891 GCUUAAGAUCCGAGCCAAU 3892 AUUGGCUCGGAUCUUAAGC 3893 CUUAAGAUCCGAGCCAAUG 3894 CAUUGGCUCGGAUCUUAAG 3895 UUAAGAUCCGAGCCAAUGA 3896 UCAUUGGCUCGGAUCUUAA 3897 UAAGAUCCGAGCCAAUGAG 3898 CUCAUUGGCUCGGAUCUUA 3899 CGAGCCAAUGAGCCUGGAG 3900 CUCCAGGCUCAUUGGCUCG 3901 CCCUUAUGUUGCAGGCGAG 3902 CUCGCCUGCAACAUAAGGG 3903 CAUUACGUAGACUUCCAGG 3904 CCUGGAAGUCUACGUAAUG 3905 AUUACGUAGACUUCCAGGA 3906 UCCUGGAAGUCUACGUAAU 3907 UUACGUAGACUUCCAGGAA 3908 UUCCUGGAAGUCUACGUAA 3909 ACUGGAUACUGCAGCCCGA 3910 UCGGGCUGCAGUAUCCAGU 3911 CUGGAUACUGCAGCCCGAG 3912 CUCGGGCUGCAGUAUCCAG 3913 UGGAUACUGCAGCCCGAGG 3914 CCUCGGGCUGCAGUAUCCA 3915 GGGUACCAGCUGAAUUACU 3916 AGUAAUUCAGCUGGUACCC 3917 CUGAAUUACUGCAGUGGGC 3918 GCCCACUGCAGUAAUUCAG 3919 UGAAUUACUGCAGUGGGCA 3920 UGCCCACUGCAGUAAUUCA 3921 UGGCAGCCCAGGCAUUGCU 3922 AGCAAUGCCUGGGCUGCCA 3923 GCAUUGCUGCCUCUUUCCA 3924 UGGAAAGAGGCAGCAAUGC 3925 CAUUGCUGCCUCUUUCCAU 3926 AUGGAAAGAGGCAGCAAUG 3927 AUUGCUGCCUCUUUCCAUU 3928 AAUGGAAAGAGGCAGCAAU 3929 UGCUGCCUCUUUCCAUUCU 3930 AGAAUGGAAAGAGGCAGCA 3931 GCUGCCUCUUUCCAUUCUG 3932 CAGAAUGGAAAGAGGCAGC 3933 CUGCCUCUUUCCAUUCUGC 3934 GCAGAAUGGAAAGAGGCAG 3935 UGCCUCUUUCCAUUCUGCC 3936 GGCAGAAUGGAAAGAGGCA 3937 GCCUCUUUCCAUUCUGCCG 3938 CGGCAGAAUGGAAAGAGGC 3939 CCUCUUUCCAUUCUGCCGU 3940 ACGGCAGAAUGGAAAGAGG 3941 CUCUUUCCAUUCUGCCGUC 3942 GACGGCAGAAUGGAAAGAG 3943 CAUUCUGCCGUCUUCAGCC 3944 GGCUGAAGACGGCAGAAUG 3945 CUUCAGCCUCCUCAAAGCC 3946 GGCUUUGAGGAGGCUGAAG 3947 UUCAGCCUCCUCAAAGCCA 3948 UGGCUUUGAGGAGGCUGAA 3949 UCAGCCUCCUCAAAGCCAA 3950 UUGGCUUUGAGGAGGCUGA 3951 CAGCCUCCUCAAAGCCAAC 3952 GUUGGCUUUGAGGAGGCUG 3953 UCCUUGGCCUGCCAGUACC 3954 GGUACUGGCAGGCCAAGGA 3955 CCUGCCAGUACCUCCUGUU 3956 AACAGGAGGUACUGGCAGG 3957 CUGCCAGUACCUCCUGUUG 3958 CAACAGGAGGUACUGGCAG 3959 UGCCAGUACCUCCUGUUGU 3960 ACAACAGGAGGUACUGGCA 3961 GCCAGUACCUCCUGUUGUG 3962 CACAACAGGAGGUACUGGC 3963 CCAGUACCUCCUGUUGUGU 3964 ACACAACAGGAGGUACUGG 3965 CAGUACCUCCUGUUGUGUC 3966 GACACAACAGGAGGUACUG 3967 GUACCUCCUGUUGUGUCCC 3968 GGGACACAACAGGAGGUAC 3969 UACCUCCUGUUGUGUCCCU 3970 AGGGACACAACAGGAGGUA 3971 ACCUCCUGUUGUGUCCCUA 3972 UAGGGACACAACAGGAGGU 3973 CCUCCUGUUGUGUCCCUAC 3974 GUAGGGACACAACAGGAGG 3975 CUCCUGUUGUGUCCCUACU 3976 AGUAGGGACACAACAGGAG 3977 UUGUGUCCCUACUGCCCGA 3978 UCGGGCAGUAGGGACACAA 3979 UGUGUCCCUACUGCCCGAA 3980 UUCGGGCAGUAGGGACACA 3981 GUGUCCCUACUGCCCGAAG 3982 CUUCGGGCAGUAGGGACAC 3983 UGUCCCUACUGCCCGAAGG 3984 CCUUCGGGCAGUAGGGACA 3985 UCUCUCUCCUCUACCUGGA 3986 UCCAGGUAGAGGAGAGAGA 3987 UCUCCUCUACCUGGAUCAU 3988 AUGAUCCAGGUAGAGGAGA 3989 CUCCUCUACCUGGAUCAUA 3990 UAUGAUCCAGGUAGAGGAG 3991 UCCUCUACCUGGAUCAUAA 3992 UUAUGAUCCAGGUAGAGGA 3993 CCUCUACCUGGAUCAUAAU 3994 AUUAUGAUCCAGGUAGAGG 3995 CUCUACCUGGAUCAUAAUG 3996 CAUUAUGAUCCAGGUAGAG 3997 UCUACCUGGAUCAUAAUGG 3998 CCAUUAUGAUCCAGGUAGA 3999 CUACCUGGAUCAUAAUGGC 4000 GCCAUUAUGAUCCAGGUAG 4001 UACCUGGAUCAUAAUGGCA 4002 UGCCAUUAUGAUCCAGGUA 4003 ACCUGGAUCAUAAUGGCAA 4004 UUGCCAUUAUGAUCCAGGU 4005 CCUGGAUCAUAAUGGCAAU 4006 AUUGCCAUUAUGAUCCAGG 4007 CUGGAUCAUAAUGGCAAUG 4008 CAUUGCCAUUAUGAUCCAG 4009 UGGAUCAUAAUGGCAAUGU 4010 ACAUUGCCAUUAUGAUCCA 4011 GGAUCAUAAUGGCAAUGUG 4012 CACAUUGCCAUUAUGAUCC 4013 GAUCAUAAUGGCAAUGUGG 4014 CCACAUUGCCAUUAUGAUC 4015 AUAAUGGCAAUGUGGUCAA 4016 UUGACCACAUUGCCAUUAU 4017 UAAUGGCAAUGUGGUCAAG 4018 CUUGACCACAUUGCCAUUA 4019 AAUGGCAAUGUGGUCAAGA 4020 UCUUGACCACAUUGCCAUU 4021 AAUGUGGUCAAGACGGAUG 4022 CAUCCGUCUUGACCACAUU 4023 AUGUGGUCAAGACGGAUGU 4024 ACAUCCGUCUUGACCACAU 4025 UGUGGUCAAGACGGAUGUG 4026 CACAUCCGUCUUGACCACA 4027 GUGGUCAAGACGGAUGUGC 4028 GCACAUCCGUCUUGACCAC 4029 UGGUCAAGACGGAUGUGCC 4030 GGCACAUCCGUCUUGACCA 4031 GGUCAAGACGGAUGUGCCA 4032 UGGCACAUCCGUCUUGACC 4033 GUCAAGACGGAUGUGCCAG 4034 CUGGCACAUCCGUCUUGAC 4035 UCAAGACGGAUGUGCCAGA 4036 UCUGGCACAUCCGUCUUGA 4037 CAAGACGGAUGUGCCAGAU 4038 AUCUGGCACAUCCGUCUUG 4039 AAGACGGAUGUGCCAGAUA 4040 UAUCUGGCACAUCCGUCUU 4041 AGACGGAUGUGCCAGAUAU 4042 AUAUCUGGCACAUCCGUCU 4043 GACGGAUGUGCCAGAUAUG 4044 CAUAUCUGGCACAUCCGUC 4045 ACGGAUGUGCCAGAUAUGG 4046 CCAUAUCUGGCACAUCCGU 4047 CGGAUGUGCCAGAUAUGGU 4048 ACCAUAUCUGGCACAUCCG 4049 GGAUGUGCCAGAUAUGGUG 4050 CACCAUAUCUGGCACAUCC 4051 GAUGUGCCAGAUAUGGUGG 4052 CCACCAUAUCUGGCACAUC 4053 GCCAGAUAUGGUGGUGGAG 4054 CUCCACCACCAUAUCUGGC 4055 CCAGAUAUGGUGGUGGAGG 4056 CCUCCACCACCAUAUCUGG 4057 CAGAUAUGGUGGUGGAGGC 4058 GCCUCCACCACCAUAUCUG 4059 AGAUAUGGUGGUGGAGGCC 4060 GGCCUCCACCACCAUAUCU 4061 GAUAUGGUGGUGGAGGCCU 4062 AGGCCUCCACCACCAUAUC 4063 AUAUGGUGGUGGAGGCCUG 4064 CAGGCCUCCACCACCAUAU 4065 CCUGUGGCUGCAGCUAGCA 4066 UGCUAGCUGCAGCCACAGG 4067 UGUGGCUGCAGCUAGCAAG 4068 CUUGCUAGCUGCAGCCACA 4069 GUGGCUGCAGCUAGCAAGA 4070 UCUUGCUAGCUGCAGCCAC 4071 UGGCUGCAGCUAGCAAGAG 4072 CUCUUGCUAGCUGCAGCCA 4073 GGCUGCAGCUAGCAAGAGG 4074 CCUCUUGCUAGCUGCAGCC 4075 CUGCAGCUAGCAAGAGGAC 4076 GUCCUCUUGCUAGCUGCAG 4077 CAGCUAGCAAGAGGACCUG 4078 CAGGUCCUCUUGCUAGCUG 4079 GCUAGCAAGAGGACCUGGG 4080 CCCAGGUCCUCUUGCUAGC 4081 AGACCAAGAUGAAGUUUCC 4082 GGAAACUUCAUCUUGGUCU 4083 UGAAGUUUCCCAGGCACAG 4084 CUGUGCCUGGGAAACUUCA 4085 GAAGUUUCCCAGGCACAGG 4086 CCUGUGCCUGGGAAACUUC 4087 UCCCAGGCACAGGGCAUCU 4088 AGAUGCCCUGUGCCUGGGA 4089 GGCAUCUGUGACUGGAGGC 4090 GCCUCCAGUCACAGAUGCC 4091 GCAUCUGUGACUGGAGGCA 4092 UGCCUCCAGUCACAGAUGC 4093 CAACCACCUGGCAAUAUGA 4094 UCAUAUUGCCAGGUGGUUG 4095 AACCACCUGGCAAUAUGAC 4096 GUCAUAUUGCCAGGUGGUU 4097 ACCACCUGGCAAUAUGACU 4098 AGUCAUAUUGCCAGGUGGU 4099 CCACCUGGCAAUAUGACUC 4100 GAGUCAUAUUGCCAGGUGG 4101 CACCUGGCAAUAUGACUCA 4102 UGAGUCAUAUUGCCAGGUG 4103 ACCUGGCAAUAUGACUCAC 4104 GUGAGUCAUAUUGCCAGGU 4105 CCUGGCAAUAUGACUCACU 4106 AGUGAGUCAUAUUGCCAGG 4107 CUGGCAAUAUGACUCACUU 4108 AAGUGAGUCAUAUUGCCAG 4109 UGGCAAUAUGACUCACUUG 4110 CAAGUGAGUCAUAUUGCCA 4111 AAUAUGACUCACUUGACCC 4112 GGGUCAAGUGAGUCAUAUU 4113 CCCUAUGGGACCCAAAUGG 4114 CCAUUUGGGUCCCAUAGGG 4115 CCUAUGGGACCCAAAUGGG 4116 CCCAUUUGGGUCCCAUAGG 4117 CUAUGGGACCCAAAUGGGC 4118 GCCCAUUUGGGUCCCAUAG 4119 UAUGGGACCCAAAUGGGCA 4120 UGCCCAUUUGGGUCCCAUA 4121 AUGGGACCCAAAUGGGCAC 4122 GUGCCCAUUUGGGUCCCAU 4123 CCCAAAUGGGCACUUUCUU 4124 AAGAAAGUGCCCAUUUGGG 4125 CCAAAUGGGCACUUUCUUG 4126 CAAGAAAGUGCCCAUUUGG 4127 CAAAUGGGCACUUUCUUGU 4128 ACAAGAAAGUGCCCAUUUG 4129 AAAUGGGCACUUUCUUGUC 4130 GACAAGAAAGUGCCCAUUU 4131 AAUGGGCACUUUCUUGUCU 4132 AGACAAGAAAGUGCCCAUU 4133 UGGGCACUUUCUUGUCUGA 4134 UCAGACAAGAAAGUGCCCA 4135 GGGCACUUUCUUGUCUGAG 4136 CUCAGACAAGAAAGUGCCC 4137 UGGCUUAUUCCAGGUUGGC 4138 GCCAACCUGGAAUAAGCCA 4139 GGCUUAUUCCAGGUUGGCU 4140 AGCCAACCUGGAAUAAGCC 4141 GCUUAUUCCAGGUUGGCUG 4142 CAGCCAACCUGGAAUAAGC 4143 CUUAUUCCAGGUUGGCUGA 4144 UCAGCCAACCUGGAAUAAG 4145 UUCCAGGUUGGCUGAUGUG 4146 CACAUCAGCCAACCUGGAA 4147 UCCAGGUUGGCUGAUGUGU 4148 ACACAUCAGCCAACCUGGA 4149 CCAGGUUGGCUGAUGUGUU 4150 AACACAUCAGCCAACCUGG 4151 CAGGUUGGCUGAUGUGUUG 4152 CAACACAUCAGCCAACCUG 4153 AGGUUGGCUGAUGUGUUGG 4154 CCAACACAUCAGCCAACCU 4155 GGUUGGCUGAUGUGUUGGG 4156 CCCAACACAUCAGCCAACC 4157 AGAUGGGUAAAGCGUUUCU 4158 AGAAACGCUUUACCCAUCU 4159 GAUGGGUAAAGCGUUUCUU 4160 AAGAAACGCUUUACCCAUC 4161 AUGGGUAAAGCGUUUCUUC 4162 GAAGAAACGCUUUACCCAU 4163 UGGGUAAAGCGUUUCUUCU 4164 AGAAGAAACGCUUUACCCA 4165 GGGUAAAGCGUUUCUUCUA 4166 UAGAAGAAACGCUUUACCC 4167 GGUAAAGCGUUUCUUCUAA 4168 UUAGAAGAAACGCUUUACC 4169 GUAAAGCGUUUCUUCUAAA 4170 UUUAGAAGAAACGCUUUAC 4171 UAAAGCGUUUCUUCUAAAG 4172 CUUUAGAAGAAACGCUUUA 4173 AAAGCGUUUCUUCUAAAGG 4174 CCUUUAGAAGAAACGCUUU 4175 AAGCGUUUCUUCUAAAGGG 4176 CCCUUUAGAAGAAACGCUU 4177 AAAGCAUGAUUUCCUGCCC 4178 GGGCAGGAAAUCAUGCUUU 4179 AAGCAUGAUUUCCUGCCCU 4180 AGGGCAGGAAAUCAUGCUU 4181 AGCAUGAUUUCCUGCCCUA 4182 UAGGGCAGGAAAUCAUGCU 4183 GCAUGAUUUCCUGCCCUAA 4184 UUAGGGCAGGAAAUCAUGC 4185 CAUGAUUUCCUGCCCUAAG 4186 CUUAGGGCAGGAAAUCAUG 4187 AUGAUUUCCUGCCCUAAGU 4188 ACUUAGGGCAGGAAAUCAU 4189 UGAUUUCCUGCCCUAAGUC 4190 GACUUAGGGCAGGAAAUCA 4191 GAUUUCCUGCCCUAAGUCC 4192 GGACUUAGGGCAGGAAAUC 4193 AUUUCCUGCCCUAAGUCCU 4194 AGGACUUAGGGCAGGAAAU 4195 UUUCCUGCCCUAAGUCCUG 4196 CAGGACUUAGGGCAGGAAA 4197 UUCCUGCCCUAAGUCCUGU 4198 ACAGGACUUAGGGCAGGAA 4199 UCCUGCCCUAAGUCCUGUG 4200 CACAGGACUUAGGGCAGGA 4201 AGAAGAUGUCAGGGACUAG 4202 CUAGUCCCUGACAUCUUCU 4203 GAAGAUGUCAGGGACUAGG 4204 CCUAGUCCCUGACAUCUUC 4205 AAGAUGUCAGGGACUAGGG 4206 CCCUAGUCCCUGACAUCUU 4207 AGAUGUCAGGGACUAGGGA 4208 UCCCUAGUCCCUGACAUCU 4209 GUCAGGGACUAGGGAGGGA 4210 UCCCUCCCUAGUCCCUGAC 4211 UACUUAGCCUCUCCCAAGA 4212 UCUUGGGAGAGGCUAAGUA 4213 AGGAGGAAGCAGAUAGAUG 4214 CAUCUAUCUGCUUCCUCCU 4215 GGAGGAAGCAGAUAGAUGG 4216 CCAUCUAUCUGCUUCCUCC 4217 GAGGAAGCAGAUAGAUGGU 4218 ACCAUCUAUCUGCUUCCUC 4219 AGGAAGCAGAUAGAUGGUC 4220 GACCAUCUAUCUGCUUCCU 4221 GGAAGCAGAUAGAUGGUCC 4222 GGACCAUCUAUCUGCUUCC 4223 GAAGCAGAUAGAUGGUCCA 4224 UGGACCAUCUAUCUGCUUC 4225 UAGAUGGUCCAGCAGGCUU 4226 AAGCCUGCUGGACCAUCUA 4227 AGAUGGUCCAGCAGGCUUG 4228 CAAGCCUGCUGGACCAUCU 4229 GAUGGUCCAGCAGGCUUGA 4230 UCAAGCCUGCUGGACCAUC 4231 AUGGUCCAGCAGGCUUGAA 4232 UUCAAGCCUGCUGGACCAU 4233 UGGUCCAGCAGGCUUGAAG 4234 CUUCAAGCCUGCUGGACCA 4235 GGUCCAGCAGGCUUGAAGC 4236 GCUUCAAGCCUGCUGGACC 4237 GUCCAGCAGGCUUGAAGCA 4238 UGCUUCAAGCCUGCUGGAC 4239 UCCAGCAGGCUUGAAGCAG 4240 CUGCUUCAAGCCUGCUGGA 4241 CCCAGGGUAAGGGCUGUUG 4242 CAACAGCCCUUACCCUGGG 4243 GGGUAAGGGCUGUUGAGGU 4244 ACCUCAACAGCCCUUACCC 4245 GGUAAGGGCUGUUGAGGUA 4246 UACCUCAACAGCCCUUACC 4247 GUAAGGGCUGUUGAGGUAC 4248 GUACCUCAACAGCCCUUAC 4249 UAAGGGCUGUUGAGGUACC 4250 GGUACCUCAACAGCCCUUA 4251 AAGGGCUGUUGAGGUACCU 4252 AGGUACCUCAACAGCCCUU 4253 AGGGCUGUUGAGGUACCUU 4254 AAGGUACCUCAACAGCCCU 4255 GGGCUGUUGAGGUACCUUA 4256 UAAGGUACCUCAACAGCCC 4257 GGCUGUUGAGGUACCUUAA 4258 UUAAGGUACCUCAACAGCC 4259 GCUGUUGAGGUACCUUAAG 4260 CUUAAGGUACCUCAACAGC 4261 CUGUUGAGGUACCUUAAGG 4262 CCUUAAGGUACCUCAACAG 4263 UGUUGAGGUACCUUAAGGG 4264 CCCUUAAGGUACCUCAACA 4265 UAAGGGAAGGUCAAGAGGG 4266 CCCUCUUGACCUUCCCUUA 4267 AAGGGAAGGUCAAGAGGGA 4268 UCCCUCUUGACCUUCCCUU 4269 CGCUGAGGGAGGAUGCUUA 4270 UAAGCAUCCUCCCUCAGCG 4271 UGAGGGAGGAUGCUUAGGG 4272 CCCUAAGCAUCCUCCCUCA 4273 GGCACUAAGCCUAAGAAGU 4274 ACUUCUUAGGCUUAGUGCC 4275 GCACUAAGCCUAAGAAGUU 4276 AACUUCUUAGGCUUAGUGC 4277 CACUAAGCCUAAGAAGUUC 4278 GAACUUCUUAGGCUUAGUG 4279 ACUAAGCCUAAGAAGUUCC 4280 GGAACUUCUUAGGCUUAGU 4281 AGAUCGAGUCUCGCUCUGU 4282 ACAGAGCGAGACUCGAUCU 4283 GAUCGAGUCUCGCUCUGUC 4284 GACAGAGCGAGACUCGAUC 4285 AUCGAGUCUCGCUCUGUCA 4286 UGACAGAGCGAGACUCGAU 4287 AGUCUCGCUCUGUCACCAG 4288 CUGGUGACAGAGCGAGACU 4289 GUCUCGCUCUGUCACCAGG 4290 CCUGGUGACAGAGCGAGAC 4291 UCUCGCUCUGUCACCAGGC 4292 GCCUGGUGACAGAGCGAGA 4293 CUCGCUCUGUCACCAGGCU 4294 AGCCUGGUGACAGAGCGAG 4295 GUCACCAGGCUGGAGUGCA 4296 UGCACUCCAGCCUGGUGAC 4297 GGCUCACUGCAACCUCCGU 4298 ACGGAGGUUGCAGUGAGCC 4299 GCUCACUGCAACCUCCGUC 4300 GACGGAGGUUGCAGUGAGC 4301 UCCGUCUCCUGGGUUCAAG 4302 CUUGAACCCAGGAGACGGA 4303 CCGUCUCCUGGGUUCAAGU 4304 ACUUGAACCCAGGAGACGG 4305 CGUCUCCUGGGUUCAAGUG 4306 CACUUGAACCCAGGAGACG 4307 GUCUCCUGGGUUCAAGUGA 4308 UCACUUGAACCCAGGAGAC 4309 UGGGUUCAAGUGAUUCUUC 4310 GAAGAAUCACUUGAACCCA 4311 GGGUUCAAGUGAUUCUUCU 4312 AGAAGAAUCACUUGAACCC 4313 GGUUCAAGUGAUUCUUCUG 4314 CAGAAGAAUCACUUGAACC 4315 GUUCAAGUGAUUCUUCUGC 4316 GCAGAAGAAUCACUUGAAC 4317 UUCAAGUGAUUCUUCUGCC 4318 GGCAGAAGAAUCACUUGAA 4319 UCAAGUGAUUCUUCUGCCU 4320 AGGCAGAAGAAUCACUUGA 4321 CGAGCAGCUGGGAUUACAG 4322 CUGUAAUCCCAGCUGCUCG 4323 CAGCUGGGAUUACAGGCGC 4324 GCGCCUGUAAUCCCAGCUG 4325 ACAUGUUGGCCAGGAUGGU 4326 ACCAUCCUGGCCAACAUGU 4327 CAUGUUGGCCAGGAUGGUC 4328 GACCAUCCUGGCCAACAUG 4329 AUGUUGGCCAGGAUGGUCU 4330 AGACCAUCCUGGCCAACAU 4331 UGUUGGCCAGGAUGGUCUC 4332 GAGACCAUCCUGGCCAACA 4333 GUUGGCCAGGAUGGUCUCA 4334 UGAGACCAUCCUGGCCAAC 4335 UUGGCCAGGAUGGUCUCAA 4336 UUGAGACCAUCCUGGCCAA 4337 UGGCCAGGAUGGUCUCAAU 4338 AUUGAGACCAUCCUGGCCA 4339 GGCCAGGAUGGUCUCAAUC 4340 GAUUGAGACCAUCCUGGCC 4341 GCCAGGAUGGUCUCAAUCU 4342 AGAUUGAGACCAUCCUGGC 4343 CCAGGAUGGUCUCAAUCUC 4344 GAGAUUGAGACCAUCCUGG 4345 CAGGAUGGUCUCAAUCUCU 4346 AGAGAUUGAGACCAUCCUG 4347 AGGAUGGUCUCAAUCUCUU 4348 AAGAGAUUGAGACCAUCCU 4349 AUUAUAGGCGUGAGCCACC 4350 GGUGGCUCACGCCUAUAAU 4351 UUAUAGGCGUGAGCCACCG 4352 CGGUGGCUCACGCCUAUAA 4353 UAUAGGCGUGAGCCACCGC 4354 GCGGUGGCUCACGCCUAUA 4355 GCGCCUGGCUUAUACUUUC 4356 GAAAGUAUAAGCCAGGCGC 4357 CGCCUGGCUUAUACUUUCU 4358 AGAAAGUAUAAGCCAGGCG 4359 CCUGGCUUAUACUUUCUUA 4360 UAAGAAAGUAUAAGCCAGG 4361 CUGGCUUAUACUUUCUUAA 4362 UUAAGAAAGUAUAAGCCAG 4363 CAAAUGUGAGUCAUAAAGA 4364 UCUUUAUGACUCACAUUUG 4365 AAUGUGAGUCAUAAAGAAG 4366 CUUCUUUAUGACUCACAUU 4367 UGAGUCAUAAAGAAGGGUU 4368 AACCCUUCUUUAUGACUCA 4369 AGUCAUAAAGAAGGGUUAG 4370 CUAACCCUUCUUUAUGACU 4371 GUCAUAAAGAAGGGUUAGG 4372 CCUAACCCUUCUUUAUGAC 4373 UCAUAAAGAAGGGUUAGGG 4374 CCCUAACCCUUCUUUAUGA 4375 CAUAAAGAAGGGUUAGGGU 4376 ACCCUAACCCUUCUUUAUG 4377 AAGAAGGGUUAGGGUGAUG 4378 CAUCACCCUAACCCUUCUU 4379 AGAAGGGUUAGGGUGAUGG 4380 CCAUCACCCUAACCCUUCU 4381 GAAGGGUUAGGGUGAUGGU 4382 ACCAUCACCCUAACCCUUC 4383 AAGGGUUAGGGUGAUGGUC 4384 GACCAUCACCCUAACCCUU 4385 AGGGUUAGGGUGAUGGUCC 4386 GGACCAUCACCCUAACCCU 4387 GGGUUAGGGUGAUGGUCCA 4388 UGGACCAUCACCCUAACCC 4389 GGGUGAUGGUCCAGAGCAA 4390 UUGCUCUGGACCAUCACCC 4391 GGUGAUGGUCCAGAGCAAC 4392 GUUGCUCUGGACCAUCACC 4393 ACAGUUCUUCAAGUGUACU 4394 AGUACACUUGAAGAACUGU 4395 CAGUUCUUCAAGUGUACUC 4396 GAGUACACUUGAAGAACUG 4397 AGUUCUUCAAGUGUACUCU 4398 AGAGUACACUUGAAGAACU 4399 CAAGUGUACUCUGUAGGCU 4400 AGCCUACAGAGUACACUUG 4401 AAGUGUACUCUGUAGGCUU 4402 AAGCCUACAGAGUACACUU 4403 GUGUACUCUGUAGGCUUCU 4404 AGAAGCCUACAGAGUACAC 4405 UGUACUCUGUAGGCUUCUG 4406 CAGAAGCCUACAGAGUACA 4407 GUACUCUGUAGGCUUCUGG 4408 CCAGAAGCCUACAGAGUAC 4409 UACUCUGUAGGCUUCUGGG 4410 CCCAGAAGCCUACAGAGUA 4411 GUAGGCUUCUGGGAGGUCC 4412 GGACCUCCCAGAAGCCUAC 4413 UAGGCUUCUGGGAGGUCCC 4414 GGGACCUCCCAGAAGCCUA 4415 AGGCUUCUGGGAGGUCCCU 4416 AGGGACCUCCCAGAAGCCU 4417 GGCUUCUGGGAGGUCCCUU 4418 AAGGGACCUCCCAGAAGCC 4419 GCUUCUGGGAGGUCCCUUU 4420 AAAGGGACCUCCCAGAAGC 4421 CUUCUGGGAGGUCCCUUUU 4422 AAAAGGGACCUCCCAGAAG 4423 UUCUGGGAGGUCCCUUUUC 4424 GAAAAGGGACCUCCCAGAA 4425 UCUGGGAGGUCCCUUUUCA 4426 UGAAAAGGGACCUCCCAGA 4427 CAUGUUAUUUGCCUUUUGA 4428 UCAAAAGGCAAAUAACAUG 4429 AUUUGCCUUUUGAAUUCUC 4430 GAGAAUUCAAAAGGCAAAU 4431 UUUGCCUUUUGAAUUCUCA 4432 UGAGAAUUCAAAAGGCAAA 4433 UUGCCUUUUGAAUUCUCAU 4434 AUGAGAAUUCAAAAGGCAA 4435 UGCCUUUUGAAUUCUCAUU 4436 AAUGAGAAUUCAAAAGGCA 4437 GCCUUUUGAAUUCUCAUUA 4438 UAAUGAGAAUUCAAAAGGC 4439 AUUGUAUUGUGGAGUUUUC 4440 GAAAACUCCACAAUACAAU 4441 UUGUAUUGUGGAGUUUUCC 4442 GGAAAACUCCACAAUACAA 4443 AGUUUUCCAGAGGCCGUGU 4444 ACACGGCCUCUGGAAAACU 4445 GUUUUCCAGAGGCCGUGUG 4446 CACACGGCCUCUGGAAAAC 4447 UUUUCCAGAGGCCGUGUGA 4448 UCACACGGCCUCUGGAAAA 4449 UUUCCAGAGGCCGUGUGAC 4450 GUCACACGGCCUCUGGAAA 4451 UUCCAGAGGCCGUGUGACA 4452 UGUCACACGGCCUCUGGAA 4453 UCCAGAGGCCGUGUGACAU 4454 AUGUCACACGGCCUCUGGA 4455 CCAGAGGCCGUGUGACAUG 4456 CAUGUCACACGGCCUCUGG 4457 CAGAGGCCGUGUGACAUGU 4458 ACAUGUCACACGGCCUCUG 4459 AGAGGCCGUGUGACAUGUG 4460 CACAUGUCACACGGCCUCU 4461 GCCGUGUGACAUGUGAUUA 4462 UAAUCACAUGUCACACGGC 4463 CCGUGUGACAUGUGAUUAC 4464 GUAAUCACAUGUCACACGG 4465 CGUGUGACAUGUGAUUACA 4466 UGUAAUCACAUGUCACACG 4467 GAUUACAUCAUCUUUCUGA 4468 UCAGAAAGAUGAUGUAAUC 4469 AUUACAUCAUCUUUCUGAC 4470 GUCAGAAAGAUGAUGUAAU 4471 UUACAUCAUCUUUCUGACA 4472 UGUCAGAAAGAUGAUGUAA 4473 UACAUCAUCUUUCUGACAU 4474 AUGUCAGAAAGAUGAUGUA 4475 AUCUUUCUGACAUCAUUGU 4476 ACAAUGAUGUCAGAAAGAU 4477 AUUGUUAAUGGAAUGUGUG 4478 CACACAUUCCAUUAACAAU 4479 GAAUGUGUGCUUGUAUGGU 4480 ACCAUACAAGCACACAUUC 4481 AAUGUGUGCUUGUAUGGUC 4482 GACCAUACAAGCACACAUU 4483 AUGUGUGCUUGUAUGGUCU 4484 AGACCAUACAAGCACACAU 4485 UGUGUGCUUGUAUGGUCUU 4486 AAGACCAUACAAGCACACA 4487 GUGUGCUUGUAUGGUCUUG 4488 CAAGACCAUACAAGCACAC 4489 UGUGCUUGUAUGGUCUUGU 4490 ACAAGACCAUACAAGCACA 4491 GUGCUUGUAUGGUCUUGUG 4492 CACAAGACCAUACAAGCAC 4493 UGCUUGUAUGGUCUUGUGU 4494 ACACAAGACCAUACAAGCA 4495 GCUUGUAUGGUCUUGUGUU 4496 AACACAAGACCAUACAAGC 4497 CUUGUAUGGUCUUGUGUUA 4498 UAACACAAGACCAUACAAG 4499 UAUGGUCUUGUGUUACAGU 4500 ACUGUAACACAAGACCAUA 4501 AUGGUCUUGUGUUACAGUC 4502 GACUGUAACACAAGACCAU 4503 AGUCUCGCUCUGUCGCCCA 4504 UGGGCGACAGAGCGAGACU 4505 CAAUCUCGGCUCACUGCAA 4506 UUGCAGUGAGCCGAGAUUG 4507 AAUCUCGGCUCACUGCAAC 4508 GUUGCAGUGAGCCGAGAUU 4509 AUCUCGGCUCACUGCAACC 4510 GGUUGCAGUGAGCCGAGAU 4511 UCUCGGCUCACUGCAACCU 4512 AGGUUGCAGUGAGCCGAGA 4513 CUCACUGCAACCUCCACCU 4514 AGGUGGAGGUUGCAGUGAG 4515 UCACUGCAACCUCCACCUC 4516 GAGGUGGAGGUUGCAGUGA 4517 CACUGCAACCUCCACCUCC 4518 GGAGGUGGAGGUUGCAGUG 4519 ACUGCAACCUCCACCUCCC 4520 GGGAGGUGGAGGUUGCAGU 4521 AGCCUCCUGAGUAGCUGGG 4522 CCCAGCUACUCAGGAGGCU 4523 GCCUCCUGAGUAGCUGGGA 4524 UCCCAGCUACUCAGGAGGC 4525 CCUCCUGAGUAGCUGGGAC 4526 GUCCCAGCUACUCAGGAGG 4527 CUCCUGAGUAGCUGGGACU 4528 AGUCCCAGCUACUCAGGAG 4529 UCCUGAGUAGCUGGGACUA 4530 UAGUCCCAGCUACUCAGGA 4531 UAGCUGGGACUACAGGCCU 4532 AGGCCUGUAGUCCCAGCUA 4533 AGCUGGGACUACAGGCCUG 4534 CAGGCCUGUAGUCCCAGCU 4535 GCCACCAUGCCCAGCUAUU 4536 AAUAGCUGGGCAUGGUGGC 4537 CCACCAUGCCCAGCUAUUU 4538 AAAUAGCUGGGCAUGGUGG 4539 CACCAUGCCCAGCUAUUUU 4540 AAAAUAGCUGGGCAUGGUG 4541 GGGUUUCACCAUGUUGGCC 4542 GGCCAACAUGGUGAAACCC 4543 GGUUUCACCAUGUUGGCCA 4544 UGGCCAACAUGGUGAAACC 4545 GUUUCACCAUGUUGGCCAG 4546 CUGGCCAACAUGGUGAAAC 4547 CACCAUGUUGGCCAGGCUG 4548 CAGCCUGGCCAACAUGGUG 4549 ACCAUGUUGGCCAGGCUGG 4550 CCAGCCUGGCCAACAUGGU 4551 CCAUGUUGGCCAGGCUGGU 4552 ACCAGCCUGGCCAACAUGG 4553 CAUGUUGGCCAGGCUGGUC 4554 GACCAGCCUGGCCAACAUG 4555 AUGUUGGCCAGGCUGGUCU 4556 AGACCAGCCUGGCCAACAU 4557 UGUUGGCCAGGCUGGUCUC 4558 GAGACCAGCCUGGCCAACA 4559 CUUGAGGUGAUCCGCCUGC 4560 GCAGGCGGAUCACCUCAAG 4561 UUGAGGUGAUCCGCCUGCC 4562 GGCAGGCGGAUCACCUCAA 4563 UGAGGUGAUCCGCCUGCCU 4564 AGGCAGGCGGAUCACCUCA 4565 CCAAAGUGCUGGGAUUACA 4566 UGUAAUCCCAGCACUUUGG 4567 CAAAGUGCUGGGAUUACAG 4568 CUGUAAUCCCAGCACUUUG 4569 GUGCUGGGAUUACAGGUCU 4570 AGACCUGUAAUCCCAGCAC 4571 UGCUGGGAUUACAGGUCUG 4572 CAGACCUGUAAUCCCAGCA 4573 GCUGGGAUUACAGGUCUGA 4574 UCAGACCUGUAAUCCCAGC 4575 CUGGGAUUACAGGUCUGAG 4576 CUCAGACCUGUAAUCCCAG 4577 GGUCUGAGCCACUGUGCCU 4578 AGGCACAGUGGCUCAGACC 4579 GUCUGAGCCACUGUGCCUA 4580 UAGGCACAGUGGCUCAGAC 4581 UCUGAGCCACUGUGCCUAA 4582 UUAGGCACAGUGGCUCAGA 4583 CUGAGCCACUGUGCCUAAC 4584 GUUAGGCACAGUGGCUCAG 4585 UGAGCCACUGUGCCUAACC 4586 GGUUAGGCACAGUGGCUCA 4587 CACUGUGCCUAACCUAAUG 4588 CAUUAGGUUAGGCACAGUG 4589 ACUGUGCCUAACCUAAUGA 4590 UCAUUAGGUUAGGCACAGU 4591 CUGUGCCUAACCUAAUGAC 4592 GUCAUUAGGUUAGGCACAG 4593 UGUGCCUAACCUAAUGACU 4594 AGUCAUUAGGUUAGGCACA 4595 GUGCCUAACCUAAUGACUU 4596 AAGUCAUUAGGUUAGGCAC 4597 UGCCUAACCUAAUGACUUU 4598 AAAGUCAUUAGGUUAGGCA 4599 GCCUAACCUAAUGACUUUU 4600 AAAAGUCAUUAGGUUAGGC 4601 CCUAACCUAAUGACUUUUA 4602 UAAAAGUCAUUAGGUUAGG 4603 ACCUAAUGACUUUUAAGAG 4604 CUCUUAAAAGUCAUUAGGU 4605 CUUUUAAGAGUAUAGAGGA 4606 UCCUCUAUACUCUUAAAAG 4607 GACUCACUGGUCUAUAGAA 4608 UUCUAUAGACCAGUGAGUC 4609 AAAGUAAGGUGUUCUAAGA 4610 UCUUAGAACACCUUACUUU 4611 GAGCUCUUCUUGCUGGGCA 4612 UGCCCAGCAAGAAGAGCUC 4613 AGCUCUUCUUGCUGGGCAC 4614 GUGCCCAGCAAGAAGAGCU 4615 GCUCUUCUUGCUGGGCACC 4616 GGUGCCCAGCAAGAAGAGC 4617 CUCUUCUUGCUGGGCACCG 4618 CGGUGCCCAGCAAGAAGAG 4619 UCUUCUUGCUGGGCACCGG 4620 CCGGUGCCCAGCAAGAAGA 4621 CUUCUUGCUGGGCACCGGU 4622 ACCGGUGCCCAGCAAGAAG 4623 UUCUUGCUGGGCACCGGUG 4624 CACCGGUGCCCAGCAAGAA 4625 CCCAGGAGUUCGAGGCUAU 4626 AUAGCCUCGAACUCCUGGG 4627 CCAGGAGUUCGAGGCUAUG 4628 CAUAGCCUCGAACUCCUGG 4629 AGUUCGAGGCUAUGAUCAC 4630 GUGAUCAUAGCCUCGAACU 4631 GUUCGAGGCUAUGAUCACA 4632 UGUGAUCAUAGCCUCGAAC 4633 UUCGAGGCUAUGAUCACAC 4634 GUGUGAUCAUAGCCUCGAA 4635 UCGAGGCUAUGAUCACACU 4636 AGUGUGAUCAUAGCCUCGA 4637 CGAGGCUAUGAUCACACUU 4638 AAGUGUGAUCAUAGCCUCG 4639 GAGGCUAUGAUCACACUUG 4640 CAAGUGUGAUCAUAGCCUC 4641 UGCACUCCAGCCUGGGCAA 4642 UUGCCCAGGCUGGAGUGCA 4643 GCACUCCAGCCUGGGCAAA 4644 UUUGCCCAGGCUGGAGUGC 4645 CACUCCAGCCUGGGCAAAU 4646 AUUUGCCCAGGCUGGAGUG 4647 ACUCCAGCCUGGGCAAAUA 4648 UAUUUGCCCAGGCUGGAGU 4649 UACAUAAAUAGCUCCUCUG 4650 CAGAGGAGCUAUUUAUGUA 46521 ACAUAAAUAGCUCCUCUGG 4652 CCAGAGGAGCUAUUUAUGU 4653 CAUAAAUAGCUCCUCUGGA 4654 UCCAGAGGAGCUAUUUAUG 4655 AUAAAUAGCUCCUCUGGAA 4656 UUCCAGAGGAGCUAUUUAU 4657 AAAUAGCUCCUCUGGAAGA 4658 UCUUCCAGAGGAGCUAUUU 4659 AGGCUGGGACAGGAGCAUG 4660 CAUGCUCCUGUCCCAGCCU 4661 GGCUGGGACAGGAGCAUGU 4662 ACAUGCUCCUGUCCCAGCC 4663 GCUGGGACAGGAGCAUGUG 4664 CACAUGCUCCUGUCCCAGC 4665 UGGGACAGGAGCAUGUGUG 4666 CACACAUGCUCCUGUCCCA 4667 GGGACAGGAGCAUGUGUGG 4668 CCACACAUGCUCCUGUCCC 4669 GGACAGGAGCAUGUGUGGG 4670 CCCACACAUGCUCCUGUCC 4671 UUUUCAGUGCCCAUUAGUC 4672 GACUAAUGGGCACUGAAAA 4673 UUUCAGUGCCCAUUAGUCU 4674 AGACUAAUGGGCACUGAAA 4675 UUCAGUGCCCAUUAGUCUG 4676 CAGACUAAUGGGCACUGAA 4677 CAGUGCCCAUUAGUCUGGU 4678 ACCAGACUAAUGGGCACUG 4679 AGUGCCCAUUAGUCUGGUC 4680 GACCAGACUAAUGGGCACU 4681 GUGCCCAUUAGUCUGGUCU 4682 AGACCAGACUAAUGGGCAC 4683 UGCCCAUUAGUCUGGUCUG 4684 CAGACCAGACUAAUGGGCA 4685 GCCCAUUAGUCUGGUCUGA 4686 UCAGACCAGACUAAUGGGC 4687 GUCUGGUCUGACUGAGCUG 4688 CAGCUCAGUCAGACCAGAC 4689 UCUGGUCUGACUGAGCUGG 4690 CCAGCUCAGUCAGACCAGA 4691 CUGGUCUGACUGAGCUGGG 4692 CCCAGCUCAGUCAGACCAG 4693 UGGUCUGACUGAGCUGGGU 4694 ACCCAGCUCAGUCAGACCA 4695 GGUCUGACUGAGCUGGGUC 4696 GACCCAGCUCAGUCAGACC 4697 GUCUGACUGAGCUGGGUCU 4698 AGACCCAGCUCAGUCAGAC 4699 UCUGACUGAGCUGGGUCUC 4700 GAGACCCAGCUCAGUCAGA 4701 CUGACUGAGCUGGGUCUCU 4702 AGAGACCCAGCUCAGUCAG 4703 UGACUGAGCUGGGUCUCUG 4704 CAGAGACCCAGCUCAGUCA 4705 GACUGAGCUGGGUCUCUGA 4706 UCAGAGACCCAGCUCAGUC 4707 ACUGAGCUGGGUCUCUGAC 4708 GUCAGAGACCCAGCUCAGU 4709 GGGAUAACUAGCCUGGGUC 4710 GACCCAGGCUAGUUAUCCC 4711 GGAUAACUAGCCUGGGUCA 4712 UGACCCAGGCUAGUUAUCC 4713 GAUAACUAGCCUGGGUCAA 4714 UUGACCCAGGCUAGUUAUC 4715 AUAACUAGCCUGGGUCAAA 4716 UUUGACCCAGGCUAGUUAU 4717 UAACUAGCCUGGGUCAAAG 4718 CUUUGACCCAGGCUAGUUA 4719 AACUAGCCUGGGUCAAAGU 4720 ACUUUGACCCAGGCUAGUU 4721 ACUAGCCUGGGUCAAAGUC 4722 GACUUUGACCCAGGCUAGU 4723 CUAGCCUGGGUCAAAGUCC 4724 GGACUUUGACCCAGGCUAG 4725 UAGCCUGGGUCAAAGUCCC 4726 GGGACUUUGACCCAGGCUA 4727 GGUCAAAGUCCCAGAUCUC 4728 GAGAUCUGGGACUUUGACC 4729 GUCAAAGUCCCAGAUCUCC 4730 GGAGAUCUGGGACUUUGAC 4731 UCAAAGUCCCAGAUCUCCC 4732 GGGAGAUCUGGGACUUUGA 4733 CCUACCUUCACCUUUUCUU 4734 AAGAAAAGGUGAAGGUAGG 4735 CCUUCACCUUUUCUUUUCC 4736 GGAAAAGAAAAGGUGAAGG 4737 AACCCACUGACCUUCCACA 4738 UGUGGAAGGUCAGUGGGUU 4739 ACCCACUGACCUUCCACAC 4740 GUGUGGAAGGUCAGUGGGU 4741 ACUGACCUUCCACACCCAA 4742 UUGGGUGUGGAAGGUCAGU 4743 CUGACCUUCCACACCCAAG 4744 CUUGGGUGUGGAAGGUCAG 4745 GGGUGGUUCUUGGAAGCAG 4746 CUGCUUCCAAGAACCACCC 4747 GGUGGUUCUUGGAAGCAGA 4748 UCUGCUUCCAAGAACCACC 4749 GUGGUUCUUGGAAGCAGAG 4750 CUCUGCUUCCAAGAACCAC 4751 UGGUUCUUGGAAGCAGAGC 4752 GCUCUGCUUCCAAGAACCA 4753 GGUUCUUGGAAGCAGAGCU 4754 AGCUCUGCUUCCAAGAACC 4755 GUUCUUGGAAGCAGAGCUA 4756 UAGCUCUGCUUCCAAGAAC 4757 UUCUUGGAAGCAGAGCUAG 4758 CUAGCUCUGCUUCCAAGAA 4759 CUUGGAAGCAGAGCUAGGA 4760 UCCUAGCUCUGCUUCCAAG 4761 UGGAAGCAGAGCUAGGAUG 4762 CAUCCUAGCUCUGCUUCCA 4763 GGAAGCAGAGCUAGGAUGU 4764 ACAUCCUAGCUCUGCUUCC 4765 AGCUAGGAUGUGGGAGGUC 4766 GACCUCCCACAUCCUAGCU 4767 GCUAGGAUGUGGGAGGUCU 4768 AGACCUCCCACAUCCUAGC 4769 CUAGGAUGUGGGAGGUCUG 4770 CAGACCUCCCACAUCCUAG 4771 UAGGAUGUGGGAGGUCUGC 4772 GCAGACCUCCCACAUCCUA 4773 AGGAUGUGGGAGGUCUGCC 4774 GGCAGACCUCCCACAUCCU 4775 GGAUGUGGGAGGUCUGCCU 4776 AGGCAGACCUCCCACAUCC 4777 GAUGUGGGAGGUCUGCCUG 4778 CAGGCAGACCUCCCACAUC 4779 AUGUGGGAGGUCUGCCUGU 4780 ACAGGCAGACCUCCCACAU 4781 UUUCCUUGUCAUGCUUCCU 4782 AGGAAGCAUGACAAGGAAA 4783 UUCCUUGUCAUGCUUCCUC 4784 GAGGAAGCAUGACAAGGAA 4785 UGUCAUGCUUCCUCCUCUU 4786 AAGAGGAGGAAGCAUGACA 4787 UCAUGCUUCCUCCUCUUUC 4788 GAAAGAGGAGGAAGCAUGA 4789 CUUCCUCCUCUUUCUCAUA 4790 UAUGAGAAAGAGGAGGAAG 4791 UCCUCCUCUUUCUCAUAAA 4792 UUUAUGAGAAAGAGGAGGA 4793 CCUCCUCUUUCUCAUAAAA 4794 UUUUAUGAGAAAGAGGAGG 4795 UCACGAUGGCAAUGCAAAU 4796 AUUUGCAUUGCCAUCGUGA 4797 CACGAUGGCAAUGCAAAUC 4798 GAUUUGCAUUGCCAUCGUG 4799 ACGAUGGCAAUGCAAAUCU 4800 AGAUUUGCAUUGCCAUCGU 4801 CGAUGGCAAUGCAAAUCUA 4802 UAGAUUUGCAUUGCCAUCG 4803 GAUGGCAAUGCAAAUCUAA 4804 UUAGAUUUGCAUUGCCAUC 4805 UGGCAAUGCAAAUCUAAAG 4806 CUUUAGAUUUGCAUUGCCA 4807 GGCAAUGCAAAUCUAAAGA 4808 UCUUUAGAUUUGCAUUGCC 4809 AUGCAAAUCUAAAGAGGCA 4810 UGCCUCUUUAGAUUUGCAU 4811 GCAAAUCUAAAGAGGCAGG 4812 CCUGCCUCUUUAGAUUUGC 4813 CAAAUCUAAAGAGGCAGGG 4814 CCCUGCCUCUUUAGAUUUG 4815 AAAUCUAAAGAGGCAGGGC 4816 GCCCUGCCUCUUUAGAUUU 4817 ACUUCCCUGUCAGGCAGUA 4818 UACUGCCUGACAGGGAAGU 4819 CUUCCCUGUCAGGCAGUAC 4820 GUACUGCCUGACAGGGAAG 4821 UUCCCUGUCAGGCAGUACC 4822 GGUACUGCCUGACAGGGAA 4823 UCCCUGUCAGGCAGUACCG 4824 CGGUACUGCCUGACAGGGA 4825 CCUGUCAGGCAGUACCGCU 4826 AGCGGUACUGCCUGACAGG 4827 CUGUCAGGCAGUACCGCUG 4828 CAGCGGUACUGCCUGACAG 4829 UGUCAGGCAGUACCGCUGG 4830 CCAGCGGUACUGCCUGACA 4831 AGGCAGUACCGCUGGGCAU 4832 AUGCCCAGCGGUACUGCCU 4833 GGCAGUACCGCUGGGCAUA 4834 UAUGCCCAGCGGUACUGCC 4835 GCAGUACCGCUGGGCAUAG 4836 CUAUGCCCAGCGGUACUGC 4837 UACCGCUGGGCAUAGCAAC 4838 GUUGCUAUGCCCAGCGGUA 4839 ACCGCUGGGCAUAGCAACC 4840 GGUUGCUAUGCCCAGCGGU 4841 CCGCUGGGCAUAGCAACCU 4842 AGGUUGCUAUGCCCAGCGG 4843 CCUCUGCCUCUCCGUUUCU 4844 AGAAACGGAGAGGCAGAGG 4845 UGCCUCUCCGUUUCUCAGA 4846 UCUGAGAAACGGAGAGGCA 4847 UCUCCGUUUCUCAGAGCUC 4848 GAGCUCUGAGAAACGGAGA 4849 CUCCGUUUCUCAGAGCUCA 4850 UGAGCUCUGAGAAACGGAG 4851 UCCGUUUCUCAGAGCUCAC 4852 GUGAGCUCUGAGAAACGGA 4853 CCGUUUCUCAGAGCUCACA 4854 UGUGAGCUCUGAGAAACGG 4855 CGUUUCUCAGAGCUCACAU 4856 AUGUGAGCUCUGAGAAACG 4857 UUUCUCAGAGCUCACAUAU 4858 AUAUGUGAGCUCUGAGAAA 4859 AGAGCUCACAUAUCCACCU 4860 AGGUGGAUAUGUGAGCUCU 4861 GAGCUCACAUAUCCACCUC 4862 GAGGUGGAUAUGUGAGCUC 4863 AGCUCACAUAUCCACCUCC 4864 GGAGGUGGAUAUGUGAGCU 4865 CAUAUCCACCUCCUGGGCU 4866 AGCCCAGGAGGUGGAUAUG 4867 AUAUCCACCUCCUGGGCUU 4868 AAGCCCAGGAGGUGGAUAU 4869 UAUCCACCUCCUGGGCUUU 4870 AAAGCCCAGGAGGUGGAUA 4871 AUCCACCUCCUGGGCUUUU 4872 AAAAGCCCAGGAGGUGGAU 4873 UCCACCUCCUGGGCUUUUA 4874 UAAAAGCCCAGGAGGUGGA 4875 CCACCUCCUGGGCUUUUAA 4876 UUAAAAGCCCAGGAGGUGG 4877 UCCUGGGCUUUUAAGUGGG 4878 CCCACUUAAAAGCCCAGGA 4879 CCUGGGCUUUUAAGUGGGC 4880 GCCCACUUAAAAGCCCAGG 4881 CUGGGCUUUUAAGUGGGCU 4882 AGCCCACUUAAAAGCCCAG 4883 UGGGCUUUUAAGUGGGCUU 4884 AAGCCCACUUAAAAGCCCA 4885 GGGCUUUUAAGUGGGCUUU 4886 AAAGCCCACUUAAAAGCCC 4887 UUUUAAGUGGGCUUUAGUG 4888 CACUAAAGCCCACUUAAAA 4889 UUUAAGUGGGCUUUAGUGA 4890 UCACUAAAGCCCACUUAAA 4891 UUAAGUGGGCUUUAGUGAG 4892 CUCACUAAAGCCCACUUAA 4893 UAAGUGGGCUUUAGUGAGG 4894 CCUCACUAAAGCCCACUUA 4895 AAGUGGGCUUUAGUGAGGG 4896 CCCUCACUAAAGCCCACUU 4897 GGGCUCCUCCUUCAACUGG 4898 CCAGUUGAAGGAGGAGCCC 4899 GGCUCCUCCUUCAACUGGG 4900 CCCAGUUGAAGGAGGAGCC 4901 GCUCCUCCUUCAACUGGGC 4902 GCCCAGUUGAAGGAGGAGC 4903 CAACUGGGCUCCUCCUUCA 4904 UGAAGGAGGAGCCCAGUUG 4905 AACUGGGCUCCUCCUUCAG 4906 CUGAAGGAGGAGCCCAGUU 4907 UGGGCUCCUCCUUCAGUUC 4908 GAACUGAAGGAGGAGCCCA 4909 GGGCUCCUCCUUCAGUUCC 4910 GGAACUGAAGGAGGAGCCC 4911 CCCAGCUCUUCUGCUUCGA 4912 UCGAAGCAGAAGAGCUGGG 4913 CCAGCUCUUCUGCUUCGAC 4914 GUCGAAGCAGAAGAGCUGG 4915 CAGCUCUUCUGCUUCGACU 4916 AGUCGAAGCAGAAGAGCUG 4917 AGCUCUUCUGCUUCGACUC 4918 GAGUCGAAGCAGAAGAGCU 4919 GCUCUUCUGCUUCGACUCC 4920 GGAGUCGAAGCAGAAGAGC 4921 CUCUUCUGCUUCGACUCCG 4922 CGGAGUCGAAGCAGAAGAG 4923 UCUUCUGCUUCGACUCCGA 4924 UCGGAGUCGAAGCAGAAGA 4925 CUUCUGCUUCGACUCCGAG 4926 CUCGGAGUCGAAGCAGAAG 4927 UUCGACUCCGAGCGGGUGU 4928 ACACCCGCUCGGAGUCGAA 4929 UCCGAGCGGGUGUCAUGUG 4930 CACAUGACACCCGCUCGGA 4931 CCGAGCGGGUGUCAUGUGU 4932 ACACAUGACACCCGCUCGG 4933 CGAGCGGGUGUCAUGUGUG 4934 CACACAUGACACCCGCUCG 4935 GAGCGGGUGUCAUGUGUGA 4936 UCACACAUGACACCCGCUC 4937

The inhibitory nucleic acid molecules disclosed herein can comprise RNA, DNA, or both RNA and DNA. The inhibitory nucleic acid molecules can also be linked or fused to a heterologous nucleic acid sequence, such as in a vector, or a heterologous label. For example, the inhibitory nucleic acid molecules disclosed herein can be within a vector or as an exogenous donor sequence comprising the inhibitory nucleic acid molecule and a heterologous nucleic acid sequence. The inhibitory nucleic acid molecules can also be linked or fused to a heterologous label. The label can be directly detectable (such as, for example, fluorophore) or indirectly detectable (such as, for example, hapten, enzyme, or fluorophore quencher). Such labels can be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radiolabels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The label can also be, for example, a chemiluminescent substance; a metal-containing substance; or an enzyme, where there occurs an enzyme-dependent secondary generation of signal. The term “label” can also refer to a “tag” or hapten that can bind selectively to a conjugated molecule such that the conjugated molecule, when added subsequently along with a substrate, is used to generate a detectable signal. For example, biotin can be used as a tag along with an avidin or streptavidin conjugate of horseradish peroxidate (HRP) to bind to the tag, and examined using a calorimetric substrate (such as, for example, tetramethylbenzidine (TMB)) or a fluorogenic substrate to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3XFLAG, 6× His or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, an epitope tag, or the Fc portion of immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes and their calorimetric, fluorogenic and chemiluminescent substrates and other labels.

The disclosed inhibitory nucleic acid molecules can comprise, for example, nucleotides or non-natural or modified nucleotides, such as nucleotide analogs or nucleotide substitutes. Such nucleotides include a nucleotide that contains a modified base, sugar, or phosphate group, or that incorporates a non-natural moiety in its structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated, aminated, deaminated, alkylated, benzylated, and fluorophor-labeled nucleotides.

The inhibitory nucleic acid molecules disclosed herein can also comprise one or more nucleotide analogs or substitutions. A nucleotide analog is a nucleotide which contains a modification to either the base, sugar, or phosphate moieties. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T/U, as well as different purine or pyrimidine bases such as, for example, pseudouridine, uracil-5-yl, hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl. Modified bases include, but are not limited to, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (such as, for example, 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

Nucleotide analogs can also include modifications of the sugar moiety. Modifications to the sugar moiety include, but are not limited to, natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include, but are not limited to, the following modifications at the 2′ position: OH; F; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; O—, S— or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl, and alkynyl may be substituted or unsubstituted C₁₋₁₀alkyl or C₂₋₁₀alkenyl, and C₂₋₁₀alkynyl. Exemplary 2′ sugar modifications also include, but are not limited to, —O[(CH₂)_(n)P]_(m)CH₃, —O(CH ₂)_(n)OCH ₃, —O(CH₂)_(n)NH₂, —O(CH₂)_(n)CH₃, —O(CH₂)_(n)—ONH₂, and —O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]₂, where n and m, independently, are from 1 to about 10. Other modifications at the 2′ position include, but are not limited to, Ci_malkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, CI, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Similar modifications may also be made at other positions on the sugar, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Modified sugars can also include those that contain modifications at the bridging ring oxygen, such as CH₂ and S. Nucleotide sugar analogs can also have sugar mimetics, such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3′-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. These phosphate or modified phosphate linkage between two nucleotides can be through a 3′-5′ linkage or a 2′-5′ linkage, and the linkage can contain inverted polarity such as 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts, and free acid forms are also included. Nucleotide substitutes also include peptide nucleic acids (PNAs).

In some embodiments, the antisense nucleic acid molecules are gapmers, whereby the first one to seven nucleotides at the 5′ and 3′ ends each have 2′-methoxyethyl (2′-MOE) modifications. In some embodiments, the first five nucleotides at the 5′ and 3′ ends each have 2′-MOE modifications. In some embodiments, the first one to seven nucleotides at the 5′ and 3′ ends are RNA nucleotides. In some embodiments, the first five nucleotides at the 5′ and 3′ ends are RNA nucleotides. In some embodiments, each of the backbone linkages between the nucleotides is a phosphorothioate linkage.

In some embodiments, the siRNA molecules have termini modifications. In some embodiments, the 5′ end of the antisense strand is phosphorylated. In some embodiments, 5′-phosphate analogs that cannot be hydrolyzed, such as 5′-(E)-vinyl-phosphonate are used.

In some embodiments, the siRNA molecules have backbone modifications. In some embodiments, the modified phosphodiester groups that link consecutive ribose nucleosides have been shown to enhance the stability and in vivo bioavailability of siRNAs The non-ester groups (—OH, ═O) of the phosphodiester linkage can be replaced with sulfur, boron, or acetate to give phosphorothioate, boranophosphate, and phosphonoacetate linkages. In addition, substituting the phosphodiester group with a phosphotriester can facilitate cellular uptake of siRNAs and retention on serum components by eliminating their negative charge. In some embodiments, the siRNA molecules have sugar modifications. In some embodiments, the sugars are deprotonated (reaction catalyzed by exo- and endonucleases) whereby the 2′-hydroxyl can act as a nucleophile and attack the adjacent phosphorous in the phosphodiester bond. Such alternatives include 2′-O-methyl, 2′-O-methoxyethyl, and 2′-fluoro modifications.

In some embodiments, the siRNA molecules have base modifications. In some embodiments, the bases can be substituted with modified bases such as pseudouridine, 5′-methylcytidine, N6-methyladenosine, inosine, and N7-methylguanosine.

In some embodiments, the siRNA molecules are conjugated to lipids. Lipids can be conjugated to the 5′ or 3′ termini of siRNA to improve their in vivo bioavailability by allowing them to associate with serum lipoproteins. Representative lipids include, but are not limited to, cholesterol and vitamin E, and fatty acids, such as palmitate and tocopherol.

In some embodiments, a representative siRNA has the following formula:

Sense: mN*mN*/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/mN/i2FN/*nnN*/32FN/Antisense:/52FN/*/i2FN/*nnN/i2FN/nnN/i2FN/nnN/i2FN/nnN/i2FN/nnN/i2FN/nnN/i2FN/nnN/i2FN/mN/i2FN/mN*N*N

wherein: “N” is the base; “2F” is a 2′-F modification; “m” is a 2′-O-methyl modification, “I” is an internal base; and “*” is a phosphorothioate backbone linkage.

The present disclosure also provides vectors comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the vectors comprise any one or more of the inhibitory nucleic acid molecules disclosed herein and a heterologous nucleic acid. The vectors can be viral or nonviral vectors capable of transporting a nucleic acid molecule. In some embodiments, the vector is a plasmid or cosmid (such as, for example, a circular double-stranded DNA into which additional DNA segments can be ligated). In some embodiments, the vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Expression vectors include, but are not limited to, plasmids, cosmids, retroviruses, adenoviruses, adeno-associated viruses (AAV), plant viruses such as cauliflower mosaic virus and tobacco mosaic virus, yeast artificial chromosomes (YACs), Epstein-Barr (EBV)-derived episomes, and other expression vectors known in the art.

The present disclosure also provides compositions comprising any one or more of the inhibitory nucleic acid molecules disclosed herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the compositions comprise a carrier and/or excipient. Examples of carriers include, but are not limited to, poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic-acid) (PLGA) microspheres, liposomes, micelles, inverse micelles, lipid cochleates, and lipid microtubules. A carrier may comprise a buffered salt solution such as PBS, HBSS, etc.

In some embodiments, the INHBE inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks at a recognition sequence(s) or a DNA-binding protein that binds to a recognition sequence within an INHBE genomic nucleic acid molecule. The recognition sequence can be located within a coding region of the INHBE gene, or within regulatory regions that influence the expression of the gene. A recognition sequence of the DNA-binding protein or nuclease agent can be located in an intron, an exon, a promoter, an enhancer, a regulatory region, or any non-protein coding region. The recognition sequence can include or be proximate to the start codon of the INHBE gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon. As another example, two or more nuclease agents can be used, each targeting a nuclease recognition sequence including or proximate to the start codon. As another example, two nuclease agents can be used, one targeting a nuclease recognition sequence including or proximate to the start codon, and one targeting a nuclease recognition sequence including or proximate to the stop codon, wherein cleavage by the nuclease agents can result in deletion of the coding region between the two nuclease recognition sequences. Any nuclease agent that induces a nick or double-strand break into a desired recognition sequence can be used in the methods and compositions disclosed herein. Any DNA-binding protein that binds to a desired recognition sequence can be used in the methods and compositions disclosed herein.

Suitable nuclease agents and DNA-binding proteins for use herein include, but are not limited to, zinc finger protein or zinc finger nuclease (ZFN) pair, Transcription Activator-Like Effector (TALE) protein or Transcription Activator-Like Effector Nuclease (TALEN), or Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) systems. The length of the recognition sequence can vary, and includes, for example, recognition sequences that are about 30-36 bp for a zinc finger protein or ZFN pair, about 15-18 bp for each ZFN, about 36 bp for a TALE protein or TALEN, and about 20 bp for a CRISPR/Cas guide RNA.

In some embodiments, CRISPR/Cas systems can be used to modify an INHBE genomic nucleic acid molecule within a cell. The methods and compositions disclosed herein can employ CRISPR-Cas systems by utilizing CRISPR complexes (comprising a guide RNA (gRNA) complexed with a Cas protein) for site-directed cleavage of INHBE nucleic acid molecules.

Cas proteins generally comprise at least one RNA recognition or binding domain that can interact with gRNAs. Cas proteins can also comprise nuclease domains (such as, for example, DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. Suitable Cas proteins include, for example, a wild type Cas9 protein and a wild type Cpf1 protein (such as, for example, FnCpf1). A Cas protein can have full cleavage activity to create a double-strand break in an INHBE genomic nucleic acid molecule or it can be a nickase that creates a single-strand break in an INHBE genomic nucleic acid molecule. Additional examples of Cas proteins include, but are not limited to, Cas1, Cas1B, Cast, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cnnr1 , Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, and homologs or modified versions thereof. In some embodiments, a Cas system, such as Cas12a, can have multiple gRNAs encoded into a single crRNA. Cas proteins can also be operably linked to heterologous polypeptides as fusion proteins. For example, a Cas protein can be fused to a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Cas proteins can be provided in any form. For example, a Cas protein can be provided in the form of a protein, such as a Cas protein complexed with a gRNA. Alternately, a Cas protein can be provided in the form of a nucleic acid molecule encoding the Cas protein, such as an RNA or DNA.

In some embodiments, targeted genetic modifications of INHBE genomic nucleic acid molecules can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences within a target genomic locus in the INHBE genomic nucleic acid molecule. For example, a gRNA recognition sequence can be located within a region of SEQ ID NO:1. The gRNA recognition sequence can include or be proximate to the start codon of an INHBE genomic nucleic acid molecule or the stop codon of an INHBE genomic nucleic acid molecule. For example, the gRNA recognition sequence can be located from about 10, from about 20, from about 30, from about 40, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the start codon or the stop codon.

The gRNA recognition sequences within a target genomic locus in an INHBE genomic nucleic acid molecule are located near a Protospacer Adjacent Motif (PAM) sequence, which is a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease. The canonical PAM is the sequence 5′-NGG-3′ where “N” is any nucleobase followed by two guanine (“G”) nucleobases. gRNAs can transport Cas9 to anywhere in the genome for gene editing, but no editing can occur at any site other than one at which Cas9 recognizes PAM. In addition, 5′-NGA-3′ can be a highly efficient non-canonical PAM for human cells. Generally, the PAM is about 2-6 nucleotides downstream of the DNA sequence targeted by the gRNA. The PAM can flank the gRNA recognition sequence. In some embodiments, the gRNA recognition sequence can be flanked on the 3′ end by the PAM. In some embodiments, the gRNA recognition sequence can be flanked on the 5′ end by the PAM. For example, the cleavage site of Cas proteins can be about 1 to about 10, about 2 to about 5 base pairs, or three base pairs upstream or downstream of the PAM sequence. In some embodiments (such as when Cas9 from S. pyogenes or a closely related Cas9 is used), the PAM sequence of the non-complementary strand can be 5′-NGG-3′, where N is any DNA nucleotide and is immediately 3′ of the gRNA recognition sequence of the non-complementary strand of the target DNA. As such, the PAM sequence of the complementary strand would be 5′-CCN-3′, where N is any DNA nucleotide and is immediately 5′ of the gRNA recognition sequence of the complementary strand of the target DNA.

A gRNA is an RNA molecule that binds to a Cas protein and targets the Cas protein to a specific location within an INHBE genomic nucleic acid molecule. An exemplary gRNA is a gRNA effective to direct a Cas enzyme to bind to or cleave an INHBE genomic nucleic acid molecule, wherein the gRNA comprises a DNA-targeting segment that hybridizes to a gRNA recognition sequence within the INHBE genomic nucleic acid molecule. Exemplary gRNAs comprise a DNA-targeting segment that hybridizes to a gRNA recognition sequence present within an INHBE genomic nucleic acid molecule that includes or is proximate to the start codon or the stop codon. For example, a gRNA can be selected such that it hybridizes to a gRNA recognition sequence that is located from about 5, from about 10, from about 15, from about 20, from about 25, from about 30, from about 35, from about 40, from about 45, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the start codon or located from about 5, from about 10, from about 15, from about 20, from about 25, from about 30, from about 35, from about 40, from about 45, from about 50, from about 100, from about 200, from about 300, from about 400, from about 500, or from about 1,000 nucleotides of the stop codon. Suitable gRNAs can comprise from about 17 to about 25 nucleotides, from about 17 to about 23 nucleotides, from about 18 to about 22 nucleotides, or from about 19 to about 21 nucleotides. In some embodiments, the gRNAs can comprise 20 nucleotides. Examples of suitable gRNA recognition sequences located within the human INHBE reference gene are set forth in Table 5 as SEQ ID NOs:9-27.

TABLE 5 Guide RNA Recognition Sequences Near INHBE Variation(s) Strand gRNA Recognition Sequence SEQ ID NO: - CGTCTGTTGAGTCTGATTGC  9 + GACGGAGCAACTGCCATCCG 10 - ATCAGGGAGCCGCATGCTCC 11 + CTGAACCAGGGCCATTCACC 12 - CCTGGTTCAGGAGCCTCGGA 13 + CATCCGAGGCTCCTGAACCA 14 + CCATCCGAGGCTCCTGAACC 15 - GCCACCTGTCTTCTATTGTC 16 - AGCCGCATGCTCCTGGTGAA 17 - GTCTGTTGAGTCTGATTGCT 18 + AAGACAGGTGGCTGTACCCT 19 - CTGATTGCTGGGGGCCAATG 20 - TGATTGCTGGGGGCCAATGA 21 - CCACCTGTCTTCTATTGTCT 22 - ATGCTCCTGGTGAATGGCCC 23 - CTGTTGAGTCTGATTGCTGG 24 - CTGGTGAATGGCCCTGGTTC 25 - ACCACTGCCACACCTACCCT 26 - TCTGTTGAGTCTGATTGCTG 27

The Cas protein and the gRNA form a complex, and the Cas protein cleaves the target INHBE genomic nucleic acid molecule. The Cas protein can cleave the nucleic acid molecule at a site within or outside of the nucleic acid sequence present in the target INHBE genomic nucleic acid molecule to which the DNA-targeting segment of a gRNA will bind. For example, formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can result in cleavage of one or both strands in or near (such as, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in the INHBE genomic nucleic acid molecule to which a DNA-targeting segment of a gRNA will bind.

Such methods can result, for example, in an INHBE genomic nucleic acid molecule in which a region of SEQ ID NO:1 is disrupted, the start codon is disrupted, the stop codon is disrupted, or the coding sequence is disrupted or deleted. Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize to additional gRNA recognition sequences within the target genomic locus in the INHBE genomic nucleic acid molecule. By contacting the cell with one or more additional gRNAs (such as, for example, a second gRNA that hybridizes to a second gRNA recognition sequence), cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.

The methods and compositions disclosed herein can utilize exogenous donor sequences (e.g., targeting vectors or repair templates) to modify an INHBE gene, either without cleavage of the INHBE gene or following cleavage of the INHBE gene with a nuclease agent. An exogenous donor sequence refers to any nucleic acid or vector that includes the elements that are required to enable site-specific recombination with a target sequence. Using exogenous donor sequences in combination with nuclease agents may result in more precise modifications within the INHBE gene by promoting homology-directed repair.

In such methods, the nuclease agent cleaves the INHBE gene to create a single-strand break (nick) or double-strand break, and the exogenous donor sequence recombines the INHBE gene via non-homologous end joining (NHEJ)-mediated ligation or through a homology-directed repair event. Optionally, repair with the exogenous donor sequence removes or disrupts the nuclease cleavage site so that alleles that have been targeted cannot be re-targeted by the nuclease agent.

Exogenous donor sequences can comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), they can be single-stranded or double-stranded, and they can be in linear or circular form. For example, an exogenous donor sequence can be a single-stranded oligodeoxynucleotide (ssODN). See, e.g., Yoshimi et al., Nat. Commun., 2016, 7, 10431. An exemplary exogenous donor sequence is from about 50 nucleotides to about 5 kb in length, from about 50 nucleotides to about 3 kb in length, or from about 50 to about 1,000 nucleotides in length. Other exemplary exogenous donor sequences are from about 40 to about 200 nucleotides in length. For example, an exogenous donor sequence can be from about 50 to about 60, from about 60 to about 70, from about 70 to about 80, from about 80 to about 90, from about 90 to about 100, from about 100 to about 110, from about 110 to about 120, from about 120 to about 130, from about 130 to about 140, from about 140 to about 150, from about 150 to about 160, from about 160 to about 170, from about 170 to about 180, from about 180 to about 190, or from about 190 to about 200 nucleotides in length. Alternately, an exogenous donor sequence can be from about 50 to about 100, from about 100 to about 200, from about 200 to about 300, from about 300 to about 400, from about 400 to about 500, from about 500 to about 600, from about 600 to about 700, from about 700 to about 800, from about 800 to about 900, or from about 900 to about 1,000 nucleotides in length. Alternately, an exogenous donor sequence can be from about 1 kb to about 1.5 kb, from about 1.5 kb to about 2 kb, from about 2 kb to about 2.5 kb, from about 2.5 kb to about 3 kb, from about 3 kb to about 3.5 kb, from about 3.5 kb to about 4 kb, from about 4 kb to about 4.5 kb, or from about 4.5 kb to about 5 kb in length. Alternately, an exogenous donor sequence can be, for example, no more than 5 kb, 4.5 kb, 4 kb, 3.5 kb, 3 kb, 2.5 kb, 2 kb, 1.5 kb, 1 kb, 900 nucleotides, 800 nucleotides, 700 nucleotides, 600 nucleotides, 500 nucleotides, 400 nucleotides, 300 nucleotides, 200 nucleotides, 100 nucleotides, or 50 nucleotides in length.

In some examples, an exogenous donor sequence is an ssODN that is from about 80 nucleotides and about 200 nucleotides in length (e.g., about 120 nucleotides in length). In another example, an exogenous donor sequences is an ssODN that is from about 80 nucleotides and about 3 kb in length. Such an ssODN can have homology arms, for example, that are each from about 40 nucleotides and about 60 nucleotides in length. Such an ssODN can also have homology arms, for example, that are each from about 30 nucleotides and 100 nucleotides in length. The homology arms can be symmetrical (e.g., each 40 nucleotides or each 60 nucleotides in length), or they can be asymmetrical (e.g., one homology arm that is 36 nucleotides in length, and one homology arm that is 91 nucleotides in length).

Exogenous donor sequences can include modifications or sequences that provide for additional desirable features (e.g., modified or regulated stability; tracking or detecting with a fluorescent label; a binding site for a protein or protein complex; and so forth).

Exogenous donor sequences can comprise one or more fluorescent labels, purification tags, epitope tags, or a combination thereof. For example, an exogenous donor sequence can comprise one or more fluorescent labels (e.g., fluorescent proteins or other fluorophores or dyes), such as at least 1, at least 2, at least 3, at least 4, or at least 5 fluorescent labels. Exemplary fluorescent labels include fluorophores such as fluorescein (e.g., 6-carboxyfluorescein (6-FAM)), Texas Red, HEX, Cy3, Cy5, Cy5.5, Pacific Blue, 5-(and-6)-carboxytetramethylrhodamine (TAMRA), and Cy7. A wide range of fluorescent dyes are available commercially for labeling oligonucleotides (e.g., from Integrated DNA Technologies). Such fluorescent labels (e.g., internal fluorescent labels) can be used, for example, to detect an exogenous donor sequence that has been directly integrated into a cleaved INHBE gene having protruding ends compatible with the ends of the exogenous donor sequence. The label or tag can be at the 5′ end, the 3′ end, or internally within the exogenous donor sequence. For example, an exogenous donor sequence can be conjugated at 5′ end with the IR700 fluorophore from Integrated DNA Technologies (5′IRDYE° 700). Exogenous donor sequences can also comprise nucleic acid inserts including segments of DNA to be integrated in the INHBE gene. Integration of a nucleic acid insert in the INHBE gene can result in addition of a nucleic acid sequence of interest in the INHBE gene, deletion of a nucleic acid sequence of interest in the INHBE gene, or replacement of a nucleic acid sequence of interest in the INHBE gene (i.e., deletion and insertion). Some exogenous donor sequences are designed for insertion of a nucleic acid insert in the INHBE gene without any corresponding deletion in the INHBE gene. Other exogenous donor sequences are designed to delete a nucleic acid sequence of interest in the INHBE gene without any corresponding insertion of a nucleic acid insert. Yet other exogenous donor sequences are designed to delete a nucleic acid sequence of interest in the INHBE gene and replace it with a nucleic acid insert.

The nucleic acid insert or the corresponding nucleic acid in the INHBE gene being deleted and/or replaced can be various lengths. An exemplary nucleic acid insert or corresponding nucleic acid in the INHBE gene being deleted and/or replaced is from about 1 nucleotide to about 5 kb in length or is from about 1 nucleotide to about 1,000 nucleotides in length. For example, a nucleic acid insert or a corresponding nucleic acid in the INHBE gene being deleted and/or replaced can be from about 1 to about 10, from about 10 to about 20, from about 20 to about 30, from about 30 to about 40, from about 40 to about 50, from about 50 to about 60, from about 60 to about 70, from about 70 to about 80, from about 80 to about 90, from about 90 to about 100, from about 100 to about 110, from about 110 to about 120, from about 120 to about 130, from about 130 to about 140, from about 140 to about 150, from about 150 to about 160, from about 160 to about 170, from about 170 to about 180, from about 180 to about 190, or from about 190 to about 200 nucleotides in length. Likewise, a nucleic acid insert or a corresponding nucleic acid in the INHBE gene being deleted and/or replaced can be from about 1 to about 100, from about 100 to about 200, from about 200 to about 300, from about 300 to about 400, from about 400 to about 500, from about 500 to about 600, from about 600 to about 700, from about 700 to about 800, from about 800 to about 900, or from about 900 to about 1,000 nucleotides in length. Likewise, a nucleic acid insert or a corresponding nucleic acid in the INHBE gene being deleted and/or replaced can be from about 1 kb to about 1.5 kb, from about 1.5 kb to about 2 kb, from about 2 kb to about 2.5 kb, from about 2.5 kb to about 3 kb, from about 3 kb to about 3.5 kb, from about 3.5 kb to about 4 kb, from about 4 kb to about 4.5 kb, or from about 4.5 kb to about 5 kb in length.

The nucleic acid insert can comprise genomic DNA or any other type of DNA. For example, the nucleic acid insert can comprise cDNA.

The nucleic acid insert can comprise a sequence that is homologous to all or part of the INHBE gene (e.g., a portion of the gene encoding a particular motif or region of an INHBE protein). For example, the nucleic acid insert can comprise a sequence that comprises one or more point mutations (e.g., 1, 2, 3, 4, 5, or more) or one or more nucleotide insertions or deletions compared with a sequence targeted for replacement in the INHBE gene. The nucleic acid insert or the corresponding nucleic acid in the INHBE gene being deleted and/or replaced can be a coding region such as an exon; a non-coding region such as an intron, an untranslated region, or a regulatory region (e.g., a promoter, an enhancer, or a transcriptional repressor-binding element); or any combination thereof.

The nucleic acid insert can also comprise a conditional allele. The conditional allele can be a multifunctional allele, as described in US 2011/0104799. For example, the conditional allele can comprise: a) an actuating sequence in sense orientation with respect to transcription of a target gene; b) a drug selection cassette (DSC) in sense or antisense orientation; c) a nucleotide sequence of interest (NSI) in antisense orientation; and d) a conditional by inversion module (COIN, which utilizes an exon-splitting intron and an invertible gene-trap-like module) in reverse orientation. See, e.g., US 2011/0104799. The conditional allele can further comprise recombinable units that recombine upon exposure to a first recombinase to form a conditional allele that i) lacks the actuating sequence and the DSC; and ii) contains the NSI in sense orientation and the COIN in antisense orientation. See, e.g., US 2011/0104799.

Nucleic acid inserts can also comprise a polynucleotide encoding a selection marker. Alternately, the nucleic acid inserts can lack a polynucleotide encoding a selection marker. The selection marker can be contained in a selection cassette. Optionally, the selection cassette can be a self-deleting cassette. See, e.g., U.S. Pat. No 8,697,851 and US 2013/0312129. As an example, the self-deleting cassette can comprise a Cre gene (comprises two exons encoding a Cre recombinase, which are separated by an intron) operably linked to a mouse Prml promoter and a neomycin resistance gene operably linked to a human ubiquitin promoter. Exemplary selection markers include neomycin phosphotransferase (near), hygromycin B phosphotransferase (hygr), puromycin-N-acetyltransferase (pure), blasticidin S deaminase (bsrr), xanthine/guanine phosphoribosyl transferase (gpt), or herpes simplex virus thymidine kinase (HSV-k), or a combination thereof. The polynucleotide encoding the selection marker can be operably linked to a promoter active in a cell being targeted. Examples of promoters are described elsewhere herein.

The nucleic acid insert can also comprise a reporter gene. Exemplary reporter genes include those encoding luciferase, βgalactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP), blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), DsRed, ZsGreen, MmGFP, mPlum, mCherry, tdTonnato, mStrawberry, J-Red, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, Cerulean, T-Sapphire, and alkaline phosphatase. Such reporter genes can be operably linked to a promoter active in a cell being targeted. Examples of promoters are described elsewhere herein.

The nucleic acid insert can also comprise one or more expression cassettes or deletion cassettes. A given cassette can comprise one or more of a nucleotide sequence of interest, a polynucleotide encoding a selection marker, and a reporter gene, along with various regulatory components that influence expression. Examples of selectable markers and reporter genes that can be included are discussed in detail elsewhere herein. The nucleic acid insert can comprise a nucleic acid flanked with site-specific recombination target sequences. Alternately, the nucleic acid insert can comprise one or more site-specific recombination target sequences. Although the entire nucleic acid insert can be flanked by such site-specific recombination target sequences, any region or individual polynucleotide of interest within the nucleic acid insert can also be flanked by such sites. Site-specific recombination target sequences, which can flank the nucleic acid insert or any polynucleotide of interest in the nucleic acid insert can include, for example, loxP, lox511, lox2272, lox66, lox71, loxM2,lox5171, FRT, FRT11, FRT71, attp, att, FRT, rox, or a combination thereof. In some examples, the site-specific recombination sites flank a polynucleotide encoding a selection marker and/or a reporter gene contained within the nucleic acid insert. Following integration of the nucleic acid insert in the INHBE gene, the sequences between the site-specific recombination sites can be removed. Optionally, two exogenous donor sequences can be used, each with a nucleic acid insert comprising a site-specific recombination site. The exogenous donor sequences can be targeted to 5′ and 3′ regions flanking a nucleic acid of interest. Following integration of the two nucleic acid inserts into the target genomic locus, the nucleic acid of interest between the two inserted site-specific recombination sites can be removed.

Nucleic acid inserts can also comprise one or more restriction sites for restriction endonucleases (i.e., restriction enzymes), which include Type I, Type II, Type III, and Type IV endonucleases. Type I and Type III restriction endonucleases recognize specific recognition sequences, but typically cleave at a variable position from the nuclease binding site, which can be hundreds of base pairs away from the cleavage site (recognition sequence). In Type II systems the restriction activity is independent of any methylase activity, and cleavage typically occurs at specific sites within or near to the binding site. Most Type II enzymes cut palindromic sequences, however Type IIa enzymes recognize non-palindromic recognition sequences and cleave outside of the recognition sequence, Type IIb enzymes cut sequences twice with both sites outside of the recognition sequence, and Type Ils enzymes recognize an asymmetric recognition sequence and cleave on one side and at a defined distance of about 1-20 nucleotides from the recognition sequence. Type IV restriction enzymes target methylated DNA. Restriction enzymes are further described and classified, for example in the REBASE database (webpage at rebase.neb.com; Roberts et al., Nucleic Acids Res., 2003, 31, 418-420; Roberts et al., Nucleic Acids Res., 2003, 31, 1805-1812; and Belfort et al., in Mobile DNA II, 2002, pp. 761-783, Eds. Craigie et al., (ASM Press, Washington, D.C.)).

Some exogenous donor sequences have short single-stranded regions at the 5′ end and/or the 3′ end that are complementary to one or more overhangs created by nuclease-mediated or Cas-protein-mediated cleavage at the target genomic locus (e.g., in the INHBE gene). These overhangs can also be referred to as 5′ and 3′ homology arms. For example, some exogenous donor sequences have short single-stranded regions at the 5′ end and/or the 3′ end that are complementary to one or more overhangs created by Cas-protein-mediated cleavage at 5′ and/or 3′ target sequences at the target genomic locus. Some such exogenous donor sequences have a complementary region only at the 5′ end or only at the 3′ end. For example, some such exogenous donor sequences have a complementary region only at the 5′ end complementary to an overhang created at a 5′ target sequence at the target genomic locus or only at the 3′ end complementary to an overhang created at a 3′ target sequence at the target genomic locus. Other such exogenous donor sequences have complementary regions at both the 5′ and 3′ ends. For example, other such exogenous donor sequences have complementary regions at both the 5′ and 3′ ends e.g., complementary to first and second overhangs, respectively, generated by Cas-mediated cleavage at the target genomic locus. For example, if the exogenous donor sequence is double-stranded, the single-stranded complementary regions can extend from the 5′ end of the top strand of the donor sequence and the 5′ end of the bottom strand of the donor sequence, creating 5′ overhangs on each end. Alternately, the single-stranded complementary region can extend from the 3′ end of the top strand of the donor sequence and from the 3′ end of the bottom strand of the template, creating 3′ overhangs.

The complementary regions can be of any length sufficient to promote ligation between the exogenous donor sequence and the INHBE gene. Exemplary complementary regions are from about 1 to about 5 nucleotides in length, from about 1 to about 25 nucleotides in length, or from about 5 to about 150 nucleotides in length. For example, a complementary region can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. Alternately, the complementary region can be from about 5 to about 10, from about 10 to about 20, from about 20 to about 30, from about 30 to about 40, from about 40 to about 50, from about 50 to about 60, from about 60 to about 70, from about 70 to about 80, from about 80 to about 90, from about 90 to about 100, from about 100 to about 110, from about 110 to about 120, from about 120 to about 130, from about 130 to about 140, from about 140 to about 150 nucleotides in length, or longer.

Such complementary regions can be complementary to overhangs created by two pairs of nickases. Two double-strand breaks with staggered ends can be created by using first and second nickases that cleave opposite strands of DNA to create a first double-strand break, and third and fourth nickases that cleave opposite strands of DNA to create a second double-strand break. For example, a Cas protein can be used to nick first, second, third, and fourth guide RNA recognition sequences corresponding with first, second, third, and fourth guide RNAs. The first and second guide RNA recognition sequences can be positioned to create a first cleavage site such that the nicks created by the first and second nickases on the first and second strands of DNA create a double-strand break (i.e., the first cleavage site comprises the nicks within the first and second guide RNA recognition sequences). Likewise, the third and fourth guide RNA recognition sequences can be positioned to create a second cleavage site such that the nicks created by the third and fourth nickases on the first and second strands of DNA create a double-strand break (i.e., the second cleavage site comprises the nicks within the third and fourth guide RNA recognition sequences). Preferably, the nicks within the first and second guide RNA recognition sequences and/or the third and fourth guide RNA recognition sequences can be off-set nicks that create overhangs. The offset window can be, for example, at least about 5 bp, 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp or more. See, Ran et al., Cell, 2013, 154, 1380-1389; Mali et al., Nat. Biotech., 2013, 31, 833-838; and Shen et al., Nat. Methods, 2014, 11, 399-404. In such cases, a double-stranded exogenous donor sequence can be designed with single-stranded complementary regions that are complementary to the overhangs created by the nicks within the first and second guide RNA recognition sequences and by the nicks within the third and fourth guide RNA recognition sequences. Such an exogenous donor sequence can then be inserted by non-homologous-end-joining-mediated ligation.

Some exogenous donor sequences (i.e., targeting vectors) comprise homology arms. If the exogenous donor sequence also comprises a nucleic acid insert, the homology arms can flank the nucleic acid insert. For ease of reference, the homology arms are referred to herein as 5′ and 3′ (i.e., upstream and downstream) homology arms. This terminology relates to the relative position of the homology arms to the nucleic acid insert within the exogenous donor sequence. The 5′ and 3′ homology arms correspond to regions within the INHBE gene, which are referred to herein as “5′ target sequence” and “3′ target sequence,” respectively.

A homology arm and a target sequence “correspond” or are “corresponding” to one another when the two regions share a sufficient level of sequence identity to one another to act as substrates for a homologous recombination reaction. The term “homology” includes DNA sequences that are either identical or share sequence identity to a corresponding sequence. The sequence identity between a given target sequence and the corresponding homology arm found in the exogenous donor sequence can be any degree of sequence identity that allows for homologous recombination to occur. For example, the amount of sequence identity shared by the homology arm of the exogenous donor sequence (or a fragment thereof) and the target sequence (or a fragment thereof) can be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity, such that the sequences undergo homologous recombination. Moreover, a corresponding region of homology between the homology arm and the corresponding target sequence can be of any length that is sufficient to promote homologous recombination. Exemplary homology arms are from about 25 nucleotides to about 2.5 kb in length, are from about 25 nucleotides to about 1.5 kb in length, or are from about 25 to about 500 nucleotides in length. For example, a given homology arm (or each of the homology arms) and/or corresponding target sequence can comprise corresponding regions of homology that are from about 25 to about 30, from about 30 to about 40, from about 40 to about 50, from about 50 to about 60, from about 60 to about 70, from about 70 to about 80, from about 80 to about 90, from about 90 to about 100, from about 100 to about 150, from about 150 to about 200, from about 200 to about 250, from about 250 to about 300, from about 300 to about 350, from about 350 to about 400, from about 400 to about 450, or from about 450 to about 500 nucleotides in length, such that the homology arms have sufficient homology to undergo homologous recombination with the corresponding target sequences within the INHBE gene. Alternately, a given homology arm (or each homology arm) and/or corresponding target sequence can comprise corresponding regions of homology that are from about 0.5 kb to about 1 kb, from about 1 kb to about 1.5 kb, from about 1.5 kb to about 2 kb, or from about 2 kb to about 2.5 kb in length. For example, the homology arms can each be about 750 nucleotides in length. The homology arms can be symmetrical (each about the same size in length), or they can be asymmetrical (one longer than the other).

The homology arms can correspond to a locus that is native to a cell (e.g., the targeted locus). Alternately, for example, they can correspond to a region of a heterologous or exogenous segment of DNA that was integrated into the genome of the cell, including, for example, transgenes, expression cassettes, or heterologous or exogenous regions of DNA. Alternately, the homology arms of the targeting vector can correspond to a region of a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC), a human artificial chromosome, or any other engineered region contained in an appropriate host cell. Still further, the homology arms of the targeting vector can correspond to or be derived from a region of a BAC library, a cosmid library, or a P1 phage library, or can be derived from synthetic DNA.

When a nuclease agent is used in combination with an exogenous donor sequence, the 5′ and 3′ target sequences are preferably located in sufficient proximity to the nuclease cleavage site so as to promote the occurrence of a homologous recombination event between the target sequences and the homology arms upon a single-strand break (nick) or double-strand break at the nuclease cleavage site. The term “nuclease cleavage site” includes a DNA sequence at which a nick or double-strand break is created by a nuclease agent (e.g., a Cas9 protein complexed with a guide RNA). The target sequences within the INHBE gene that correspond to the 5′ and 3′ homology arms of the exogenous donor sequence are “located in sufficient proximity” to a nuclease cleavage site if the distance is such as to promote the occurrence of a homologous recombination event between the 5′ and 3′ target sequences and the homology arms upon a single-strand break or double-strand break at the nuclease cleavage site. Thus, the target sequences corresponding to the 5′ and/or 3′ homology arms of the exogenous donor sequence can be, for example, within at least 1 nucleotide of a given nuclease cleavage site or within at least 10 nucleotides to about 1,000 nucleotides of a given nuclease cleavage site. As an example, the nuclease cleavage site can be immediately adjacent to at least one or both of the target sequences.

The spatial relationship of the target sequences that correspond to the homology arms of the exogenous donor sequence and the nuclease cleavage site can vary. For example, target sequences can be located 5′ to the nuclease cleavage site, target sequences can be located 3′ to the nuclease cleavage site, or the target sequences can flank the nuclease cleavage site.

Also provided are therapeutic methods and methods of treatment or prophylaxis of a metabolic disorder in a subject having or at risk for the disease using the methods disclosed herein for modifying or altering expression of an endogenous INHBE gene. Also provided are therapeutic methods and methods of treatment or prophylaxis of a metabolic disorder in a subject having or at risk for the disease using methods for decreasing expression of INHBE mRNA transcripts or using methods for providing recombinant nucleic acids encoding INHBE proteins, providing mRNAs encoding INHBE proteins, or providing INHBE proteins to the subject. The methods can comprise introducing one or more nucleic acids or proteins into the subject, into the liver of the subject, or into a cell (e.g., liver cell) of the subject (e.g., in vivo or ex vivo).

Also provided are therapeutic methods and methods of treatment or prophylaxis of a cardiovascular disease in a subject having or at risk for cardiovascular disease using the methods disclosed herein for modifying or altering expression of an endogenous INHBE gene. Also provided are therapeutic methods and methods of treatment or prophylaxis of a cardiovascular disease in a subject having or at risk for cardiovascular disease using methods for decreasing expression of INHBE mRNA transcripts or using methods for providing recombinant nucleic acids encoding INHBE proteins, providing mRNAs encoding INHBE proteins, or providing INHBE proteins to the subject. The methods can comprise introducing one or more nucleic acids or proteins into the subject, into the liver of the subject, or into a cell (e.g., liver cell) of the subject (e.g., in vivo or ex vivo).

Such methods can comprise genome editing or gene therapy. For example, an endogenous INHBE gene that does not encode a loss-of-function variant can be modified to comprise any of the loss-of-function variants described herein. As another example, an endogenous INHBE gene that does not encode a loss-of-function variant can be knocked out or inactivated. Likewise, an endogenous INHBE gene that does not encode a loss-of-function variant can be knocked out or inactivated, and an INHBE gene comprising any one of or any combination of the INHBE loss-of-function variants described herein can be introduced and expressed. Similarly, an endogenous INHBE gene that does not encode a loss-of-function variant can be knocked out or inactivated, and a recombinant DNA encoding any one of or any combination of the INHBE loss-of-function variants described herein can be introduced and expressed, an mRNA encoding any one of or any combination of INHBE loss-of-function variants described herein (or fragments thereof) can be introduced and expressed (e.g., intracellular protein replacement therapy), or a cDNA encoding any one of or any combination of INHBE loss-of-function variants described herein (or fragments thereof) can be introduced (e.g., protein replacement therapy).

Other such methods can comprise introducing and expressing a recombinant INHBE gene comprising any one of or any combination of INHBE loss-of-function variants described herein (e.g., the full INHBE variant or a minigene comprising the modification), introducing and expressing recombinant nucleic acids (e.g., DNA) encoding any one of or any combination of INHBE loss-of-function variants described herein or fragments thereof, introducing and expressing one or more mRNAs encoding any one of or any combination of INHBE loss-of-function variants described herein fragments thereof (e.g., intracellular protein replacement therapy), or introducing any one of or any combination of INHBE loss-of-function variants described herein (e.g., protein replacement therapy) without knocking out or inactivating an endogenous INHBE gene that does not encode a loss-of-function variant.

An INHBE gene or minigene or a DNA encoding any one of or any combination of INHBE loss-of-function variants described herein or fragments thereof can be introduced and expressed in the form of an expression vector that does not modify the genome, it can be introduced in the form of a targeting vector such that it genomically integrates into an INHBE locus, or it can be introduced such that it genomically integrates into a locus other than the INHBE locus, such as a safe harbor locus. The genomically integrated INHBE gene can be operably linked to an INHBE promoter or to another promoter, such as an endogenous promoter at the site of integration. Safe harbor loci are chromosomal sites where transgenes can be stably and reliably expressed in all tissues of interest without adversely affecting gene structure or expression. Safe harbor loci can have, for example, one or more or all of the following characteristics: distance of greater than 50 kb from the 5′ end of any gene; distance of greater than 300 kb from any cancer-related gene; distance of greater than 300 kb from any microRNA; outside a gene transcription unit, and outside of ultra-conserved regions. Examples of suitable safe harbor loci include adeno-associated virus site 1 (AAVS1), the chemokine (CC motif) receptor 5 (CCRS) gene locus, and the human orthologue of mouse ROSA26 locus.

Combinations of INHBE protein isoforms or nucleic acids encoding INHBE protein isoforms that can be introduced and expressed include, any one or any combination of protein or mRNA isoforms described herein. For example, INHBE a nucleic acid encoding Isoform 1 (SEQ ID NO:2) encoding any one or any combination of loss-of-function variants described herein (alone or in combination with other isoforms) is introduced or expressed. Exemplary sequences for each of these isoforms and transcripts are provided elsewhere herein. It is understood, however, that gene sequences and within a population, mRNA sequences transcribed from such genes, and proteins translated from such mRNAs can vary due to polymorphisms such as single-nucleotide polymorphisms. The sequences provided herein for each transcript and isoform are only exemplary sequences. Other sequences are also possible.

In some embodiments, the methods comprise treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject: a) a nuclease agent (or nucleic acid encoding) that binds to a nuclease recognition sequence within an INHBE gene, wherein the nuclease recognition sequence includes or is proximate to a position of one of the INHBE variant nucleic acid molecules described herein; and b) an exogenous donor sequence comprising a 5′ homology arm that hybridizes to a target sequence 5′ of the position of one of the INHBE variant nucleic acid molecules described herein, a 3′ homology arm that hybridizes to a target sequence 3′ of the same INHBE variant nucleic acid molecule, and a nucleic acid insert comprising one or more of the variant nucleotides flanked by the 5′ homology arm and the 3′ homology arm. The nuclease agent can cleave the INHBE gene in a liver cell in the subject, and the exogenous donor sequence can recombine with the INHBE gene in the liver cell, wherein upon recombination of the exogenous donor sequence with the INHBE gene the nucleic acid insert encoding the loss-of-function variant is introduced, substituting the wild type nucleotide. Examples of nuclease agents (e.g., a Cas9 protein and a guide RNA) that can be used in such methods are disclosed elsewhere herein. Examples of suitable guide RNAs and guide RNA recognition sequences are disclosed elsewhere herein. Examples of exogenous donor sequences that can be used in such methods are disclosed elsewhere herein.

As another example, the methods can comprise treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject an exogenous donor sequence comprising a 5′ homology arm that hybridizes to a target sequence 5′ of the position of one of the INHBE variant nucleic acid molecules described herein, a 3′ homology arm that hybridizes to a target sequence 3′ of the same INHBE variant nucleic acid molecule, and a nucleic acid insert comprising one or more of the variant nucleotides flanked by the 5′ homology arm and the 3′ homology arm. The exogenous donor sequence can recombine with the INHBE gene in the liver cell, wherein upon recombination of the exogenous donor sequence with the INHBE gene the nucleic acid insert encoding the loss-of-function variant is introduced, substituting the wild type nucleotide. Examples of exogenous donor sequences that can be used in such methods are disclosed elsewhere herein.

In some embodiments, the methods comprise treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject: a) a nuclease agent (or nucleic acid encoding) that binds to a nuclease recognition sequence within an INHBE gene, wherein the nuclease recognition sequence comprises the start codon for the INHBE gene or is within about 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000 nucleotides of the start codon. The nuclease agent can cleave and disrupt expression of the INHBE gene in a liver cell in the subject. In some embodiments, the methods comprise treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the INHBE variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject: a) a nuclease agent (or nucleic acid encoding) that binds to a nuclease recognition sequence within an INHBE gene, wherein the nuclease recognition sequence comprises the start codon for the INHBE gene or is within about 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000 nucleotides of the start codon or is selected from SEQ ID NOs: 1-7; and b) an expression vector comprising a recombinant INHBE gene comprising any one or any combination of loss-of-function variants described herein. The expression vector can be one that does not genomically integrate. Alternately, a targeting vector (i.e., exogenous donor sequence) can be introduced comprising a recombinant INHBE gene comprising any one or any combination of loss-of-function variants described herein. The nuclease agent can cleave and disrupt expression of the INHBE gene in a liver cell in the subject, and the expression vector can express the recombinant INHBE gene in the liver cell in the subject. Alternately, the genomically integrated, recombinant INHBE gene can express in the liver cell in the subject. Examples of nuclease agents (e.g., a nuclease-active Cas9 protein and guide RNA) that can be used in such methods are disclosed elsewhere herein. Examples of suitable guide RNAs and guide RNA recognition sequences are disclosed elsewhere herein. Step b) can Alternately comprise introducing an expression vector or targeting vector comprising a nucleic acid (e.g., DNA) encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE isoform described herein or a fragment thereof and comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. Likewise, step b) can alternately comprise introducing an mRNA encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE mRNA isoform described herein or a fragment thereof and comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. Likewise, step b) can alternately comprise introducing a protein comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE protein isoform described herein or a fragment thereof and comprising any one or any combination of loss-of-function variant polypeptides described herein.

In some embodiments, a second nuclease agent is also introduced into the subject or into the liver cell in the subject, wherein the second nuclease agent binds to a second nuclease recognition sequence within the INHBE gene, wherein the second nuclease recognition sequence comprises the stop codon for the INHBE gene or is within about 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000 nucleotides of the stop codon, wherein the nuclease agent cleaves the INHBE gene in the liver cell within both the first nuclease recognition sequence and the second nuclease recognition sequence, wherein the liver cell is modified to comprise a deletion between the first nuclease recognition sequence and the second nuclease recognition sequence. For example, the second nuclease agent can be a Cas9 protein and a guide RNA. Suitable guide RNAs and guide RNA recognition sequences in proximity to the stop codon are disclosed elsewhere herein.

Such methods can also comprise a method of treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the INHBE variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject: a) a DNA-binding protein (or nucleic acid encoding) that binds to a DNA-binding protein recognition sequence within an INHBE gene, wherein the DNA-binding protein recognition sequence comprises the start codon for the INHBE gene or is within about 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000 nucleotides of the start codon. The DNA-binding protein can alter (e.g., reduce) expression of the INHBE gene in a liver cell in the subject. Such methods can also comprise a method of treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the INHBE variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject: a) a DNA-binding protein (or nucleic acid encoding) that binds to a DNA-binding protein recognition sequence within an INHBE gene, wherein the DNA-binding protein recognition sequence comprises the start codon for the INHBE gene or is within about 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000 nucleotides of the start codon; and b) an expression vector comprising a recombinant INHBE gene comprising any one or any combination of loss-of-function variants described herein. The expression vector can be one that does not genomically integrate. Alternately, a targeting vector (i.e., exogenous donor sequence) can be introduced comprising a recombinant INHBE gene comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. The DNA-binding protein can alter (e.g., reduce) expression of the INHBE gene in a liver cell in the subject, and the expression vector can express the recombinant INHBE gene in the liver cell in the subject. Alternately, the genomically integrated, recombinant INHBE gene can express in the liver cell in the subject. Examples of DNA-binding proteins suitable for use in such methods are disclosed elsewhere herein. Such DNA-binding proteins (e.g., Cas9 protein and guide RNA) can be fused or operably linked to a transcriptional repressor domain. For example, the DNA-binding protein can be a catalytically inactive Cas9 protein fused to a transcriptional repressor domain. Examples of suitable guide RNAs and guide RNA recognition sequences are disclosed elsewhere herein. Step b) can alternately comprise introducing an expression vector or targeting vector comprising a nucleic acid (e.g., DNA) encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE isoform described herein or a fragment thereof and comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. Likewise, step b) can alternately comprise introducing an mRNA encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical any INHBE mRNA isoform described herein or a fragment thereof and comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. Likewise, step b) can alternately comprise introducing a protein comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE protein isoform described herein or a fragment thereof and comprising any one or any combination of loss-of-function variant polypeptides described herein.

Other such methods can comprise method of treating a subject who is not a carrier of any of the INHBE variant nucleic acid molecules described herein (or is only a heterozygous carrier of any one or any combination of the INHBE variant nucleic acid molecules described herein) and has or is susceptible to developing a metabolic disorder and/or a cardiovascular disease, comprising introducing into the subject or introducing into a liver cell in the subject an expression vector, wherein the expression vector comprises a recombinant INHBE gene comprising any one or any combination of loss-of-function variants described herein, wherein the expression vector expresses the recombinant INHBE gene in a liver cell in the subject. The expression vector can be one that does not genomically integrate. Alternately, a targeting vector (i.e., exogenous donor sequence) can be introduced comprising a recombinant INHBE gene comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. In methods in which an expression vector is used, the expression vector can express the recombinant INHBE gene in the liver cell in the subject. Alternately, in methods in which a recombinant INHBE gene is genomically integrated, the recombinant INHBE gene can express in the liver cell in the subject. Such methods can alternately comprise introducing an expression vector or targeting vector comprising a nucleic acid (e.g., DNA) encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE isoform described herein or a fragment thereof and comprising any one or any combination of loss-of-function variants described herein. Likewise, such methods can alternately comprise introducing an mRNA encoding an INHBE protein that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE mRNA isoform described herein or a fragment thereof and comprising any one or any combination of the INHBE variant nucleic acid molecules described herein. Likewise, such methods can alternately comprise introducing a protein comprising a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any INHBE protein isoform described herein or a fragment thereof and comprising any one or any combination of loss-of-function variant polypeptides described herein.

Suitable expression vectors and recombinant INHBE genes for use in any of the above methods are disclosed elsewhere herein. For example, the recombinant INHBE gene can be the full length variant gene or can be an INHBE minigene in which one or more nonessential segments of the gene have been deleted with respect to a corresponding wild type INHBE gene. As an example, the deleted segments can comprise one or more intronic sequences. An example of a full INHBE gene is one that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:1 when optimally aligned with SEQ ID NO:1.

In some embodiments, the methods comprise modifying a cell (e.g., a liver cell) in a subject having or susceptible to developing a chronic liver disease. In some embodiments, the methods comprise modifying a cell (e.g., a cardiac cell) in a subject having or susceptible to developing a cardiovascular disease. In such methods, the nuclease agents and/or exogenous donor sequences and/or recombinant expression vectors can be introduced into the cell via administration in an effective regime meaning a dosage, route of administration and frequency of administration that delays the onset, reduces the severity, inhibits further deterioration, and/or ameliorates at least one sign or symptom of the disease being treated.

The term “symptom” refers to a subjective evidence of a disease as perceived by the subject, and a “sign” refers to objective evidence of a disease as observed by a physician. If a subject is already suffering from a disease, the regime can be referred to as a therapeutically effective regime. If the subject is at elevated risk of the disease relative to the general population but is not yet experiencing symptoms, the regime can be referred to as a prophylactically effective regime. In some instances, therapeutic or prophylactic efficacy can be observed in an individual patient relative to historical controls or past experience in the same subject. In other instances, therapeutic or prophylactic efficacy can be demonstrated in a preclinical or clinical trial in a population of treated subjects relative to a control population of untreated subjects.

Delivery can be any suitable method, as disclosed elsewhere herein. For example, the nuclease agents or exogenous donor sequences or recombinant expression vectors can be delivered by vector delivery, viral delivery, particle-mediated delivery, nanoparticle-mediated delivery, liposome-mediated delivery, exosome-mediated delivery, lipid-mediated delivery, lipid-nanoparticle-mediated delivery, cell-penetrating-peptide-mediated delivery, or implantable-device-mediated delivery. Some specific examples include hydrodynamic delivery, virus-mediated delivery, and lipid-nanoparticle-mediated delivery. Administration can be by any suitable route including, for example, parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. A specific example which is often used, for example, for protein replacement therapies is intravenous infusion. The frequency of administration and the number of dosages can depend on the half-life of the nuclease agents or exogenous donor sequences or recombinant expression vectors, the condition of the subject, and the route of administration among other factors. Pharmaceutical compositions for administration are preferably sterile and substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., the dosage for a single administration). Pharmaceutical compositions can be formulated using one or more physiologically and pharmaceutically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen. The term “pharmaceutically acceptable” means that the carrier, diluent, excipient, or auxiliary is compatible with the other ingredients of the formulation and not substantially deleterious to the recipient thereof.

Other such methods comprise an ex vivo method in a cell from a subject having or susceptible to developing a chronic liver disease and/or a cardiovascular disease. The cell with the targeted genetic modification can then be transplanted back into the subject.

In some embodiments, the INHBE inhibitor comprises a small molecule. In some embodiments, the INHBE inhibitor is any of the inhibitory nucleic acid molecules described herein. In some embodiments, the INHBE inhibitor comprises an antibody.

In some embodiments, the methods of treatment further comprise detecting the presence or absence of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, or the presence of the corresponding INHBE polypeptide, or the quantification of the INHBE polypeptide or nucleic acid (such as RNA) in a biological sample from the subject. As used throughout the present disclosure, an “an INHBE variant nucleic acid molecule” is any INHBE nucleic acid molecule (such as, for example, genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding an INHBE polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a metabolic disorder, wherein the subject is suffering from the metabolic disorder. In some embodiments, the methods comprise determining whether the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by obtaining or having obtained a biological sample from the subject, and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule. When the subject is INHBE reference, the therapeutic agent that treats or inhibits the metabolic disorder is administered or continued to be administered to the subject in a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject is heterozygous for an INHBE variant nucleic acid molecule, the therapeutic agent that treats or inhibits the metabolic disorder is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject is homozygous for an INHBE variant nucleic acid molecule, the therapeutic agent that treats or inhibits the metabolic disorder is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount. The presence of a genotype having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing a metabolic disorder. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

For subjects that are genotyped or determined to be either INHBE reference or heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, such subjects can be treated with an INHBE inhibitor, as described herein.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a cardiovascular disease, wherein the subject is suffering from the cardiovascular disease. In some embodiments, the methods comprise determining whether the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by obtaining or having obtained a biological sample from the subject, and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule. When the subject is INHBE reference, the therapeutic agent that treats or inhibits the cardiovascular disease is administered or continued to be administered to the subject in a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject is heterozygous for an INHBE variant nucleic acid molecule, the therapeutic agent that treats or inhibits the cardiovascular disease is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject is homozygous for an INHBE variant nucleic acid molecule, the therapeutic agent that treats or inhibits the cardiovascular disease is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount. The presence of a genotype having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing a cardiovascular disease. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

For subjects that are genotyped or determined to be either INHBE reference or heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, such subjects can be treated with an INHBE inhibitor, as described herein.

Detecting the presence or absence of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide in a biological sample from a subject and/or determining whether a subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, when the subject is INHBE reference, the subject is also administered a therapeutic agent that treats or inhibits a metabolic disorder in a standard dosage amount. In some embodiments, when the subject is heterozygous or homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits the metabolic disorder in a dosage amount that is the same as or lower than a standard dosage amount.

In some embodiments, when the subject is INHBE reference, the subject is also administered a therapeutic agent that treats or inhibits a cardiovascular disease in a standard dosage amount. In some embodiments, when the subject is heterozygous or homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits the cardiovascular disease in a dosage amount that is the same as or lower than a standard dosage amount.

In some embodiments, the treatment methods further comprise detecting the presence or absence of an INHBE predicted loss-of-function polypeptide in a biological sample from the subject. In some embodiments, when the subject does not have an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits a metabolic disorder in a standard dosage amount. In some embodiments, when the subject has an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits the metabolic disorder in a dosage amount that is the same as or lower than a standard dosage amount.

In some embodiments, the treatment methods further comprise detecting the presence or absence of an INHBE predicted loss-of-function polypeptide in a biological sample from the subject. In some embodiments, when the subject does not have an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits a cardiovascular disease in a standard dosage amount. In some embodiments, when the subject has an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits the cardiovascular disease in a dosage amount that is the same as or lower than a standard dosage amount.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a metabolic disorder, wherein the subject is suffering from the metabolic disorder. In some embodiments, the method comprises determining whether the subject has an INHBE predicted loss-of-function polypeptide by obtaining or having obtained a biological sample from the subject, and performing or having performed an assay on the biological sample to determine if the subject has an INHBE predicted loss-of-function polypeptide. When the subject does not have an INHBE predicted loss-of-function polypeptide, the therapeutic agent that treats or inhibits the metabolic disorder is administered or continued to be administered to the subject in a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject has an INHBE predicted loss-of-function polypeptide, the therapeutic agent that treats or inhibits the metabolic disorder is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount, and an INHBE inhibitor is administered to the subject. The presence of an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing a metabolic disorder. In some embodiments, the subject has an INHBE predicted loss-of-function polypeptide. In some embodiments, the subject does not have an INHBE predicted loss-of-function polypeptide.

The present disclosure also provides methods of treating a subject with a therapeutic agent that treats or inhibits a cardiovascular disease, wherein the subject is suffering from the cardiovascular disease. In some embodiments, the method comprises determining whether the subject has an INHBE predicted loss-of-function polypeptide by obtaining or having obtained a biological sample from the subject, and performing or having performed an assay on the biological sample to determine if the subject has an INHBE predicted loss-of-function polypeptide. When the subject does not have an INHBE predicted loss-of-function polypeptide, the therapeutic agent that treats or inhibits the cardiovascular disease is administered or continued to be administered to the subject in a standard dosage amount, and an INHBE inhibitor is administered to the subject. When the subject has an INHBE predicted loss-of-function polypeptide, the therapeutic agent that treats or inhibits the cardiovascular disease is administered or continued to be administered to the subject in an amount that is the same as or lower than a standard dosage amount, and an INHBE inhibitor is administered to the subject. The presence of an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing a cardiovascular disease. In some embodiments, the subject has an INHBE predicted loss-of-function polypeptide. In some embodiments, the subject does not have an INHBE predicted loss-of-function polypeptide.

Detecting the presence or absence of an INHBE predicted loss-of-function polypeptide in a biological sample from a subject and/or determining whether a subject has an INHBE predicted loss-of-function polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the polypeptide can be present within a cell or blood sample obtained from the subject, or maybe imputed from other information about the subject that has previously been generated from collection of a cell or blood sample from the subject or biological relatives of the subject. In any of these embodiments, determination by quantification of the amount of INHBE polypeptide can be included as a determination of loss of function due to the effective absence or reduction in the amount of the INHBE polypeptide. In any of these embodiments, detection, sequencing, and/or quantification of INHBE DNA and RNA can serve as methods for determining INHBE loss of function or absence of INHBE entirely.

Examples of therapeutic agents that treat or inhibit type 2 diabetes include, but are not limited to: metformin, insulin, sulfonylureas (such as glyburide, glipizide, and glimepiride), meglitinides (such as repaglinide and nateglinde), thiazolidinediones (such as rosiglitazone and pioglitazone), DPP-4 inhibitors (such as sitagliptin-saxaghptin and linagliptin), GLP-1 receptor agonists (such as exenatide, liraglutide, and semagiutide), and SGLT2 inhibitors (such as canagliflozin, dapagliflozin, and empagliflozin In some embodiments, the therapeutic agent is metformin, insulin:, glyburide, glipizide, glirnepiride, repaglinide, nateglinide, rosiglitazone, pioglitazone, sitagliptin, saxagliptin, linagliptin, exenatide, liraglutide, sernaglutide, canagliflozin, dapagliflozin, or ernpagliflozin. In some embodiments, the therapeutic agent is metformin. In some embodiments, the therapeutic agent is insulin. In some embodiments, the therapeutic agent is glyburide. In some embodiments, the therapeutic agent is glipizide. In some embodiments, the therapeutic agent is glirnepiride. In some embodiments, the therapeutic agent is repaglinide. In some embodiments, the therapeutic agent is nateglinide. In some embodiments, the therapeutic agent is rosiglitazone. In some embodiments, the therapeutic agent is pioglitazone. In some embodiments, the therapeutic agent is sitagliptin. In some embodiments, the therapeutic agent is saxagIiptin. In some embodiments, the therapeutic agent is linagIiptin, In some embodiments, the therapeutic agent is exenatide. In some embodiments, the therapeutic agent is liraglutide. In some embodiments, the therapeutic agent is semaglutide, In some embodiments, the therapeutic agent is canagliflozin. In some embodiments, the therapeutic agent is cIapagliflozin, In some embodiments, the therapeutic agent is empagliflozin.

Examples of therapeutic agents that treat or inhibit obesity include, but are not limited to: orlistat, phentermine, topiramate, bupropion, naltrexone, and liraglutide. In some embodiments, the therapeutic agent is orlistat. In some embodiments, the therapeutic agent is phentermine. In some embodiments, the therapeutic agent is topiramate. In some embodiments, the therapeutic agent is bupropion. In some embodiments, the therapeutic agent is naltrexone. In some embodiments, the therapeutic agent is liraglutide.

Examples of therapeutic agents that treat or inhibit elevated triglyceride include, but are not limited to: statins (such as rosuvastatin, simvastatin, and atorvastatin), fibrates (such as fenofibrate, gemfibrozil, and fenofibric acid), nicotinic acid (such as niacin), and fatty acids (such as omega-3 fatty acids). In some embodiments, the therapeutic agent is a statin.

Examples of therapeutic agents that treat or inhibit lipodystrophy include, but are not limited to: EGRIFTA® (tesamorelin), GLUCOPHAGE® (metformin), SCULPTRA® (poly-L-lactic acid), RADIESSE® (calcium hydroxyapatite), polymethylmethacrylate (e.g., PMMA), ZYDERM® (bovine collagen), COSMODERM® (human collagen), silicone, glitazones, and hyaluronic acid. In some embodiments, the therapeutic agent that treats or inhibits lipodystrophy include, but are not limited to: tesamorelin, metformin, poly-L-lactic acid, a calcium hydroxyapatite, polymethylmethacrylate, a bovine collagen, a human collagen, silicone, and hyaluronic acid.

Examples of therapeutic agents that treat or inhibit liver inflammation include, but are not limited to hepatitis therapeutics and hepatitis vaccines.

Examples of therapeutic agents or procedures that treat or inhibit fatty liver disease include, but are not limited to, bariatric surgery and/or dietary intervention.

Examples of therapeutic agents that treat or inhibit hypercholesterolemia include, but are not limited to: statins (e.g., LIPITOR® (atorvastatin), LESCOL® (fluvastatin), lovastatin, LIVALO® (pitavastatin), PRAVACHOL® (pravastatin), CRESTOR® (rosuvastatin calcium), and ZOCOR® (simvastatin)); bile acid sequestrants (e.g., PREVALITE® (cholestyramine), WELCHOL® (colesevelam), and COLESTID® (colestipol)); PCSK9 Inhibitors (e.g., PRALUENT® (alirocumab) and REPATHA® (evolocumab); niacin (e.g., niaspan and niacor); fibrates (e.g., fenofibrate and LOPID® (gemfibrozil)); and ATP Citrate Lyase (ACL) Inhibitors (e.g., NEXLETOL® (bempedoic)). In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia include, but are not limited to: statins (e.g., atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin calcium, and simvastatin); bile acid sequestrants (e.g., cholestyramine, colesevelam, and colestipol); PCSK9 Inhibitors (e.g., alirocumab and evolocumab; niacin (e.g., niaspan and niacor); fibrates (e.g., fenofibrate and gemfibrozil); and ACL Inhibitors (e.g., bempedoic). In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is alirocumab or evolocumab. In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is alirocumab. In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is evolocumab.

Examples of therapeutic agents that treat or inhibit elevated liver enzymes (such as, for example, ALT and/or AST) include, but are not limited to, coffee, folic acid, potassium, vitamin B6, a statin, and fiber, or any combination thereof.

Examples of therapeutic agents that treat or inhibit NASH include, but are not limited to, OCALIVA® (obeticholic acid), Pioglitazone or other glitazones, Selonsertib, Elafibranor, Cenicriviroc, GR_MD_02, MGL_3196, IMM124E, arachidyl amido cholanoic acid (ARAMCHOL™), GS0976, Emricasan, Volixibat, NGM282, GS9674, Tropifexor, MN_001, LMB763, BI_1467335, MSDC_0602, PF_05221304, DF102, Saroglitazar, BMS986036, Lanifibranor, Semaglutide, Nitazoxanide, GRI_0621, EYP001, VK2809, Nalmefene, LIK066, MT_3995, Elobixibat, Namodenoson, Foralumab, SAR425899, Sotagliflozin, EDP_305, Isosabutate, Gemcabene, TERN_101, KBP_042, PF_06865571, DUR928, PF_06835919, NGM313, BMS_986171, Namacizumab, CER_209, ND_L02_s0201, RTU_1096, DRX_065, IONIS_DGAT2Rx, INT_767, NC_001, Seladepar, PXL770, TERN_201, NV556, AZD2693, SP_1373, VK0214, Hepastem, TGFTX4, RLBN1127, GKT_137831, RYI_018, CB4209-CB4211, and JH_0920.

In some embodiments, the therapeutic agent that treats or metabolic disorders is a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the MC4R agonist comprises a protein, a peptide, a nucleic acid molecule, or a small molecule. In some embodiments, the protein is a peptide analog of MC4R. In some embodiments, the peptide is setmelanotide. In some embodiments, the therapeutic agent that treats or inhibits type 2 diabetes and/or reduces BMI is a combination of setmelanotide and one or more of sibutramine, orlistat, phentermine, lorcaserin, naltrexone, liraglutide, diethylpropion, bupropion, metformin, pramlintide, topiramate, and zonisamide. In some embodiments, the MC4R agonist is a peptide comprising the amino acid sequence His-Phe-Arg-Trp. In some embodiments, the small molecule is 1,2,3R,4-tetrahydroisoquinoline-3-carboxylic acid. In some embodiments, the MC4R agonist is ALB-127158(a).

Examples of therapeutic agents that treat or inhibit cardiomyopathy include, but are not limited to: 1) blood pressure lowering agents, such as ACE inhibitors, angiotensin II receptor blockers, beta blockers, and calcium channel blockers; 2) agents that slow heart rate, such as beta blockers, calcium channel blockers, and digoxin; 3) agents that keep the heart beating with a normal rhythm, such as antiarrhythmics; 4) agents that balance electrolytes, such as aldosterone blockers; 5) agents that remove excess fluid and sodium from the body, such as diuretics; 6) agents that prevent blood clots from forming, such as anticoagulants or blood thinners; and 7) agents that reduce inflammation, such as corticosteroids.

Examples of therapeutic agents that treat or inhibit heart failure include, but are not limited to: ACE inhibitors, angiotensin-2 receptor blockers, beta blockers, mineralocorticoid receptor antagonists, diuretics, ivabradine, sacubitril valsartan, hydralazine with nitrate, and digoxin.

Examples of therapeutic agents that treat or inhibit high blood pressure include, but are not limited to: diuretics (such as, chlorthalidone, chlorothiazide, hydrochlorothiazide, indapamide, and metolazone), beta-blockers (such as acebutolol, atenolol, betaxolol, bisoprolol fumarate, carteolol hydrochloride, metoprolol tartrate, metoprolol succinate, nadolol, etc.), ACE inhibitors (such as benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril, perindopril, quinapril hydrochloride, ramipril, and trandolapril), angiotensin II receptor blockers (such as candesartan, eprosartan mesylate, irbesartan, losartan potassium, telrnisartan, and valsartan), calcium channel blockers (such as amlodipine besylate, bepridil, diltiazem hydrochloride, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, and verapamil hydrochloride), alpha blockers (such as doxazocin: mesylate, prazosin hydrochloride, and terazosin hydrochloride), Alpha-2 Receptor Agonists (such as methyldopa), combined alpha and beta-blockers (such as carvedilol and labetalol hydrochloride), central agonists (such as alpha methyldopa, clonidine hydrochloride, guanabenz acetate, and guanfacine hydrochloride), peripheral adrenergic inhibitors (such as guanadrel, guanethidine monosulfate, and reserpine), and vasodilators (such as hydralazine hydrochloride and minoxidil),

In some embodiments, the dose of the therapeutic agents that treat or inhibit metabolic disorders and/or cardiovascular diseases can be reduced by about 10%, by about 20%, by about 30%, by about 40%, by about 50%, by about 60%, by about 70%, by about 80%, or by about 90% for subjects that are heterozygous for an INHBE predicted loss-of-function variant (i.e., a lower than the standard dosage amount) compared to subjects that are INHBE reference (who may receive a standard dosage amount). In some embodiments, the dose of the therapeutic agents that treat or inhibit metabolic disorders and/or cardiovascular diseases can be reduced by about 10%, by about 20%, by about 30%, by about 40%, or by about 50%. In addition, the subjects that are heterozygous for an INHBE predicted loss-of-function variant can be administered less frequently compared to subjects that are INHBE reference.

In some embodiments, the dose of the therapeutic agents that treat or a metabolic disorder and/or a cardiovascular disease can be reduced by about 10%, by about 20%, by about 30%, by about 40%, by about 50%, for subjects that are homozygous for a predicted loss-of-function variant INHBE nucleic acid molecule compared to subjects that are heterozygous for a predicted loss-of-function variant INHBE nucleic acid molecule. In some embodiments, the dose of the therapeutic agents that treat or inhibit a metabolic disorder and/or a cardiovascular disease can be reduced by about 10%, by about 20%, by about 30%, by about 40%, or by about 50%. In addition, the dose of therapeutic agents that treat or inhibit metabolic disorder and/or a cardiovascular disease in subjects that are homozygous for a predicted loss-of-function variant INHBE nucleic acid molecule can be administered less frequently compared to subjects that are heterozygous for a predicted loss-of-function variant INHBE nucleic acid molecule.

Administration of the therapeutic agents that treat or inhibit metabolic disorders and/or cardiovascular diseases and/or INHBE inhibitors can be repeated, for example, after one day, two days, three days, five days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, eight weeks, two months, or three months. The repeated administration can be at the same dose or at a different dose. The administration can be repeated once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times, or more. For example, according to certain dosage regimens a subject can receive therapy for a prolonged period of time such as, for example, 6 months, 1 year, or more.

Administration of the therapeutic agents that treat or inhibit metabolic disorders and/or cardiovascular diseases and/or INHBE inhibitors can occur by any suitable route including, but not limited to, parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. Pharmaceutical compositions for administration are desirably sterile and substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., the dosage for a single administration). Pharmaceutical compositions can be formulated using one or more physiologically and pharmaceutically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen. The term “pharmaceutically acceptable” means that the carrier, diluent, excipient, or auxiliary is compatible with the other ingredients of the formulation and not substantially deleterious to the recipient thereof.

The terms “treat”, “treating”, and “treatment” and “prevent”, “preventing”, and “prevention” as used herein, refer to eliciting the desired biological response, such as a therapeutic and prophylactic effect, respectively. In some embodiments, a therapeutic effect comprises one or more of a decrease/reduction in metabolic disorders and/or cardiovascular diseases, a decrease/reduction in the severity of metabolic disorders and/or cardiovascular diseases (such as, for example, a reduction or inhibition of development or metabolic disorders and/or cardiovascular diseases), a decrease/reduction in symptoms and metabolic disorder-related effects and/or cardiovascular disease-related effects, delaying the onset of symptoms and metabolic disorder-related effects and/or cardiovascular disease-related effects, reducing the severity of symptoms of metabolic disorder-related effects and/or cardiovascular disease-related effects, reducing the number of symptoms and metabolic disorder-related effects and/or cardiovascular disease-related effects, reducing the latency of symptoms and metabolic disorder-related effects and/or cardiovascular disease-related effects, an amelioration of symptoms and metabolic disorder-related effects and/or cardiovascular disease-related effects, reducing secondary symptoms, reducing secondary infections, preventing relapse to metabolic disorders and/or cardiovascular diseases, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, increasing time to sustained progression, speeding recovery, or increasing efficacy of or decreasing resistance to alternative therapeutics, and/or an increased survival time of the affected host animal, following administration of the agent or composition comprising the agent. A prophylactic effect may comprise a complete or partial avoidance/inhibition or a delay of metabolic disorders and/or cardiovascular disease development/progression (such as, for example, a complete or partial avoidance/inhibition or a delay), and an increased survival time of the affected host animal, following administration of a therapeutic protocol. Treatment of metabolic disorders encompasses the treatment of subjects already diagnosed as having any form of metabolic disorders and/or cardiovascular diseases at any clinical stage or manifestation, the delay of the onset or evolution or aggravation or deterioration of the symptoms or signs of metabolic disorders and/or cardiovascular diseases, and/or preventing and/or reducing the severity of metabolic disorders and/or cardiovascular diseases.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a metabolic disorder. In some embodiments, the method comprises determining or having determined in a biological sample obtained from the subject the presence or absence of an INHBE variant nucleic acid molecule (such as a genomic nucleic acid molecule, mRNA molecule, and/or cDNA molecule) encoding an INHBE predicted loss-of-function polypeptide. When the subject lacks an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide (i.e., the subject is genotypically categorized as an INHBE reference), then the subject has an increased risk for developing a metabolic disorder. When the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide (i.e., the subject is heterozygous or homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide), then the subject has a decreased risk for developing a metabolic disorder. In some embodiments, liver expression quantitative trait loci (eQTL) can be analyzed.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a cardiovascular disease. In some embodiments, the method comprises determining or having determined in a biological sample obtained from the subject the presence or absence of an INHBE variant nucleic acid molecule (such as a genomic nucleic acid molecule, mRNA molecule, and/or cDNA molecule) encoding an INHBE predicted loss-of-function polypeptide. When the subject lacks an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide (i.e., the subject is genotypically categorized as an INHBE reference), then the subject has an increased risk for developing a cardiovascular disease. When the subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide (i.e., the subject is heterozygous or homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide), then the subject has a decreased risk for developing a cardiovascular disease. In some embodiments, liver expression quantitative trait loci (eQTL) can be analyzed.

Having a single copy of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide is more protective of a subject from developing a metabolic disorder and/or a cardiovascular disease than having no copies of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. Without intending to be limited to any particular theory or mechanism of action, it is believed that a single copy of an INHBE variant nucleic acid molecule (i.e., heterozygous for an INHBE variant nucleic acid molecule) is protective of a subject from developing a metabolic disorder and/or a cardiovascular disease, and it is also believed that having two copies of an INHBE variant nucleic acid molecule (i.e., homozygous for an INHBE variant nucleic acid molecule) may be more protective of a subject from developing a metabolic disorder and/or a cardiovascular disease, relative to a subject with a single copy. Thus, in some embodiments, a single copy of an INHBE variant nucleic acid molecule may not be completely protective, but instead, may be partially or incompletely protective of a subject from developing a metabolic disorder and/or a cardiovascular disease. While not desiring to be bound by any particular theory, there may be additional factors or molecules involved in the development of metabolic disorders and/or cardiovascular diseases that are still present in a subject having a single copy of an INHBE variant nucleic acid molecule, thus resulting in less than complete protection from the development of metabolic disorders and/or cardiovascular diseases.

Determining whether a subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide in a biological sample from a subject and/or determining whether a subject has an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide can be carried out by any of the methods described herein. In some embodiments, these methods can be carried out in vitro. In some embodiments, these methods can be carried out in situ. In some embodiments, these methods can be carried out in vivo. In any of these embodiments, the nucleic acid molecule can be present within a cell obtained from the subject.

In some embodiments, when a subject is identified as having an increased risk of developing a metabolic disorder, the subject is further treated with a therapeutic agent that treats or inhibits metabolic disorders and/or an INHBE inhibitor, as described herein. For example, when the subject is INHBE reference, and therefore has an increased risk for developing a metabolic disorder, the subject is administered an INHBE inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits metabolic disorders. In some embodiments, when the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats or inhibits metabolic disorders in a dosage amount that is the same as or lower than a standard dosage amount, and is also administered an INHBE inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits metabolic disorders. In some embodiments, when the subject is homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats or inhibits metabolic disorders in a dosage amount that is the same as or lower than a standard dosage amount. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. In some embodiments, the subject is homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

In some embodiments, when a subject is identified as having an increased risk of developing a cardiovascular disease, the subject is further treated with a therapeutic agent that treats or inhibits cardiovascular diseases and/or an INHBE inhibitor, as described herein. For example, when the subject is INHBE reference, and therefore has an increased risk for developing a cardiovascular disease, the subject is administered an INHBE inhibitor.

In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits cardiovascular diseases. In some embodiments, when the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats or inhibits cardiovascular diseases in a dosage amount that is the same as or lower than a standard dosage amount, and is also administered an INHBE inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats or inhibits cardiovascular diseases. In some embodiments, when the subject is homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats or inhibits cardiovascular diseases in a dosage amount that is the same as or lower than a standard dosage amount. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. In some embodiments, the subject is homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

In some embodiments, any of the methods described herein can further comprise determining the subject's gene burden of having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, and/or an INHBE predicted loss-of-function variant polypeptide associated with a decreased risk of developing a metabolic disorder and/or a cardiovascular disease. The gene burden is the aggregate of all variants in the INHBE gene, which can be carried out in an association analysis with metabolic disorders and/or cardiovascular diseases. In some embodiments, the subject is homozygous for one or more INHBE variant nucleic acid molecules encoding an INHBE predicted loss-of-function polypeptide associated with a decreased risk of developing a metabolic disorder and/or a cardiovascular disease. In some embodiments, the subject is heterozygous for one or more INHBE variant nucleic acid molecules encoding an INHBE predicted loss-of-function polypeptide associated with a decreased risk of developing a metabolic disorder and/or a cardiovascular disease. The result of the association analysis suggests that INHBE variant nucleic acid molecules encoding an INHBE predicted loss-of-function polypeptide are associated with decreased risk of developing a metabolic disorder and/or a cardiovascular disease. When the subject has a lower gene burden, the subject is at a higher risk of developing a metabolic disorder and/or a cardiovascular disease and the subject is administered or continued to be administered the therapeutic agent that treats, prevents, or inhibits a metabolic disorder and/or a cardiovascular disease in a standard dosage amount, and/or an INHBE inhibitor. When the subject has a greater gene burden, the subject is at a lower risk of developing a metabolic disorder and/or a cardiovascular disease and the subject is administered or continued to be administered the therapeutic agent that treats, prevents, or inhibits a metabolic disorder and/or a cardiovascular disease in an amount that is the same as or less than the standard dosage amount. The greater the gene burden, the lower the risk of developing a metabolic disorder and/or a cardiovascular disease.

In some embodiments, the subject's gene burden of having any one or more INHBE variant nucleic acid molecules encoding an INHBE predicted loss-of-function polypeptide represents a weighted sum of a plurality of any of the INHBE variant nucleic acid molecules encoding an INHBE predicted loss-of-function polypeptide. In some embodiments, the gene burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, at least about 1,000, at least about 10,000, at least about 100,000, or at least about or more than 1,000,000 genetic variants present in or around (up to 10 Mb) the INHBE gene where the gene burden is the number of alleles multiplied by the association estimate with a metabolic disorder or related outcome for each allele (e.g., a weighted burden score). This can include any genetic variants, regardless of their genomic annotation, in proximity to the INHBE gene (up to 10 Mb around the gene) that show a non-zero association with a metabolic disorder-related traits and/or a cardiovascular disease-related traits in a genetic association analysis. In some embodiments, when the subject has a gene burden above a desired threshold score, the subject has a decreased risk of developing a metabolic disorder and/or a cardiovascular disease. In some embodiments, when the subject has a gene burden below a desired threshold score, the subject has an increased risk of developing a metabolic disorder and/or a cardiovascular disease.

In some embodiments, the gene burden may be divided into quintiles, e.g., top quintile, intermediate quintile, and bottom quintile, wherein the top quintile of the gene burden corresponds to the lowest risk group and the bottom quintile of the gene burden corresponds to the highest risk group. In some embodiments, a subject having a greater gene burden comprises the highest weighted gene burdens, including, but not limited to the top 10%, top 20%, top 30%, top 40%, or top 50% of gene burdens from a subject population. In some embodiments, the genetic variants comprise the genetic variants having association with a metabolic disorder and/or a cardiovascular disease in the top 10%, top 20%, top 30%, top 40%, or top 50% of p-value range for the association. In some embodiments, each of the identified genetic variants comprise the genetic variants having association with a metabolic disorder and/or a cardiovascular disease with p-value of no more than about 10⁻², about 10^(−3,) about 10⁻⁴, about 10⁻⁵, about 10⁻⁶, about 10⁻⁷, about 10⁻⁸, about 10⁻⁹, about 10⁻⁹, about 10⁻¹¹, about 10⁻¹², about 10⁻¹³, about 10⁻¹⁴, about or 10⁻¹⁵. In some embodiments, the identified genetic variants comprise the genetic variants having association with a metabolic disorder and/or a cardiovascular disease with p-value of less than 5×10⁻⁸. In some embodiments, the identified genetic variants comprise genetic variants having association with a metabolic disorder and/or a cardiovascular disease in high-risk subjects as compared to the rest of the reference population with odds ratio (OR) about 1.5 or greater, about 1.75 or greater, about 2.0 or greater, or about 2.25 or greater for the top 20% of the distribution; or about 1.5 or greater, about 1.75 or greater, about 2.0 or greater, about 2.25 or greater, about 2.5 or greater, or about 2.75 or greater. In some embodiments, the odds ratio (OR) may range from about 1.0 to about 1.5, from about 1.5 to about 2.0, from about 2.0 to about 2.5, from about 2.5 to about 3.0, from about 3.0 to about 3.5, from about 3.5 to about 4.0, from about 4.0 to about 4.5, from about 4.5 to about 5.0, from about 5.0 to about 5.5, from about 5.5 to about 6.0, from about 6.0 to about 6.5, from about 6.5 to about 7.0, or greater than 7.0. In some embodiments, high-risk subjects comprise subjects having gene burdens in the bottom decile, quintile, or tertile in a reference population. The threshold of the gene burden is determined on the basis of the nature of the intended practical application and the risk difference that would be considered meaningful for that practical application.

In some embodiments, when a subject is identified as having an increased risk of developing a metabolic disorder, the subject is further administered a therapeutic agent that treats, prevents, or inhibits a metabolic disorder, and/or an INHBE inhibitor, as described herein. For example, when the subject is INHBE reference, and therefore has an increased risk of developing a metabolic disorder, the subject is administered an INHBE inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats, prevents, or inhibits a metabolic disorder. In some embodiments, when the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats, prevents, or inhibits a metabolic disorder in a dosage amount that is the same as or less than a standard dosage amount, and is also administered an INHBE inhibitor. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. Furthermore, when the subject has a lower gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, and therefore has an increased risk of developing a metabolic disorder, the subject is administered a therapeutic agent that treats, prevents, or inhibits a metabolic disorder. In some embodiments, when the subject has a lower gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats, prevents, or inhibits a metabolic disorder in a dosage amount that is the same as or greater than the standard dosage amount administered to a subject who has a greater gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

In some embodiments, when a subject is identified as having an increased risk of developing a cardiovascular disease, the subject is further administered a therapeutic agent that treats, prevents, or inhibits a cardiovascular disease, and/or an INHBE inhibitor, as described herein. For example, when the subject is INHBE reference, and therefore has an increased risk of developing a cardiovascular disease, the subject is administered an INHBE inhibitor. In some embodiments, such a subject is also administered a therapeutic agent that treats, prevents, or inhibits a cardiovascular disease. In some embodiments, when the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats, prevents, or inhibits a cardiovascular disease in a dosage amount that is the same as or less than a standard dosage amount, and is also administered an INHBE inhibitor. In some embodiments, the subject is INHBE reference. In some embodiments, the subject is heterozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide. Furthermore, when the subject has a lower gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, and therefore has an increased risk of developing a cardiovascular disease, the subject is administered a therapeutic agent that treats, prevents, or inhibits a cardiovascular disease. In some embodiments, when the subject has a lower gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is administered the therapeutic agent that treats, prevents, or inhibits a cardiovascular disease in a dosage amount that is the same as or greater than the standard dosage amount administered to a subject who has a greater gene burden for having an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide.

The present disclosure also provides methods of diagnosing a metabolic disorder in a subject. The methods comprise determining or having determined whether the subject has any one or more of the INHBE variant nucleic acid molecules or polypeptides produced therefrom described herein. When the subject is INHBE reference, and has one or more symptoms of a metabolic disorder, the subject is diagnosed as having a metabolic disorder. In some embodiments, the subject is homozygous for a reference INHBE nucleic acid molecule. In some embodiments, the subject is homozygous or heterozygous for an INHBE variant nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide. In some embodiments, when a subject is identified as having metabolic disorder (such as having one or more symptoms of metabolic disorder and being homozygous or heterozygous for an INHBE variant nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide), the subject is further treated with a therapeutic agent that treats or inhibits the metabolic disorder, such as any of those described herein.

The present disclosure also provides methods of diagnosing a cardiovascular disease in a subject. The methods comprise determining or having determined whether the subject has any one or more of the INHBE variant nucleic acid molecules or polypeptides produced therefrom described herein. When the subject is INHBE reference, and has one or more symptoms of a cardiovascular disease, the subject is diagnosed as having a cardiovascular disease. In some embodiments, the subject is homozygous for a reference INHBE nucleic acid molecule. In some embodiments, the subject is homozygous or heterozygous for an INHBE variant nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide. In some embodiments, when a subject is identified as having cardiovascular disease (such as having one or more symptoms of cardiovascular disease and being homozygous or heterozygous for an INHBE variant nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide), the subject is further treated with a therapeutic agent that treats or inhibits the cardiovascular disease, such as any of those described herein.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a metabolic disorder, wherein the method comprises determining or having determined in a biological sample obtained from the subject the presence or absence of an INHBE predicted loss-of-function polypeptide. In some embodiments, the method is a blood based quantitative assay, such as a somalogic assay to quantify inhibin E.

The present disclosure also provides methods of identifying a subject having an increased risk for developing a cardiovascular disease, wherein the method comprises determining or having determined in a biological sample obtained from the subject the presence or absence of an INHBE predicted loss-of-function polypeptide. In some embodiments, the method is a blood based quantitative assay, such as a somalogic assay to quantify inhibin E.

The presence of INHBE polypeptides in suitable fluid samples, such as blood, plasma, and/or serum, can be determined by detecting the INHBE polypeptide using numerous methods for measuring INHBE or INHBE activity. For example, INHBE polypeptide can be detected by immunoassays using antibodies specific for INHBE. The antibody being capable of binding selectively to an INHBE polypeptide and/or CEA. The antibody can be used, for example, in Western blots of one- or two-dimensional gels, in high throughput methods such as enzyme linked immunoassay and/or in dot blot (Antibody Sandwich) assays of total cellular protein, or partially purified protein. In some embodiments, the concentration of INHBE in a suitable fluid is measured by an enzyme-linked immunosorbent assay (ELISA). In one example of the assay, a serum sample is diluted 400-fold and applied to a plate to which INHBE polypeptide antibodies from one animal origin (primary antibody) are attached. If enough INHBE is present in the serum, the INHBE may bind to these INHBE antibodies. The plate is then washed to remove all other components of the serum. A specially prepared “secondary antibody”, such as from an animal origin different from that of the primary antibody, an antibody that binds to the primary antibody—is then applied to the plate, followed by another wash. This secondary antibody is chemically linked in advance to, for example, an enzyme. Thus, the plate will contain enzyme in proportion to the amount of secondary antibody bound to the plate. A substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in color or fluorescence. Samples that generate a signal that is stronger than the known healthy sample are “positive”. Those that generate weaker signal than the known healthy sample are “negative.”

Alternately, the concentration of INHBE polypeptide in a suitable fluid can be determined by detecting the INHBE polypeptide using spectrometric methods, such as LC-MS/MS mass spectrometer, GCMS mass spectrometer, SDS PAGE methods later quantified with densitometry or mass spectrometry methods or any similar methods of quantifying proteins. Additional methods of quantifying polypeptide levels include, but are not limited to, HPLC (high performance liquid chromatography), SEC (size exclusion chromatography), modified Lowry assay, spectrophotometry, SEC-MALLS (size exclusion chromatography/multi-angle laser light scattering), and NMR (nuclear magnetic resonance).

Aptamers specific for INHBE polypeptides can also be used. A suitable aptamer is capable of binding selectively an INHBE polypeptide for measuring blood, plasma or serum concentration of INHBE polypeptide, or for detecting the presence of a variant INHBE. An INHBE polypeptide produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate aptamers that recognize the INHBE polypeptide. The term “aptamer” refers to a non-naturally occurring oligonucleotide chain or peptide molecule that has a specific action on a target compound (such as a specific epitope, therapeutic drug marker or surrogate marker). A specific action includes, but is not limited to, binding of the target compound, catalytically changing the target compound, and/or reacting with the target compound in a way that modifies/alters the target compound or the functional activity of the target compound. Aptamers can be engineered through repeated rounds of in vitro selection or SELEX™ (systematic evolution of ligands by exponential enrichment) to bind to various molecular targets such as small molecules. Methods for production/synthesis are described in, for example: Ellington et al., Nature, 1990, 346, 818-822; and Tuerk et al., Science, 1990, 249, 505-510. The “SELEX™” methodology involves the combination of selected nucleic acid ligands, which interact with a specific epitope in a desired action, for example binding to a protein, with amplification of those selected nucleic acids. Optional iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids, which interact most strongly with the specific epitope from a pool, which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. The SELEX methodology is described in the following U.S. patents U.S. Pat. Nos. 5,475,096 and 5,270,163.

The present disclosure also provides methods of identifying a subject having a disease, such as a metabolic disorder, who may respond differentially to treatment with an INHBE inhibitor or other therapeutic agent affecting fat distribution. In some embodiments, the method comprises determining or having determined in a biological sample (liver, plasma, serum, and/or whole blood) obtained from the subject the presence or absence of an INHBE pLOF or pGOF or that are associated with liver expression of INHBE or measurement of INHBE in circulation or expression in liver. When the subject lacks such an INHBE variant (i.e., the subject is genotypically categorized as an INHBE reference), then the subject has an increased risk for developing a metabolic disorder and may be amenable to treatment with an INHBE inhibitor or other therapeutic agent affecting fat distribution. When the subject has such an INHBE variant nucleic acid molecule (i.e., the subject is heterozygous for an INHBE pLOF/pGOF or homozygous for an INHBE pLOF/pGOF), then the subject has a decreased risk for developing a metabolic disorder.

The present disclosure also provides methods of detecting the presence or absence of an INHBE variant nucleic acid molecule (genomic, mRNA, or cDNA) encoding a predicted loss-of-function INHBE polypeptide in a biological sample from a subject. It is understood that gene sequences within a population and mRNA molecules encoded by such genes can vary due to polymorphisms such as single-nucleotide polymorphisms.

The biological sample can be derived from any cell, tissue, or biological fluid from the subject. The sample may comprise any clinically relevant tissue, such as a bone marrow sample, a tumor biopsy, a fine needle aspirate, or a sample of bodily fluid, such as blood, gingival crevicular fluid, plasma, serum, lymph, ascitic fluid, cystic fluid, or urine. In some cases, the sample comprises a buccal swab. The sample used in the methods disclosed herein will vary based on the assay format, nature of the detection method, and the tissues, cells, or extracts that are used as the sample. A biological sample can be processed differently depending on the assay being employed. For example, when detecting any predicted loss-of-function variant INHBE nucleic acid molecule, preliminary processing designed to isolate or enrich the sample for the genomic DNA can be employed. A variety of techniques may be used for this purpose. When detecting the level of any predicted loss-of-function variant INHBE mRNA, different techniques can be used enrich the biological sample with mRNA. Various methods to detect the presence or level of an mRNA or the presence of a particular variant genomic DNA locus can be used.

In some embodiments, detecting an INHBE variant nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide in a subject comprises assaying or genotyping a biological sample obtained from the subject to determine whether an INHBE genomic nucleic acid molecule in the biological sample, and/or an INHBE mRNA molecule in the biological sample, and/or an INHBE cDNA molecule produced from an mRNA molecule in the biological sample, comprises one or more variations that cause a loss-of-function (partial or complete) or are predicted to cause a loss-of-function (partial or complete), such as any of the INHBE variant nucleic acid molecules encoding a predicted loss-of-function INHBE polypeptide described herein.

In some embodiments, the methods of detecting the presence or absence of an INHBE variant nucleic acid molecule (such as, for example, a genomic nucleic acid molecule, an mRNA molecule, and/or a cDNA molecule produced from an mRNA molecule) in a subject, comprise performing an assay on a biological sample obtained from the subject. The assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence.

In some embodiments, the biological sample comprises a cell or cell lysate. Such methods can further comprise, for example, obtaining a biological sample from the subject comprising an INHBE genomic nucleic acid molecule or mRNA molecule, and if mRNA, optionally reverse transcribing the mRNA into cDNA. Such assays can comprise, for example determining the identity of these positions of the particular INHBE nucleic acid molecule. In some embodiments, the method is an in vitro method.

In some embodiments, the determining step, detecting step, or genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the INHBE genomic nucleic acid molecule, the INHBE mRNA molecule, or the INHBE cDNA molecule in the biological sample, wherein the sequenced portion comprises one or more variations that cause a loss-of-function (partial or complete) or are predicted to cause a loss-of-function (partial or complete), such as any of the predicted loss-of-function variant INHBE nucleic acid molecules described herein.

In some embodiments, the determining step, detecting step, or genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the INHBE genomic nucleic acid molecule in the biological sample, the nucleotide sequence of the INHBE mRNA molecule in the biological sample, or the nucleotide sequence of the INHBE cDNA molecule produced from the INHBE mRNA in the biological sample. In some embodiments, the determining step, detecting step, or genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the INHBE genomic nucleic acid molecule in the biological sample. In some embodiments, the determining step, detecting step, or genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the INHBE mRNA molecule in the biological sample. In some embodiments, the determining step, detecting step, or genotyping assay comprises sequencing at least a portion of the nucleotide sequence of the INHBE cDNA molecule produced from the INHBE mRNA molecule in the biological sample.

In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only an INHBE genomic nucleic acid molecule is analyzed. In some embodiments, only an INHBE mRNA is analyzed. In some embodiments, only an INHBE cDNA obtained from INHBE mRNA is analyzed.

In some embodiments, the determining step, detecting step, or genotyping assay comprises: a) amplifying at least a portion of the nucleic acid molecule that encodes the INHBE polypeptide; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising an alteration-specific probe; and d) detecting the detectable label.

In some embodiments, the nucleic acid molecule is mRNA and the determining step further comprises reverse-transcribing the mRNA into a cDNA prior to the amplifying step.

In some embodiments, the determining step, detecting step, or genotyping assay comprises: contacting the nucleic acid molecule in the biological sample with an alteration-specific probe comprising a detectable label, wherein the alteration-specific probe comprises a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of the amplified nucleic acid molecule; and detecting the detectable label. Alteration-specific polymerase chain reaction techniques can be used to detect mutations such as SNPs in a nucleic acid sequence. Alteration-specific primers can be used because the DNA polymerase will not extend when a mismatch with the template is present.

In some embodiments, the nucleic acid molecule in the sample is mRNA and the mRNA is reverse-transcribed into a cDNA prior to the amplifying step. In some embodiments, the nucleic acid molecule is present within a cell obtained from the subject.

In some embodiments, the assay comprises contacting the biological sample with a primer or probe, such as an alteration-specific primer or alteration-specific probe, that specifically hybridizes to an INHBE variant nucleic acid molecule (genomic, mRNA, or cDNA) and not the corresponding INHBE reference sequence under stringent conditions, and determining whether hybridization has occurred. In some embodiments, the assay comprises RNA sequencing (RNA-Seq). In some embodiments, the assays also comprise reverse transcribing mRNA into cDNA, such as by the reverse transcriptase polymerase chain reaction (RT-PCR).

In some embodiments, the methods utilize probes and primers of sufficient nucleotide length to bind to the target nucleotide sequence and specifically detect and/or identify a polynucleotide comprising an INHBE variant nucleic acid molecule (genomic, mRNA, or cDNA) encoding a predicted loss-of-function INHBE polypeptide. The hybridization conditions or reaction conditions can be determined by the operator to achieve this result. The nucleotide length may be any length that is sufficient for use in a detection method of choice, including any assay described or exemplified herein. Such probes and primers can hybridize specifically to a target nucleotide sequence under high stringency hybridization conditions. Probes and primers may have complete nucleotide sequence identity of contiguous nucleotides within the target nucleotide sequence, although probes differing from the target nucleotide sequence and that retain the ability to specifically detect and/or identify a target nucleotide sequence may be designed by conventional methods. Probes and primers can have about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity or complementarity with the nucleotide sequence of the target nucleic acid molecule.

Illustrative examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing. Other methods involve nucleic acid hybridization methods other than sequencing, including using labeled primers or probes directed against purified DNA, amplified DNA, and fixed cell preparations (fluorescence in situ hybridization (FISH)). In some methods, a target nucleic acid molecule may be amplified prior to or simultaneous with detection. Illustrative examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA). Other methods include, but are not limited to, ligase chain reaction, strand displacement amplification, and thermophilic SDA (tSDA).

In hybridization techniques, stringent conditions can be employed such that a probe or primer will specifically hybridize to its target. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target sequence to a detectably greater degree than to other non-target sequences, such as, at least 2-fold, at least 3-fold, at least 4-fold, or more over background, including over 10-fold over background. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence to a detectably greater degree than to other nucleotide sequences by at least 2-fold. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence to a detectably greater degree than to other nucleotide sequences by at least 3-fold. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence to a detectably greater degree than to other nucleotide sequences by at least 4-fold. In some embodiments, a polynucleotide primer or probe under stringent conditions will hybridize to its target nucleotide sequence to a detectably greater degree than to other nucleotide sequences by over 10-fold over background. Stringent conditions are sequence-dependent and will be different in different circumstances.

Appropriate stringency conditions which promote DNA hybridization, for example, 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by a wash of 2×SSC at 50® C., are known or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Typically, stringent conditions for hybridization and detection will be those in which the salt concentration is less than about 1.5 M Na⁺ ion, typically about 0.01 to 1.0 M Na⁺ ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (such as, for example, 10 to 50 nucleotides) and at least about 60° C. for longer probes (such as, for example, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Optionally, wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of the wash time will be at least a length of time sufficient to reach equilibrium.

The present disclosure also provides methods of detecting the presence of a human INHBE predicted loss-of-function polypeptide comprising performing an assay on a sample obtained from a subject to determine whether an INHBE polypeptide in the subject contains one or more variations that causes the polypeptide to have a loss-of-function (partial or complete) or predicted loss-of-function (partial or complete).

In some embodiments, the detecting step comprises sequencing at least a portion of the polypeptide. In some embodiments, the detecting step comprises an immunoassay for detecting the presence of a polypeptide.

In some embodiments, when the subject does not have an INHBE predicted loss-of-function polypeptide, then the subject has an increased risk for developing a metabolic disorder or any of type 2 diabetes, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, elevated liver enzymes (such as, for example, ALT and/or AST), obesity, high blood pressure, NASH, and/or elevated triglyceride level. In some embodiments, when the subject has an INHBE predicted loss-of-function polypeptide, then the subject has a decreased risk for developing a metabolic disorder or any of type 2 diabetes, obesity, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, elevated liver enzymes (such as, for example, ALT and/or AST), high blood pressure, NASH, and/or elevated triglyceride level.

In some embodiments, when the subject does not have an INHBE predicted loss-of-function polypeptide, then the subject has an increased risk for developing a cardiovascular disease or any of cardiomyopathy, heart failure, and high blood pressure. In some embodiments, when the subject has an INHBE predicted loss-of-function polypeptide, then the subject has a decreased risk for developing a cardiovascular disease or any of cardiomyopathy, heart failure, and high blood pressure.

The present disclosure also provides uses of isolated nucleic acid molecules that hybridize to INHBE variant genomic nucleic acid molecules, INHBE variant mRNA molecules, and/or INHBE variant cDNA molecules (such as any of the genomic variant nucleic acid molecules, mRNA variant molecules, and cDNA variant molecules disclosed herein) in any of the methods described herein.

In some embodiments, such isolated nucleic acid molecules comprise or consist of at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 2000, at least about 3000, at least about 4000, or at least about 5000 nucleotides. In some embodiments, such isolated nucleic acid molecules comprise or consist of at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, or at least about 25 nucleotides. In some embodiments, the isolated nucleic acid molecules comprise or consist of at least about 18 nucleotides. In some embodiments, the isolated nucleic acid molecules comprise or consists of at least about 15 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 10 to about 35, from about 10 to about 30, from about 10 to about 25, from about 12 to about 30, from about 12 to about 28, from about 12 to about 24, from about 15 to about 30, from about 15 to about 25, from about 18 to about 30, from about 18 to about 25, from about 18 to about 24, or from about 18 to about 22 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 18 to about 30 nucleotides. In some embodiments, the isolated nucleic acid molecules comprise or consist of at least about 15 nucleotides to at least about 35 nucleotides.

In some embodiments, such isolated nucleic acid molecules hybridize to INHBE variant nucleic acid molecules (such as genomic nucleic acid molecules, mRNA molecules, and/or cDNA molecules) under stringent conditions. Such nucleic acid molecules can be used, for example, as probes, primers, alteration-specific probes, or alteration-specific primers as described or exemplified herein, and include, without limitation primers, probes, antisense RNAs, shRNAs, and siRNAs, each of which is described in more detail elsewhere herein, and can be used in any of the methods described herein.

In some embodiments, the isolated nucleic acid molecules hybridize to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to INHBE variant genomic nucleic acid molecules, INHBE variant mRNA molecules, and/or INHBE variant cDNA molecules. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 100 nucleotides, or from about 15 to about 35 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 100 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of or comprise from about 15 to about 35 nucleotides.

In some embodiments, the alteration-specific probes and alteration-specific primers comprise DNA. In some embodiments, the alteration-specific probes and alteration-specific primers comprise RNA.

In some embodiments, the probes and primers described herein (including alteration-specific probes and alteration-specific primers) have a nucleotide sequence that specifically hybridizes to any of the nucleic acid molecules disclosed herein, or the complement thereof. In some embodiments, the probes and primers specifically hybridize to any of the nucleic acid molecules disclosed herein under stringent conditions.

In some embodiments, the primers, including alteration-specific primers, can be used in second generation sequencing or high throughput sequencing. In some instances, the primers, including alteration-specific primers, can be modified. In particular, the primers can comprise various modifications that are used at different steps of, for example, Massive Parallel Signature Sequencing (MPSS), Polony sequencing, and 454 Pyrosequencing. Modified primers can be used at several steps of the process, including biotinylated primers in the cloning step and fluorescently labeled primers used at the bead loading step and detection step. Polony sequencing is generally performed using a paired-end tags library wherein each molecule of DNA template is about 135 bp in length. Biotinylated primers are used at the bead loading step and emulsion PCR. Fluorescently labeled degenerate nonamer oligonucleotides are used at the detection step. An adaptor can contain a 5′-biotin tag for immobilization of the DNA library onto streptavidin-coated beads.

The probes and primers described herein can be used to detect a nucleotide variation within any of the INHBE variant genomic nucleic acid molecules, INHBE variant mRNA molecules, and/or INHBE variant cDNA molecules disclosed herein. The primers described herein can be used to amplify INHBE variant genomic nucleic acid molecules, INHBE variant mRNA molecules, or INHBE variant cDNA molecules, or a fragment thereof.

In the context of the disclosure “specifically hybridizes” means that the probe or primer (such as, for example, the alteration-specific probe or alteration-specific primer) does not hybridize to a nucleic acid sequence encoding an INHBE reference genomic nucleic acid molecule, an INHBE reference mRNA molecule, and/or an INHBE reference cDNA molecule.

In some embodiments, the probes (such as, for example, an alteration-specific probe) comprise a label. In some embodiments, the label is a fluorescent label, a radiolabel, or biotin.

The present disclosure also provides supports comprising a substrate to which any one or more of the probes disclosed herein is attached. Solid supports are solid-state substrates or supports with which molecules, such as any of the probes disclosed herein, can be associated. A form of solid support is an array. Another form of solid support is an array detector. An array detector is a solid support to which multiple different probes have been coupled in an array, grid, or other organized pattern. A form for a solid-state substrate is a microtiter dish, such as a standard 96-well type. In some embodiments, a multiwell glass slide can be employed that normally contains one array per well.

The nucleotide sequence of an INHBE reference genomic nucleic acid molecule is set forth in SEQ ID NO:1 (ENST00000266646.3 encompassing chr12:57455307-57458025 in the GRCh38/hg38 human genome assembly).

The nucleotide sequence of an INHBE reference mRNA molecule is set forth in SEQ ID NO:2. The nucleotide sequence of another INHBE reference mRNA molecule is set forth in SEQ ID NO:3. The nucleotide sequence of another INHBE reference mRNA molecule is set forth in SEQ ID NO:4.

The nucleotide sequence of an INHBE reference cDNA molecule is set forth in SEQ ID NO:5. The nucleotide sequence of another INHBE reference cDNA molecule is set forth in SEQ ID NO:6. The nucleotide sequence of another INHBE reference cDNA molecule is set forth in SEQ ID NO:7.

The amino acid sequence of an INHBE reference polypeptide is set forth in SEQ ID NO:8. Referring to SEQ ID NO:8, the INHBE reference polypeptide is 350 amino acids in length.

The genomic nucleic acid molecules, mRNA molecules, and cDNA molecules can be from any organism. For example, the genomic nucleic acid molecules, mRNA molecules, and cDNA molecules can be human or an ortholog from another organism, such as a non-human mammal, a rodent, a mouse, or a rat. It is understood that gene sequences within a population can vary due to polymorphisms such as single-nucleotide polymorphisms. The examples provided herein are only exemplary sequences. Other sequences are also possible.

The isolated nucleic acid molecules disclosed herein can comprise RNA, DNA, or both RNA and DNA. The isolated nucleic acid molecules can also be linked or fused to a heterologous nucleic acid sequence, such as in a vector, or a heterologous label. For example, the isolated nucleic acid molecules disclosed herein can be within a vector or as an exogenous donor sequence comprising the isolated nucleic acid molecule and a heterologous nucleic acid sequence. The isolated nucleic acid molecules can also be linked or fused to a heterologous label. The label can be directly detectable (such as, for example, fluorophore) or indirectly detectable (such as, for example, hapten, enzyme, or fluorophore quencher). Such labels can be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radiolabels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The label can also be, for example, a chemiluminescent substance; a metal-containing substance; or an enzyme, where there occurs an enzyme-dependent secondary generation of signal. The term “label” can also refer to a “tag” or hapten that can bind selectively to a conjugated molecule such that the conjugated molecule, when added subsequently along with a substrate, is used to generate a detectable signal. For example, biotin can be used as a tag along with an avidin or streptavidin conjugate of horseradish peroxidate (HRP) to bind to the tag, and examined using a calorimetric substrate (such as, for example, tetramethylbenzidine (TMB)) or a fluorogenic substrate to detect the presence of HRP. Exemplary labels that can be used as tags to facilitate purification include, but are not limited to, myc, HA, FLAG or 3× FLAG, 6× His or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, an epitope tag, or the Fc portion of immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes and their calorimetric, fluorogenic and chemiluminescent substrates and other labels.

The disclosed nucleic acid molecules can comprise, for example, nucleotides or non-natural or modified nucleotides, such as nucleotide analogs or nucleotide substitutes. Such nucleotides include a nucleotide that contains a modified base, sugar, or phosphate group, or that incorporates a non-natural moiety in its structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated, aminated, deaminated, alkylated, benzylated, and fluorophor-labeled nucleotides.

The nucleic acid molecules disclosed herein can also comprise one or more nucleotide analogs or substitutions. A nucleotide analog is a nucleotide which contains a modification to either the base, sugar, or phosphate moieties. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T/U, as well as different purine or pyrimidine bases such as, for example, pseudouridine, uracil-5-yl, hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl. Modified bases include, but are not limited to, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (such as, for example, 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

Nucleotide analogs can also include modifications of the sugar moiety. Modifications to the sugar moiety include, but are not limited to, natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include, but are not limited to, the following modifications at the 2′ position: OH; F; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; O—, S— or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl, and alkynyl may be substituted or unsubstituted C₁₋₁₀alkyl or C₂₋₁₀alkenyl, and C₂₋₁₀alkynyl. Exemplary 2′ sugar modifications also include, but are not limited to, —O[(CH₂)_(n)O]_(m)CH₃, —O(CH₂)_(n)OCH₃, —O(CH₂)_(n)NH₂, —O(CH₂)_(n)CH₃, —O(CH₂)_(n)—ONH₂, and —O(CH₂)_(n)ON[(CH₂)_(n)CH₃)]₂, where n and m are from 1 to about 10. Other modifications at the 2′ position include, but are not limited to, Ci_malkyl, substituted lower alkyl, alkaryl, aralkyl, 0-alkaryl or 0-aralkyl, SH, SCH₃, OCN, CI, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Similar modifications may also be made at other positions on the sugar, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Modified sugars can also include those that contain modifications at the bridging ring oxygen, such as CH₂ and S. Nucleotide sugar analogs can also have sugar mimetics, such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3′-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. These phosphate or modified phosphate linkage between two nucleotides can be through a 3′-5′ linkage or a 2′-5′ linkage, and the linkage can contain inverted polarity such as 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts, and free acid forms are also included. Nucleotide substitutes also include peptide nucleic acids (PNAs).

The present disclosure also provides therapeutic agents that treat or inhibit a metabolic disorder for use in the treatment of the metabolic disorder in a subject having: an INHBE variant genomic nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide; an INHBE variant mRNA molecule encoding a predicted loss-of-function INHBE polypeptide; or an INHBE variant cDNA molecule encoding a predicted loss-of-function INHBE polypeptide.

In some embodiments, the metabolic disorder is type 2 diabetes, and the therapeutic agent is chosen from metformin, insulin, glyburide, glipizide, glimepiride, repaglinide, nateglinice, thiazolidinediones, rosiglitazone, pioglitazone, sitagliptin, saxagliptin, linagliptin, exenatide, liraglutide, semaglutide, canagliflozin, dapagliflozin, and empagliflozin.

In some embodiments, the metabolic disorder is obesity, and the therapeutic agent is chosen from orlistat, phentermine, topiramate, bupropion, naltrexone, and liraglutide.

In some embodiments, the metabolic disorder is high blood pressure, and the therapeutic agent is chosen from chlorthalidone, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, acebutolol, atenolol, betaxolol, bisoprolol fumarate, carteolol hydrochloride, metoprolol tartrate, metoprolol succinate, nadolol, benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril, perindopril, quinapril hydrochloride, ramipril, trandolapril, candesartan, eprosartan mesylate, irbesartan, losartan potassium, telmisartan, valsa tan, amlodipine besylate, bepridil, diltiazem hydrochloride, felodipine, Isradipine, nicardipine, nifedipine, nisoldipine, verapamil hydrochloride, doxazosin mesylate, prazosin hydrochloride, terazosin hydrochloride, methyldopa, carvedilol labetalol hydrochloride, alpha methyldopa, clonidine hydrochloride, guanabenz acetate, guanfacine hydrochloride, guanadrel, guanethidine monosulfate, reserpine, hydralazine hydrochloride, and minoxidil.

In some embodiments, the metabolic disorder is elevated triglyceride, and the therapeutic agent is chosen from rosuvastatin, simvastatin, atorvastatin, fenofibrate, gemfibrozil, fenofibric acid, niacin, and an omega-3 fatty acid.

In some embodiments, the metabolic disorder is lipodystrophy, and the therapeutic agent is chosen from EGRIFTA® (tesamorelin), GLUCOPHAGE® (metformin), SCULPTRA® (poly-L-lactic acid), RADIESSE® (calcium hydroxyapatite), polymethylmethacrylate (e.g., PMMA), ZYDERM® (bovine collagen), COSMODERM® (human collagen), silicone, and hyaluronic acid. In some embodiments, the therapeutic agent that treats or inhibits lipodystrophy include, but are not limited to: tesamorelin, metformin, poly-L-lactic acid, a calcium hydroxyapatite, polymethylmethacrylate, a bovine collagen, a human collagen, silicone, and hyaluronic acid.

In some embodiments, the metabolic disorder is liver inflammation, and the therapeutic agent is chosen from hepatitis therapeutics and hepatitis vaccines.

In some embodiments, the metabolic disorder is fatty liver disease include, and the therapeutic agent or procedure is bariatric surgery and/or dietary intervention.

In some embodiments, the metabolic disorder is hypercholesterolemia, and the therapeutic agent is chosen from: statins (e.g., LIPITOR® (atorvastatin), LESCOL® (fluvastatin), lovastatin, LIVALO® (pitavastatin), PRAVACHOL® (pravastatin), CRESTOR® (rosuvastatin calcium), and ZOCOR® (simvastatin)); bile acid sequestrants (e.g., PREVALITE® (cholestyramine), WELCHOL® (colesevelam), and COLESTID® (colestipol)); PCSK9 Inhibitors (e.g., PRALUENT® (alirocumab) and REPATHA® (evolocumab); niacin (e.g., niaspan and niacor); fibrates (e.g., fenofibrate and LOPID® (gemfibrozil)); and ATP Citrate Lyase (ACL) Inhibitors (e.g., NEXLETOL® (bempedoic)). In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia include, but are not limited to: statins (e.g., atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin calcium, and simvastatin); bile acid sequestrants (e.g., cholestyramine, colesevelam, and colestipol); PCSK9 Inhibitors (e.g., alirocumab and evolocumab; niacin (e.g., niaspan and niacor); fibrates (e.g., fenofibrate and gemfibrozil); and ACL Inhibitors (e.g., bempedoic). In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is alirocumab or evolocumab. In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is alirocumab. In some embodiments, the therapeutic agent that treats or inhibits hypercholesterolemia is evolocumab.

In some embodiments, the metabolic disorder is elevated liver enzymes (such as, for example, ALT and/or AST), and the therapeutic agent is chosen from coffee, folic acid, potassium, vitamin B6, a statin, and fiber, or any combination thereof.

In some embodiments, the metabolic disorder is NASH and the therapeutic agent is obeticholic acid, Selonsertib, Elafibranor, Cenicriviroc, GR_MD_02, MGL_3196, IMM124E, arachidyl amido cholanoic acid, GS0976, Emricasan, Volixibat, NGM282, GS9674, Tropifexor, MN_001, LMB763, BI_1467335, MSDC_0602, PF_05221304, DF102, Saroglitazar, BMS986036, Lanifibranor, Semaglutide, Nitazoxanide, GRI_0621, EYP001, VK2809, Nalmefene, LIK066, MT_3995, Elobixibat, Namodenoson, Foralumab, SAR425899, Sotagliflozin, EDP_305, Isosabutate, Gemcabene, TERN_101, KBP_042, PF_06865571, DUR928, PF_06835919, NGM313, BMS_986171, Namacizumab, CER_209, ND_L02_s0201, RTU_1096, DRX_065, ION IS_DGAT2Rx, INT_767, NC_001, Seladepar, PXL770, TERN_201, NV556, AZD2693, SP_1373, VK0214, Hepastem, TGFTX4, RLBN1127, GKT_137831, RYI_018, CB4209-CB4211, and JH_0920.

In some embodiments, the therapeutic agent that treats or inhibits the metabolic disorder is a melanocortin 4 receptor (MC4R) agonist. In some embodiments, the MC4R agonist comprises a protein, a peptide, a nucleic acid molecule, or a small molecule. In some embodiments, the protein is a peptide analog of MC4R. In some embodiments, the peptide is setmelanotide. In some embodiments, the MC4R agonist is a peptide comprising the amino acid sequence His-Phe-Arg-Trp. In some embodiments, the small molecule is 1,2,3R,4-tetrahydroisoquinoline-3-carboxylic acid. In some embodiments, the MC4R agonist is ALB-127158(a).

The present disclosure also provides therapeutic agents that treat or inhibit a cardiovascular disease for use in the treatment of the cardiovascular disease in a subject having: an INHBE variant genomic nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide; an INHBE variant mRNA molecule encoding a predicted loss-of-function INHBE polypeptide; or an INHBE variant cDNA molecule encoding a predicted loss-of-function INHBE polypeptide.

In some embodiments, the cardiovascular disease is high blood pressure, and the therapeutic agent is chosen from chlorthalidone, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, acebutolol, atenolol, betaxolol, bisoprolol fumarate, carteolol hydrochloride, metoproloi tartrate, metoprolol succinate, nadoloi, benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril, perindopril, quinapril hydrochloride, ramipril, trandolapril, candesartan, eprosartan mesylate, irbesartan, losartan potassium, telmisartan, valsartan, amlodipine besylate, bepridil, diltiazem hydrochloride, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil hydrochloride, doxazosin mesylate, prazosin hydrochloride, terazosin hydrochloride, methyldopa, carvedilol labetalol hydrochloride, alpha methyldopa, clonidine hydrochloride, guanabenz acetate, guanfacine hydrochloride, guanadrel, guanethidine monosulfate, reserpine, hydralazine hydrochloride, and minoxidil,

In some embodiments, the cardiovascular disease is cardiomyopathy, and the therapeutic agent is chosen from: 1) blood pressure lowering agents, such as ACE inhibitors, angiotensin II receptor blockers, beta blockers, and calcium channel blockers; 2) agents that slow heart rate, such as beta blockers, calcium channel blockers, and digoxin; 3) agents that keep the heart beating with a normal rhythm, such as antiarrhythmics; 4) agents that balance electrolytes, such as aldosterone blockers; 5) agents that remove excess fluid and sodium from the body, such as diuretics; 6) agents that prevent blood clots from forming, such as anticoagulants or blood thinners; and 7) agents that reduce inflammation, such as corticosteroids.

In some embodiments, the cardiovascular disease is heart failure, and the therapeutic agent is chosen from: an ACE inhibitor, an angiotensin-2 receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist, a diuretic, ivabradine, sacubitril valsartan, hydralazine with nitrate, and digoxin.

The present disclosure also provides INHBE inhibitors that treat or inhibit a metabolic disorder for use in the treatment of the metabolic disorder in a subject having: an INHBE variant genomic nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide; an INHBE variant mRNA molecule encoding a predicted loss-of-function INHBE polypeptide; or an INHBE variant cDNA molecule encoding a predicted loss-of-function INHBE polypeptide.

The present disclosure also provides INHBE inhibitors that treat or inhibit a cardiovascular disease for use in the treatment of the cardiovascular disease in a subject having: an INHBE variant genomic nucleic acid molecule encoding a predicted loss-of-function INHBE polypeptide; an INHBE variant mRNA molecule encoding a predicted loss-of-function INHBE polypeptide; or an INHBE variant cDNA molecule encoding a predicted loss-of-function INHBE polypeptide.

In some embodiments, the INHBE inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to an INHBE mRNA. In some embodiments, the INHBE inhibitor comprises a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an INHBE genomic nucleic acid molecule. In some embodiments, the Cas protein is Cas9 or Cpf1. In some embodiments, the gRNA recognition sequence is located within SEQ ID NO:1. In some embodiments, a Protospacer Adjacent Motif (PAM) sequence is about 2 to 6 nucleotides downstream of the gRNA recognition sequence. In some embodiments, the gRNA comprises from about 17 to about 23 nucleotides. In some embodiments, the gRNA recognition sequence comprises a nucleotide sequence according to any one of SEQ ID NOs:9-27.

All patent documents, websites, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise, if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure can be used in combination with any other feature, step, element, embodiment, or aspect unless specifically indicated otherwise. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

The following examples are provided to describe the embodiments in greater detail. They are intended to illustrate, not to limit, the claimed embodiments. The following examples provide those of ordinary skill in the art with a disclosure and description of how the compounds, compositions, articles, devices and/or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (such as, for example, amounts, temperature, etc.), but some errors and deviations may be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric.

EXAMPLES Example 1 Loss of Function in INHBE is Associated with a More Favorable Fat Distribution and Protection Against Type 2 Diabetes in Humans

An exome-wide association analysis for fat distribution, measured by the waist-to-hip circumference ratio adjusted for body mass index (BMI-adjusted WHR), was performed. BMI-adjusted WHR is a measure of body fat distribution independent of overall adiposity. For each gene in the genome, associations with BMI-adjusted WHR for the burden of rare predicted loss-of-function genetic variants (pLOF variants with alternative allele frequency [AAF] <1%) were estimated. In this analysis, the burden of rare (AAF<1%) predicted loss-of-function (pLOF) variants in INHBE was associated with a more favorable fat distribution (i.e., lower WHR adjusted for BMI; see, FIG. 1 and FIG. 2) at the exome-wide level of statistical significance (p<3.6×10⁻⁷, corresponding to a Bonferroni correction for the number of tests). Table 6 shows results of associations with fat distribution for pLOF variants in INHBE in 285,605 European ancestry participants in the UKB cohort (associations with BMI-adjusted WHR; genetic exposure is the burden of pLOF variants with AAF <1%). INHBE pLOF were strongly associated with lower BMI-adjusted WHR (see, Table 6). This statistically significant association was further replicated in a meta-analysis of additional data including a second tranche of UKB data (over 140,000 European ancestry participants) and over 95,000 admixed American participants from the MCPS study (see, FIG. 1).

TABLE 6 INHBE gene-burden association result for BMI adjusted WHR in the UKB Per allele Genotype Per allele beta effect counts, (95% Cl) in (95% Cl) in RR|RA|AA BMI adjusted AAF SD units P-value genotypes WHR units 0.0012 −0.21 2.80E−08 285,605: −0.02 (−0.29, −0.14) 284,942|663|0 ( −0.02, −0.01) Abbreviations: UKB = UK biobank study population, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss-of-function, SD = standard deviation.

Table 6 shows the association of INHBE pLOF with BMI-adjusted WHR in the European ancestry individuals of the UK Biobank study population. The effect of INHBE pLOF variants was estimated in standard deviation (SD) units and in the ratio units of WHR. Table 6 shows that INHBE pLOF carriers have a lower BMI adjusted WHR compared to the average of individuals not carrying these genetic variants in analyses adjusting for covariates, ancestry and relatedness. Genotype counts display the number of individuals in the population studies carrying no variants leading to pLOF of INHBE (RR), one or more variants resulting in pLOF of a single INHBE allele (RA), or one or more pLOF variants in both INHBE alleles (AA).

This association of INHBE pLOF variants with lower BMI-adjusted WHR was consistent in men and women from the UK Biobank cohort (see, Table 7; genetic exposure is the burden of pLOF variants with AAF <1%).

TABLE 7 Sex-stratified INHBE pLOF variants association in the UKB Per allele beta Per allele effect Genotype counts, (95% Cl) in Cohort (95% Cl) RR|RA|AA BMI adjusted (Sub-population) AAF in SD units P-value genotypes waist-hip ratio units UKB 0.001 −0.19 2.8E−06 232,890: −0.01 (EUR women) (−0.27, −0.11) 232,329|561|0 (−0.02, −0.01) UKB 0.001 −0.16 3.6E−04 196,500: −0.01 (EUR men) (−0.25, −0.07) 196,056|444|0 (−0.01, 0.005) Abbreviations: UKB = UK biobank study population, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss of function, SD = standard deviation.

Table 7 shows the association of INHBE pLOF with BMI-adjusted WHR in European ancestry individuals from the UK Biobank study stratified by sex. The effect of INHBE pLOF variants was estimated in standard deviation (SD) units and in ratio units of WHR. Genotype counts display the number of individuals in the population studies carrying no variants leading to pLOF of INHBE (RR), one or more variants resulting in pLOF of a single INHBE allele (RA), or one or more pLOF variants in both INHBE alleles (AA). The association of INHBE pLOF variants with lower BMI-adjusted WHR was similarly strong in men and women included in this analysis.

Among pLOF variants in INHBE, the variant with the strongest association with BMI-adjusted WHR was a c.299-1G>C (12:57456093:G:C according to GRCh38/hg38 human genome assembly coordinates) mutation, predicted to affect the intron 1 acceptor splice site shortening exon 2 by 12 nucleotides at the 5′ end (see, FIG. 3 and Table 8) and result in an in-frame deletion within the pro-domain of the INHBE protein (see, FIG. 4).

TABLE 8 Effect on splicing for the 12:57456093:G:C acceptor splice-site variant as predictec by the SpliceAI software VARIANT SPLICE CHANGE DELTA SCORE 12:57456093:G:C Acceptor loss 0.98 Acceptor gain 0.9  Delta score: Value between 0-1, interpreted as the probability of the variant having a splice-change effect on the INHBE gene.

Table 8 shows the predicted effect of the variant 12:57456093:G:C on splicing of the INHBE gene.

In Chinese hamster ovary (CHO) cells, the c.299-1G>C splice variant was expressed and was found to result in a lower molecular weight protein that is not secreted outside the cell, indicating a loss-of-function (see, FIG. 5).

pLOF variants in INHBE were associated with larger hip circumference, higher arm and leg fat mass, suggestive of greater ability to store calories in peripheral adipose tissue (see, FIG. 6 and Table 9).

TABLE 9 Association of pLOF genetic variants in INHBE with adiposity phenotypesmeta- analyzed across the UKB, Geisinger Health System (GHS) and MCPS studies Per allele effect Genotype counts Per allele beta Outcome (95% Cl) RR|RA|AA (95% Cl) (Clinical Units) Genetic exposure in SD units P-value genotypes in clinical units BMI (kg/m²) INHBE pLOF;  0.06 0.02 645,626: 0.33 AAF <1% (0.01, 0.11) 644,402|1,224| (0.04, 0.61) 0 Waist (cm) −0.03 0.26 526,076: −0.45  (−0.09, 0.03)  525,034|1,042| (−1.22, 0.33)  0 Hip (cm)  0.07 0.03 526,031: 0.63 (0.01, 0.13) 524,989|1,042| (0.08, 1.19) 0 Abbreviations: UKB = UK biobank study population, GHS = Geisinger Health System study population, MCPS = Mexico City Prospective Study population, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss-of-function, SD = standard deviation, kg/m² = kilograms per meter square, cm = centimeters. Genotype counts display the number of individuals in the population studies carrying no variants leading to pLOF of INHBE (RR), one or more variants resulting in pLOF of a single INHBE allele (RA), or one or more pLOF variants in both INHBE alleles (AA).

Table 9 shows the association of INHBE pLOF with BMI, waist circumference, and hip circumference. The effect of INHBE pLOF is quantified in units of standard deviation, or in the respective clinical units of each anthropometric variable.

Rare pLOF variants in INHBE were also associated with protection against type 2 diabetes in humans. It was also found that INHBE pLOF variants were associated with lower risk of type 2 diabetes (T2D) (see, Table 10; genetic exposure is the burden of pLOF variants with AAF <1%), constituting the first evidence linking LOF in INHBE with type 2 diabetes in humans.

TABLE 10 Association of pLOF genetic variants in INHBE with T2D in the UKB, GHS and MCPS studies Genotype Genotype counts counts Per allele RR|RA|AA RR|RA|AA OR genotypes genotypes Cohort AAF (95% Cl) P-value (cases) (controls) UKB 0.001  0.82 0.15   23,907: 402,934: (0.62, 1.08) 23,862|45|0 401,981|953|0 GHS 0.001  0.44 0.0006  25,846: 63,749: (0.28, 0.70) 25,828|18|0 63,639|110|0 MCPS 0.0002 0.38 0.08   13,739: 83,278: (0.13, 1.11) 13,738|1|0 83,243|35|0 Meta- 0.001  0.68 0.00097 63,492: 549,961:  analysis (0.54, 0.85) 63,428|64|0 548,863|1,098|0 Abbreviations: Meta-analysis = Joint analysis of all listed study populations, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss-of-function, SD = standard deviation. Genotype counts display the number of individuals in the population studies either being cases of T2D or not in the T2D category carrying no variants leading to pLOF of INHBE (RR), one or more variants resulting in pLOF of a single INHBE allele (RA), or one or more pLOF variants in both INHBE alleles (AA).

Table 10 shows the association with T2D for pLOF variants in INHBE from an analysis of the UK Biobank (UKB), Geisinger Health System (GHS), and Mexico City Prospective study (MCPS) populations. The results show that, within each study population, INHBE pLOF variants were associated with lower risk of T2D and this was confirmed in a meta-analysis which combines results across all three study populations.

Furthermore, INHBE pLOF variants were associated with a favorable metabolic profile in an analysis across multiple cohorts (see, Table 11; genetic exposure is the burden of INHBE pLOF variants with AAF <1%), including lower HbA1c, ALT, triglycerides and LDL-C and higher HDL-C.

TABLE 11 Association of pLOF genetic variants in INHBE with metabolic meta-analyzed across the UKB, GHS and MCPS studies Per allele effect Genotype counts Per allele beta Outcome (95% Cl) in RR|RA|AA (95% Cl) in (Clinical Units) AAF SD units P-value genotypes Clinical Units Glucose 0.001  0.04 0.24   460,195|1,023|0  0.76 (mg/dL) (−0.02, 0.10)   (−0.51, 2.03)  HbA1c (%) 0.001 −0.06 0.038  574,104|1,086|0 −0.05 (−0.11, −0.003)  (−0.10, −0.003) AST (U/L) 0.001 0.0028 0.92   514,592|1,122|0  0.03 (−0.05, 0.06)   (−0.5, 0.6)  ALT (U/L) 0.001 −0.07 0.014  517,194|1,123|0 −1.0  (−0.13, −0.01)  (−1.7, −0.2) Triglycerides 0.001 −0.11 0.00017 500,594|1,092|0 −9.2  (mg/dL) (−0.16, −0.05)  (−14.1, −4.4)  HDL-C (mg/dL) 0.001  0.13 3.1 × 10⁻⁰⁶ 466,201|1,024|0 2.0 (0.08, 0.19)  (1.1, 2.8) LDL-C (mg/dL) 0.001 −0.06 0.04   499,334|1,092|0 −1.9  (−0.11, −0.003) (−3.7, −0.1) Abbreviations: UKB = UK biobank study population, GHS = Geisinger Health System study population, MCPS = Mexico City Prospective Study, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss-of-function, SD = standard deviation, nng/dL = milligrams per deciliter, U/L = Units per liter. Genotype counts display the number of individuals in the population studies carrying no variants leading to pLOF of INHBE (RR), one or more variants resulting in pLOF of a single INHBE allele (RA), or one or more pLOF variants in both INHBE alleles (AA).

Table 11 shows the association of INHBE pLOF variants with a range of metabolic phenotypes as estimated in a meta-analysis of the UKB, GHS, and MCPS study populations. Results are shown both in units of standard deviation, and in the original clinical units of the relevant metabolic phenotype.

In addition, INHBE pLOF variants were associated with reduced liver inflammation indices at magnetic resonance imaging (see, Table 12; genetic exposure is the burden of INHBE pLOF variants with AAF <1%).

TABLE 12 Association of pLOF genetic variants in INHBE with liver imaging phenotypes in the UKB ALT Effect (95% allele Outcome Cl) in SD Effect (95% Cl) Allele count carriers (Clinical Units) units in Clinical units P-value cases AAF % ECF −0.25 −0.012 0.026 36,690|70|0 0.00095 0.19% (Fraction of (−0.47, −0.03) (−0.029, −0.002) sampled pixels) ECF adjusted^(a) −0.29 −0.018 0.0060 35,205|69|0 0.00098 0.20% (Fraction of (−0.50, −0.08) (−0.031, −0.005) sampled pixels) PDFF 0.06 0.29 0.560 36,690|70|0 0.00095 0.19% (Fraction of (−0.15, 0.27) (−0.72, 1.31) sampled pixels) PDFF 0.05 0.24 0.569 35,205|69|0 0.00098 0.20% adjusted^(a) (−0.12, 0.22) (−0.58, 1.06) (Fraction of sampled pixels) cT1 −0.23 −10.4 0.047 36,690|70|0 0.00095 0.19% (time in (−0.45, −0.00) (−21.3, −0.00) milliseconds) cT1 adjusted^(a) −0.26 −11.83 0.012 35,205|69|0 0.00098 0.20% (time in (−0.47, −0.06) (−21.38, −2.73) milliseconds) T1 −0.33 −15.3 0.0035 36,690|70|0 0.00095 0.19% (time in (−0.56, −0.11) (−25.95, −5.10) milliseconds) T1 adjusted^(a) −0.36 −16.68 0.00097 35,205|69|0 0.00098 0.20% (time in (−0.57, −0.14) (−26.41, −6.49) milliseconds) ^(a)Adjusted for technical covariates including BMI, alcohol usage, and diabetes. Abbreviations: PDFF = Proton density fat fraction (defined as the ratio of density of mobile protons from fat (triglycerides) and the total density of protons from mobile triglycerides and mobile water and reflects the concentration of fat within a tissue), ECF = extracellular fluid, T1 = time constant for recovery of longitudinal magnetization. It's a relaxation time which measures how quickly the net magnetization recovers to its ground state. It can differ significantly based on the strength of the magnetic field and based on tissue composition. Furthermore, it increases with increased magnetic field, while it decreases with presence of fat and/or iron in the tissue, cT1 = T1 corrected for the effects of liver iron content which result in T1 values being underestimated, UKB = UK biobank study population, AAF = frequency of pLOF alleles across pLOF variants in the gene, RR = count of individuals having no heterozygous or homozygous observations of pLOFs variants in the gene, RA = count of individuals with at least one heterozygous pLOF and no homozygotes pLOF variants in the gene, AA = count of individuals with at least one homozygous pLOF variants in the gene, Cl = confidence interval, pLOF = predicted loss-of-function, SD = standard deviation.

Table 12 shows the association of INHBE pLOF variants with a range of liver imaging phenotypes in European ancestry individuals from the UK Biobank study population. The results show that INHBE pLOF variants are associated with lower levels of ECF and cT1 which are measures of liver inflammation, as defined by magnetic resonance imaging.

It was additionally investigated whether INHBE pLOF variants were associated with liver histopathology phenotypes in 3,565 bariatric surgery patients from the GHS cohort who underwent exome sequencing and a perioperative wedge biopsy of the liver. There were only three carriers for pLOF variants in INHBE in that set, but carrier status was associated with lower nonalcoholic fatty liver disease activity score (see, Table 13), a measure of the severity of liver disease at biopsy that sums steatosis, lobular inflammation and ballooning grades (Kleiner et al., Hepatology, 2005, 41, 1313-21).

TABLE 13 Association with lower nonalcoholic fatty liver disease activity score for rare pLOF variants in INHBE Beta in SD of NAFLD activity INHBE pLOF score per allele genotypes Outcome (95% Cl) P-value (Ref/Het/Hom) NAFLD activity −1.05 0.026 3,565|3|0 score (−1.98, −0.12)

The association with NAFLD activity score (outcome) for rare pLOF variants in INHBE was reported. The association was estimated in 3,565 bariatric surgery patients from GHS.

Finally, it was found that a common variant near INHBE (12:57259799:A:C; r57966846; AAF, 0.28) is associated with higher liver expression levels of INHBE mRNA (per-allele beta, 0.3 SDs of INHBE transcript abundance as quantified by RNASeq in over 2,000 participants to GHS who underwent a liver biopsy as part of bariatric surgery). It was also found that the 12:57259799:A:C variant is associated with higher BMI-adjusted WHR, triglycerides and risk of type 2 diabetes. The expression raising allele C was associated with higher BMI-adjusted WHR (p-value=1.5×10⁻⁴), higher triglycerides (p-value=2.0×10⁻¹¹), higher T2D risk (p-value=0.03) (see, Table 14). This shows that genetically-determined overexpression of INHBE is associated with higher metabolic disease risk, while a loss of function is associated favorable metabolic profile and lower diabetes risk (as noted above from the pLOF variants associations).

TABLE 14 Association of an INHBE eQTL, 12:57259799:A:C, with various metabolic phenotypes in the UKB and GHS cohorts Per allele Per allele effect beta Outcome (95% Cl) in (95% Cl) in Genetic (Clinical SD units or Clinical Genotype counts, exposure Units) AAF odds ratio Units P-value RR|RA|AA genotypes 12:5725979 Triglycerides 0.285 0.01 SDs 0.9 2.0 × 10⁻¹¹ 274,658|216,943|43,3 9:A:C, (mg/dL) (0.009, 0.02) (0.9, 1.0) 88 Count of BMI-adj 0.285 0.008 SDs 0.00064 1.5 × 10⁻⁴ 235,613|187,407|37,7 INHBE liver WHR (0.004, (0.00032, 40 expression (ratio units) 0.012) 0.00080) raising T2D 0.285 1.02^(a) — 0.037 T2D Controls: allele C (1.00^(a), 1.04^(a)) 255,408|201,524|40,2 10 T2D Cases: 27,105|21,053|4,295 ^(a)Estimates are in odds ratios. Abbreviations: AAF = allele frequency of INHBE liver expression raising allele (i.e., alternate allele), Cl = confidence interval, SD = standard deviation, RR = reference-reference allele, RA = reference-alternative allele, AA = alternative-alternative allele, mg/dL = milligrams per deciliter. Genotype counts display the number of individuals in the population studies having no copies of the INHBE liver expression raising allele (RR), having only one copy of the INHBE liver expression raising allele (RA), and having 2 copies of the INHBE liver expression raising allele (AA). Genotype counts are further stratified within individuals classified as T2D cases in the study population.

The association of 12:57259799:A:C with triglyceride levels, WHRadjBMI, and T2D risk was studied in all European ancestry participants from the UK Biobank and Geisinger Health studies. The results show that 12:57259799:A:C was significantly associated with higher triglyceride levels and higher BMI-adjusted WHR; in addition, there was an association with higher T2D risk.

Example 2 INHBE is Highly Expressed in Human Hepatocytes and its Expression was Upregulated in Patients with Steatosis and Nonalcoholic Steatohepatitis

The mRNA expression of INHBE across tissues in humans from the Genotype Tissue Expression consortium (GTEx) was examined and it was found that INHBE is most highly expressed in liver among the GTEx tissues (see, FIG. 7). The mRNA expression of INHBE among cell types was also examined in data from the Human Protein Atlas (HPA) and it was found that INHBE was most highly expressed in hepatocytes (see, FIG. 7). The level of expression of INHBE in the liver of over 2,000 bariatric surgery patients in GHS who underwent liver RNASeq was also estimated. It was discovered that INHBE expression was upregulated in patients with steatosis of the liver compared to individuals with normal liver, in patients with nonalcoholic steatohepatitis compared to individuals with normal liver, and in patients with nonalcoholic steatohepatitis compared to patients with steatosis (see, FIG. 8).

Example 3 Associations with Visceral to Gluteofemoral Fat Ratio as Measured by MRI for INHBE Identified in the BMI-Adjusted WHR Discovery Analysis

A subset of approximately 46,000 participants in UKB underwent two-point Dixon (Dixon, Radiology, 1984, 153, 189-194) MRI using Siemens MAGNETOM Aera 1.5T clinical MRI scanners (Littlejohns et al., Nat. Commun., 2020, 11, 2624), split into six different imaging series. This subset included 38,880 people with available exome sequencing. Stitching of the six different scan positions corrected for overlapping slices, partial scans, repeat scans, fat-water swaps, misalignment between imaging series, bias-field, artificially dark slices and local hotspots, similar to what has previously been performed (Basty et al., Image Processing and Quality Control for Abdominal Magnetic Resonance Imaging in the UK Biobank, 2020, ArXiv abs/2007.01251). A total of 52 subjects had their whole-body Dixon MRI manually annotated into six different classes of fat: upper body fat, abdominal fat, visceral fat, mediastinal fat, gluteofemoral fat and lower-leg fat. Special care was taken to tailor the training dataset to attempt to span the phenotypic diversity expected by specifically including training subjects that have genetic mutations that predispose them to abnormal fat and muscle phenotypes such as PPARG (Ludtke et al., J. Med. Genet., 2007, 44, e88), PLIN1 (Gandotra et al., N. Engl. J. Med., 2011, 364, 740-748), LMNA (Jeru et al., J. Med. Genet., 2017, 54, 413-416), LIPE (Zolotov et al., Am. J. Med. Genet., 2017, A 173, 190-194) and MC4R (Akbari et al., Science, 2021, 373). These annotations were then used to train a multi-class segmentation deep neural-net which employed a UNet (Weng et al., IEEE Access, 2021, 9, 16591-16603) architecture with a ResNet34 (He et al., in 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2016, 770-778) backbone, and a loss function of a sum of the Jaccard Index and categorical focal loss (Lin et al., IEEE Transactions on Pattern Analysis and Machine Intelligence, 2020, 42, 318-327). Fat volume phenotypes were calculated by summing the resulting segmentation maps from the neural net for each corresponding fat class. The visceral-to-gluteofemoral fat ratio was then calculated as the ratio of visceral to gluteofemoral fat volume for a given individual.

Rare coding variants in INHBE associated with BMI-adjusted WHR showed highly consistent associations with visceral-to-gluteofemoral fat ratio at MRI, a refined measure of fat distribution, in a subset of 38,880 people (i.e., ˜6% of the discovery sample) who had undergone a whole-body MRI in UKB (see, Table 15). There was a nominally-significant association with lower MRI-defined visceral-to-gluteofemoral fat ratio for INHBE pLOF variants in the subset of UKB with MRI data (beta in SD units of fat ratio per allele, −0.24; 95% CI, −0.45 to −0.02; p=0.03; see, Table 15).

TABLE 15 Beta (95% Cl) per allele in SD Genotype counts, AAF, units of visceral to gluteofemoral RR|RA|AA fraction fat ratio from MRI P genotypes of 1 −0.238 3.0E−02 38802|78|0 0.0010 (−0.453, −0.023) Each gene-burden result in the table was analyzed in a model that accounted for the sex specific effects of age, body mass index, and height on visceral to gluteofemoral fat ratio. Abbreviations: pLOF, predicted loss of function; AAF, alternative allele frequency; CI, confidence intervals; SD, standard deviation; BMI, body mass index; p, P-value; RR, reference homozygote genotype; RA, reference-alternative genotype; AA, alternative homozygote genotype.

Example 4 INHBE Predicted Loss-of-Function Association with Increased Left Ventricular Ejection Fraction and Protection of Cardiomyopathy

Cases in the present example were any study participant without heart disease. The results were based on meta-analyses of UKB, GHS, SINAI, UPENN-PMBB, MDCS, Indiana-Chalasani. Predicted loss-of-function in INHBE associated with increased left ventricular ejection fraction and protection of cardiomyopathy are shown in Table 16 (Burden of INHBE rare pLoF variants (M1.1)).

TABLE 16 Case allele Control allele Beta_(SD) or Clin. count count AA Outcome OR [95% Cl] unit P-value (RR|RA|AA) (RR|RA|AA) carriers 1 0.26 1.57% 0.019 38,651|80|0 — 0.21% (0.04, 0.47) 2 0.46 — 0.034 5,111|2|0 342,838|650|0 0.19% (0.23, 0.95) Outcome 1 is left ventricular ejection fraction*. Outcome 2 is non-ischemic cardiomyopathy**. *Left ventricular ejection fraction obtained by cardiac MRI in participants of the UK Biobank. **Non-ischemic cardiomyopathy cases were defined as study participants with one or more of the following ICD10 codes: 1420 (Dilated Cardiomyopathy), 1425 (Other restrictive cardiomyopathy), 1428(Other noncompaction cardiomyopathies), 1429 (primary cardiomyopathy|unspecified), and absence of one or more of any ICD10 code indicative of myocardial infarction (121|122|123|1252|1256) and hypertrophic cardiomyopathy (1421, 1422).

Association of pLOF variants with lower blood pressure (see, Table 17; burden of INHBE rare pLOF variants—M1.1) is consistent with beneficial effect on hemodynamic traits.

TABLE 17 Beta (95% Cl) per allele Effect in mmHg Genotype Counts Trait in SD units (95% Cl) per allele P-value AAF,fraction of 1 (RR|RA|AA) 1 −0.06 −0.56 0.03  0.00102 599,306|1,224|0 (−0.11, −0.01) (−1.07, −0.05) 2 −0.05 −0.84 0.0614 0.00102 599,608|1,224|0 (−0.10, 0.00)  (−1.72, 0.04)  Trait 1 is diastolic blood pressure (treatment corrected). Trait 2 is systolic blood pressure (treatment corrected).

Various modifications of the described subject matter, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, and the like) cited in the present application is incorporated herein by reference in its entirety and for all purposes. 

1. A method of treating a subject having or at risk of developing a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and/or heart failure, the method comprising administering an Inhibin Subunit Beta E (INHBE) inhibitor to the subject. 2-14. (canceled)
 15. The method according to claim 1, wherein the INHBE inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), ef a short hairpin RNA (shRNA) that hybridizes to an INHBE mRNA, or a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an INHBE genomic nucleic acid molecule. 16-20. (canceled)
 21. The method according to claim 15, wherein the gRNA recognition sequence comprises a nucleotide sequence according to any one of SEQ ID NOs:9-27.
 22. The method according to claim 1, further comprising detecting the presence or absence of an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide in a biological sample from the subject.
 23. The method according to claim 22, wherein when the subject is INHBE reference, the subject is also administered a therapeutic agent that treats or inhibits metabolic disorders or cardiovascular diseases in a standard dosage amount, and when the subject is heterozygous or homozygous for an INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide, the subject is also administered a therapeutic agent that treats or inhibits metabolic disorders or cardiovascular diseases in a dosage amount that is the same as or lower than a standard dosage amount.
 24. (canceled)
 25. The method according to claim 22, wherein the INHBE variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated INHBE polypeptide. 26-33. (canceled)
 34. A method of treating a subject with a therapeutic agent that treats or inhibits a metabolic disorder, wherein the subject is suffering from a metabolic disorder, the method comprising the steps of: determining whether the subject has an Inhibin Subunit Beta E (INHBE) variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in a standard dosage amount, and administering to the subject an INHBE inhibitor; and when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in an amount that is the same as or lower than a standard dosage amount, and administering to the subject an INHBE inhibitor; when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the metabolic disorder in an amount that is the same as or lower than a standard dosage amount; wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing the metabolic disorder.
 35. The method according to claim 34, wherein the subject is INHBE reference, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits the metabolic disorder in a standard dosage amount, and is administered an INHBE inhibitor.
 36. The method according to claim 34, wherein the subject is heterozygous for an INHBE variant nucleic acid molecule, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits the metabolic disorder in an amount that is the same as or lower than a standard dosage amount, and is administered an INHBE inhibitor.
 37. A method of treating a subject with a therapeutic agent that treats or inhibits a cardiovascular disease, wherein the subject is suffering from a cardiovascular disease, the method comprising the steps of: determining whether the subject has an Inhibin Subunit Beta E (INHBE) variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by: obtaining or having obtained a biological sample from the subject; and performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in a standard dosage amount, and administering to the subject an INHBE inhibitor; and when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in an amount that is the same as or lower than a standard dosage amount, and administering to the subject an INHBE inhibitor; when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits the cardiovascular disease in an amount that is the same as or lower than a standard dosage amount; wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing the cardiovascular disease.
 38. The method according to claim 37, wherein the subject is INHBE reference, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits the cardiovascular disease in a standard dosage amount, and is administered an INHBE inhibitor.
 39. The method according to claim 37, wherein the subject is heterozygous for an INHBE variant nucleic acid molecule, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits the cardiovascular disease in an amount that is the same as or lower than a standard dosage amount, and is administered an INHBE inhibitor. 40-45. (canceled)
 46. The method according to claim 34 or claim 37, wherein the INHBE variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated INHBE polypeptide. 47-52. (canceled)
 53. The method according to claim 34, wherein the INHBE inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), ef a short hairpin RNA (shRNA) that hybridizes to an INHBE mRNA, or a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an INHBE genomic nucleic acid molecule. 54-59. (canceled)
 60. The method according to claim 34, wherein the metabolic disorder is type 2 diabetes, and the therapeutic agent is chosen from metformin, insulin, glyburide, glipizide, glimepiride, repaglinide, nateglinide, thiazolidinediones, rosiglitazone, pioglitazone, sitagliptin, saxagliptin, linagliptin, exenatide, liraglutide, semaglutide, canagliflozin, dapagliflozin, and empagliflozin, or any combination thereof; wherein the metabolic disorder is obesity, and the therapeutic agent is chosen from orlistat, phentermine, topiramate, bupropion, naltrexone, and liraglutide, or any combination thereof: wherein the metabolic disorder is elevated triglyceride, and the therapeutic agent is chosen from rosuvastatin, simvastatin, atorvastatin, fenofibrate, gemfibrozil, fenofibric acid, niacin, and an omega-3 fatty acid, or any combination thereof, wherein the metabolic disorder is lipodystrophy, and the therapeutic agent is chosen from tesamorelin, metformin, poly-L-lactic acid, calcium hydroxyapatite, polymethylmethacrylate, bovine collagens, human collagens, silicone, and hyaluronic acid, or any combination thereof; wherein the metabolic disorder is liver inflammation, and the therapeutic agent is a hepatitis therapeutic or a hepatitis vaccine; wherein the metabolic disorder is fatty liver disease include, and the subject is administered bariatric surgery and/or dietary intervention; wherein the metabolic disorder is hypercholesterolemia, and the therapeutic agent is chosen from: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin calcium, simvastatin, cholestyramine, colesevelam, and colestipol, alirocumab, evolocumab, niaspan, niacor, fenofibrate, gemfibrozil, and bempedoic, or any combination thereof; wherein the metabolic disorder is an elevated liver enzyme), and the therapeutic agent is chosen from coffee, folic acid, potassium, vitamin B6, a statin, and fiber, or any combination thereof; and wherein the metabolic disorder is nonalcoholic steatohepatitis (NASH) and the therapeutic agent is obeticholic acid, Selonsertib, Elafibranor, Cenicriviroc, GR MD 02, MGL 3196, IMM124E, arachidyl amido cholanoic acid, GS0976, Emricasan, Volixibat, NGM282, GS9674, Tropifexor, MN 001, LMB763, BI 1467335, MSDC 0602, PF 05221304, DF102, Saroglitazar, BMS986036, Lanifibranor, Semaglutide, Nitazoxanide, GRI 0621, EYP001, VK2809, Nalmefene, LIK066, MT 3995, Elobixibat, Namodenoson, Foralumab, SAR425899, Sotagliflozin, EDP 305, Isosabutate, Gemcabene, TERN 101, KBP 042, PF 06865571, DUR928, PF 06835919, NGM313, BMS 986171, Namacizumab, CER 209, ND L02 s0201, RTU 1096, DRX 065, IONIS DGAT2Rx, INT 767, NC 001, Seladepar, PXL770, TERN 201, NV556, AZD2693, SP 1373, VK0214, Hepastem, TGFTX4, RLBN1127, GKT 137831, RYI 018, CB4209-CB4211, and JH
 0920. 61-75. (canceled)
 76. The method according to claim 37, wherein the cardiovascular disease is high blood pressure, and the therapeutic agent is chosen from chlorthalidone, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, acebutolol, atenolol, betaxolol, bisoprolol fumarate, carteolol hydrochloride, metoprolol tartrate, metoprolol succinate, nadolol, benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril, perindopril, quinapril hydrochloride, ramipril, trandolapril, candesartan, eprosartan mesylate, irbesartan, losartan potassium, telmisartan, valsartan, amlodipine besylate, bepridil, diltiazem hydrochloride, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil hydrochloride, doxazosin mesylate, prazosin hydrochloride, terazosin hydrochloride, methyldopa, carvedilol labetalol hydrochloride, alpha methyldopa, clonidine hydrochloride, guanabenz acetate, guanfacine hydrochloride, guanadrel, guanethidine monosulfate, reserpine, hydralazine hydrochloride, and minoxidil, or any combination thereof,. wherein the cardiovascular disease is cardiomyopathy, and the therapeutic agent is an ACE inhibitor, an angiotensin II receptor blocker, a beta blocker, a calcium channel blocker, digoxin, an antiarrhythmic, an aldosterone blocker, a diuretic, an anticoagulant, a blood thinner, and a corticosteroid, and wherein the cardiovascular disease is heart failure, and the therapeutic agent is an ACE inhibitor, an angiotensin-2 receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist, a diuretic, ivabradine, sacubitril valsartan, hydralazine with nitrate, and digoxin. 77-160. (canceled)
 161. The method according to claim 37, wherein the INHBE variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated INHBE polypeptide.
 162. The method according to claim 37, wherein the INHBE inhibitor comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), a short hairpin RNA (shRNA) that hybridizes to an INHBE mRNA, or a Cas protein and guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an INHBE genomic nucleic acid molecule. 